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Abstract 
Despite major reductions in child mortality, decrease in neonatal (first month of life) deaths has 
been substantially slower.  To further reduce neonatal deaths, scale-up of relevant and timely 
health interventions is necessary.  Such scale-up needs to be supported by evidence, but 
important gaps remain in our knowledge regarding the timing and causes of neonatal deaths.  
 
Birth and the days immediately following carry the highest daily risk of death, yet standard life 
tables do not present daily mortality risks within the neonatal period.  Around three-quarters 
of neonatal deaths occur during the first week, and most interventions to prevent these deaths 
must be delivered very quickly.  Thus, understanding the neonatal day-of-death distribution is 
important for delivering appropriate and timely interventions.  We fitted an exponential 
function to survey data to model the daily neonatal mortality risk, focusing on the first day and 
week after birth.  Using this model and observed data, we estimated the daily risk of death in 
the neonatal period for 186 countries in 2013.   
 
Targeted interventions also require reliable estimates of neonatal cause-of-death distributions.  
Cause-of-death estimation is challenging because of limited data quantity and quality in many 
countries.  Previous work highlighted the need to expand the existing country-specific neonatal 
cause-of-death estimates and improve the methods.  We developed a multinomial model to 
estimate the neonatal cause-of-death distribution by the early (days 0-6) and late (days 7-27) 
neonatal periods.  We then focused on methodological improvements, including evaluating 
performance and developing a proof-of-concept Bayesian mixed effects model.   
 
This thesis straddles two topics that are receiving increased attention: cause-of-death 
estimation and neonatal health.  Ideally, the results from this work can help current neonatal 
health policies and programmes while contributing to the growing area of cause-of-death 
modelling.  However, the longer-term aim should be to improve data collection to obviate the 
need for statistical modelling exercises.  
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Neonatal period: first four weeks (days 0-27) of life 
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Note: Throughout this thesis, I use the terms “observed data” or “empirical data” to refer to 
ground-level data collection (i.e. primary data collection).  I use the terms “estimates” and 
“predictions” to refer to the outputs of statistical models.   
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1 Background 
1.1 Motivation  
This is a special time for global health.  We stand at a crossroads as the Millennium Development 
Goals (MDGs) ended in 2015 and progress towards the Sustainable Development Goals (SDGs) 
is now underway.  In the last few decades, we have seen remarkable progress in health 
worldwide, including substantial drops in child mortality across most countries and reductions 
in the incidence of diseases like HIV/AIDS, tuberculosis, and malaria [1].  But a staggering 
number of preventable deaths still occur each year, including most of the 2.5 million estimated 
deaths among newborns under one month old [2, 3].   
 
This is also a special time for data.  The quantity of data is exploding, with more than 2.5x1018 
bytes created each day in 2018 and 90% of the data worldwide created in the last two years [4].  
Yet in the era of “big data”, we still have shockingly little information on some of the most basic 
but important topics regarding many of the world’s citizens.  For example, more than half of 
countries have no or poor quality systems for recording births and deaths, resulting in only 
about 40% of annual deaths being recorded globally [5].  The majority of countries lacking such 
systems are in Sub-Saharan Africa and Asia.  Just as with inequality in general, data inequality 
means that the places with the greatest need but fewest resources have the least data available 
to help inform priorities, practice, and progress.   
 
This thesis views these two topics – global health and data – through the lens of neonatal 
mortality (deaths in the first four weeks of life).  This is an area of global health that has 
traditionally been high in burden but low in data.  Although there have been major recent 
reductions in overall under-5 mortality, the decrease in deaths during the first month of life 
(neonatal period) has been substantially slower [6].  The estimated 2.5 million annual neonatal 
deaths, many from preventable causes, now account for about 47% of all under-5 child deaths 
[3].  One hundred and thirty-three countries were unable to achieve the fourth MDG target of 
a two-thirds reduction in under-5 mortality between 1990 and 2015 [7], at least partly due to 
limited reductions in neonatal deaths [8].  At the current rates of decline, it will take nearly 70 
years for Southern Asia and 90 years for Sub-Saharan Africa to achieve neonatal mortality rates 
presently observed in most European and North American countries (Figure 1.1). 
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Figure 1.1: Projected time for regions to reach 3 neonatal deaths per 1,000 live births based on 
their average annual rate of reduction for neonatal mortality from 2000-2016 
Note: 3 deaths per 1,000 live births was the average neonatal mortality rate in the MDG “developed 
countries” region in 2016; this an updated version of a figure created by the author for [6].   
 
To further reduce neonatal deaths, scale-up of relevant and timely health interventions is 
necessary.  Such scale-up needs to be supported by evidence, but important gaps remain in our 
knowledge regarding the timing and causes of neonatal deaths.  This is particularly true for the 
highest burden countries, for which we have the fewest data.  For such countries, statistical 
modelling exercises are necessary to provide estimates to inform decisions.  To be credible and 
thus useful, such estimates need to be reliable.  In this thesis, I aim to address some of these 
information and reliability gaps.  Below is an overview of the topics that I will cover.   
 
Birth and the days immediately following carry the highest daily risk of death, yet standard life 
tables do not present daily mortality risks within the neonatal period.  Deaths on the day of birth 
(day 0) are particularly important because they account for a large number of deaths that can 
be targeted by interventions at the time of birth [9].  A dramatic fall in risk occurs even within 
hours of birth.  For example, the risk of death (per 1,000 live births) in the first hour after birth 
in the US is 0.91 [10]. In contrast, the risk in the following 23 hours is 1.58, which translates to 
an average hourly risk of about 0.07, indicating a dramatic decline in risk.  Additionally, the 
causes of day 0 deaths more closely resemble those of intrapartum stillbirths than those of 
deaths later in the neonatal period [11].  Around three-quarters of neonatal deaths occur during 
1""3"deaths"per"1,000"live"births"is"the"average"neonatal"mortality"rate"observed"in"the"MDG"“developed"countries”"region"in"2016."""
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the early period (days 0-6) [12], and most interventions to prevent these deaths need to be 
delivered within a very short window of time.  Thus, understanding the day-of-death 
distribution within the neonatal period is important for delivering appropriate and timely 
interventions.  Yet, there have been no systematic, nationally comparable estimates of risk 
during the first day or week of life, despite increasing programmatic focus on these important 
time periods.   
 
Targeted interventions to prevent neonatal deaths also require reliable estimates of the 
neonatal cause-of-death distribution.  Ideally, country-specific neonatal cause-of-death 
estimates would 1) provide accurate information about both levels and trends, 2) include all 
major programmatically relevant causes of death, 3) distinguish between deaths in the early 
(days 0-6) and late (days 7-27) neonatal periods, and 4) identify relevant subnational variation.  
Cause-of-death estimation is challenging because of the limited quantity and quality of data 
available for many countries, especially regarding trends.  Since 2005, there have been regular 
estimates of neonatal causes of death by country [13, 14], as well as some recent time trend 
analyses [15].  While an important start, these estimates have highlighted the need to expand 
the estimates where possible (e.g. early/late neonatal period split), improve the statistical 
models, and test the reliability of the models against empirical data.   
 
For my PhD, I present a body of work whose aim is to improve our understanding of the 
temporal and causal distribution of deaths within the neonatal period and to address some of 
the important remaining challenges in neonatal cause-of-death estimation.  Much of the work 
presented here sits at the junction of epidemiology, statistics, and public health, with some 
influences from medicine and computer science.   
 
1.2 Thesis objectives 
My overall research goal is to improve our understanding of the temporal and causal 
distributions of deaths within the neonatal period.  This includes both conducting analyses to 
fill knowledge gaps and making improvements to existing statistical models.   
 
The key objectives are divided into three main themes, as follows:   
Theme 1: Filling knowledge gaps  
o Objective 1: Estimate risk of death by day within the neonatal period by country 
(chapter 3) 
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o Objective 2: Estimate cause-of-death distributions for the early and late neonatal 
periods (chapter 4) 
 
Theme 2: Improving modelling techniques 
o Objective 3: Identify limitations of the existing neonatal cause-of-death models  
(chapter 5) 
o Objective 4: Investigate improvements to the neonatal cause-of-death models 
(chapters 6 and 7) 
 
Theme 3: Discussion and recommendations  
o Objective 5: Synthesize main findings and relevant lessons learned for researchers, 
policy makers, and programme implementers (chapter 8) 
 
1.3 Structure of thesis 
This thesis is divided into nine main chapters.   
 
In chapter 2, I give an overview of available data sources for causes and levels of neonatal 
mortality, as well as for covariates used in our neonatal cause-of-death regression models.  This 
includes a discussion of the strengths and limitations of each data source type. 
 
I present our work on estimating the distribution of deaths by day within the neonatal period in 
chapter 3.  For this, we developed and fitted a mathematical model to empirical data on daily 
deaths during the neonatal period.  We then used this model to estimate the proportion of daily 
neonatal deaths for countries without adequate vital registration data, with a focus on deaths 
within the first day and week after birth.   
 
Our work on estimating causes of death separately for the early and late neonatal periods is 
included in chapter 4.  I describe how we modified the existing neonatal cause-of-death models 
to include this finer age gradation and discuss the implications of this.   
 
In chapter 5, I describe the limitations we identified with the existing neonatal multinomial 
cause-of-death models.  I investigate model performance issues, particularly focused on 
predictive accuracy and model stability, and consider whether and how to weight country-
specific empirical data for a country’s modelled estimates.   
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I then describe our work to improve the neonatal cause-of-death models in chapters 6 and 7.  
Our results of implementing a set of binomial models and comparing these to the multinomial 
model results are included in chapter 6.  In chapter 7, I present our work on shifting our models 
to the Bayesian framework, including with covariate selection and country-level random effects, 
and how these results compare to the multinomial model results.   
 
In chapter 8, I summarize the main findings of this thesis, compare our results with work done 
by others, and discuss overall strengths and limitations.  Drawing from the body of work 
presented in this thesis, I also provide recommendations on some aspects of statistical 
modelling, including a discussion about core modelling principles and the uses and limitations 
of modelled estimates.   
 
1.4 Contributions by the candidate 
The work presented in this thesis is that of the author, with the following exceptions: 
o Chapter 3 – the majority of text in this chapter has been published, and thus has been 
through revisions based on suggestions from co-authors and peer reviewers.   
o Chapter 4 – the majority of text in this chapter has been published, and thus has been 
through revisions based on suggestions from co-authors and peer reviewers.   
 
I worked closely with Professor Simon Cousens on various technical aspects described in this 
work.  I also benefited from discussions with several colleagues (see Acknowledgements) 
regarding many of the topics presented in this thesis.     
 
1.5 Ethical approval 
All of the work presented in this thesis used only data that is fully available in the public domain, 
downloadable from published literature, the World Health Organization, and the Demographic 
and Health Surveys website.   
 
1.6 Funding 
I am grateful to have received funding for several aspects of the work presented in this thesis.  
Funding was provided from the following sources: 
o Timing of neonatal deaths (chapter 3): Save the Children USA 
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o Neonatal cause-of-death estimates and model improvement (chapters 4-7): United 
Nations Children’s Fund (UNICEF) and Child Health Epidemiology Reference Group (CHERG) 
(through the Bill and Melinda Gates Foundation [BMGF]); the Maternal and Child 
Epidemiology Estimation group (MCEE) (through BMGF).   
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2 Data sources for neonatal estimates on timing and causes of 
death 
Here I describe the mortality, cause of death, and covariate data sources used for the work in 
this thesis, including some strengths and limitations of these sources.  While many of these 
sources are generalizable to all ages, the focus of this chapter is on sources relevant for the 
neonatal age group.  My aim is to provide some context to help the reader better understand 
the nuances of the input data used in this work.  This, paired with the descriptions of methods 
in later chapters, should help the reader better gauge our modelled estimates, including their 
strengths and limitations.   
 
2.1 Introduction 
For the statistical models we use to produce various neonatal estimates, we need input data on 
all-cause mortality levels, cause-of-death (COD) distributions, and explanatory variables 
(covariates).  These data come from a variety of sources and range widely in type, data collection 
methodology, and quality.  We obtain and use some of these data in their unaltered raw form 
(e.g. COD distributions from studies) while others are provided to us already processed to deal 
with issues like missingness or the need for smoothing (e.g. nationally comparable covariate 
time-series data received from the World Health Organization [WHO]).    
 
The various data collection and estimation methods (e.g. registries, household surveys, 
modelling) have different benefits and limitations, often balancing feasibility against quality 
and/or completeness.  For example, improving quality may come at a financial or human 
resource cost that is untenable, or a study may only be possible for a small non-representative 
population sample.  Understanding the nuances of these different methodologies is useful when 
interpreting the data coming out of them, as well as data that are indirectly related (e.g. 
modelled estimates – like ours – that rely on such input data).   
 
In this chapter, I provide a brief background on the mortality rate, cause of death, and covariate 
data sources that are relevant for the neonatal estimates we developed.  The complexities of 
each data source mentioned are greater than can fully be addressed in the short summary 
presented here; there are entire manuals and books dedicated to most of these data source 
types.  Thus, this chapter should be viewed as a non-exhaustive overview that highlights the key 
points relevant to the specific work described in this thesis.   
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2.2 Mortality data sources 
Registering births and deaths at the national level has wide-ranging implications for health, from 
population estimation and resource allocation to identifying demographic and mortality 
patterns.  Mortality information is especially useful for understanding the overall health of a 
population and how well the health system is functioning.  In this section, I discuss mortality 
data from civil registration and vital statistics (CRVS) systems, as well as alternative data sources 
for areas lacking adequate CRVS systems.  I also discuss how we use neonatal mortality data in 
our work.   
 
2.2.1 Civil registration and vital statistics systems 
Recognition that official birth and death statistics are useful dates back to at least 1685, when 
churches in Norway reported aggregated birth, death, and marriage numbers from local 
parishes [16].  Over the ensuing 300+ years, such recording of major life events has evolved into 
formalized national CRVS systems.  Vital registration (VR) data are the accumulated data on vital 
events collected through birth and death certifications in these systems.  Defining 
characteristics of well-functioning CRVS systems are that the individual-level VR data within 
them are collected in real-time, continuously, and at the local level [17].    
 
Well-functioning CRVS systems have several benefits, including health benefits for the 
population [18].  For individuals, these records are useful for a number of reasons, including 
providing documentation (e.g. birth certificates), conveying legal status, and allowing access to 
various services and social protections [19].  When aggregated (typically by national-level health 
or statistics offices), these data provide an important lens onto the population at local, regional, 
and national levels [17].  For example, age- and sex-specific death rates, regional mortality 
differences, and excess mortality can all be ascertained from these data.  VR data can thus 
provide much of the information needed for determining policies and priorities relevant to 
mortality reduction.  Importantly, the continuous nature of VR data allows the tracking of trends 
over time [20].   
 
However, this seemingly basic task of registering births and deaths is in fact a complex process 
that requires reliable long-term financial, regulatory, and political/legislative commitments 
alongside adequate infrastructure, organisation, and training [20, 21].  A 2015 study estimated 
that only 65% of births and 38% of deaths worldwide are registered [5].  The majority of low-
resource, high-mortality settings lack CRVS systems.  Of countries with national records, many 
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suffer from incomplete or low-quality recording of deaths (e.g. misreporting of age or cause of 
death) [22], leaving important gaps in understanding even basic health outcomes.  Additionally, 
the availability and quality of VR data in a country may change over time, especially in countries 
with newly emerging registration systems [23].  
 
Several factors contribute to the quality of VR data.  The WHO assesses the quality of death 
registration data by coverage, completeness, COD data quality, and (to a lesser extent) 
timeliness of data reporting [24].  Coverage refers to the percentage of a country’s population 
covered by the CRVS system.  Completeness refers to the percentage of recorded deaths (out 
of all deaths) in areas covered by the CRVS system in that country.  The quality of COD VR data 
can be assessed by the proportion of deaths attributed to ill-defined and/or non-specific codes 
[24].  Recently, an alternative “vital statistics performance index” was developed [25].  This 
composite score assesses VR data using six factors consisting of completeness, COD data quality, 
level of cause-specific detail, quality of age and sex reporting, data availability and timeliness, 
and internal consistency.   
 
Based on the WHO quality measures, only 25% (49/194) of WHO member states had high-
quality death registration data whereas 42% (81/194) had no or very low-quality data between 
2005-2015 [26].  The latter category was dominated by some of the poorest and highest 
mortality countries; 94% (43/47) of African countries and 73% (8/11) of Asian countries (based 
on WHO regions) had no or very low-quality VR data.  However, there is growing momentum to 
implement new systems and improve existing ones in countries lacking adequate CRVS systems  
[27, 28].  Innovative solutions are also being deployed to overcome the challenges of 
implementing such systems in resource-limited settings.  Some of these include trying to link 
health service records (e.g. hospital data) with CRVS systems [29], incorporating verbal 
autopsies (described in section 2.3.2) into CRVS systems [30, 31], and using community health 
workers to increase vital event registration [32].    
 
For neonates, high-quality VR data are a key source of information on the number, timing, and 
causes of death [33, 34].  Unfortunately, neonatal deaths are among the most underreported 
(i.e. low completeness) in lower-quality CRVS systems [17, 35, 36], highlighting the fact that 
there are substantial barriers towards registering births and deaths within this first month.  
Other data quality issues for neonatal VR data include misrecording of deaths by day (i.e. age of 
death) and by cause (further discussed in section 2.3.1), as well as misreporting very early 
neonatal deaths as stillbirths.   
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2.2.2 Alternatives to CRVS systems 
Given that the majority of countries lack adequate VR data, alternative data sources are needed 
to estimate mortality in these countries.  Here, I describe some of the key alternatives.   
 
Continuous data collection systems 
Various methods that allow for continuous recording of vital events have been implemented in 
countries lacking adequate CRVS systems.  Most of these options lack the coverage of a well-
functioning CRVS system but can still provide much-needed mortality information for the 
covered populations.     
 
Sample registration systems (SRSs) are similar to CRVS systems but only cover a nationally (or 
subnationally) representative sample of the population [37].  Alongside the continuous 
collection of demographic information in these systems, SRSs often also include regular 
household surveys about these demographic events [38].   This dual recording helps catch errors 
and acts as a form of quality control and evaluation between the two data collection methods.  
Advantages of an SRS include lower costs compared to a full CRVS system, (sub)nationally 
representative samples if done well, and acting as a step towards a more comprehensive CRVS 
system in the future.  However, SRSs require substantial infrastructure and resources to 
maintain representative samples, and can suffer from similar completeness, coverage, and 
quality issues as CRVS systems (section 2.2.1).  Countries currently with SRSs include India, 
Bangladesh, Indonesia, and China [37, 39, 40].   
 
Health and demographic surveillance systems (HDSSs) are well-defined geographic areas which 
have continuous monitoring of health and demographic indicators/outcomes [20].  Numerous 
HDSSs have been established in low- and middle-income countries (largely in Africa, Asia, and 
Oceania) since the 1940s [20].  Some HDSSs are part of networks (e.g. INDEPTH) which result in 
better standardization and comparability across sites [41].  Advantages of HDSSs include that 
they are generally well-monitored sites with good completeness and coverage of key indicators 
(e.g. mortality) at the community-level and over time [42].  However, they typically cover small 
areas and are not (sub)nationally representative, thereby limiting the generalisability of their 
results.   
 
Various programme- or disease-specific registers also collect continuous mortality data.  For 
example, the Maternal Newborn Health Registry is a prospective, population-based registry of 
pregnancy outcomes across Global Network sites [43].  This allows the continuous collection of 
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demographic and health information on relevant topics, including on neonatal mortality.  Such 
registers are usually limited in scope geographically (similar to HDSSs) and topic area.  Thus, 
these registers have similar drawbacks to localized HDSS sites.    
 
Health management and information systems (HMISs) are medical record systems which 
typically collect data on patients accessing health services.  The data from these systems can 
then be aggregated at the subnational or national level for calculation of relevant health 
statistics.  The patient-level information in HMISs can be relatively extensive, including, 
potentially, medically certified death records.  However, many births and deaths in low-resource 
high-mortality settings do not occur within the healthcare system (e.g. at a hospital or clinic), 
and thus are not likely to be included in the HMIS.  This limits the generalisability of HMIS 
records in many countries.  Even for deaths with associated medical records, these records may 
not be aggregated, cross-checked, or analysed in settings with weak or fragmented HMISs [44].  
Initiatives to improve the quality and completeness of HMISs [45], their reach beyond health 
facilities [46], and their integration with wider data collection systems (e.g. nascent CRVS 
systems) [47] have potential to yield better quality and higher coverage data in such settings.   
 
One-off or periodic data collection methods 
Retrospective household surveys such as the Demographic and Health Surveys (DHS) and 
UNICEF’s Multiple Indicator Cluster Surveys (MICS) have been a vital source of mortality 
information for many countries with inadequate CRVS systems [48].  These surveys ask female 
respondents for birth histories including information about deceased children.  These data can 
be used to calculate child mortality rates.  Key advantages of such surveys are that they are 
standardized, feasible to conduct in many low-resource settings (e.g. DHS have been conducted 
in over 90 countries [49]), and can provide all-cause mortality statistics that are (at a minimum) 
nationally representative.  Unfortunately, such surveys have well-documented limitations, 
including having various biases (e.g. recall), being retrospective instead of real-time, and not 
being useable for local information below the representative level (e.g. national or subnational) 
[50].  Additionally, nearly all of these surveys are one-offs or conducted periodically with several 
year gaps, making it infeasible to track time trends in real time [51].   
 
Population censuses, which are typically done every five to ten years, are a source of periodic 
demographic data.  These are similar to household surveys in requesting retrospective 
information from respondents, but collect much less detailed information.  For example, a 
census may collect a summary birth history which requires various assumptions to be made in 
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order to estimate mortality rates.   Censuses also have similar limitations to household surveys 
as well (e.g. recall biases, not continuous data collection) [22].     
 
2.2.3 Modelling 
The mortality data sources described in the previous section are collected at the local, 
subnational, or national level.  Two main groups currently produce annual nationally 
comparable all-cause neonatal mortality rate estimates with time trends: the United Nations 
Inter-agency Group for Child Mortality Estimation (UN-IGME) [3, 52] and the Institute for Health 
Metrics and Evaluation (IHME) [53].  UN-IGME, as part of the UN, is led by UNICEF and includes 
membership from the World Bank, UN Population Division, and the WHO.  These groups use 
various empirical data (including those described in sections 2.2.1 and 2.2.2) as inputs into 
statistical models to estimate mortality levels across countries and over time.   
 
A key benefit of these modelled estimates is that they allow the comparison of mortality levels 
across countries, and also provide a foundation for producing nationally comparable estimated 
numbers of deaths by various sub-categories (e.g. cause, day of death).  However, these 
estimates rely on statistical models and imperfect input data (as described in the previous 
sections) and thus may suffer from issues of predictive accuracy.  Indeed, substantial differences 
have been documented between the results of the different modelling strategies [54] and 
between modelled estimates and empirical data (e.g. DHS) from countries [55].   
 
2.2.4 How we use mortality data in our work 
We use neonatal mortality data and estimates in several ways for the work presented in this 
thesis.  Here, I have included a brief description of these uses; full details are provided in the 
relevant chapters later in the thesis.    
 
Risk of death by day analysis (chapter 3) 
o We used neonatal mortality data from DHS and high-quality VR as inputs into our 
models 
o We applied day-of-death proportions to the nationally comparable UN-IGME total 
neonatal death numbers (or envelopes) to calculate day-specific numbers  
Cause-of-death analysis (chapters 4-7) 
o Neonatal mortality rate (NMR) levels were used to separate modelled countries into 
high (NMR~≥15) and low mortality (NMR~<15) countries 
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o We used neonatal, infant, and child mortality rates from UN-IGME as input and 
prediction covariates in our models (see section 2.4) 
o We applied COD proportions to the nationally comparable UN-IGME total neonatal 
death numbers to calculate cause-specific numbers  
 
2.3 Cause-of-death data sources 
Beyond counting deaths, understanding the distribution of causes of deaths is important for 
identifying appropriate interventions and programme priorities.  However, ascertaining causes 
of death is not a trivial task even in low-mortality high-resource settings.  Here, I discuss various 
COD data sources and how we use neonatal COD data in our work.   
 
2.3.1 CRVS systems 
CRVS systems are one of the main sources of individual-level COD data.  The importance of COD 
data in these systems is highlighted by the fact that the quality of these data is a key metric for 
gauging the overall quality of CRVS systems (see section 2.2.1 for details on CRVS systems).  
When aggregated and analysed, VR-based COD data provide valuable information on COD levels 
and trends to help inform policies and programmes.    
 
In well-functioning CRVS systems, COD data include official death certification by a medical 
examiner with information on the immediate and underlying causes of death and the medical 
chain of events leading to the death [56].  Assigning standardized COD codes using the 
International Statistical Classification of Diseases and Related Health Problems (ICD) has made 
comparability of medically-certified deaths possible over time and across countries [23].  This 
intricate coding system (currently in its 10th revision; ICD-10), with multiple levels and thousands 
of codes, reflects the complexities of classifying causes of death.  Further details on death 
certification are included in sections 8.3.2 and 8.4.    
 
Cause-of-death data from CRVS systems can have several limitations.  First, the patterns of COD 
data availability in CRVS systems mimic those of all-cause mortality data (section 2.2.1), but with 
even lower levels of completeness and quality.  For example, a recent report estimated that 
only 27% of global deaths were registered with a cause of death, and an even smaller 13% were 
reported to the WHO with a meaningful ICD code [26].  There are also major differences in VR 
COD data by region.  The completeness of COD data was estimated to range from 6% in the 
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WHO Africa region and 10% in South-East Asia to percentages in the mid-90s or higher for the 
Americas and Europe [57].     
 
Additionally, differences in coding practices can affect accuracy and comparability of VR data 
over time and across countries.  Correctly coding deaths using ICD classification rules requires 
extensive training.  Problems with accurate COD coding are well-documented even in countries 
with high-quality VR data [58, 59], including substantial use of codes for unknown or ill-defined 
causes (sometimes referred to as “garbage codes”).  Previous studies have found that coding 
practices for ascertaining causes of death can vary between and even within countries [60, 61], 
sometimes due to transitions between different ICD revisions [62].  Finally, ICD-10 codes are not 
always ideal for neonatal causes, particularly because several programmatically relevant causes 
are relegated to the often-unused fourth digit/level in the codes.   
 
Well-functioning CRVS systems remain the best option for high-quality VR data that are useful 
at the local, subnational, and national levels.  However, the limited availability and quality of 
these data in many high-mortality countries mean that alternative data sources and methods 
are also needed (sections 2.3.2-2.3.3).    
 
2.3.2 Verbal autopsies  
For settings where medical certification of cause of death is irregular or unavailable, alternative 
methods are required to provide insight into the probable cause(s) that led to an individual’s 
death.  The main alternative method for this is verbal autopsy (VA).  Since its first uses in Asia 
and Africa in the 1950s and 1960s [63], VA has become increasingly common in areas where 
CRVS is not well established and/or deaths commonly occur outside of the health system.  
Typically, VA involves trained interviewers obtaining information on the signs, symptoms, and 
events surrounding a death from a family member of the deceased person [64].  The probable 
cause of death is then determined based on this information either through physician review or 
analytically using computer-based algorithms [65].   
 
Although VAs provide a much-needed source of COD information, they remain an imperfect 
alternative to high-quality VR data [63].  VA data are known to be of variable quality, and the 
reported cause distributions depend heavily on factors like the causal hierarchies and case 
definitions used to attribute deaths to particular causes [66-69].  The lack of both standardized 
VA methods and full reporting of methods has made comparisons between studies even more 
challenging [68, 69].  This is true even for some of the (otherwise standardized) DHS which now 
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include neonatal COD assessments [70].  Accurate cause attribution using VA is especially 
problematic for causes that are difficult to distinguish between, such as neonatal sepsis and 
pneumonia, or difficult to identify, such as congenital disorders without external signs.  
Unsurprisingly, VA methods work better for causes with clear symptoms [71] and less well for 
illnesses like malaria which have non-specific signs and symptoms [72].  VA for neonatal deaths 
has the added complication that the sick baby is unable to communicate symptoms to a 
caretaker.   
 
To address some of these VA concerns, several improvements have been proposed and tested 
in recent years, including standardization of VA tools [67, 73, 74] and probabilistic algorithms 
for assigning deaths [73, 75].  Several networks (e.g. INDEPTH [41]) and multi-country studies 
(e.g. AMANHI [76]) have also implemented VAs at their sites, which helps to enforce 
standardised methods and increases within-network comparability.  Additionally, using 
computers to process large amounts of raw VA data has potential to greatly increase both 
efficiency and standardisation of results [77].  Portable electronic devices have also been found 
to improve effectiveness and timeliness of results when conducting VAs [77, 78].   
 
Recently, more countries and donors are investing in large nationally representative VA studies 
in countries without adequate CRVS system.  There are also increasing discussions on how best 
to integrate VA into CRVS systems [30, 79].  While not easy, such integration has potential to 
strengthen weak CRVS systems which currently lack COD information.  Despite their limitations, 
verbal autopsies remain the only viable large-scale option for ascertaining causes of deaths in 
places without adequate medical certification of deaths.  Further discussions of VA methods 
and limitations are included in sections 4.5 and 5.1.3, and additional details on methods to 
improve VA quality are included in section 8.5.  
 
2.3.3 Alternatives to CRVS systems and verbal autopsies 
In the event of death, patient medical records (preferably as part of an HMIS) can be a rich 
source of data even in countries without adequate CRVS systems.  These records ideally include 
medical certification of death by a clinician with cause of death listed using standard ICD 
classifications.  However, no or poor-quality medical certification of deaths even in hospital 
settings is common in many countries [17, 80].  Additionally, these data have limited 
generalisability in the many settings where the majority of deaths occur outside of the health 
system [42].   
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Mortality audits aim to assess factors contributing to individual deaths, with goals of improving 
quality of care and identifying ways to avoid similar deaths in the future where possible [81].  Of 
particular relevance to neonates are perinatal mortality audits, which are focused on the time 
period immediately before and after birth.  However, perinatal audits are still far less common 
than maternal mortality audits in low-resource settings [81].  Mortality audits range in their 
scope, but may include investigations of factors related to clinical causes of death (through 
medical certification or verbal autopsy), access to and quality of care, and other societal and 
health system issues that may have contributed to a death [82].  These audits can provide deep 
insights into the multifaceted factors surrounding deaths while also helping to reduce 
undercounting and underreporting [81].  However, mortality audits have typically been 
conducted at the facility level, which has limited their scope and generalisability [83].  Recent 
increases in community-based mortality audits, integration of mortality audit systems into 
national health data, and expansion of mortality audits within national programmes have 
potential to improve the reach of mortality audit systems [81, 83].   
 
Finally, minimally invasive autopsy (MIA; sometimes called minimally invasive tissue sampling 
[MITS]) is a promising recent method aimed at improving accuracy of COD ascertainment in low- 
and middle-income countries [84].  MIA/MITS typically involves using needle sampling to obtain 
post-mortem tissue samples from various organs, followed by histopathologic examinations and 
identification of infectious organisms [85].  These methods have equipment, training, and 
financial costs which are higher than clinical diagnoses or verbal autopsies, but lower than 
conventional autopsies.  Recent studies have investigated the feasibility, acceptability, and 
diagnostic accuracy of MIA/MITS with generally positive results except where cultural/religious 
beliefs conflicted with post-mortem examinations [84-86].  While unlikely to replace VA studies 
at least in the short term, MIA/MITS could be used for evaluation of VAs to help improve the 
accuracy of VA data and better identify patterns of bias in VA COD ascertainment [87].   
 
2.3.4 Modelling 
Modelled estimates are another source of cause-of-death numbers.  We do not use modelled 
COD estimates as an input source in our work, but they are a product of our work.  I have 
therefore included a brief history and description of neonatal COD modelling here.   
 
History of COD modelling 
For countries which lack recent high-quality VR data, modelling exercises have remained 
necessary to provide relevant COD estimates.  The first systematic exercise to develop nationally 
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comparable estimates of disease burden was released in 1993 for the year 1990 by the World 
Bank and WHO as part of the Global Burden of Disease (GBD) study, with several related 
publications through 1997 [88-92].  Prior to this work, different groups often produced 
estimates for single causes, which when summed together resulted in all-cause mortality 
estimates that far exceeded the actual global mortality totals [93].  A key goal of the GBD study 
was to estimate the COD distribution by country, including for those without high-quality data, 
while enforcing the condition that the cause-specific deaths in a country summed to the total 
national number of deaths.  Since this seminal work, COD estimation has become an important 
area of research.  While this first GBD exercise did not report neonates as a distinct age group, 
it established a foundation for developing such estimates. 
 
Since the early 2000s, the Child Health Epidemiology Reference Group (CHERG) and the GBD 
project have released COD estimates pertaining to the neonatal period.  A brief history of their 
efforts (up until the start of the work presented in this thesis) is summarized in Figure 2.1.  Note 
that CHERG is now the Maternal Child Epidemiology Estimation (MCEE) group (as of 2013) and 
the GBD project has been based at the Institute for Health Metrics and Evaluation (IHME) since 
2010.  CHERG/MCEE and IHME work independently from each other.  CHERG/MCEE 
collaborates closely with the WHO and other parts of the UN system, including UNICEF.     
 
Figure 2.1: Major global cause-of-death estimation exercises pertaining to neonatal mortality 
from 1993-2013 
 
Notes: WB = World Bank; references: 1[88-92]; 2[94]; 3[95]; 4[13]; 5[33]; 6[96-98]; 7[99]; 8[14]; 9[93]; 10[15] 
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In 2003, Morris et al. used a regression model to estimate the child COD distribution – with 
neonatal deaths grouped with other ages into a broad category of “neonatal and other” – for 
countries with poor VR data [94].  Subsequently, others estimated under-5 deaths while 
including neonates in a separate “neonatal disorders” category [95].  The first nationally 
comparable COD estimates of neonatal mortality using programmatically relevant cause 
categories were published by Lawn et al. in 2005 for the year 2000 [13].  These estimates, 
produced on behalf of CHERG, were developed using multi-cause multinomial logistic regression 
models based on high-quality VR data for low mortality countries and research studies from 
high mortality/low resource settings for high mortality countries.  Although the second GBD 
project did not estimate COD for neonates as a distinct age group, they applied the 2005 CHERG 
neonatal results [13, 33] alongside their own adjustments to distinguish neonates within their 
0-4 year age group estimates [98].   
 
Updated neonatal COD estimates were subsequently published on behalf of CHERG for 2008 
[14] and 2010 [15], with the latter including annual trends since 2000.  None of these estimates 
distinguished between the early and late neonatal periods.  Additionally, the analyses relied on 
regression strategies that are unlikely to account fully for the complexities in the data and 
modelling.  I address several of these topics in this thesis (chapters 4-7).  
IHME released neonatal COD estimates by country and neonatal period for 1990 and 2010 
through the third major GBD exercise in 2012 [93].  IHME used a Bayesian framework to develop 
single-cause ensemble models (for most causes) to estimate death rates and then applied an 
algorithm to proportionally rescale cause-specific estimates to sum to overall age-sex envelopes 
[93].  They estimated distributions for 235 causes for 20 age groups and thus multi-cause models 
were not computationally feasible.  
 
Since 2013, updated neonatal COD estimates have continued to be produced by IHME and 
CHERG/MCEE [100-103].  In this thesis, I describe some of our work (on behalf of CHERG/MCEE) 
of splitting neonatal causes of death by the early/late periods (chapter 4) and investigating 
improvements to the existing COD models (chapters 5-7).  I also provide a brief comparison of 
the CHERG/MCEE versus IHME approaches in section 8.2.   
 
2.3.5 How we use cause-of-death data in our work 
As noted in the previous section, nationally comparable neonatal COD estimates are a product 
of our work.  We use empirical neonatal COD data as model inputs to produce these estimates.   
Specifically, we use high-quality VR data (section 2.3.1) and data extracted from published VA 
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studies (section 2.3.2) as inputs to model the COD distributions for countries with inadequate 
CRVS systems.  For countries with high-quality VR data, we report their VR COD data as-is.  
Further details of our neonatal COD modelling strategy, including on the COD input data, are 
provided in section 4.2.  Selection criteria for inclusion of VA studies are included in section 
4.2.2, and a list of literature review search terms conducted can be found in Appendix B.2.3. 
 
2.4 Covariate data sources 
The cornerstone of a regression analysis is the relationship between the covariate(s) (i.e. 
independent variables) and the outcome(s) (i.e. dependent variables).  Thus, covariates play an 
essential role in regression-based models, including those presented in this thesis.  Here, I 
discuss the various sources of covariate data used in this work, and how these data are 
processed to develop nationally comparable covariate time series.   
 
2.4.1 Overview of covariates used in this thesis 
We use covariate data in both the input and prediction datasets for our neonatal COD models.  
Specifically, we run regression models with covariates as the independent variables and the 
associated COD inputs as the dependent variables.  We then apply the estimated regression 
coefficients for these covariates to a set of nationally comparable covariate time series data to 
obtain COD distribution predictions by country and year.  Further details of our neonatal COD 
modelling strategy, including the use of covariates, are provided in section 4.2.  Discussion of 
how covariate data availability and quality impact our work is included in section 5.1.3. 
 
Since the goal of our work is to produce nationally comparable time series estimates, we were 
only able to include in our models those covariates which had annual, nationally comparable 
times series estimates available across 194+ countries.  The WHO collates and processes various 
nationally comparable covariate time series data annually.  For our neonatal COD estimation 
work, we were provided with a database of all relevant covariate time series data by the WHO.  
Table 2.1 includes a description of these covariates alongside the data sources used by the WHO.  
In the following sections, I describe the raw data sources relevant to these covariates, and give 
a brief description of the types of processing which are done to develop complete covariate 
time series.   
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Table 2.1: Description of covariates relevant to the neonatal cause-of-death models 
Covariate Source1 Description 
Neonatal mortality 
rate (NMR) 
UN-IGME Number of deaths in first 28 days from birth 
per 1,000 live births 
Infant mortality rate 
(IMR) 
UN-IGME Number of deaths in first 1 year from birth per 
1,000 live births 
Under-5 mortality rate 
(U5MR) 
UN-IGME Number of deaths in first 5 years from birth 
per 1,000 live births 
Low birthweight 
(LBW) 
World Bank % of babies weighing <2500 g within first hours 
of birth 
General fertility rate 
(GFR) 
MMEIG2 Total number of live births divided by number 
of women 15-49 years old in a given year 
Antenatal care (ANC) World Bank % of women with 1+ antenatal care visit during 
pregnancy  
Female literacy rate 
(FLR) 
World Bank % of women aged 15+ who can read and write 
at least short simple statements 
Diphtheria/Pertussis/ 
Tetanus vaccine (DPT) 
WHO-UNICEF % of children ages 12-23 months immunized 
with DPT vaccine 
Bacillus Calmette-
Guerin vaccine (BCG) 
WHO-UNICEF % of children ages 12-23 months immunized 
with BCG vaccine 
Protected at birth 
(PAB) against tetanus 
WHO-UNICEF % of births by women of child-bearing age who 
are protected against tetanus 
Skilled birth 
attendance (SBA) 
WHO-UNICEF % of births with a skilled attendant at delivery  
Gross national income 
(GNI) 
World Bank Sum of money earned per year by people and 
business in a country (in US dollars) 
GINI coefficient World Bank Statistical measure of economic inequality 
based on income distribution in a population 
1 Main source as listed in WHO database; 2 MMEIG = UN Maternal Mortality Inter-agency Group 
 
2.4.2 From “raw” empirical covariate data to nationally comparable time series 
As noted in the previous section, the covariates listed in Table 2.1 were provided to us in a 
database by the WHO as complete nationally comparable time series.  For example, values for 
LBW were available in this database from 1980 to 2015 for 194 countries (i.e. 6,984 country-
year datapoints).  There is a multi-stage process involved in going from incomplete “raw” 
empirical data from multiple sources to a single complete nationally comparable covariate time 
series.  A simplified example of the process is as follows: 1) data for a (somewhat) standardized 
covariate are collected over time in different countries through various means (e.g. household 
surveys, national reporting systems, censuses); 2) these data are collated and processed (e.g. 
weighted averages) by a secondary source (e.g. World Bank, UN-IGME; see “source” column in 
Table 2.1) to produce nationally comparable time series data for the covariate; and 3) this time 
series is further processed (e.g. for completeness, smoothing) by the WHO prior to being made 
available for use in estimation models.  Thus, the 6,984 datapoints for a complete nationally 
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comparable 35-year covariate time series for 194 countries may be a combination of “raw” 
empirical data, slightly processed empirical data (e.g. weighted averages if there are multiple 
sources with data for same country/year), and modelled data (e.g. imputation, extrapolation, 
smoothing).   
 
The “raw” data sources typically include a variety of standardized household surveys (e.g. DHS, 
MICS), other surveys (e.g. country- or topic-specific, facility-based), and data from national 
statistical systems (e.g. GNI data reported by countries).  Each of these have strengths and 
limitations.  For example, household surveys such as DHS allow for standardized 
implementation of questionnaires across many countries, but have important limitations (e.g. 
recall bias).  A few covariate time series rely on only one or two sources of underlying raw data, 
but the majority have data from a combination of sources.  For example, the World Bank reports 
that their SBA (i.e. “skilled birth attendance”) covariate time series is collated from UNICEF, 
State of the World’s Children, ChildInfo, and DHS data sources [104].  The large number of data 
sources has the potential to decrease comparability of the covariate.  For example, primary data 
collection sources may apply different definitions for what a “skilled attendant” means for the 
SBA covariate.   
 
The collation and processing steps use a diverse set of methods.  For example, various methods 
used within or between covariates listed in Table 2.1 include weighted averages, Bayesian B-
spline smoothing, Loess regression smoothing, flat-trend extrapolation, regression-based 
extrapolation, linear interpolation, backward/forward progression based on annual rates of 
change (ARC), and backward/forward progression based on average of flat trend and ARC trend 
[104-106].  This extensive list is indicative of the data gaps and quality issues that exist when 
trying to develop comparable time series.  The main implication of this is that there can be 
substantial amounts of measurement error between and within national covariate time series 
data, both at the level of primary data collection and through the collation and processing of 
these data.  These issues are discussed in greater detail in sections 2.5 and 5.1.3.   
 
2.4.3 Local covariate data collection 
An additional source of covariate data which we use in our work is locally collected data 
reported in VA studies.  As noted in section 2.3.5, we extract cause-of-death data from verbal 
autopsy studies for inputs into our models.  We also try to extract covariate information from 
the same geographic area, population, and time period as the extracted cause-of-death data.  
This is done because regression-based models inherently depend on the relationship between 
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outcome variables and covariates, which should ideally come from the same population and 
time period.  For example, a study may report the local NMR, which may be substantially 
different from national- or subnational NMR estimates.  However, we are not always able to 
find corresponding local-level covariate information, and thus use regional- or national-level 
covariates when such local-level data are missing.  Additionally, studies often state a covariate 
value without explaining its source, thus making it difficult to gauge its accuracy and method 
of primary data collection.   
 
2.5 Discussion 
The data used in this thesis come from a diverse range of sources of varying availability and 
quality.  This speaks to the dearth of strong data collection infrastructure in many countries and 
the complexities of the data being collected.  High-quality mortality and cause-of-death data, 
such as those from well-functioning CRVS systems, are a rich source of information but are 
limited by the number of countries with such systems.  Commonly used alternatives, such as 
household surveys and verbal autopsy methods, provide much-needed data in low-resource 
high-mortality settings but with important quality limitations.   
 
There is also considerable heterogeneity in data availability and quality for the covariates used 
in our neonatal cause-of-death models.  The covariate data in our models are a mixture of data 
reported by countries, determined from household surveys, modelled, and/or imputed.  A 
particular covariate time series may have a combination of these sources across countries or 
over time for the same country.  Such variation may not always be known or fully understood, 
and is usually impossible to specifically identify within the given time series data.   
 
The data quality and quantity issues discussed here have the potential to affect predictive 
accuracy and stability of our models.  In particular, the various types of measurement error – 
both for outcomes and covariates – can mask true covariate-cause relationships, which are the 
cornerstone of regression analyses.  This would weaken our model’s ability to produce robust 
and stable estimates.  It is important to keep these data issues in mind when reading the rest of 
the thesis.  The implications of various data sources and how they are used in our work are 
discussed throughout the thesis, particularly in chapters 5 and 8.  In section 5.1, I more closely 
investigate how several data issues, including the noise from measurement error, may affect 
our estimates.   
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3 Timing of neonatal deaths 
In this chapter, I present our work on estimating the distribution of deaths by day in the neonatal 
period.  Preliminary results were published in Save the Children’s State of the World’s Mothers 
2013 report [12], and final results were published in the Lancet Global Health under the 
following citation: Oza S, Cousens SN, Lawn JE. Estimation of the daily risk of neonatal death, 
including the day of birth, in 186 countries in 2013: a vital-registration and modelling-based 
study. Lancet Global Health 2014; 2(11): e635-644 [107].  The text in this chapter is adapted 
from this journal article and its associated web appendix.  The open-access article can be found 
at: https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(14)70309-2/ 
 
3.1 Introduction 
Birth and the following few days are biologically and emotionally remarkable, and yet also the 
riskiest.  While the Millennium Development Goals (MDGs) galvanised efforts leading to major 
reductions in maternal and child mortality in recent years, deaths during the neonatal period 
(first four weeks after birth) have decreased at a substantially slower rate [108, 109]. The 
estimated average annual rate of mortality reduction for neonates was 2.2% from 1990-2013 
[110], compared to 4.0% for children aged 1-59 months [110] and 2.6% for maternal deaths 
[111].  The high risk of death in the first days after birth is striking.  In 2013, 45% of the estimated 
6.2 million deaths in children under the age of five occurred during the neonatal period [110], 
along with an estimated 1.2 million intrapartum stillbirths [112].  Around three-quarters of 
neonatal deaths are estimated to occur during the early neonatal period (see Panel 3.1 for 
neonatal time period definitions) [13, 113]. 
 
Panel 3.1: Definitions for the neonatal period 
o The neonatal period refers to the first four weeks (28 days) after birth.   
o The early neonatal period consists of the first week (7 days) and the late neonatal 
period consists of the last three weeks (21 days) of the neonatal period.   
o The first day is typically called “day 0” in household survey and vital registration data 
or “day 1” in clinical practice.  The neonatal period ranges from days 0-27 when using 
“day 0” as the first day, and from days 1-28 when using “day 1” instead.  
Here, we use the term “day 0” to refer to the first day.  Thus, we use days 0-6 for the early 
neonatal period (week 1), days 7-27 for the late neonatal period (weeks 2-4), and days 0-
27 for the full neonatal period.   
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Deaths on the day of birth (day 0) are particularly important to assess because they account for 
a large number of deaths that can be targeted by interventions at birth.  A dramatic fall in risk 
occurs even within hours of birth.  The risk of death (per 1,000 live births) in the first hour after 
birth in the US is 0.91 [10].  In contrast, the risk in the following 23 hours is 1.58 which translates 
to an average hourly risk of about 0.07, indicating a dramatic decline in risk.  The causes of day 
0 deaths more closely resemble those of intrapartum stillbirths than of deaths later in the 
neonatal period.  This has led some to propose an indicator combining intrapartum stillbirths 
and day 0 deaths as a marker of the quality of intrapartum care [11], as these are far more 
common than maternal deaths and thus offer a more practical indicator. Yet, there have been 
no systematic, nationally comparable estimates for risk during the first day or week of life, 
despite increasing programmatic focus on these important time periods.  
 
Vital registration (VR) data, collected through birth and death certificates, are available for more 
than half of the 193 UN member states [114].  However, these data are reliable for only about 
half of these countries, which are generally the wealthiest and account for fewer than 5% of the 
world’s 3 million estimated neonatal deaths in 2013 [115].  For the majority of countries in the 
world, day-of-death data for the neonatal period are either unavailable or are derived from 
cross-sectional surveys, such as the Demographic and Health Surveys (DHS), which ask women 
of reproductive age how many of their children have died and the child’s age at death [116].  
Such data are susceptible to error with possible underreporting of deaths, including stillbirths, 
and misreporting of the day of death [117-119].  Particularly important for the present work is 
the potential for misrecording of deaths between day 0 and day 1, and misclassification 
between stillbirths and very early neonatal deaths (Panel 3.2).  
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Panel 3.2: Measurement challenges in the neonatal period 
 
Misclassification between stillbirths and live births: The probability of recording the baby as 
being alive at birth has been shown to be associated with the perception of viability of 
survival.  For example, if babies are not assessed at birth and resuscitated, a live term baby 
that is not breathing may be misclassified as an intrapartum stillbirth [112, 120].  This is 
typically the direction in which misclassification between live births and stillbirths occurs. 
Note: stillbirths are categorized as antepartum (those occurring before the onset of labour) 
and intrapartum (those occurring after the onset of labour).   
 
Variation of registration with gestational age: As complexity of care increases, and even 
very preterm babies under 25 weeks of gestation are given intensive care, the registration 
of live very preterm babies under 28 weeks increases, as documented in Denmark [121].  
Some countries without care for extremely preterm babies still may not count some live 
born babies as live births. 
 
Misrecording of day of death: Importantly, the perception of what time period this “first day” 
refers to can lead to critical differences in recording practices.  Some different ways in which 
the first day is perceived include 1) the first 24 hours after birth, 2) until sundown of the day 
of birth, or 3) the calendar date.  These various perceptions can lead to differences in how 
deaths are classified between “day 0” and “day 1” and can result in misclassification if survey 
interviewers or respondents misunderstand “day 1” as meaning the day of birth.  Even in the 
absence of such misunderstanding, deaths on “day 0” will not include all deaths within 24 
hours of birth if, for example, calendar dates are used.  Additionally, misclassification 
between days is possible if only the dates but not the exact times of birth and death are 
reported in vital registration systems.    
 
Hence, to provide estimates for countries lacking recent VR data of adequate quality, modelling 
exercises remain necessary.  Regular estimates of under-five and neonatal mortality by country 
are provided by the United Nations (UN) and the Institute for Health Metrics and Evaluation 
(IHME) [102, 110, 115, 122].  However, while it is well recognised that mortality is highest during 
the first few days, we were unable to identify any multi-country analyses of the daily risk of 
death within the first week or month after birth, with current standard life tables and survival 
curves grouping the time periods in months or years instead of by day [123]. Although the 
literature on modelling survival curves within the neonatal period is sparse, previous work has 
suggested that exponential functions are suitable for modelling the neonatal period, while other 
functions, like the Gompertz and Weibull, are better for later periods in the lifespan [124, 125]. 
  
 
39 
Exponential functions have been used to smooth day of death heaping (preference for reporting 
deaths on certain days, e.g. “at one week”) within the neonatal period [117].  Previous analyses 
of DHS suggested that up to 50% of neonatal deaths occur in the first 24-48 hours, but 
highlighted data limitations including misclassification between day 0 and day 1, and “heaping” 
of deaths on particular days [13].  
 
Here, we report results obtained using a mathematical model with a good fit to the available 
empirical data and present global, regional, and national estimates of risk and number of deaths 
(with uncertainty ranges) for the day of birth, first week of life, and the late neonatal period for 
186 countries in 2013.   
 
3.2 Methods 
3.2.1 Data inputs 
First, we searched PubMed, Web of Knowledge, Medline, and Google Scholar with various 
search terms that covered timing of deaths in the neonatal period.  The search terms included 
“neonatal” or “newborn” and one or more of “day of birth”, “day 0”, “day 1”, “deaths”, 
“mortality”, “risk of death by day”, “daily risk”, “survival”, “survival curves”, “day 0 risk”, “day 1 
risk”, “temporal distribution”, “day of death”, and “time of death”.  We found no systematic 
national estimates of daily risk of death during the neonatal period. 
 
We then reviewed data on the timing of neonatal deaths from two main sources.  First, we 
obtained the most recent publicly available VR data from the World Health Organization (WHO) 
for the years 2006 to 2010.  These VR data are reported by countries to the WHO and thus may 
not reflect the full extent of relevant data recorded in a country’s CRVS system, especially for 
countries with multiple registration systems.  For Canada, we used data from Statistics Canada 
rather than WHO due to the availability of more recent data.  Second, we acquired DHS data 
from 1986-2011 using the STATcompiler tool from MEASURE DHS 
(http://www.measuredhs.com/).  Finally, to derive estimates of the absolute risk of death and 
numbers of deaths by time period, we applied our results to the 2013 estimates of neonatal 
deaths and live births produced by the UN Inter-agency Group for Mortality Estimation (UN-
IGME) [110].  An overview of the data inputs, exclusion criteria, and estimation techniques is 
shown in Figure 3.1. 
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Figure 3.1: Strategy for neonatal day-of-death analysis 
 
 
3.2.2 Data inclusion and exclusion criteria 
We used the reported VR data to generate national risk estimates if the country had 1) VR 
coverage of adult mortality of 80% [126] or higher and 2) the VR data available classified 
neonatal deaths into the following time periods: day 0, days 1-6, and days 7-27. We used these 
three categories because the VR dataset from the WHO did not provide a more detailed 
breakdown of neonatal deaths by day.  For the 50 countries with more than 50 neonatal deaths 
in the most recent year with available data, we used the data from the most recent year.  For 
seven countries with fewer than 50 neonatal deaths in the most recent year with data available, 
we combined deaths from the previous two to five years to avoid instability due to small 
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numbers, stopping as soon as the total number of neonatal deaths was 50 or higher.  We 
excluded data from countries with ≤20% of deaths on day 0 (n=13) or no deaths on days 1-6 
(n=1) on the grounds that these proportions are implausibly low based on the data from all 
countries and thus likely indicate poor data quality (see section 3.4 for further details).  
 
We obtained DHS data on neonatal deaths and live births for 206 surveys in 79 countries.  While 
15 surveys had fewer than 50 neonatal deaths, we did not exclude these because we combined 
deaths across surveys in our mathematical model, as described below.  Similarly, we sought to 
account for misclassification of deaths between days 0 and 1 in these surveys through our model 
rather than discarding implausible data.   
 
Lists of included and excluded data are provided in Appendix A.1. 
 
3.2.3 Model fitting 
All statistical analyses were undertaken using Stata version 12 (www.stata.com).  We postulated 
a model for the risk of neonatal death by day of life.  We then applied this model to the DHS 
data to estimate the proportion of neonatal deaths occurring on each day of the neonatal period 
for countries without adequate VR data.  Our model assumes that the probability of dying on 
day t conditional on surviving until that day declines exponentially.  In addition, the model allows 
the probability of dying on day 0 to differ from this pattern.  Mathematically, this can be 
expressed as: 
 
ℎ𝑡 = {  
𝛼      𝑡 = 0
   𝛽𝛾𝑡−1      1 ≤ 𝑡 ≤ 27
                          (Eq. 3.1) 
 
where ht is the probability of dying on day t given survival until that day.  Given this model, the 
unconditional probability of dying on day t of the neonatal period, pt, is:  
 
𝑝𝑡 = {
𝛼 𝑡 = 0
(1 − 𝛼) ∗ 𝛽 𝑡 = 1
(1 − 𝛼) ∗ (𝛽𝛾𝑡−1)∏ (1 − 𝛽𝛾𝜏−2)𝑡2 𝑡 ≥ 2
           (Eq. 3.2) 
 
The probability of surviving the neonatal period, ps, is then given by (1 − 𝛼) ∗ ∏ (1 − 𝛽𝛾𝜏−1)271 .  
Thus, the probability of dying in the neonatal period is 1 − (1 − 𝛼) ∗ ∏ (1 − 𝛽𝛾𝜏−1)271 .  So the 
probability of dying on a given day conditional on dying in the neonatal period (i.e. the expected 
proportion of neonatal deaths on day t) is: 
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𝑚𝑡 = 
{
 
 
 
 
𝛼
1−(1−𝛼)∗∏ (1−𝛽𝛾𝜏−1)271
𝑡 = 0
(1−𝛼)∗𝛽
1−(1−𝛼)∗∏ (1−𝛽𝛾𝜏−1)271
𝑡 = 1
(1−𝛼)∗(𝛽𝛾𝑡−1)∏ (1−𝛽𝛾𝜏−2)𝑡2
1−(1−𝛼)∗∏ (1−𝛽𝛾𝜏−1)271
   𝑡 ≥ 2
       (Eq. 3.3) 
 
Based on the multinomial distribution, we can write an expression for the likelihood of 
observing n0, …, n27 deaths in the neonatal period (days 0 to 27) given N live births and the 
proportion surviving the neonatal period pS as: 
 
𝑝0
𝑛0 ∗ 𝑝1
𝑛1 ∗ 𝑝2
𝑛2 …𝑝27
𝑛27 ∗ 𝑝𝑆
𝑁−∑ 𝑛𝑡
27
0 = 𝑝𝑆
𝑁−∑ 𝑛𝑡
27
0 ∗ ∏ 𝑝𝑡
𝑛𝑡27
0       (Eq. 3.4) 
 
To deal with potential misclassification between days 0 and 1 in the DHS data, we combined 
observed deaths on days 0 and 1 and re-wrote the likelihood as: 
 
(𝑝0 + 𝑝1)
𝑛0+𝑛1 ∗ 𝑝2
𝑛2 …𝑝27
𝑛27 ∗ 𝑝𝑆
𝑁−∑ 𝑛𝑡
27
0 = 𝑝𝑆
𝑁−∑ 𝑛𝑡
27
0 ∗ (𝑝0 + 𝑝1)
𝑛0+𝑛1 ∗ ∏ 𝑝𝑡
𝑛𝑡27
2          
(Eq. 3.5) 
 
Maximum likelihood estimation 
We used maximum likelihood to estimate the parameters α, β, and γ.  For this, we used 
maximum likelihood estimation implemented by the built-in Stata command “ml”.  To do this, 
we first wrote a log-likelihood function based on the mathematical function described in 
Equation 3.5 and assumed that the number of deaths observed on each day together with the 
number of survivors follows the multinomial probability distribution.  The log-likelihood 
function L(α,β,γ) is built from the following functions Lt(α,β,γ) which indicate the log-likelihood 
of observing nt deaths on day t with ns survivors of the neonatal period: 
      𝐿𝑡(𝛼, 𝛽, 𝛾) =
{
ln(𝛼 + (1 − 𝛼) ∗ 𝛽) ∗ 𝑛𝑡           𝑡 = 0.5
          ln((1 − 𝛼) ∗ (𝛽𝛾𝑡−1)∏ 1 − 𝛽𝛾𝜏−2)𝑡2 ) ∗ 𝑛𝑡           2 ≤ 𝑡 ≤ 27
ln ((1 − 𝛼) ∗ ∏ (1 − 𝛽𝛾𝜏−1)271 ) ∗ 𝑛𝑠  contribution of survivors
          (Eq. 3.6) 
 
where t is the day of death (0.5 represents days 0 and 1 combined) and the arguments for the 
maximum likelihood equation are α, β, and γ.  This is obtained by taking the log of the probability 
of observing nt deaths of day t when the probability of dying on day t is pt, where pt is a function 
of α, β, and γ.  Finally, the overall log-likelihood L(α, β, γ) is obtained by summing the log 
likelihoods for the different days: L(α, β, γ) = ∑ 𝐿𝑡𝑡 (α, β, γ). 
  
 
43 
The input dataset contained information on the number of deaths by day (with deaths on days 
0 and 1 combined as deaths on “day 0.5”).  We then used the “ml model lf” and “ml maximize” 
commands in Stata, which maximize the equation L(a,b) above using Stata’s default method, 
which is a modified Newton-Raphson algorithm. 
 
Daily proportions of neonatal deaths 
This model allows us to estimate a “corrected” proportion of neonatal deaths on day 0 under 
the assumption encoded in the model that the probability of dying on subsequent days declines 
exponentially.  Using these estimates, we calculated the expected proportion of neonatal 
deaths on a given day (Equation 3.3) and during various time periods, including days 0-6, days 
1-6, and days 7-27.  We initially applied the model to the aggregated DHS data.  We also fitted 
the model to subsets of the data categorized by neonatal mortality rate (NMR), national income 
category, geographic region, and study period to assess whether there was any evidence that 
the proportional distribution of deaths varied by any of these factors.  
 
We compared this model to a simpler 2-parameter model, which assumes that =1, using a 
likelihood ratio test (see section 3.4).  Because we wished to correct for misreporting between 
day 0 and 1, we needed to use a model in which the relationship between day 1 deaths and 
deaths on subsequent days was constrained.  Otherwise, the proportions of deaths occurring 
on each of days 0 and 1 are not identifiable with the likelihood in Equation 3.5.   
 
3.2.4 Estimation of daily neonatal mortality risk and numbers by country 
We generated estimates for 186 countries with 1,000 or more live births in 2013.  These 
countries account for an estimated 2.76 million neonatal deaths, greater than 99% of the global 
total. 
 
For the 57 countries with adequate VR data, we calculated the proportion of deaths on day 0 
and days 0-6 directly from the data to produce the final risk estimates.  For the remaining 129 
countries, we used the day 0 and days 0-6 proportions estimated using our model.  We 
calculated the number of deaths by applying the day 0 and days 0-6 proportions to the UN 2013 
neonatal death estimates.  We then derived the day 0, days 0-6, and days 7-27 risks by dividing 
these time period-specific numbers of deaths by the 2013 live births in the country.   
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3.2.5 Uncertainty estimation 
We developed uncertainty estimates for the modelled proportions by drawing 1,000 bootstrap 
samples with replacement from the 206 DHS in the input dataset.  We then re-ran the analysis 
to estimate the model parameters and used these to estimate the proportion of deaths by day 
for each of these 1,000 datasets.  Finally, we took the 2.5th and 97.5th centiles from the resulting 
distributions of these proportions for our uncertainty range.  These uncertainty estimates do 
not include uncertainty in total neonatal deaths.  For countries where we used VR data, we 
calculated the uncertainty for the proportions by assuming a Poisson distribution for the 
number of deaths during those periods (i.e. the standard error is equal to the square root of the 
reported number of deaths).  
 
3.3 Main results 
3.3.1 Description of data inputs 
The input dataset, after applying the exclusion criteria, consisted of data from 57 VR countries 
(median year: 2010) with 122,757 neonatal deaths and 206 DHS (median year: 1999) with 
50,396 neonatal deaths in the 5 years prior to the survey for 79 countries.  Nine countries had 
both VR and DHS data.  Thus, the final input dataset contained information from 127 countries 
and included 173,153 neonatal deaths (Figure 3.1).  For VR countries, the median proportions 
of neonatal deaths occurring in different periods were as follows: 0.35 (interquartile range 
[IQR]: 0.29-0.46) on day 0; 0.36 (IQR: 0.32-0.42) on days 1-6; and 0.25 (IQR: 0.22-0.30) on days 
7-27 (Figure 3.2).  The median proportion of deaths in the first week (i.e. days 0-6) was 0.75 
(IQR: 0.70-0.78).  The proportion of deaths on day 0 was relatively variable compared to the 
proportions for the other two time periods (Figure 3.2).  The three countries with the highest 
proportions (with 95% confidence intervals) of deaths on day 0 were Switzerland (0.71 ± 0.04), 
Canada (0.69 ± 0.02), and Austria (0.62 ± 0.07), and the three with the lowest proportions were 
the Czech Republic (0.23 ± 0.06), Belize (0.24 ± 0.10), and Macedonia (0.25 ± 0.07).   
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Figure 3.2: Proportion of neonatal deaths for VR countries on days 0, 1-6, and 7-27 
 
Note: VR = vital registration 
 
Of the 79 countries with DHS, 29 countries had one survey while 50 had between two and six 
surveys each.  Across all of the surveys, the median proportion of reported deaths was 0.26 
(IQR: 0.19-0.32) on day 0, 0.19 (IQR: 0.15-0.24) on day 1, 0.46 (IQR: 0.40-0.52) on days 1-6, and 
0.72 (IQR: 0.68-0.78) for the first week (Figure 3.3a).  The median proportion for days 0 and 1 
combined was 0.46 (IQR: 0.39-0.52).  Sixty-six DHS (32%) had higher proportions of deaths on 
day 1 than day 0, suggesting substantial misclassification of deaths between these days.  For 
surveys with higher day 0 than day 1 proportions, the median proportions of reported deaths 
were 0.29 (IQR: 0.25-0.35) on day 0, 0.16 (IQR: 0.13-0.21) on day 1, 0.43 (IQR: 0.39-0.48) for 
days 1-6, and 0.73 (IQR: 0.69-0.78) for the first week (Figure 3.3b).   
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Figure 3.3: Proportion of neonatal deaths for DHS on days 0, 1-6, and 7-27 
a) all 206 DHS 
 
 
b) 140 DHS that reported more deaths on day 0 than day 1 
 
Note: DHS = Demographic and Health Surveys 
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Figure 3.4 shows a plot of the reported proportion of deaths on day 0 against NMR for VR 
countries and DHS.  The DHS data are likely to include day 0/1 misclassification, ranging from 
severe to mild or none depending on the survey.  The only discernible pattern is that several 
countries with very low NMR (<5), which are all countries with high-quality VR data, have higher 
reported day 0 proportions.   
 
Figure 3.4: Proportion of day 0 deaths reported in VR and DHS by neonatal mortality rate 
 
Note: severe underreporting of day 0 deaths or misrecording between day 0 and 1 in DHS (fewer day 0 
than day 1 deaths) is noted by hollow circles; VR = vital registration; DHS = Demographic and Health 
Surveys. 
 
 
3.3.2 Model fitting 
We summed the reported births and neonatal deaths by day across the 206 DHS.  The 3-
parameter model fitted the observed DHS data better than the 2-parameter model (p<0.0001).  
Visual inspection of the modelled distribution of deaths by day compared to the observed 
distribution in the DHS data also indicated a good fit (Figure 3.5), with the poorest fit occurring 
on days 7, 14, and 15.  This likely reflects day-of-death heaping at 1 and 2 weeks of age (Figure 
3.6).  Based on these results, we used the 3-parameter model in the remainder of this work.  
The estimated parameter values (from Equation 3.1) were α=0.012 (uncertainty range [UR]: 
0.010-0.014), β=0.003 (UR: 0.002-0.003), and γ=0.872 (UR: 0.868-0.875).      
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Figure 3.5: Observed and modelled cumulative mortality in the neonatal period (conditional on 
dying in the neonatal period) 
 
Note: the combined proportion of day 0 and day 1 deaths is about 0.45 in both the observed data and 
modelled estimates; DHS = Demographic and Health Surveys. 
 
Figure 3.6: Observed and modelled proportions of deaths in the neonatal period 
 
Note: red bars show 95% confidence intervals; DHS = Demographic and Health Surveys.  
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The modelled proportions for deaths during the neonatal period were 0.36 (UR: 0.34-0.38) on 
day 0 and 0.73 (UR: 0.72-0.74) for days 0-6.  These estimates are very similar to the median 
proportions observed in the VR data: 0.35 for day 0 and 0.75 for days 0-6.  The probability of 
dying on a given day and the cumulative probability of surviving that day conditional on 1) 
survival up to that day and 2) dying during the neonatal period, is given in Table 3.1. 
 
Table 3.1: Probability of dying and cumulative probability of surviving by day in the neonatal 
period 
Day Probability of 
dying on the 
given day 
Cumulative 
probability 
of surviving 
Day Probability of 
dying on the 
given day 
Cumulative 
probability 
of surviving 
0 0.36 0.64 14 0.01 0.08 
1 0.08 0.55 15 0.01 0.07 
2 0.07 0.48 16 0.01 0.06 
3 0.06 0.42 17 0.01 0.05 
4 0.06 0.36 18 0.01 0.04 
5 0.05 0.31 19 0.01 0.03 
6 0.04 0.27 20 0.01 0.02 
7 0.04 0.23 21 0.01 0.02 
8 0.03 0.20 22 0.00 0.01 
9 0.03 0.17 23 0.00 0.01 
10 0.02 0.15 24 0.00 0.01 
11 0.02 0.13 25 0.00 0.00 
12 0.02 0.11 26 0.00 0.00 
13 0.02 0.09 27 0.00 0.00 
 
If we do not correct for day 0 and 1 misclassification (i.e. by running our model with day 0 and 
1 separate), the estimated proportions for the DHS data are 0.26 on day 0 (UR: 0.24-0.27) and 
0.73 (UR: 0.72-0.74) for days 0-6.   
 
Analysis across subsets of data 
We also summed births and neonatal deaths by day across subsets of surveys based on NMR 
level, income level, region, and time period and fitted the model to these data (see Appendix 
A.2 for a list of countries by region and income category).  The estimated day 0 proportion did 
not vary importantly by NMR level or income category (Table 3.2, Figures 3.7a-b).  There does 
appear to be some variation between regions and by survey period (Table 3.2, Figures 3.7c-d).  
We combined data from the Western Asia, Northern Africa, and Caucasus/Central Asia MDG 
regions to form a “mid-east” region for this DHS analysis to avoid small numbers and because 
of the similarities in the data and the health system context for these regions.  Among the 28 
datasets from this combined region, 75% (n=21) had fewer day 0 deaths than day 1 deaths, 
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suggesting widespread undercounting of day 0 deaths and/or misreporting of day 0 deaths as 
day 1 in surveys from this region.  In comparison, 26% of surveys from Latin America and the 
Caribbean, the region with the next highest percentage of such surveys, had more day 1 than 
day 0 deaths.  The estimated day 0 proportions for the other regions do not show much 
variation. If the “mid-east” region is excluded from the analysis, the overall results remain 
largely unchanged with 0.36 (UR: 0.35-0.38) for the day 0 proportion and 0.73 (UR: 0.72-0.74) 
for the week 1 proportion.  For survey period, earlier surveys had, on average, lower proportions 
of deaths in the first few days than later surveys.  If only surveys from 2000 or later are included 
in the analysis, the proportions are 0.39 (UR: 0.37-0.41) for day 0 and 0.75 (UR: 0.73-0.76) for 
week 1. 
 
Table 3.2: Estimated proportions of day 0 and week 1 deaths (with uncertainty ranges) by 
neonatal mortality rate, income, region, and survey period  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Day 0 Week 1 
Neonatal 
mortality 
rate 
5 ≤ NMR < 15 0.34 (0.31-0.38) 0.72 (0.71-0.74) 
15 ≤ NMR < 30 0.37 (0.35-0.39) 0.73 (0.71-0.74) 
NMR ≥ 30 0.36 (0.33-0.38) 0.74 (0.72-0.76) 
Income 
Low 0.36 (0.34-0.39) 0.73 (0.72-0.74) 
Lower middle 0.36 (0.33-0.38) 0.73 (0.72-0.74) 
Upper middle 0.38 (0.35-0.41) 0.73 (0.70-0.75) 
Region 
East Asia & Southeast Asia 0.39 (0.33-0.43) 0.74 (0.72-0.78) 
Southern Asia 0.36 (0.33-0.39) 0.73 (0.71-0.75) 
Sub-Saharan Africa 0.37 (0.34-0.39) 0.74 (0.72-0.75) 
Latin America/Caribbean 0.39 (0.36-0.42) 0.72 (0.70-0.74) 
North Africa/West & Central Asia 0.28 (0.25-0.32) 0.70 (0.68-0.71) 
Period 
1986-1995 0.32 (0.30-0.35) 0.71 (0.69-0.73) 
1996-2005 0.37 (0.35-0.39) 0.73 (0.72-0.75) 
2006-2011 0.41 (0.37-0.43) 0.76 (0.73-0.78) 
Overall  0.36 (0.34-0.38) 0.73 (0.72-0.74) 
  
 
51 
Figure 3.7: Observed and modelled cumulative mortality in the neonatal period (conditional on 
dying in the neonatal period) by neonatal mortality rate, income, region, and survey period for 
DHS 
Note: These include data from 206 DHS (50,396 neonatal deaths) from 1986-2011. 
 
a) Neonatal mortality rate  
 
b) Income category 
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c) Geographic region 
 
d) Survey period 
 
 
In theory, our model requires the total number of live births to be known as well as neonatal 
deaths per day.  However, we found that varying the number of live births while keeping the 
number of deaths fixed across wide ranges of NMR (from 1 to 1,000) resulted in negligible 
changes (<0.5 percentage points) to the estimated day 0 and week 1 proportions.  Thus, in 
practice, the results do not appear to be sensitive to the number of live births.   
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3.3.3 Risk and numbers by neonatal period 
An estimated 2.76 million neonatal deaths occurred in the 186 countries included in this analysis 
[110]. Of these, an estimated 1.00 million (36.3%) (UR: 0.94 million – 1.05 million) occurred on 
day 0 and 2.02 million (73.2%) (UR: 1.99 million – 2.05 million) occurred within the first week 
(including on day 0).  
 
Regional estimates are provided in Table 3.3.  Sub-Saharan Africa had the highest risk (deaths 
per 1,000 live births), with 11.2 (UR: 10.6-11.8) on day 0 and 21.5 (UR: 21.2-21.8) in week 1.  
Southern Asia had a lower risk but a larger number of births, and thus the largest number of 
deaths, with 392,300 (UR: 369,100-412,500) on day 0 and 793,300 (UR: 781,500-803,300) during 
week 1.   
 
Table 3.3: Risk and number of deaths (with uncertainty ranges) by MDG region for day 0, week 
1, and weeks 2-4 in 2013 
 Day 0 Week 1 Weeks 2-4 
 Risk1,2 Deaths2 
(1000s) 
Risk 
 
Deaths 
(1000s) 
Risk Deaths 
(1000s) 
Sub-Saharan 
Africa 
11.2 
(10.6-11.8) 
385.2 
(362.6-404.9) 
22.7 
(22.4-23.0) 
779.1 
(767.5-788.9) 
8.4 
(8.1-8.7) 
286.2 
(276.6-297.8) 
Southern Asia 
10.6 
(10.0-11.2) 
392.3 
(369.1-412.5) 
21.5 
(21.2-21.8) 
793.3 
(781.5-803.3) 
7.9 
(7.7-8.2) 
292.0 
(282.2-303.9) 
Oceania 
7.7 
(7.3-8.1) 
2.0 
(1.9-2.1) 
15.6 
(15.4-15.8) 
4.1 
(4.1-4.2) 
5.7 
(5.6-6.0) 
1.5 
(1.5-1.6) 
Caucasus / 
Central Asia 
5.4 
(5.1-5.7) 
9.5 
(8.9-10.0) 
11.0 
(10.8-11.2) 
19.2 
(18.8-19.5) 
3.8 
(3.6-3.9) 
6.6 
(6.3-6.9) 
South-eastern 
Asia 
5.2 
(4.9-5.5) 
58.0 
(54.5-60.9) 
10.5 
(10.4-10.6) 
117.2 
(115.5-118.7) 
3.9 
(3.7-4.0) 
43.1 
(41.7-44.9) 
Western Asia 
4.9 
(4.6-5.2) 
24.0 
(22.6-25.3) 
10.0 
(9.8-10.1) 
48.6 
(47.9-49.3) 
3.7 
(3.6-3.8) 
18.0 
(17.3-18.7) 
Northern 
Africa 
4.8 
(4.5-5.1) 
19.3 
(18.1-20.3) 
9.7 
(9.6-9.8) 
39.0 
(38.4-39.5) 
3.6 
(3.5-3.7) 
14.3 
(13.9-14.9) 
Latin America 
/ Caribbean 
3.2 
(3.1-3.4) 
35.4 
(33.8-36.9) 
6.8 
(6.7-7.0) 
74.3 
(72.7-75.9) 
2.4 
(2.3-2.5) 
26.2 
(25.1-27.3) 
Eastern Asia 
2.8 
(2.6-2.9) 
54.3 
(51.1-57.1) 
5.6 
(5.5-5.7) 
109.8 
(108.2-111.2) 
2.1 
(2.0-2.2) 
40.4 
(39.1-42.1) 
Developed 
regions 
1.6 
(1.5-1.7) 
22.9 
(21.6-24.2) 
2.6 
(2.5-2.7) 
36.6 
(35.2-38.1) 
0.8 
(0.7-0.9) 
11.5 
(10.6-12.4) 
World 
7.3 
(6.9-7.6) 
1002.7  
(944.2-
1054.1) 
14.7 
(14.4-14.9) 
2021.3  
(1989.7-
2048.5) 
5.4 
(5.2-5.6) 
739.8 
(714.3-770.6) 
1 risk is deaths per 1,000 live births; 2 uncertainty ranges do not include uncertainty in total neonatal 
deaths 
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In the USA and Canada, the risk of death on day 0 was 2.4 and 2.3 per 1,000 live births, 
respectively, whereas in several Northern European countries (e.g. Norway, Sweden, and 
Finland), the risk was 0.6 or lower.  Figure 3.8 shows the risk on day 0 and the overall neonatal 
period, alongside the preterm birth rate, for 31 industrialized countries with high-quality VR. 
 
Figure 3.8: Risk of death on day 0 and during the neonatal period in 2013 (alongside preterm 
birth rates) for 31 countries with high-quality VR data 
 
Note: the preterm birth rates are for 2010 from Blencowe et al [121]. 
 
The risk of death (per 1,000 live births) ranged widely for the 186 countries, from 1 to 47 for the 
full neonatal period, 1 to 34 for the first week, and <1 to 17 for day 0.  Nine of the ten countries 
with the highest risk were in Sub-Saharan Africa.  The risk of death for these ten countries 
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ranged from 14 to 17 on day 0 and 29 to 34 in the first week (Table 3.4).  Full details of country-
specific estimates are in the web appendix of the published paper [107].   
 
Table 3.4:  Risk of death per 1,000 live births (with uncertainty ranges) within the neonatal 
period for the ten countries with highest risks in 2013 
Country Day 0 Week 1 Weeks 2-4 
Angola 17 (16-18)1 34 (34-34) 13 (12-13) 
Somalia 17 (16-18) 34 (33-34) 12 (12-13) 
Sierra Leone 16 (15-17) 32 (32-33) 12 (12-12) 
Guinea-Bissau 16 (15-17) 32 (32-33) 12 (11-12) 
Lesotho 16 (15-17) 32 (31-32) 12 (11-12) 
Central African Republic 16 (15-16) 31 (31-32) 12 (11-12) 
Pakistan 15 (14-16) 31 (30-31) 11 (11-12) 
Mali 15 (14-15) 29 (29-30) 11 (10-11) 
Chad 14 (14-15) 29 (29-29) 11 (10-11) 
Zimbabwe 14 (13-15) 29 (28-29) 11 (10-11) 
1 Uncertainty estimates do not include uncertainty in total neonatal deaths 
 
The number of deaths during each time period also varied widely.  The ten countries with the 
largest numbers of deaths are dominated by populous countries, but are also affected by the 
level of risk.  The number of deaths in these ten countries ranged from 14,300 to 270,100 on 
day 0 and 28,900 to 546,300 in the first week (Table 3.5).   
 
Table 3.5: Number of deaths in the thousands (with uncertainty ranges) within the neonatal 
period for the ten countries with the most neonatal deaths in 2013 
Country Day 0 Week 1 Weeks 2-4 
India 270.1 (254.1-284.0)1 546.3 (538.2-553.1) 201.1 (194.3-209.3) 
Nigeria 94.4 (88.8-99.3) 191.0 (188.1-193.4) 70.3 (67.9-73.2) 
Pakistan 70.0 (65.9-73.6) 141.6 (139.5-143.3) 52.1 (50.4-54.2) 
China 51.8 (48.7-54.4) 104.7 (103.1-106.0) 38.5 (37.2-40.1) 
DRC2 37.8 (35.6-39.7) 76.4 (75.3-77.4) 28.1 (27.2-29.3) 
Ethiopia 30.5 (28.7-32.1) 61.7 (60.8-62.4) 22.7 (21.9-23.6) 
Bangladesh 27.7 (26.1-29.2) 56.1 (55.2-56.8) 20.6 (19.9-21.5) 
Indonesia 23.8 (22.4-25.0) 48.1 (47.4-48.7) 17.7 (17.1-18.4) 
Angola 15.4 (14.5-16.2) 31.1 (30.7-31.5) 11.5 (11.1-11.9) 
Kenya 14.3 (13.4-15.0) 28.9 (28.5-29.3) 10.6 (10.3-11.1) 
Total3 649.7 (611.3-683.2) 1314.0 (1294.5-1330.5) 483.7 (467.5-503.4) 
1 Uncertainty estimates do not include uncertainty in total neonatal deaths; 2 DRC = Democratic 
Republic of the Congo; 3 the total is based on rounded estimates. 
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3.4 Sensitivity and validation analyses 
In this section, I describe sensitivity and validation exercises we performed.  
3.4.1 Inclusion of excluded vital registration data 
As noted in section 3.2, the decision to exclude VR data for countries with implausibly low 
proportions of deaths on day 0 (≤20% of neonatal deaths) or days 1-6 (≤10% of neonatal deaths) 
was based on evaluating the data from all countries.  Using these criteria, thirteen countries had 
≤20% of neonatal deaths on day 0 and one country had 0% deaths on days 1-6.  Such low 
proportions are likely an indicator of poor data quality due to issues such as underreporting, 
misclassification between live births and stillbirths, and/or misrecording of deaths between 
days.  Therefore, we used the modelled proportions rather than actual VR data for the final 
estimates for these countries.  Since the VR data were not used in the model themselves, these 
exclusion criteria only affect the data for the individual countries rather than the overall model.  
In Table 3.6 we have included the day 0 and week 1 proportions from the actual VR data for 
these countries for comparison.   
 
Table 3.6: Vital registration data for countries with implausibly low early neonatal death 
proportions     
Country Year Day 0 
proportion 
Days 1-6 
proportion 
Week 1 
proportion 
Azerbaijan 2007 0.02 0.84 0.86 
Bahamas 2008 0 0.64 0.64 
Barbados 2008 0.09 0.54 0.63 
Cuba 2010 0.16 0.51 0.67 
Fiji 2009 0 0.69 0.69 
Grenada 2010 0.05 0.77 0.82 
Guatemala 2008 0.12 0.52 0.63 
Latvia 2010 0.70 0 0.70 
Montenegro 2009 0.20 0.55 0.75 
Romania 2010 0.16 0.51 0.67 
Saint Lucia 2008 0.04 0.77 0.81 
Saint Vincent / 
Grenadines 
2010 0.02 0.77 0.78 
Sri Lanka 2006 0 0.75 0.75 
Suriname 2009 0.01 0.71 0.71 
 
Using the proportions above for these countries instead of applying our modelled proportions 
would result in 3,800 fewer day 0 deaths and 600 fewer week 1 deaths in total.  Note that these 
proportions, as stated above, were not used in the final estimates as we believed their values 
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were implausibly low, suggesting poor data quality (and potentially noisy data from the smaller 
countries).   
 
3.4.2 Validation exercises 
We conducted validation exercises, including out-of-sample validation and the addition of VR 
data to the model.  
 
Out-of-sample validation 
We performed out-of-sample validation to see how well our model predicted the observed DHS 
data.  Our model predicts a higher proportion of day 0 deaths than the observed because of our 
day 0 correction, and thus we do not expect very good “agreement” between the observed data 
and modelled estimates for day 0.  Therefore, we performed the validation for days 0-1 
(combined), 2-6, and 7-27.  We performed this out-of-sample validation using the jackknife 
approach.  For this, we left out one survey at a time (n=206) and re-estimated the α, β, and γ 
parameters using maximum likelihood with the remaining data points.  We then compared the 
modelled results for days 0-1, days 2-6, and days 7-27 to those observed in the DHS that was 
left out. 
 
Figure 3.9a shows the distribution of the differences in the predicted and observed proportions 
based on the out-of-sample validation exercise.  The median difference in predicted and 
observed proportions is as follows: 1) -1 percentage point for days 0-1 combined, 2) 1.4 
percentage points for days 2-6, and 3) -0.8 percentage points for days 7-27.  Dropping small 
surveys (i.e. those with <50 neonatal deaths) resulted in similar median differences but fewer 
“outliers” (Figure 3.9b).  None of the time periods had a 25th or 75th percentile difference 
between predicted and observed proportions greater than 7 percentage points.  The mean 
absolute differences between the predicted and observed proportions are 3.4 percentage 
points for days 0-1, 2.7 percentage points for days 2-6, and 3.1 percentage points for days 7-27.   
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Figure 3.9: Differences between predicted versus observed day 0-1, 2-6, and 7-27 values for 
out-of-sample validation 
a) all 206 DHS 
  
  
b) 191 surveys with ≥50 reported neonatal deaths 
 
 
 
 
 
 
 
 
 
 
 
 
Given that the observed proportions are themselves subject to sampling error, we also tested 
whether the predicted proportions lay inside or outside the 95% confidence intervals (CI) of the 
observed proportions.  We found that the predicted proportions falling outside of the 95% CIs 
for observed proportions were as follows: 1) 28 out of 206 studies (14%) for days 0-1; 2) 26 
(13%) for week 1; and 3) 26 (13%) for days 7-27.  Since underreporting of early neonatal deaths 
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would lead to lower observed proportions in the first days and week, we repeated this analysis 
after removing surveys with potentially severe underreporting (as discussed in section 3.4.1).  
After doing this, we found that the predicted proportions falling outside of the 95% CIs for 
observed proportions were as follows: 1) 12 out of 180 (7%) for days 0-1; 2) 12 (7%) for week 1; 
and 11 (6%) for days 7-27.   
 
These results suggest that for a high proportion of surveys there is good agreement between 
the observed and modelled results.  It is also important to note that the DHS are of varying 
quality, which may affect the comparison of observed and modelled results.   
 
Including vital registration data in the model 
We also performed an analysis in which we added contributions from the VR data to the 
likelihood function.  We ran two versions of this analysis, one with the USA included and one 
with it excluded.  The reason we excluded the USA is because it is an extreme outlier (95% 
percentile) for day 0 deaths (61%) while contributing far more deaths than any other 
country/survey.  The day 0 and week 1 proportions were as follows: 1) USA excluded – 0.36 (day 
0) and 0.75 (week 1); 2) USA included – 0.39 (day 0) and 0.75 (week 1).  These proportions, 
particularly when the USA is excluded, are quite similar to the results we found in our DHS-only 
analysis (day 0: 0.36 and week 1: 0.73).   
 
3.4.3 Alternative mathematical models 
To determine if simpler models performed as well as the 3-parameter model (Equation 3.1) we 
used, we conducted the additional analyses described here.  As noted in section 3.3, the 2-
parameter model fitted less well than the 3-parameter model, and we therefore rejected using 
this simpler model in our analysis.  
 
Two-parameter model 
In this model, which is a simplification of the 3-parameter model, we assumed that γ = 1.  
Therefore, the probability of dying on a day t > 0 equals the constant β.  The likelihood ratio test 
comparing this model to the 3-parameter model provided strong evidence that the 3-parameter 
model fitted the data better than the 2-parameter model (p<0.0001).   
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More complex models 
We were unable to test more complex models because high-quality daily day-of-death data for 
the neonatal period were unavailable.  While we did use high-quality VR data in our analysis, 
these data only contained three data points: day 0, days 1-6, and days 7-27 and these data could 
therefore not be used to test models with greater complexity than our 3-parameter model.   
 
3.4.4 Assumption of Poisson error for vital registration data 
In estimating uncertainty intervals for countries with high-quality VR data, we assumed a 
Poisson distribution for the number of deaths during the neonatal time periods.  Others have 
found that, at least for older ages, the Poisson distribution may underestimate the actual 
variance and thus a negative binomial distribution may be more appropriate [127].  
 
In theory, we should be able to assess the variance in our dataset to determine if our Poisson 
assumption is appropriate.  This is difficult to do with the data we have since we effectively have 
one dataset per country instead of multiple samples of mortality data for a country.  We do, 
however, have VR data from previous years.  We tested the Poisson distribution assumption for 
each VR country using this data (for years 2000 and later) under the assumption that there was 
no real change in the day of death distribution over time.  We found that there was no evidence 
against the Poisson distribution for 52 of the 57 countries.  For the other five countries, it is 
difficult to gauge whether the data are truly overdispersed or if our assumption about the lack 
of time trend is incorrect.  However, since variation in the day of death distribution over time 
should appear as overdispersion, the lack of evidence against the Poisson distribution for 52 of 
57 countries suggests that our assumption that the neonatal day of death distribution data are 
Poisson distributed is reasonable.   
 
3.5 Identifying data quality issues in Demographic and Health Surveys 
In our paper, we identified some data quality issues in DHS that may affect the interpretation 
around timing of neonatal deaths.  Here, we suggest analytical checks for gauging whether a 
given DHS may have misrecording of deaths between days 0 and 1 and/or underreporting of 
very early neonatal deaths.   
 
3.5.1 Misrecording of day 0 and day 1 deaths 
As discussed earlier, a number of DHS appear to have misrecording of deaths between days 0 
and 1.  While the most severe cases are identifiable through having more day 1 deaths than day 
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0 deaths, other surveys may have milder misrecording.  Based on the analysis in which we 
sought to correct for this misrecording, we estimated that, on average, 80% of day 0 + day 1 
deaths occur on day 0.  Based on this ratio, the following equation can be used to determine if 
a DHS may have substantial misrecording issues: 
 
0.8(𝑑0 + 𝑑1) − 𝑑0 > 1.2√𝑑0 + 𝑑1                     (Eq. 3.7) 
 
where d0 is the number of deaths on day 0 and d1 is the number of deaths on day 1.  If Equation 
3.7 holds for a given dataset, this suggests that some day 0 deaths have been misclassified as 
having occurred on day 1.  We derived Equation 3.7 as follows: 1) the left side of the equation 
is the difference between the expected day 0 deaths (out of day 0 + day 1 deaths) and the 
observed day 0 deaths, and 2) the right side is 3 standard deviations for the number of day 0 
deaths (i.e. 3*sqrt(0.8*0.2)*sqrt(d0 + d1)), which yields 1.2*sqrt(d0+d1).  We chose to use 3 
standard deviations to account for real variation in the d0:d1 ratio.  If the true ratio of d0:d1 
deaths is 0.8:0.2, we would only expect 5 surveys in 1,000 to breach this cut-off in the absence 
of misclassification.   
  
When this equation was applied to the surveys in our analysis, 74% (152/206) of surveys showed 
some evidence of misclassification.   
 
3.5.2 Underreporting of very early neonatal deaths 
If there is underreporting of very early neonatal deaths, we expect that the proportion of day 0 
and day 1 deaths (summed together because we are assuming misrecording between those 
days may exist) will be low.  Based on the analysis in our paper, we found that, on average, 45% 
of neonatal deaths occurred on days 0 and 1.  Using a similar approach to that for Equation 3.7, 
the following equation can be used to determine if a DHS may have underreporting of very early 
neonatal deaths: 
 
0.45𝑑 − (𝑑0 + 𝑑1) > 1.5√𝑑                     (Eq. 3.8) 
 
where d0 is the number of deaths on day 0, d1 is the number of deaths on day 1, and d is the 
sum of deaths across all 28 days.  If Equation 3.8 holds for a given dataset, then this suggests 
evidence of underreporting of very early neonatal deaths.  Specifically, it means that this 
distribution of deaths would arise by chance only 0.5% of the time in the absence of 
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underreporting.  We derived Equation 3.8 (using a similar approach to Equation 3.7) as follows: 
1) the left side of the equation is the difference between the expected day 0+1 deaths (out of 
all neonatal deaths) and the observed day 0+1 deaths, and 2) the right side is 3 standard 
deviations for the number of day 0+1 deaths (i.e. 3*sqrt(0.45*0.55)*sqrt(d)) where d is the # of 
neonatal deaths.  This yields 1.5*sqrt(d) on the right side.  We chose to use 3 standard deviations 
to account for real variation in the (d0+d1):d ratio.  Underreporting of very early neonatal deaths 
is a serious issue, as it may result in an underestimate of the neonatal mortality rate.   
 
When this equation was applied to the surveys in our analysis, 13% (26/206) surveys showed 
some evidence of underreporting of very early neonatal deaths.  Of these surveys, 85% (22/26) 
also showed some evidence of misclassification between day 0 and day 1 deaths (section 3.5.1). 
 
3.6 Discussion 
We estimated the risk of dying and number of deaths for the day of birth, first week of life, and 
the late neonatal period for 186 countries in 2013.  Along with our preliminary results [12], to 
our knowledge this was the first systematic multi-country analysis of the daily risk of neonatal 
death around the world. Of the estimated 2.76 million neonatal deaths worldwide, 
approximately 36.3% of deaths occurred on the day of birth and 73.2% occurred within the first 
week.  Hence, more than one million babies die on their day of birth, in addition to 1.2 million 
intrapartum stillbirths estimated to occur each year.  This highlights the fact that the hours just 
before birth and the first few days of life are the riskiest in the human lifespan, a period which 
also carries an elevated risk for the mother.  
 
For countries without high-quality VR data, we estimated the proportional distribution of 
neonatal deaths by day by aggregating DHS data from countries with a range of NMRs.  The 
parameter estimates we obtained (for , , ) thus represent “average” values of these 
parameters, which we used to estimate the average distribution of deaths by day.  We then 
applied this average distribution to all countries without high-quality VR data.  We examined 
whether it was appropriate to apply the same average distribution to countries with different 
NMRs by fitting the model to subsets of the data defined by NMR level.  The proportion of 
deaths on day 0 appears remarkably consistent across countries with different NMR (and 
income) levels (Table 3.2, Figure 3.4, Figures 3.7a-b).  The proportion of day 0 deaths showed 
some regional variation, but this may reflect underreporting or misclassification of day 0 deaths.  
The proportion of day 0 deaths varied slightly with time period of the survey, with evidence of 
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earlier surveys having a lower proportion of day 0 deaths than later surveys.  However, we chose 
to include all survey years in our model because it is not clear whether this is a real change in 
proportion over time.  A 2008 study concluded that in a number of countries, enumeration of 
child deaths was poorer in the more recent surveys compared to earlier ones for the same 
country [128]. Additionally, several countries with multiple surveys have wide fluctuations in 
their proportion of deaths on day 0, which are not consistently in an upward direction.  Since 
the day 0 proportion is slightly higher when restricting the analysis to surveys from 2000 or later, 
we chose a conservative approach to estimating day 0 proportions. 
 
We noted variation in the proportion of day 0 deaths for some very low mortality countries 
(NMR <5 per 1,000) (Figure 3.4).  We might expect that countries with comprehensive neonatal 
intensive care would have a higher proportion of neonatal deaths on day 0 and the first week 
since many late neonatal deaths – which are classically due to infections – should have already 
been prevented [129, 130]. However, one effect of neonatal intensive care is also to shift first 
day deaths to later days, for example through ventilation of very preterm babies who die later 
from complications like intracranial haemorrhage or infection.  Thus, while the overall risk is 
lower, the proportion may remain similar due to some deaths shifting to later days or even 
beyond the neonatal period.   
 
While there is a greater than 30-fold difference in risk of death on day 0 between the poorest 
and richest countries, there is also, surprisingly, an almost 10-fold difference in day 0 risk across 
the richest countries.  Given the very high quality of data collection and intensive care in these 
countries, it is likely that this variation is real and not an artefact of underreporting.  The much 
higher preterm birth rate in North America may be a contributor, especially in the USA, where 
12%, or over half a million, of all births are preterm each year (Figure 3.8) [121]. 
 
The exponential function we used as our model fitted the DHS data well.  We applied the 
modelled estimates to countries with no day-of-death data, and also to those with DHS because 
of the substantial day 0/day 1 misclassification biases evident in some individual DHS.  One-third 
of DHS reported more deaths on day 1 than day 0, which is biologically implausible.  In fact, 
when comparing countries that had both VR and DHS data (with 50+ neonatal deaths), no DHS 
with more day 1 than day 0 deaths were supported by the VR data in that country.  Others are 
likely to have misclassification that is less obvious (i.e. more day 0 than day 1 deaths, but with 
some misrecorded as day 1).  We tried to correct for this using our mathematical model on the 
combined surveys.  However, we did not account for misclassification between stillbirths and 
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early neonatal deaths, which is another well recognized issue in DHS [131].  If neonatal deaths 
in the first minutes of life are recorded as stillbirths (which is the most common direction of 
misclassification), very early neonatal deaths will be undercounted, and we would expect the 
proportion of deaths during week 1 to be lower than the average regardless of day 0/day 1 
misclassification.  Nineteen of the 206 DHS had observed week 1 proportions with uncertainty 
ranges that fell outside our estimated uncertainty range.  Of these, 7 had more day 1 than day 
0 deaths.  The remaining 12 all had low proportions for week 1, with a median week 1 proportion 
of 0.60 (IQR: 0.56-0.63) versus 0.73 (IQR: 0.69-0.78) for the other 194 surveys.  This pattern is 
consistent with undercounting of early neonatal deaths.  Finally, several of the countries with 
multiple DHS had fluctuations in day 0 and week 1 proportions that are unlikely to be explained 
by real changes.  For example, the day 0 proportion in Ethiopia varied from 0.30 in 2000, to 0.19 
in 2005, to 0.42 in 2011.  Due to these data quality issues (and random error) within individual 
surveys, we chose to apply our model to countries with DHS data to predict their day 0 and week 
1 proportions instead of using their raw DHS data.  In section 3.5, I presented simple analytical 
methods to identify DHS with substantial misclassification of deaths between days 0 and 1 and 
underreporting of very early neonatal deaths. 
 
We hope that our estimates will be improved upon as better data become available.  While our 
DHS-based model appears to be robust, it is clearly not ideal to apply a single model to all 
countries lacking reliable VR data of their own.  Although we believe that, on average, our results 
likely represent the day 0 and week 1 proportions for many of the modelled countries, this 
approach will mask any variation that does exist between countries.  Since the same proportions 
for day 0 and week 1 were applied to all non-VR countries, the rankings are tied to the variation 
in NMR and in the number of neonatal deaths occurring in the country.  Also, our uncertainty 
ranges do not reflect the uncertainty in NMR, which was unavailable for the most recent NMR 
estimates.  Thus, as with all modelled estimates, our results represent a starting point for 
understanding the burden of day 0 and week 1 deaths in each country.  If relevant high-quality 
VR data were available for individual days, we would be able to compare our DHS-based model 
against these survival curves, and test more complex models.  For example, since we attempted 
to correct for misreporting of deaths between days 0 and 1, we assumed that from day 1 
onwards the daily hazard declines exponentially.  While the model appears to fit the data well, 
external validation would require high-quality day-of-death data.  Currently, the VR data 
available through the WHO are limited to three time periods (day 0, days 1-6, and days 7-27) 
and therefore cannot be used to construct neonatal survival curves.  Additionally, characteristics 
such as income and NMR level of countries that currently have high-quality VR are substantially 
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different from those that are being modelled, thus making a comparison with existing data 
difficult.   
 
Another desirable improvement would be subnational estimates, particularly for large countries 
with decentralised systems and high variability such as India and Nigeria.  Subnational estimates 
are not available even for many countries with adequate national VR data, but are important 
for priority setting and sharing lessons from within the same health system. For example, the 
risk of day 0 death per 1,000 live births in the United States ranged from 1.3 in Alaska to 4.8 in 
the District of Columbia from 2007-2010 [10].  The county-level differences were even wider, 
from a risk of 0.9 in Hidalgo County, Texas to 6.2 in Baltimore City, Maryland [10]. Additionally, 
a few studies have evaluated differences in the neonatal cause-of-death distribution by day, and 
found marked differences between not only the early and late neonatal periods, but also day 0 
and later days [132, 133].  While a better understanding of this distribution by day is needed in 
order to improve care, the availability of relevant data from high-mortality settings are currently 
too insufficient to support such an analysis.   
 
In the post-MDG era, we need to accelerate the impressive but unfinished recent progress in 
reducing preventable child deaths, especially for the immense burden of nearly 3 million 
neonatal deaths, which is highest on the first day and week of life.  Effective and low-cost 
interventions exist but are still not reaching every woman and newborn, especially during the 
time around birth, the most vulnerable for both death and long-term disability [109]. A Lives 
Saved Tool analysis estimated that simple and cost-effective intervention (e.g. resuscitation 
devices, chlorhexidine cord cleansing, and injectable antibiotics) could save up to one million 
newborn lives each year [12]. A more comprehensive approach with full obstetric and improved 
newborn care, linked to community based programmes [134, 135], could prevent almost all of 
these deaths, as well as many of the estimated 1.2 million intrapartum stillbirths (which are 
rarely seen in rich countries) and 289,000 maternal deaths [111] each year [9, 136].  The Every 
Newborn Action Plan, endorsed at the 2014 World Health Assembly by over 190 countries, was 
an important step towards accelerating progress [137].  Subsequently, the Sustainable 
Development Goals set explicit targets that all countries should reach 12 or fewer neonatal 
deaths per 1,000 live births by 2030 [138]. Around the world, a marker of development is when 
a society no longer accepts that stillbirths and neonatal deaths are inevitable, that babies can 
be named at birth and counted in national data systems, and that a baby’s birth day should not 
be his or her last day.    
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4 Cause-of-death estimation by neonatal period 
In this chapter, I present our work on estimating neonatal causes of deaths in the early and late 
neonatal periods for 194 countries.  Preliminary estimates were published in the WHO’s World 
Health Statistics 2014 report [139], and final estimates were used in UNICEF’s “A Promise 
Renewed Progress Report 2014” [140] and the 2014 Liu et al. Lancet article [100].  We published 
detailed methods and results in the Bulletin of the World Health Organization under the 
following citation: Oza S, Lawn J, Hogan D, Mathers C, Cousens S. Neonatal cause-of-death 
estimates for the early and late neonatal periods for 194 countries: 2000-2013.  Bulletin of the 
World Health Organization 2015; 93:19-28 [141].  The text in this chapter is adapted from this 
journal article and its associated web appendix.  The open-access article can be found at: 
https://www.who.int/bulletin/volumes/93/1/14-139790/en/ 
 
4.1 Introduction 
Most of the estimated 2.76 million neonatal (first month of life) deaths in 2013 occurred from 
preventable causes [142]. While the global neonatal mortality rate (NMR) is decreasing, its rate 
of reduction has been substantially slower than the decreases in under-5 and maternal mortality 
[108, 143].  Neonatal deaths constituted 44% of all deaths in children under 5 years old in 2014 
[142].  One hundred and thirty-three countries were unable to achieve the fourth Millennium 
Development Goal (MDG) target of a two-thirds reduction in child mortality (U5MR) between 
1990 and 2015 [7], at least partly due to limited reductions in neonatal deaths.  The Every 
Newborn Action Plan, launched in June 2014 [144], provided a stimulus to accelerate progress 
by implementing effective cause-specific interventions to rapidly reduce neonatal mortality.  
Subsequently, the Sustainable Development Goals (SDGs) included a target of 12 or fewer 
neonatal deaths per 1,000 live births for all countries by 2030 [138].   
 
Understanding the neonatal cause-of-death (COD) distribution is important for identifying 
appropriate interventions and programme priorities.  Ideally, such a distribution would be as 
local as possible, current, and distinguish programmatically relevant causes.  Moreover, 
separate COD estimates are required for the early (days 0-6) and late (days 7-27) neonatal 
periods since both our understanding of pathology and empirical data suggest that the COD 
distribution differs substantially between these periods [145, 146].  Around three-quarters of 
neonatal deaths occur during the early period [12], and most interventions to prevent these 
deaths need to be delivered within a very short window of time.  
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For countries with high-quality vital registration (VR) data by cause and age at death, such data 
provide the information needed to determine policies and priorities.  VR data quality is 
dependent on the completeness of reporting and the quality of COD coding [24, 66].  
Unfortunately, high-quality VR data are available for only about one-third of countries [147], 
which account for only about 4% of neonatal deaths.  Thus, statistical modelling remains 
necessary to estimate COD distributions in the majority of countries.   
 
Systematic estimates of neonatal deaths classified into programmatically relevant cause 
categories were first published in 2005, for the year 2000 [13], by the Child Health Epidemiology 
Research Group (CHERG). These estimates were developed using data from high-quality VR 
systems and from research studies in high-mortality/low-resource settings in which high-quality 
VR data were lacking.  Updated neonatal COD estimates using this approach were subsequently 
published for 2008 [14] and 2010 [15].   
 
The current work goes beyond these previous exercises by estimating neonatal causes of death 
separately for the early and late neonatal periods, and by adding injuries as a distinct cause for 
low mortality countries.  The separation of early and late neonatal deaths is an important 
advance which will ideally aid policy makers and programme managers.  The input data have 
also been updated and modifications made to the modelling strategy, particularly for the split 
of neonatal infections between pneumonia and sepsis.  
 
Here, we present global, regional, and national estimates (with uncertainty) of proportions, 
risks, and numbers of deaths for key programmatically relevant neonatal causes of death by the 
early and late neonatal periods for 194 countries for 2000-2013.  
 
4.2 Methods 
4.2.1 Overview of cause-of-death estimation  
We divided 194 countries into three groups based on the quality of their VR data and their child 
mortality rates (Appendix B.1.1).  Different methods were used to estimate the proportional 
COD distributions for countries in each group (Figure 4.1).  For the 65 countries with high-quality 
VR data, the proportional COD distribution from 2000-2013 was obtained directly from the 
country’s VR data.  For the 49 countries without high-quality VR but with low child mortality, 
this distribution was estimated using a multi-cause model (“low mortality model”) with input 
data from high-quality VR countries.  
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Figure 4.1: Strategy for cause-of-death estimation by neonatal period 
 
Note: VR = vital registration 
 
For the high-quality VR countries and low mortality model, we used seven cause categories: 
complications of preterm birth (“preterm”), intrapartum-related complications (“intrapartum”), 
congenital disorders, pneumonia, sepsis and other severe infections (“sepsis”), injuries, and 
other causes.  For the 80 countries with inadequate VR and high child mortality, we used studies 
that identified neonatal COD in high mortality settings as input data in a separate multi-cause 
model (“high mortality model”).  The eight cause categories for this model were preterm, 
intrapartum, congenital disorders, pneumonia, diarrhoea, neonatal tetanus, sepsis, and other 
causes.  Table 4.1 includes the case definitions used for each of these causes.  
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Table 4.1: Case definitions for neonatal causes of death 
 
Used in VR and preferred in study data 
Alternative definition 
accepted in study data 
Preterm birth 
complications 
o Specific complications of preterm birth, such 
as surfactant deficiency (Respiratory Distress 
Syndrome), intraventricular haemorrhage, 
necrotizing enterocolitis 
o Prematurity (<34 weeks) at which level 
preterm complications occur for most babies 
o Neonatal death with birth weight < 2000 g 
with unknown gestational age  
o  “Prematurity” 
o “Very low birth weight” 
Intrapartum-
related 
complications 
o Neonatal encephalopathy with criteria 
suggestive of intrapartum events 
o Early neonatal death in a full-term baby with 
no congenital malformations and a specific 
history of acute intrapartum insult or 
obstructed labour 
o “Birth asphyxia” with 
Apgar-based definition 
but excluding preterm 
infants  
o Fits and/or coma in the 
first two days of life in a 
baby born at baby 
o Acute intrapartum 
complications 
Congenital 
disorders 
o Major or lethal congenital abnormalities 
o Specific abnormality listed (e.g. neural tube 
defect, cardiac defect) 
o Congenital abnormality 
or malformation 
Sepsis 
o Sepsis/septicaemia, meningitis, or neonatal 
infection 
o Neonatal infection 
Pneumonia 
o Pneumonia or acute respiratory tract 
infection 
o Pneumonia 
Neonatal 
tetanus 
o Tetanus o Spasms and poor 
feeding after age of 3 
days 
Diarrhoea o Diarrhoea --- 
Injuries o Injuries (in VR data only) N/A 
Other 
Specific causes not included in the above-listed 
causes, including:  
o Neonatal jaundice 
o Haemorrhagic disease of the newborn 
o Term baby dying due to in-utero growth 
restriction 
o Injuries (only searched for in study data) 
o Author grouping of 
“other” causes 
(excluding unknown)  
Notes: Table is slightly modified from Lawn [148], which adapted it from Wigglesworth 
[149, 150] and NICE [150]; ICD codes for VR COD data are included in Appendix B.2.1.   
 
 
4.2.2 Data inputs 
Cause-of-death data from vital registration 
For the 65 high-quality VR countries, we obtained publicly available VR COD data by the early 
and late neonatal periods from the World Health Organization (WHO) for years 2000 and later.  
We mapped the reported causes of death to our cause categories (Appendix B.2.1).   
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We then generated a proportional cause distribution by dividing the number of deaths 
attributed to each cause by the total deaths across the seven causes.  To create a full time series, 
we imputed the cause-specific proportions for years with missing VR data.  For years with 
missing data that were between years with existing data, we used linear interpolation to impute 
the missing proportions.  For years that were before the earliest or after the latest available 
data year, we applied the proportions from the nearest year with available data to the missing 
data.  The imputed proportions were only used as estimates for the high-quality VR countries; 
the low mortality model input dataset only included the non-imputed data.  A list of the missing 
data years for the high-quality VR countries is included in Appendix B.2.2.  Note that these data 
years were missing in the data received by the WHO from the given country, but the relevant 
data may not be missing within the country itself.   
 
Cause-of-death data from high mortality setting studies 
The high mortality model input data consisted of neonatal COD distribution data from studies 
in high mortality settings.  We updated a previously developed database of neonatal COD 
studies [151] by conducting an extensive literature review for relevant research published from 
January 2011 to May 2013.  We used the same criteria for selecting new studies to include in 
the input dataset as used in previous iterations of this work [151].  The criteria were as follows:  
o Publication in 1980 or later 
o Study set in one of nine (of a total f 14) subregions with no or few countries with >90% 
VR coverage 
o Community-based study or hospital based in populations with over 90% hospital delivery 
and defined catchment population 
o Case ascertainment: follow up of newly born infants from birth to at least 7 or 28 days 
o Number of deaths with known cause ≥ 20 
o Study duration ≥ 12 months 
o Included four or more of the eight selected causes of neonatal death 
o Deaths of unknown cause ≤ 25% of total deaths 
o Cause attribution based on skilled clinical investigation, post-mortem, or verbal autopsy 
o Case definitions specified and comparable with other studies 
Our search strategy involved doing a literature review in ten databases for articles published 
between January 2011 and May 2013.  Previous searches covered periods from 1980 to 
December 2010.  We searched Pubmed, Embase, Web of Knowledge, Medline, Global Health, 
Popline, and region-specific indices (LILACS, Africa-Wide Information, Western Pacific Region, 
Eastern Mediterranean, IndMed).  Full search terms are in Appendix B.2.3.   
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For each study, we extracted COD data and, when necessary, re-categorized the causes into our 
cause categories.  While we included injuries as a separate category in the low mortality model, 
the study data lacked enough information on injuries for separate estimation in the high 
mortality model.  We recorded deaths separately by early or late neonatal period whenever 
possible.  The full list of studies is in Appendix B.2.4. 
  
Covariate data 
We chose for investigation covariates that we believed might partly predict variation in the COD 
distribution across countries.  We expect that these covariates act either directly (e.g. increased 
skilled birth attendance may lead to decrease in intrapartum-related complications) or as 
proxies (e.g. gross national income [GNI] for system-level factors like healthcare availability).  
We could only use covariates for which national time series are publicly available.  The full set 
of covariate options in the model are listed in Table 4.2.   
 
Table 4.2:  List of potential covariates in the low and high mortality cause-of-death models 
Covariate1 
Included in models?2 
Low mortality High mortality 
Neonatal mortality rate (NMR) Yes Yes 
Infant mortality rate (IMR) Yes Yes 
Under-5 mortality rate (U5MR) Yes Yes 
Low birth weight (LBW) Yes Yes 
General fertility rate (GFR) Yes Yes 
Antenatal care (ANC) Yes Yes 
Female literacy rate (FLR) Yes Yes 
Diphtheria/Pertussis/Tetanus vaccine (DPT) Yes Yes 
Bacillus Calmette-Guerin vaccine (BCG) No Yes 
Protected at birth (PAB) against neonatal tetanus No Yes 
Skilled birth attendance (SBA) No Yes 
Region (LAC, SSA, or SA)3 No Yes 
Neonatal period No Yes 
Premature versus LBW distinction No Yes 
Gross national income (GNI) Yes No 
GINI coefficient Yes No 
1 See section 2.4 for descriptions and sources of covariates; 2 “Included in models” means the 
covariate was part of the covariate selection process for the model, and does not indicate 
that it was selected for the final model; 3 LAC = Latin America and the Caribbean, SSA = Sub-
Saharan Africa, SA = South Asia (see Appendix A.2.1 for countries in each region) 
 
Note that not all of these are included in the final models (see “Statistical modelling” section 
below for further details).  The majority of covariates were included in both models.  GNI and 
the GINI coefficient were excluded from the high mortality model because these covariates are 
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only available at the national level, whereas nearly all of the input data come from local studies.  
Covariates were excluded from the low mortality model based on lack of relevance (e.g. preterm 
vs LBW distinction; neonatal period) or due to lack of variability for prediction countries (e.g. 
SBA, PAB). 
 
The covariates were used in two ways: 1) as inputs into the multinomial models, and 2) as 
predictor variables to which the final model coefficients were applied to estimate the national 
proportional COD distributions.  We used national-level covariates as inputs to the low mortality 
model since the input COD data are national, and, whenever possible, local-level data extracted 
from the studies for the high mortality model.  When local-level data were unavailable, we used 
subnational- or national-level covariate data instead.  For the predictions, we used national-
level covariate data, with the exception of India for which we used state-level data to produce 
state-level estimates.  We applied the same rules for imputing missing covariate data as for the 
VR data.  For prediction purposes, we restricted covariate values to the input data ranges, and 
performed a sensitivity analysis without this restriction.   
 
4.2.3 Statistical modelling  
All statistical analyses were done using Stata (version 12).  For each model, a baseline cause was 
chosen; this cause was preterm for the low mortality model (the most common cause) and 
intrapartum for the high mortality model (reported in all studies).  Our overall estimation 
process had two stages.  First, we selected covariates.  Then, we estimated the log of the ratio 
of each of the other causes to the baseline cause (the “log-cause ratio”) as a function of the 
selected covariates using a multinomial logistic regression model.  For both the low and high 
mortality models, we ran separate models for the early and late neonatal periods.  Since not all 
studies in the high mortality model reported deaths by period, we included the studies reporting 
only overall neonatal deaths in both the early and late high mortality models, and included a 
binary covariate for period in these models.   
 
Covariate selection for models 
For each of the four models, we used a previously developed jackknife procedure [15] to select 
the set of covariates that minimized the jackknife out-of-sample prediction error for each log-
cause ratio separately.  The jackknife process involves conducting the analysis on n-1 
observations, using the results to predict the value of interest for the left-out observation, and 
repeating this for all n observations.  This allows a comparison between the out-of-sample 
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predictions and the observed data.  For our covariate selection, we first determined if the 
relationship between each covariate and log-cause ratio in the input data was best represented 
by a linear, quadratic, or restricted cubic spline relationship.  We did this by choosing the 
covariate relationship which yielded the smallest chi-squared goodness-of-fit statistic (sum of 
the squared differences between observed and expected deaths divided by expected deaths) 
for the given log-cause ratio with the jackknife process.  We then selected the covariate with 
the best goodness of fit (i.e. smallest chi-squared statistic) as the first covariate in the model.  
Finally, we added one covariate at a time, retaining it in the model only if the chi-squared 
statistic decreased and cycling through all the remaining covariates again.  In this way, we 
selected a set of covariates for each non-baseline cause in each model.   
 
Multi-cause models 
The multi-cause multinomial logistic regression models fit the data for all causes simultaneously.  
Each input observation received a weight inversely proportional to the square root of the total 
deaths contributed by that observation.  This weighting is intermediate between giving equal 
weight to each death and equal weight to each study or country year in the input data.  We 
made assumptions about the cause category into which deaths from an unreported cause would 
have been assigned and re-wrote the likelihood function accordingly.  If preterm, congenital, or 
sepsis were unreported, we assumed deaths from these to be in the “other” category.  If 
pneumonia, diarrhoea, or tetanus were unreported, these were assumed to have been in the 
“sepsis” category.   
 
The coefficient values from the multinomial logistic regression models were applied to the 
country- and year-specific national level predictor covariates to estimate the proportional COD 
distribution for each modelled country from 2000-2013.  
 
4.2.4 Estimation of cause-specific deaths and risks  
We applied our estimated COD fractions to the neonatal deaths and live births estimated for 
each country from 2000-2013 by the United Nations Inter-agency Group for Child Mortality 
Estimation (UN-IGME) [142].  We split the overall neonatal deaths from UN-IGME into early and 
late neonatal deaths.  For high-quality VR countries, we took this split directly from the data.  
For the other countries, we assumed that 74% of neonatal deaths occurred during the early 
period and 26% in the late period (based on work presented in chapter 3).  We also performed 
a sensitivity analysis in which we assumed the early proportion was 65% or 85% instead of 74%.  
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To determine the number of deaths by cause, neonatal period, and year for each country, we 
applied the cause-specific proportions derived from the VR data (for high-quality VR countries) 
or the relevant models to the period-specific neonatal deaths for each country and year.  We 
then divided these by the relevant country-specific live births to obtain the risk (per 1,000 live 
births) for each cause by neonatal period and year.  We aggregated cause-specific proportions, 
risks, and numbers of deaths for regional and global estimates (see Appendix B.1.2 for regional 
categories).    
 
4.2.5 Uncertainty estimation 
For the modelled estimates, we generated uncertainty estimates by drawing 1,000 bootstrap 
samples with replacement from the input data and re-running the multi-cause models to 
produce new proportional cause distributions.  We took the 2.5th and 97.5th percentile values 
for each cause as the uncertainty bounds.  For the high-quality VR data, we developed 
uncertainty estimates by assuming a Poisson distribution for the number of deaths (i.e. the 
standard error equalled the square root of the reported number of deaths).   
 
4.2.6 Methodological differences between this work and previous estimates 
Appendix B.3 contains a detailed overview of how the COD estimation methods have changed 
since the first CHERG neonatal COD estimates were published in 2005 for the year 2000.  Key 
methodological changes since the last round of neonatal cause-of-death estimates [15] are 
described below.  
 
Early/late neonatal period estimates 
We are now reporting the results by the early and late neonatal periods.  As described above, 
we run 4 separate models (early and late separately for both the low and high mortality models).   
 
Changes to country groupings 
We have now included Kuwait, Macedonia, Montenegro, Republic of Korea, and Saint Lucia in 
the high-quality VR countries instead of the low mortality model.  We made this change because 
VR time series data recently became available from the WHO for these countries.  Additionally, 
due to improved VR data collection in South Africa, we included South Africa in the group of 
high-quality VR countries instead of the high mortality model.   
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Covariate selection  
Previously [15], we allowed the relationship between each covariate and the log of the 
cause/baseline cause ratio to be described either linearly or quadratically.  In this work, we also 
included the possibility of a restricted cubic spline relationship to include potentially more 
flexible non-linear relationships.  We also included more covariates in the low mortality model 
than were previously used.  
  
Additional cause categories within the multinomial 
In the low mortality model, we added injuries as a separate cause, while in the previous work 
injuries were included in the “other” category.  In the high mortality model, we included sepsis, 
pneumonia, and tetanus as separate cause categories.  In the previous work, the high mortality 
model included a broader “infections” category that included sepsis and pneumonia, and these 
were then split in a separate regression using the results from the multinomial.  Additionally, 
tetanus deaths were previously estimated using a single-cause model, but tetanus is now 
included in the multinomial itself.   
 
India estimates 
Similar to the 2010 estimates [15], we produced national estimates for India by aggregating 
state-level estimates.  For the 2010 estimates, a separate multinomial was developed using 
India-only input data.  This time, however, we estimated the state-level proportional cause 
distribution for each Indian state/year within the overall high mortality model.  We did this 
because there were not enough Indian studies that reported sepsis and pneumonia separately 
in order to estimate these causes in an India-only multinomial model, and because the COD 
distribution between Indian studies and non-Indian studies appeared to be quite similar.    
 
4.3 Main results 
4.3.1 Description of data inputs 
Cause-of-death data from vital registration 
The high-quality VR input dataset, which was also used in the low mortality model, included 65 
countries with 1,267,404 neonatal deaths and 665 country-years for each neonatal period from 
2000-2013 (Figure 4.1).  Of these deaths, 75.8% occurred in the early period.  None of the seven 
causes we modelled for low mortality countries were missing in these data.  Preterm and 
congenital were the most common causes during both neonatal periods (Figure 4.2).   
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Figure 4.2: Proportional COD distribution by period in the low mortality model input data  
 
 
Cause-of-death data from high mortality setting studies 
The high mortality model input dataset included 112 data points consisting of 98,222 deaths 
from 36 countries (Figure 4.1).  This includes the addition of nearly 4,100 neonatal deaths from 
15 new studies, representing 10 countries across five MDG regions.  The overall dataset had 31 
observations for the early period, 18 for the late period, and 63 for the overall neonatal period.  
Thirty-four observations had no causes missing, 37 had one cause missing, 13 had two causes 
missing, 23 had three causes missing, and 5 had four causes missing.  No observations were 
missing data for the “intrapartum” or “other” cause categories; pneumonia and diarrhoea were 
the causes most commonly unreported (Table 4.3).  All observations missing “sepsis” were also 
missing all other infection categories (i.e. diarrhoea, pneumonia, and tetanus).  See section 4.2.3 
for a description of the assumptions we made regarding which cause an unreported cause 
would be contained within. 
 
Table 4.3: Number of observations with a given cause missing 
Cause # of observations1 Cause # of observations1 
Intrapartum 0 (0%) Pneumonia 62 (55.4%) 
Preterm 1 (0.9%) Diarrhoea 42 (37.5%) 
Congenital 13 (11.6%) Tetanus 31 (27.7%) 
Sepsis 3 (2.7%) Other 0 (0%) 
1 out of 112 total observations 
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Preterm and intrapartum were the most common causes of death during the early period, while 
infections (sepsis and pneumonia) dominated during the late period (Figure 4.3).   
 
Figure 4.3: Proportional COD distribution by period in the high mortality model input data 
 
 
Covariate data 
Most covariate values were within the ranges of the input data (low mortality model, Table 4.4; 
high mortality model, Table 4.5).  However, a few prediction covariates had values substantially 
outside the input data range, especially in the low mortality model.  Notable examples were 
Monaco with an average GNI about 3.5 times larger than the maximum input data and Egypt 
with female literacy and ANC coverage 15-20 percentage points below the input ranges.  An 
India-specific comparison is included in Appendix B.4.1.   
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Table 4.4: Comparison of input and prediction covariates in the low mortality model 
 Input data Prediction data1 
 Mean 
(SD2) 
Median  
(IQR3) 
Range  
(min-max) 
Mean 
(SD) 
Median 
(IQR) 
Range 
(min-max) 
NMR4 
6.2 
(4.3) 
4.7  
(2.8-8.8) 
1.1-24.4 9.2  
(4.5) 
9.1  
(5.4-12.4) 
1.1-22.5 
IMR 
9.6 
(7.2) 
7.0  
(4.2-13.6) 
1.8-49.9 15.0  
(7.7) 
15.1  
(8.4-20.6) 
2.2-35.9 
U5MR 
11.4 
(8.8) 
8.2  
(5.0-15.6) 
2.3-76.9 17.8  
(9.3) 
17.6 
(9.9-24.3) 
3.0-44.8 
LBW 
7.3 
(2.5) 
7.0  
(5.7-8.2) 
3.8-23.2 8.7  
(3.6) 
8.4  
(6.3-10.2) 
0.0-22.3 
GNI 
21026 
(13292) 
18130 
(11021- 30090) 
1490-67970 20450 
(38356) 
7302 
(4450-19600) 
1400-327346 
GFR 
0.055 
(0.018) 
0.050 
(0.040-0.065) 
0.033-0.119 0.076 
(0.029) 
0.075 
(0.050-0.096) 
0.032-0.171 
GINI 
37.6 
(9.7) 
34.3 
(30.9-45.3) 
24.2-67.4 39.3 
(7.7) 
39.4 
(32.6-42.1) 
25.6-69.2 
ANC 
96.7 
(4.3) 
97.9 
(96.3-99.4) 
71.3-100 93.6 
(7.2) 
96.3 
(90.3-98.9) 
52.9-100.0 
DPT 
94.2 
(5.6) 
96.0 
(93.0-98.0) 
62.0-99.0 93.1 
(8.6) 
96.0  
(92.0-98.0) 
41.0-99.0 
FLR 
93.0 
(4.7) 
92.4 
(90.7-97.0) 
70.3-99.8 87.8 
(9.0) 
90.1  
(81.9-93.5) 
50.6-99.7 
1 bolded values are those outside the input data range; 2 SD = standard deviation; 3 IQR = 
interquartile range; 4 see Table 4.2 for covariate acronym definitions 
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Table 4.5: Comparison of input and prediction covariates in the high mortality model 
 Input data Prediction data1 
 Mean 
(SD2) 
Median  
(IQR3) 
Range  
(min-max) 
Mean 
(SD) 
Median 
(IQR) 
Range 
(min-max) 
NMR4 33.0 
(15.9) 
30.2 
(18.8-47.2) 
10.5-70.1 30.2 
(10.2) 
29.7 
(21.8-37.3) 
8.8-55.1 
IMR 62.1 
(30.0) 
58.7 
(35.7-81.6) 
14.7-142.0 60.3 
(24.9) 
57.2 
(40.0-76.5) 
14.4-141.3 
U5MR 88.6 
(45.8) 
89.1 
(52.9-125.4) 
17.1-227.0 89.2 
(45.1) 
83.0 
(52.0-116.7) 
16.3-231.5 
LBW 18.9 
(11.3) 
15.9 
(10.6-27.6) 
2.5-50.0 14.2 
(6.7) 
12.8 
(10.2-16.7) 
4.2-35.6 
GFR 0.127 
(0.043) 
0.118 
(0.092-0.158) 
0.057-0.235 0.140 
(0.046) 
0.145 
(0.101-0.175) 
0.054-0.246 
ANC 67.5 
(26.5) 
73.9 
(50.0-92.0) 
5.0-98.3 78.6 
(18.5) 
84.1 
(71.0-92.7) 
16.1-100.0 
DPT 67.9 
(24.6) 
73.5 
(60.5-83.5) 
0.0-99.0 76.3 
(18.5) 
80.0 
(66.0-91.0) 
3.0-99.0 
BCG 78.8 
(23.9) 
87.0 
(73.0-93.0) 
0.0-100.0 85.1 
(14.2) 
90.0 
(78.0-96.0) 
24.0-99.0 
PAB 63.3 
(25.0) 
68.0 
(51.4-83.5) 
0.0-98.5 76.0 
(13.1) 
79.7 
(68.2-85.0) 
24.0-97.0 
FLR 51.9 
(24.7) 
48.7 
(34.6-77.3) 
4.0-94.0 62.2 
(23.6) 
61.8 
(43.9-83.6) 
9.4-100.0 
SBA 48.7 
(33.1) 
45.3 
(18.9-83.7) 
0.0-100.0 60.1 
(25.3) 
60.2 
(42.0-82.0) 
5.6-100.0 
Region 
 
East Asia and Pacific: n = 4; Europe and 
Central Asia: n = 5; Latin 
America/Caribbean: n = 16; Middle 
East and North Africa: n = 8; South 
Asia: n = 52; Sub-Saharan Africa: n = 26 
High income: n = 1 
East Asia and Pacific: n = 14; Europe and 
Central Asia: n = 6; Latin 
America/Caribbean: n = 4; Middle East 
and North Africa: n = 6; South Asia: n = 5 
Sub-Saharan Africa: n = 44; High income: 
n = 0 
1 bolded values are those outside the input data range, results do not include Indian states (see 
Appendix B.4.1 for comparisons of Indian state data); 2 SD = standard deviation; 3 IQR = 
interquartile range; 4 see Table 4.2 for covariate acronym definitions 
 
4.3.2 Statistical modelling  
Covariate selection for models 
Table 4.6 lists the covariates that were selected for each of the four models, as well as the 
performance of each equation in reducing the out-of-sample residuals.  The latter was based on 
calculating the relative difference of the equation’s chi-squared statistic with that of the null 
model with no covariates (herein “% reduction from null”).  The model equations varied 
substantially in their performance, from 0% reduction in the chi-squared statistic (injuries, low 
mortality model, late period) to 87% reduction (diarrhoea, high mortality model, early period) 
(Table 4.6).  Overall, equations in the high mortality model appeared to have better 
performance, with an average of 50% reduction from null the equations compared to an 
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average of 30% in the low mortality model equations.  The poorer performance for some causes 
may be due to a number of factors, including the limited range of covariates available for 
inclusion, inaccurate measurement of included covariates, or the possibility that there is no 
pattern that can be predicted based on the input data.  
 
Table 4.6: Selected covariates in cause equations of the low and high mortality models and % 
reduction from null 
 Early neonatal period Late neonatal period 
 Selected covariates1 % red.2 Selected covariates % red. 
Low mortality model3 
Intrapartum L: FLR 16% S: FLR, DPT 21% 
Congenital 
L: GINI, DPT, FLR 
S: IMR, U5MR, LBW 
62% L: NMR, DPT 10% 
Sepsis 
L: GNI, GINI, ANC;  
S: IMR, DPT 
66% L: FLR, GINI; Q: IMR; S: DPT 67% 
Pneumonia L: GNI 25% L: GNI; S: ANC 40% 
Injuries Q: GFR 17% none 0% 
Other Q: GFR 19% L: LBW; Q: DPT; S:NMR     16% 
High mortality model4 
Preterm 
L: BCG, PAB, SBA, DPT 
S: LBW, GFR 
47% S: LBW, PAB, GFR 
B: SSA 
61% 
Congenital 
L: LBW; Q: NMR, U5MR; 
S: BCG; B: per 
77% Q: SBA, U5MR 
B: per, SSA 
71% 
Sepsis L: LBW; Q: BCG; B: per, SA 81% Q: PAB; S: LBW; B: per  13% 
Pneumonia L: U5MR, LBW; B: per 16% Q: PAB 23% 
Diarrhoea 
L: DPT, GFR; Q: NMR 
B: per, SA, SSA 
     87% L: DPT, BCG, GFR, FLR 
S: LBW; B: LAC 
45% 
Tetanus 
 
L: PAB, ANC, NMR;  
B: per 
86% L: NMR, IMR, U5MR, PAB 
B: period 
44% 
Other S: GFR; B: SSA 6% S: GFR; B: per, SSA      49% 
1 L = linear; Q = quadratic; S = restricted cubic spline; B = binary; per = neonatal period;  
reg = region; see Table 4.2 for covariate acronym definitions; 2 % red. = % reduction from null;  
3 preterm as baseline cause; 4 intrapartum as baseline cause 
  
Multi-cause models 
Model regression coefficients are in Appendix B.4.2.   
  
4.3.3 Overall cause-specific deaths and risks  
Globally, the leading causes of neonatal death in 2013 were estimated to be preterm (35.7%), 
intrapartum (23.4%), and sepsis (15.6%), accounting for 2.1 (uncertainty range [UR]: 1.4-2.8) of 
the estimated 2.8 million neonatal deaths (Table 4.7).  The proportional cause distribution 
varied by both neonatal period and NMR level.  In the early period, preterm (40.8%) and 
intrapartum (27.0%) accounted for the majority of deaths while in the late neonatal period 
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nearly half of all deaths occurred from infectious causes (sepsis, pneumonia, tetanus, and 
diarrhoea) (Table 4.7).  The proportion of deaths from congenital disorders was relatively stable 
across the periods.  A comparison of the estimated COD proportions in this round of estimation 
versus previous rounds is presented in Appendix B.4.3. 
 
Table 4.7: Global cause-specific proportions, risks, and numbers of neonatal deaths (with 
uncertainty) in 2013 
 Early period Late period Overall period 
 % # of deaths 
in 1000s1 
% # of deaths 
in 1000s 
% # of deaths 
in 1000s 
Risk2 
 
Preterm 40.8 
834.8 
(608.1-1083.5) 
21.2 
152.1 
(91.0-229.0) 
35.7 
986.9 
(699.1-1312.5) 
7.2 
Intrapartum 27.0 
552.7  
(407.6-711.4) 
12.9 
92.1 
(54.8-133.4) 
23.4 
644.8 
(462.4-844.7) 
4.7 
Congenital 10.6 
217.0 
(140.9-325.9) 
10.2 
72.8 
(42.5-124.5) 
10.5 
289.8 
(183.3-450.4) 
2.1 
Sepsis 8.0 
163.7 
(62.4-271.6) 
37.2 
266.7 
(156.5-393.2) 
15.6 
430.4 
(218.9-664.8) 
3.1 
Pneumonia 4.8 
98.9 
(48.8-200.3) 
5.2 
37.6  
(21.5-58.7) 
4.9 
136.4 
(70.3-259.0) 
1.0 
Diarrhoea3 0.3 
6.7  
(0-57.4) 
1.4 
10.0  
(3.2-25.6) 
0.6 
16.6 
(3.2-83.0) 
0.1 
Tetanus3 1.0 
21.1 
(7.4-53.2) 
3.8 
27.1 
(8.1-67.2) 
1.7 
48.2 
(15.5-120.4) 
0.3 
Other4 7.3 
149.9 
(72.7-250.3) 
8.1 
57.9 
(26.3-117.2) 
7.5 
207.8 
(99.0-367.4) 
1.5 
1 uncertainty ranges are in parentheses; 2 risk is per 1,000 live births; 3 estimated only for the 
80 high mortality model countries; 4 injuries are included within the “other” category  
 
While the absolute risks of death due to intrapartum and preterm were predicted by the model 
to have fallen in the early period, they decreased less in the late period.  Risk of tetanus declined 
in both periods (Figure 4.4).    
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Figure 4.4: Global cause-specific risks of death from 2000-2013 for the early and late neonatal 
periods 
 
 
4.3.4 Cause-specific deaths and risks by neonatal mortality rate, income, and 
region 
Higher NMR (Figure 4.5a) and lower income (Figure 4.5b) were associated with higher 
proportions of deaths attributable to intrapartum and infectious causes.  Globally, risks for all 
causes decreased as the global NMR decreased over time.  The risk of death from each cause 
was substantially higher in higher mortality settings, even for causes that dominated 
proportionally in low mortality settings (e.g. preterm and congenital disorders).  The risks of 
death due to preterm, intrapartum, and sepsis were 10, 36, and 34 times greater in settings with 
NMR≥30 compared to NMR≤5 (Figure 4.5a).  In every MDG region, preterm was the leading 
cause of neonatal death, with the highest risks in Southern Asia (11.9 per 1,000 live births) and 
Sub-Saharan Africa (9.5 per 1,000 live births) (Figure 4.6).  
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Figure 4.5: Cause-specific risk of death by a) neonatal mortality rate and b) income groupings 
 
 
Figure 4.6: Cause-specific risk of neonatal death by MDG region in 2013 
 
 
4.3.5 Cause-specific deaths and risks by estimation method 
Table 4.8 includes the cause-specific proportions, risks, and numbers of deaths by estimation 
method (i.e. high-quality VR data, low mortality model, and high mortality model).  As expected, 
the proportional COD distribution for the low and high morality models mimics the differences 
seen across low and high NMR areas (e.g. higher intrapartum and infection in the high mortality 
model; higher congenital and other in the low mortality model and high-quality VR data).  These 
differences are unsurprising because the estimation groups are determined by mortality level 
and availability of high-quality data.  The risk of death from most causes, including preterm and 
intrapartum, decreased at a slower rate for high compared to low mortality countries (Figures 
4.7a-c).   
 
 
a) b) 
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Table 4.8: Cause-specific proportions, risks, and numbers of deaths (with uncertainty) in 2013 
by estimation method 
 Early period Late period 
 % # of deaths  
in 1000s1 
Risk2 % # of deaths  
in 1000s 
Risk 
High-quality VR countries 
Preterm 41.5 35.9 (34.0-37.7) 1.7 25.9 7.3 (6.4-8.2) 0.3 
Intrapartum 16.1 13.9 (12.8-15.0) 0.7 7.5 2.1 (1.7-2.6) 0.1 
Congenital 20.2 17.5 (16.1-18.8) 0.8 26.4 7.5 (6.6-8.4) 0.4 
Sepsis 7.3 6.3 (5.6-7.0) 0.3 21.3 6.0 (5.4-6.7) 0.3 
Pneumonia 2.2 1.9 (1.5-2.2) 0.1 6.8 1.9 (1.6-2.3) 0.1 
Injuries 0.5 0.4 (0.3-0.6) <0.05 1.6 0.4 (0.3-0.6) <0.05 
Other 12.3 10.6 (9.7-11.5) 0.5 10.5 3.0 (2.5-3.5) 0.1 
Total 100 86.4 4.1 100 28.2 1.3 
Low mortality model countries 
Preterm 43.0 80.8 (68.8-91.8) 2.6 27.9 18.4 (16.0-22.2) 0.6 
Intrapartum 15.8 29.7 (22.3-36.5) 0.9 9.0 5.9 (3.4-8.1) 0.2 
Congenital 21.8 41.0 (30.3-57.1) 1.3 27.6 18.2 (15.9-21.6) 0.6 
Sepsis 5.8 11.0 (7.0-14.5) 0.4 17.6 11.6 (7.6-14.8) 0.4 
Pneumonia 2.9 5.4 (3.5-8.3) 0.2 9.9 6.5 (4.1-9.7) 0.2 
Injuries 0.7 1.2 (0.9-1.8) <0.05 1.5 1.0 (0.8-1.3) <0.05 
Other 10.1 19.0 (13.8-23.3) 0.6 6.7 4.4 (2.6-7.4) 0.1 
Total 100 188.1 6.0 100 66.1 2.1 
High mortality model countries 
Preterm 40.6 718.1 (505.3-954.0) 8.4 20.3 126.4 (68.6-198.6) 1.5 
Intrapartum 28.8 509.2 (372.6-659.9) 6.0 13.5 84.0 (49.7-122.7) 1.0 
Congenital 9.0 158.6 (94.5-250.0) 1.9 7.6 47.1 (20.0-94.6) 0.6 
Sepsis 8.3 146.5 (49.7-250.2) 1.7 40.0 249.0 (143.6-371.7) 2.9 
Pneumonia 5.2 91.5 (43.8-189.7) 1.1 4.7 29.2 (15.8-46.7) 0.3 
Tetanus 1.2 21.1 (7.4-53.2) 0.2 4.4 27.1 (8.1-67.2) 0.3 
Diarrhoea 0.4 6.7 (0-57.4) 0.1 1.6 10.0 (3.2-25.6) 0.1 
Other 6.7 118.6 (48.1-213.1) 1.4 7.9 49.1 (20.2-104.5) 0.6 
Total 100 1770.2 20.8 100 622.0 7.3 
1 uncertainty ranges are in parentheses; 2 risk is per 1,000 live births  
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
85 
Figure 4.7: Cause-specific risk from 2000-2013 by neonatal period and estimation method 
a) high-quality VR, b) low mortality model, and c) high mortality model. Note: the y-axes (risk) 
are different on the 3 graphs due to different mortality risks between the estimation 
categories.   
 
a) 
b)  
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c)  
 
 
4.4 Sensitivity analyses 
In this section, I describe sensitivity and validation exercises we performed for this work.  
 
4.4.1 Analysis assuming 65% and 85% for the proportion of early neonatal deaths  
Based on previous work [12], we assumed that 74% and 26% of neonatal deaths occurred in the 
early and late periods, respectively, for countries without adequate VR data.  The three-
quarters/one-quarter split is quite consistent across countries, including ones with widely 
varying contexts [12].  However, to test how this affected our results, we estimated the global 
cause-of-death distribution for the overall neonatal period if the proportion of early neonatal 
deaths was 65% or 85% instead of 74%.  The results are shown in Table 4.9.  There was little 
difference in the estimates when the proportion of early deaths was assumed to be 65% or 85% 
instead of 74% for modelled countries, and these changes made no difference to the ranking of 
causes.   
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Table 4.9: Global cause-specific proportions and numbers of neonatal deaths in 2013 (with 
uncertainty) assuming different proportions of deaths in the early neonatal period 
 Assuming 74%1 
deaths in early 
neonatal period 
(current method) 
Assuming 65%1 
deaths in early 
neonatal period* 
Assuming 85%1 
deaths in early 
neonatal period* 
% # of deaths 
in 1000s2 
% # of deaths 
in 1000s 
% # of deaths 
in 1000s 
Preterm 35.7 
986.9 
(699.1-1312.5) 
34.0 939.8 37.8 1044.4 
Intrapartum 23.4 
644.8 
(462.4-844.7) 
22.1 610.4 24.9 686.9 
Congenital 10.5 
289.8 
(183.3-450.4) 
10.4 288.1 10.6 291.8 
Sepsis 15.6 
430.4 
(218.9-664.8) 
18.2 501.5 12.4 343.6 
Pneumonia 4.9 
136.4 
(70.3-259.0) 
5.0 137.0 4.9 135.8 
Diarrhoea3 0.6 
16.6 
(3.2-83.0) 
0.7 19.3 0.5 13.4 
Tetanus3 1.7 
48.2 
(15.5-120.4) 
2.0 55.0 1.4 39.8 
Other4 7.5 
207.8 
(99.0-367.4) 
7.6 209.8 7.4 205.4 
1 this split is only applied to countries for which modelled estimates are needed – the split 
for countries with high-quality VR data is taken from the data as is; 2 uncertainty ranges 
are in parentheses; ; 3 estimated only for the 80 high mortality model countries;  
4 injuries are included within the “other” category 
 
 
4.4.2 Uncapped prediction covariate values 
As noted in section 4.2.2, we capped the predication covariate values to the minimum and 
maximum of the input covariate values in both the low and high mortality models to avoid 
predicting on covariates outside of the input data range.  Capping the prediction data will tend 
to “shrink” the predicted cause distribution towards that seen in the input data.  Here, I present 
the results of a sensitivity analysis in which we ran the low and high mortality models without 
the caps on the covariate values (Table 4.10). 
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Table 4.10: Estimates with capped versus uncapped prediction covariate values for 2013 
 Early period Late period 
 % of 
deaths 
(capped)1 
% of  
deaths 
(uncapped)2 
Absolute 
difference 
% of 
deaths 
(capped) 
% of  
deaths 
(uncapped) 
Absolute 
difference 
Low mortality model 
Preterm 43.0 44.2 +1.2 27.9 27.7 -0.2 
Intrapartum 15.8 16.5 +0.7 9.0 9.2 +0.2 
Congenital 21.8 19.1 -2.7 27.6 27.4 -0.2 
Sepsis 5.8 6.1 +0.3 17.6 17.9 +0.3 
Pneumonia 2.9 3.0 +0.1 9.9 9.8 -0.1 
Injuries 0.7 0.7 0 1.5 1.5 0 
Other 10.1 10.4 +0.3 6.7 6.6 -0.1 
High mortality model 
Preterm 40.6 40.6 0 20.3 20.3 0 
Intrapartum 28.8 28.7 -0.1 13.5 13.5 0 
Congenital 9.0 9.0 0 7.6 7.6 0 
Sepsis 8.3 8.3 0 40.0 40.1 +0.1 
Pneumonia 5.2 5.2 0 4.7 4.7 0 
Tetanus 1.2 1.2 0 4.4 4.3 -0.1 
Diarrhoea 0.4 0.4 0 1.6 1.6 0 
Other 6.7 6.7 0 7.9 7.9 0 
1 “capped” analysis is the main analysis; 2 “uncapped” is the sensitivity analysis.   
 
In the low mortality model, excluding countries with few deaths (<50), the key differences (>5 
percentage point difference) in countries were:  
o Egypt (both periods, 2000-2006) – intrapartum was 5-9 percentage points higher with 
the uncapped covariates 
o Syria (both periods, 2012-2013) – sepsis was 9-11 percentage points higher and 
congenital was 6 percentage points lower with the uncapped covariates 
o Honduras (early period, 2000) – injuries was 8 percentage points higher with the 
uncapped covariates 
o Jordan (early period, 2000) – injuries was 5 percentage points higher with the uncapped 
covariates 
 
In the high mortality model, both Niger (2000, other) and Kazakhstan (2013, congenital) were 2 
percentage points higher in the early period with uncapped covariates.  No other countries had 
more than a one percentage point difference between the sensitivity versus main analysis.   
 
Overall, the decision to cap or not appears to have had minimal influence on the results. 
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4.4.3 Comparison of different neonatal cause-of-death estimates for China 
We used the low mortality model to estimate the proportional cause distribution in China due 
to its relatively low NMR (18.8 in 2000; 7.7 in 2013), obtaining around 14.4% of neonatal deaths 
attributable to intrapartum-related complications (Appendix B.4.4).  While we chose to retain 
the low mortality model results for China, we have included two different estimates in Appendix 
B.4.4 for comparison.  The first are the WHO estimates for China (Table B.8a; Appendix B.4.4) 
[152], based on single-cause models for the overall neonatal period, and the second are 
estimates for China using the high mortality model instead of low mortality model in our analysis 
(Tables B.8b and B.8c; Appendix B.4.4).  
 
 
4.5 Discussion 
We developed systematic, nationally comparable estimates of programmatically relevant 
neonatal causes of death.  These estimates go beyond CHERG’s previous estimates in providing 
separate decompositions for the early and late neonatal periods.  The proportional neonatal 
cause distribution varies with a number of factors, including the early versus late neonatal 
periods, NMR level, and over time.  To reduce neonatal deaths, such variations must be 
understood, and this knowledge must be incorporated into decisions regarding the selection of 
appropriate interventions.  With the launch of the Sustainable Development Goals for the 
period 2015 to 2030, this is a particularly opportune time for affecting such change within 
countries.  
 
The three leading categories of causes of neonatal death (preterm, intrapartum, and infections) 
are the same for the early and late neonatal periods, but their distribution is substantially 
different between the two periods.  Globally, in the early period, preterm and intrapartum 
account for nearly 68% of deaths while infections (pneumonia, sepsis, tetanus, and diarrhoea) 
account for around 14%.  In the late period, around 34% of deaths are due to intrapartum or 
preterm while roughly 48% are from infections.  Intrapartum-related complications are 
expected to occur in the minutes or hours after birth, and hence cause more deaths during the 
early period.   
 
Even within each neonatal period, considerable differences exist in the proportional cause 
distribution by NMR level.  Generally, NMR is closely linked to the level of care available to 
neonates.  Settings with very low NMR tend to have readily available intensive care for 
newborns, while areas with high NMRs often lack even simple interventions like clean delivery 
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kits and resuscitation equipment.  In this analysis, low mortality countries had higher 
proportions of deaths from congenital disorders and lower proportions from intrapartum and 
infections, while the opposite was true in high mortality settings.  While infection deaths 
accounted for 51% of deaths in the late period in high mortality countries, they caused less than 
30% of late neonatal deaths in low mortality countries.  This is likely because of better access to 
and availability of treatment and infection control in low mortality countries.  
 
We used our model to predict trends in individual causes of death.  Our model predicts that 
deaths due to intrapartum-related complications had the largest absolute risk reduction 
between 2000 and 2013, from 7.2 (UR: 4.8-9.5) to 4.7 (UR: 3.4-6.1) per 1,000 live births, possibly 
because of increased coverage of skilled obstetric care.  The largest relative decrease in risk was 
predicted for neonatal tetanus, which dropped by 73% (from 1.1 [UR: 0.3-2.8] to 0.3 [UR: 0.1-
0.9]) between 2000 and 2013.  This may be due to increases in clean deliveries, facility birth, 
cord care, and tetanus toxoid vaccination (a predictor in the model; PAB), as well as contextual 
changes in maternal education and social norms.  Additionally, a few countries in the low 
mortality model eliminated neonatal tetanus after 2000.  Since tetanus is not estimated in the 
low mortality model, we may thus be underestimating the relative decline in risk.   
 
The smallest predicted relative decrease in risk was for congenital (13% drop; from 2.4 [UR: 1.4-
4.1] to 2.1 [UR: 1.3-3.3]).  While the predicted risk of death due to preterm complications fell by 
2.4 per 1,000 live births between 2000 and 2013 (from 9.6 [UR: 6.7-12.8] to 7.2 [UR: 5.1-9.5]), 
this represented the second smallest relative decrease (25%), despite the existence of simple 
and cost-effective interventions such Kangaroo Mother Care [12, 153]. In addition to 
prematurity, there is also evidence that babies that are small-for-gestational age are at higher 
risk of death [154].   
 
Broadly, our results are similar to those from 2010 [15], with the exception that we estimated 
substantially fewer pneumonia deaths than before. This is likely due to improvements to the 
estimation approach, namely the inclusion of additional studies that split pneumonia from 
sepsis and the inclusion of pneumonia directly in the multinomial model.   
 
We used the low mortality model to estimate the proportional cause distribution in China due 
to its low NMR (18.8 in 2000; 7.7 in 2013), obtaining around 14.4% of neonatal deaths 
attributable to intrapartum-related complications.  Others have also estimated the neonatal 
COD distribution in China and their results differ somewhat from ours, most notably with higher 
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proportions of intrapartum-related deaths [155, 156].  Our approach differs in three important 
ways: 1) we used multi-cause instead of single-cause models, 2) we estimated results for the 
early and late neonatal periods separately, and 3) we included input data from outside of China.  
We believe the first two are advantages in our work, while using China-only data is an advantage 
of the other models.  The global COD distribution changes little when we apply the WHO COD 
proportions [152] for China instead of ours, with the biggest differences in 2013 being 
intrapartum-related and other deaths increasing by about 2 percentage points.  
 
Although the quantity and quality of data has improved in recent years, enormous data gaps 
still exist.  We now have nearly 100,000 deaths and over 90 studies in the high mortality model 
compared to <14,000 deaths and <60 studies when the estimates were produced in 2005 [13].  
However, while we used the high mortality model for 80 countries, the inputs only included 
data from 36 countries.  Many of these studies were relatively small, and few were nationally 
representative.  We could include data from only 13 Sub-Saharan African countries, the region 
with the highest risk of neonatal death.  Excluding a large South African dataset, the studies 
from these countries contribute only 4,000 deaths to our database.  It is an unfortunate reality 
that we know the least about the areas with the highest burdens.  
 
As with all such modelling exercises, our estimates should be viewed as an interim measure to 
help policymakers, particularly in settings with little or no data currently.  It is important to 
distinguish estimates from data and to recognize that not all estimates are “equal”.  We used 
UN-IGME estimates of the NMR and total number of neonatal deaths in each country.  The UN-
IGME estimates of all-cause mortality in each country are derived from data for that country 
and therefore it can be argued that they “track” mortality in each country, though not in real 
time.  For most countries, our cause-specific estimates are not based on data from that country, 
but from a model bringing together data from many countries.  The model then predicts the 
cause-of-death distribution, and changes in the cause-of-death distribution, in individual 
countries based on covariate values for the individual country.  Some countries contribute little 
or no input data to the modelling process.  For example, only 24 deaths in our input data come 
from Nigeria, one of the most populous countries.  Our estimates should not therefore be 
interpreted as “tracking” changes in causes of death for the majority of countries, but rather as 
predictions of what might be occurring in countries.  To track changes in burden due to specific 
causes of death requires each country to collect representative and consistent data on causes 
of death on a continuing basis.  We emphasise that our estimates are not a panacea for actual 
data collection and should not be an excuse for a failure to collect data. 
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Fortunately, rapid but sensible improvements in data collection are possible.  Recent examples 
of countries like South Africa improving their data systems to the point where their VR data is 
considered high quality are encouraging.  As data systems improve, regression-based models 
should be replaced by reliable local COD data.   
 
The validity of our estimates relies on the quality of the input/prediction data, and our modelling 
techniques.  Quality is of particular concern for verbal autopsy studies, in which the reported 
cause distributions depend heavily on the case definitions and causal hierarchies used to 
attribute deaths [66]. Accurate cause attribution using VA will always be problematic for causes 
that are difficult to distinguish, such as sepsis and pneumonia, or difficult to identify, such as 
internal congenital abnormalities.  The potential lack of comparability between different VA 
studies can affect the ability of our model to predict variation between settings.  By following 
standardized methods when conducting VA studies, some of these problems can be partially 
alleviated [68]. Additionally, regression-based models inherently depend on the relationship 
between outcome variables and covariates, which should ideally come from the same 
population and time period.  While we sought to include as much local covariate information as 
possible for the input studies, 52% of the total covariate information came from national data 
instead of from local/regional data.  Finally, when re-categorizing reported VA causes of death 
(Table 4.1), we had to make choices, for example placing deaths reported as being due to “very 
low birth weight” into the preterm complication category.  This may introduce a degree of 
misclassification as some “very low birth weight” deaths may be attributable to congenital 
abnormalities.  We made those choices that we believed would introduce the least 
misclassification, but until VA methods improve, this will continue to be a challenge.  Similar 
issues exist in ICD coding, but are more common in VA studies because of the limited and lower 
quality information collected.   
 
Even high-quality VR data can have problems.  Unfortunately, ICD-10 codes are not ideal for 
neonatal causes, particularly because several programmatically relevant causes are relegated 
to the often-unused fourth digit in the codes.  Codes for the upcoming ICD-11 revision are being 
drafted, providing the opportunity to develop more appropriate, clinically relevant coding for 
neonatal causes.  Additionally, ICD coding practices can vary between and even within countries 
and over time [60, 61].  Such variations reduce our model’s ability to predict true variation in 
causes of death.  Other issues in VR coding include changes during the transition between ICD 
revisions, differences in relegating certain causes to non-specific/ill-defined cause categories, 
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and the assumption inherent in our exclusion of such codes that the deaths attributed to them 
are a random sample of all deaths.  Finally, the availability and quality of VR data in a country 
may change over time, especially in countries with newly emerging surveillance systems.  
Developing consistent time trend estimates given such changes remains a challenge.   
   
We used multinomial models because they naturally ensure that proportional cause 
distributions sum to one, and thus the sum of cause-specific deaths equals total deaths.  Single-
cause models require post-hoc adjustments to retain this property, and there may be limited 
information on which to base such adjustments.  An important concern for both types of 
models, however, is the attribution of death to a single cause.  This does not allow for co-
morbidities, which are a frequent occurrence in neonatal deaths, and may thus underestimate 
the impact of a given cause.  
 
Given the considerable variations in health systems and contextual factors within individual 
countries, subnational neonatal COD estimates are needed and should be a target for future 
estimation exercises and data collection.  National-level estimates like ours aim to ascertain the 
average causal distribution for a country, which can help guide national priorities, but may mask 
subnational variation.  Some countries are beginning to collect the necessary information for 
subnational estimates.  For example, our national India estimates were produced by aggregating 
state-level estimates.  In the future, we also hope to further differentiate causes within the 
current broad categories like congenital disorders.  However, such differentiation may only be 
possible for VR-based models, as VA-based data generally lack the detail needed to do this.  
Finally, we strongly believe that the production of such estimates should be transparent.  In 
accordance with this, the datasets and Stata code we used for this analysis are available on the 
WHO Global Health Observatory website. 
 
Neonates constitute an important component of the unfinished agenda of the fourth MDG, and 
reducing preventable neonatal deaths will be essential to achieve the “grand convergence” to 
which the global community now aspires [157].  The SDGs include a target of 12 or fewer 
neonatal deaths per 1,000 live births for all countries by 2030 [138], which provides fresh 
impetus for ending preventable newborn deaths and a future in which every baby has an equal 
chance of survival. 
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Theme 2: Improving modelling techniques 
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5 Issues with the current neonatal multinomial cause-of-death 
models 
While revising the neonatal cause-of-death (COD) models to produce separate estimates by 
neonatal period (chapter 4), we identified modelling issues that we wanted to investigate 
further.  In this chapter, I focus on three key issues that we identified.  The first two, predictive 
accuracy and model stability, are separate but interlinked aspects of model performance.  The 
third issue is whether and how to give more weight to country-specific empirical data when 
producing a country’s modelled COD estimates.  The work presented here was not an exhaustive 
investigation into these issues, but instead an attempt to understand how they may affect our 
estimates and identify possible solutions as we determined model improvement priorities.   As 
such, the focus of this chapter is on potential weaknesses in our existing modelling approach 
rather than strengths; I provide a description of the strengths in sections 4.5 and 8.3.    
 
5.1 Model performance 
5.1.1 Introduction 
Evaluating model performance is always important, but especially so for prediction models like 
ours where the main priority is to produce estimates that are as reliable as possible.  This 
includes accuracy (i.e. unbiasedness), precision, and repeatability.  In this section, I investigate 
two aspects of model performance that we identified for further investigation with our models: 
model stability and predictive accuracy.   
 
Model instability, or large changes in the model due to small changes in the input data, can lead 
to unreliable results.  In our case, changes in the model could include different covariates 
selected for inclusion in the regressions and/or differences in the estimated coefficient values.  
Substantial changes in the predictions derived from the model results would mean unreliable 
results.  Mitigating this instability as much as possible is important for developing robust 
estimates.  To evaluate predictive accuracy, we would ideally have separate datasets for 
building a model and then validating it [158].  These are commonly referred to as training and 
test datasets.  Predictive accuracy of a model can be assessed by applying the coefficients 
estimated from the training dataset to the separate validation (i.e. test) dataset.  Comparing the 
model predictions to the data in the test dataset thus results in true out-of-sample validation.  
However, in data sparse situations such as ours, predictive accuracy is typically gauged using 
the input dataset (or variations of it, e.g. using k-fold cross-validation) for both building and 
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validating the model [159].  Although not ideal, this type of internal validation is often the only 
possible solution when working with small datasets.   
 
In the rest of this subsection, I present preliminary results of predictive accuracy and stability 
tests in our models, investigate factors that may affect model performance, and identify some 
potential solutions.   
 
Note: the following metrics are used in this subsection.   
o Chi-squared goodness-of-fit statistic (χ2): this metric is the sum of the squared 
differences between observed and estimated deaths divided by estimated deaths for 
each cause.  The equation is as follows: 
𝜒2 = ∑
(𝑂𝑖−𝐸𝑖)
2
𝐸𝑖
𝑖        (Eq. 5.1)  
where O is the number of cause-specific observed deaths, E is the number of cause-
specific estimated deaths, and i is the observation (i.e. country-year or study).   
o % reduction in residuals from the null (herein “% reduction from null”): this goodness-
of-fit metric is used to select the best fitting equations during the covariate selection 
process.  It is calculated by comparing the chi-squared statistic (Eq. 5.1) of the selected 
equation with that of the null model with no covariates.  A positive value indicates an 
improvement in out-of-sample performance over the null model, while a negative value 
indicates worse performance.  The equation is as follows: 
% 𝑟𝑒𝑑𝑢𝑐𝑡𝑖𝑜𝑛 𝑖𝑛 𝑟𝑒𝑠𝑖𝑑𝑢𝑎𝑙𝑠 =  
𝜒𝑛𝑢𝑙𝑙
2 −𝜒𝑒𝑞𝑢𝑎𝑡𝑖𝑜𝑛
2
𝜒𝑛𝑢𝑙𝑙
2 ∗ 100          (Eq. 5.2)    
o Average chi-squared statistic (𝜒2̅̅ ̅): this variation of the χ2 metric is used to compare 
models with different numbers of observations.  The equation is as follows: 
𝜒2̅̅ ̅ =  
𝜒2
𝑛
      (Eq. 5.3) 
where χ2 is the chi-squared statistic (Eq. 5.1) and n is the total number of observations 
(i.e. country-years or studies). 
o Normalized root mean square error (NRMSE): this metric is conventionally used for 
certain model averaging methods (e.g. bagging) to estimate the error rate between 
estimated and observed deaths.  The equation is as follows: 
√
∑ (𝑂𝑖−𝐸𝑖)2𝑖
𝑛
(𝑂𝑚𝑎𝑥 − 𝑂𝑚𝑖𝑛)⁄     (Eq. 5.4) 
where O is the number of cause-specific observed deaths, E is the number of cause-
specific estimated deaths, i is the observation, n is the total number of observations, 
and Omax and Omin are the maximum and minimum number of deaths for the given cause 
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in the observed data.  The denominator (Omax-Omin), used for standardization, measures 
the total range of variation of the observed quantity.  The NRMSE thus tells us what 
fraction of this variation corresponds to the residual root mean square error.   
 
5.1.2 Do we have model performance issues? 
Predictive accuracy 
To evaluate predictive accuracy, we used our standard two-step modelling approach for 
neonatal COD estimates (section 4.2.1) with a slight modification (italicized): 1) covariate 
selection based on minimizing the jackknife out-of-sample prediction error for each non-
baseline cause, and 2) running the multinomial regressions using the selected covariates and 
applying the resulting coefficients to covariates in the input dataset.  By applying the coefficients 
to the input dataset, we can compare the predictions from our model to the observed data.  We 
expect this to be an overestimate of our model performance since we used the input dataset 
for both training and testing the model, and thus overfitting is likely.  However, this should 
provide an initial indication of how well our models are performing as a best-case scenario.  We 
compared these modelled estimates with the observed data to evaluate the model 
performance.  We did this for all four models: low mortality (early and late neonatal periods) 
and high mortality (early and late neonatal periods).  We used the same input and prediction 
datasets as described in section 4.2.2, with the following updates: 1) the prediction datasets 
now had data through 2015 instead of 2013, 2) recent VR data (through 2014) was added to the 
low mortality model input dataset, and 3) 8 new studies with a total of 2,102 new deaths were 
added to the high mortality model input dataset.  See Appendix C.1 for updated input 
datapoints.     
 
The predictive accuracy of the low mortality model was variable (Figure 5.1).  Some causes had 
overall reasonable agreement between the observed and estimated values in the validation 
(e.g. Figure 5.1a) while others had poorer agreement (e.g. Figure 5.1b).  For the latter 
(intrapartum; early period), the model predicted little variation in the proportion of deaths 
while the observed data suggested substantial variation.  A few causes had good agreement on 
average but with a wide spread, suggesting poorer agreement for some observations (e.g. 
Figure 5.1c).     
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Figure 5.1: Low mortality model validation examples: observed versus estimated cause-specific 
estimates. a) pneumonia/late; b) intrapartum/early; c) sepsis/late. Note: circles are weighted 
by total neonatal deaths for given country-year compared to all other country-years.    
 
 
A similar pattern was seen for the high mortality validation exercise (Figure 5.2).  Some causes 
had reasonable agreement between the observed and predicted estimates (e.g. Figure 5.2a), 
some had a more mixed performance (e.g. Figure 5.2b), and others showed poorer agreement 
(e.g. Figure 5.2c).   
 
Figure 5.2: High mortality model validation examples: observed versus estimated cause-specific 
estimates. a) congenital/late; b) preterm/early; c) pneumonia/early. Note: circles are weighted 
by total neonatal deaths for given study compared to all other studies.    
 
This exercise indicates that our models tend to “squeeze” the cause-specific proportions into a 
narrower range than the observed proportions.  (i.e. the observed data typically have wider 
ranges than the predicted) (Table 5.1).  Some of this “squeezing” of the predicted estimates 
appears to be severe.  For instance, in both models there were causes with a predicted upper 
bound that was at least 30 percentage points lower than the observed upper bound (Table 5.1).   
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Table 5.1: Observed versus predicted cause-specific proportions by model and period 
 Low mortality model High mortality model 
 Early period Late period Early period Late period 
Obs1 
range 
(%) 
Pred2 
range 
(%) 
Obs 
range 
(%) 
Pred 
range 
(%) 
Obs 
range 
(%) 
Pred 
range 
(%) 
Obs 
range 
(%) 
Pred 
range 
(%) 
Intrapartum 1-54 12-20 0-25 6-11 4-51 17-36 0-51 11-35 
Congenital 3-65 7-33 5-66 6-42 0-35 3-20 0-36 2-26 
Preterm 8-79 39-54 0-65 20-35 6-71 24-51 0-69 19-47 
Sepsis 0-26 1-12 0-38 6-41 0-58 1-23 0-87 2-31 
Pneumonia 0-31 0-10 0-36 2-28 0-29 4-17 0-44 6-17 
Injuries 0-9 0-3 0-10 0-2 --- --- --- --- 
Diarrhoea --- --- --- --- 0-21 0-8 0-33 0-8 
Tetanus --- --- --- --- 0-50 0-29 0-50 0-32 
Other 0-41 0-16 0-29 5-16 0-35 1-13 0-35 1-13 
1 obs = observed; 2 pred = predicted 
 
Some level of “squeezing” is expected because random stochastic noise will tend to widen the 
range of the observed data compared with the range in the underlying proportions.  The 
squeezing seen here brings the estimates closer to the average, thereby removing some of the 
variability seen in the observed data.  The wide range in data quality and sample sizes of our 
input data increases the likelihood of high levels of stochastic noise in the observed data.  Thus, 
pulling of the modelled estimates towards the mean is arguably reasonable.  However, the 
severity of some of the squeezing may limit the models’ ability to predict variations in the 
proportions of certain causes.  I discuss potential reasons for suboptimal prediction accuracy in 
section 5.1.3.  
 
Model stability 
While running our COD models, we noticed a potential model instability issue.  Our choice of 
covariates for each equation in the multinomial model is based on out-of-sample goodness-of-
fit (GOF) as described in section 4.2.3.  A potential source of instability is if there are large 
differences in the choice of covariates as a result of small changes in the GOF metric.  We 
sometimes noticed the presence of such instability in this work.  For example, the difference 
between the first- and second-best equations based on GOF for intrapartum (early; low 
mortality model) was only 3.7% (χ2 of 17025 versus 17649).  But there was no overlap in 
covariates between these top two equations: female literacy for the top equation; DPT, GNI, 
and U5MR for the second-best equation.  A similar example in the high mortality model was 
tetanus (early period).  For this cause, the two best equations based on GOF both had female 
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literacy and the early/late period covariates.  But the first equation also had BCG and NMR while 
the second had ANC and DPT instead.  The GOF difference between these equations was only 
1.4% (χ2 of 1619 versus 1642).    
 
The key concern here is that slightly different GOF metrics may yield different covariate 
equations which could potentially lead to substantially different final COD estimates.  
Differences in which covariates are selected for an equation are not necessarily a problem if 1) 
the primary goal is predictive accuracy rather than model interpretability and 2) the predicted 
estimates themselves are stable.  The latter is possible because the modelled covariate 
coefficients in different equations can still yield similar final estimates.  However, such stability 
is more likely for the global average rather than across all predicted country-years, and 
ultimately our models need to be stable at the country-year level.  Furthermore, there is no 
guarantee that there will be similar final estimates when there are large differences in which 
covariates are included in a cause equation.  For instance, despite only a 3% difference in GOF, 
the modelled numbers of deaths for sepsis (early; high mortality model) were 97,000 (5.6%) 
versus 245,000 (14.3%) between the first- and second-best models.  While large differences in 
number of deaths between top models were uncommon in our results, such instability is 
impossible to predict in advance.  Therefore, even this simple demonstration of model instability 
is enough to warrant further investigation because it is an indication that such differences could 
occur again, unpredictably, in future models.  In the next subsection, I discuss our work on 
ascertaining some potential causes of model instability.  
 
5.1.3 Factors affecting model performance 
Model performance can be affected by several factors.  Here, I discuss quality and quantity of 
the COD input data, covariate availability and quality, the strength of the covariate-cause 
relationships, and the covariate selection method.  The choice of modelling strategy, which is 
also an important factor, is discussed in more detail in chapters 6 and 7.   
 
Quality and quantity of the cause-of-death input data 
As noted in section 2.3, the COD input data in our models are of variable quality.  This is 
particularly true for the high mortality model, which is largely based on VA studies.  Some 
concerns with VA data include misidentification of causes, unclassified deaths, and use of 
different case definitions and causal hierarchies across studies (section 2.3.2).  Some of these 
can manifest as systematic biases in the data (e.g. inevitably underreported causes in VAs like 
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“hidden” congenital abnormalities).  Others add “noise” to our input data, which can obscure 
true covariate-cause relationships.  The lack of standardization for both VA methods and 
reporting of results for publication can lead to noisy input data in our models even when data 
may otherwise have been comparable.  Additionally, the COD input dataset is moderate in size, 
with about 100,000 deaths across 124 observations from 95 studies in the most recent dataset 
version.  Only 37 of 81 countries in the high mortality model have COD input data.  Issues like 
noise, overfitting, and outliers can be more pronounced in smaller datasets.   
 
The low mortality model has fewer COD input quality issues because it uses high-quality VR 
data.  Although there are some quality concerns with VR data (section 2.3.1), these are less 
extreme than those found in the VA data.  There are also more input data, with over 2.2 million 
neonatal deaths across 4,000 observations from 73 countries.  Thus, the data issues noted for 
the high mortality model may be less of a concern (though model instability is not precluded, as 
demonstrated by the intrapartum example in section 5.1.2).  One potential issue for the low 
mortality model, however, is that the input versus prediction countries do not overlap (i.e. 
prediction countries do not have input data).  Both the input and prediction countries have 
many similarities, including low mortality levels (less than an NMR of about 10).  But the input 
countries are on average wealthier and have somewhat better health indicators (e.g. median 
NMR of 4.7 vs 9.1 for input versus prediction countries; Table 4.5a).  This has the potential to 
affect predictive accuracy (even if the model had good validation performance) if the covariates 
have different relationships with the COD distribution in these different country groups.  
Including lower-quality VR data from modelled countries into the input dataset, and the trade-
off this involves between data quality/noise versus inclusivity, is discussed later (section 8.4).  
 
The data quality and quantity issues discussed here have the potential to affect predictive 
accuracy and stability of the models.  For example, different causal hierarchies being used across 
studies can mask true covariate-cause relationships.  Such relationships are the cornerstone of 
regression analyses, and thus such data issues can weaken our ability to produce robust, stable 
estimates.  Unfortunately, we have no control over these issues without being directly involved 
in original data collection.  I provide recommendations for improved COD data collection and 
reporting in section 8.5. 
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Covariate availability and quality 
The underlying assumption of our modelling strategy is that a set of covariates, in an appropriate 
modelling framework, can be used to predict the outcome.  The accuracy and stability of the 
predictions thus depends partly on the covariates themselves.  The two main covariate-related 
issues that may affect the performance of our models are availability of covariates and noise.  
 
Availability of covariates  
In our models, we included those covariates which had annual, nationally comparable estimates 
available across 194+ countries from at least 2000 onward (section 2.4.1).  The covariates we 
were able to include cover a wide range of areas, from indicators directly linked to neonates 
(e.g. NMR, SBA, ANC) and various health system factors (e.g. vaccination coverage) to broader 
socioeconomic metrics (e.g. GNI, GFR).  The restriction on being able to include only covariates 
with nationally comparable time series is necessary for the type of model we use and the aim 
of our work (i.e. country-year predictions).  Ideally, however, we would include in our models 
all covariates that best predict the COD distribution.  This means including the “right” covariates 
(i.e. those that have the strongest predictive power).   
 
The covariates we were unable to include are heterogenous.  Some are expected to be directly 
linked to specific causes (e.g. access to antibiotics for infection) while others likely affect a 
number of causes (e.g. exclusive breastfeeding).  Some are directly associated with the health 
system (e.g. facility births) while others capture broader socioeconomic factors (e.g. occupation 
or neighbourhood characteristics).  There are also factors that likely have some association with 
the COD distribution but are difficult or nearly impossible to capture as covariates.  For such 
factors, a variable (or some combination of variables) could be used as a proxy, but this may not 
fully capture the intended information.  For example, we included vaccination coverage 
covariates as proxies for access to and availability of basic healthcare interventions.  These 
proxies may be reasonable given the available covariates, but they do not necessarily capture 
the full extent of information we would have liked to include.   
 
Several of the covariates in our models are coverage rather than quality indicators.  For example, 
our models include ANC and SBA coverage, which indicate the percentage of women attending 
antenatal visits or giving birth with a skilled birth attendant present.  But the quality of these 
interactions may be particularly important for the COD distribution.  Measuring quality instead 
of only coverage is a complicated issue, but increasingly acknowledged as crucial [160].  Such 
quality-based covariates are not yet reliably available as nationally comparable time series 
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[161], so we were unable to include them in our models.  But these would be important to 
consider for inclusion if and when such time series do become available.   
 
Noise from covariates 
Another important covariate issue is “noise”.  Two main sources of noise in our covariate dataset 
are measurement error (including through incomplete data) and stochastic noise due to finite 
sample sizes.   
 
First, covariates can be difficult to measure.  Some, like the percentage of women attending 
ANC visits, typically come from self-reported responses in cross-sectional household surveys 
and thus can suffer from biases common to such surveys.  Even a core annual economic measure 
like GNI can be underestimated in countries with large informal sectors [162], which are 
common in low-income countries.  Other covariates, like SBA, are either difficult to define 
precisely or it is difficult to apply their definition precisely when collecting data.   
 
There can also be differences in measurement certainty within a covariate.  The covariate data 
in our models are a mixture of data reported by countries, determined from household surveys, 
modelled, and/or imputed (section 2.4).  A particular covariate time series may have a 
combination of these sources across countries or over time for the same country.  For example, 
the uncertainty in NMR estimates varies widely across countries, largely because of the 
mortality and birth data sources available in a country (section 2.2).  Such a mix in quality within 
a covariate series can add noise to the dataset.  Some of these noise issues are mitigated in our 
models since we run the low and high mortality models separately.  The covariate data for the 
low mortality models tend to have less uncertainty (e.g. NMR calculated from CRVS data), while 
those for the high mortality models have more uncertainty (e.g. NMR modelled based on survey 
data).  Other causes of variation within a covariate series are also important.  The nationally 
comparable covariate time series data we use involve many datapoints.  For example, a time 
series for 194 countries from 1980 to 2015 consists of 6,984 country-year observations.  
Ensuring that the data within these time series are truly comparable is a difficult task, especially 
when covariate definitions or data collection methods change over time.   
 
Within the high mortality input data, an additional source of noise is due to the mismatch of 
local-level COD distributions against regional/national-level covariates.  Although we use the 
local-level COD distribution from a given study, we do not always have corresponding local-level 
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covariate information (section 2.4).  We use regional or national-level covariates when such 
local-level data are missing.  This noise can further mask true covariate-cause relationships.   
 
There is substantial heterogeneity in data quality for the covariates in our models, both between 
and within covariates.  This is because of a combination of what is being measured, how it is 
measured, and how the time series data are put together.  Such variation may not always be 
known or fully understood, and is usually impossible to specifically identify within national 
covariate time series data.  We have worked to reduce some of these noise issues by verifying 
that the covariate data are reasonable (e.g. do not have unrealistic spikes in the time series), 
and working directly with the World Health Organization (WHO) to correct such noise issues in 
their covariate time series data through smoothing algorithms and searching for additional data 
sources. 
 
Covariate and cause relationships 
The cornerstone of a regression analysis is the relationship between the covariates (i.e. 
independent variables) and the outcomes (i.e. dependent variables).  The stronger the 
relationship between a covariate (or set of covariates) and the COD distribution, the better our 
ability to predict this distribution.  Without a strong relationship, both the predictive accuracy 
and stability of the model will be more challenging to achieve.  More minor but still important 
relationships include those between covariates and those between causes.   
 
Relationships between causes and covariates 
Evaluating the relationship between a covariate and outcome is an important step in both 
understanding the strength of their relationship and whether the right functional relationship 
is being used (e.g. linear versus quadratic).  To assess the relationship between the covariates 
and causes of death in our models, we graphed each covariate against the respective outcome 
for each cause (e.g. female literacy versus log(other/intrapartum) in the high mortality model).  
Figure 5.3 includes representative examples of the covariate-cause relationships in our data in 
the low mortality model (top row) and high mortality model (bottom row).  There were some 
covariate-cause pairs which seemed to visually have a relatively strong association.  For 
example, both pneumonia/GNI (Figure 5.3a) and congenital/NMR (Figure 5.3d) appear to have 
decreasing proportional burden as the covariate value increases, which is to be expected.  
However, the majority of covariate-cause relationships appeared to be cloud-like without clear 
patterns (e.g. Figures 5.3b-c and 5.3e-f).  This included instances for which we would expect to 
have seen a relationship, such as intrapartum/ANC (Figure 5.3b) and preterm/LBW (Figure 5.3e).   
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Figure 5.3: Examples of covariate-cause relationships in the low (top row) and high (bottom 
row) mortality models for the early neonatal period. a) pneumonia and GNI; b) intrapartum 
and ANC; c) congenital and female literacy; d) congenital and NMR; e) preterm and LBW; and 
f) other and GFR.   
 
 
For simplicity, we graphed these associations for single covariate-cause pairs instead of the 
multidimensional combinations that are relevant for multinomial or multivariate models.  
Multinomial models have additional complexity because the multiple equations are fit 
simultaneously, and thus the covariates for one cause could affect the estimates of another 
cause.  However, the single covariate-cause graphs still give an indication of the strength of 
these relationships.   
 
Overall, these analyses indicate relatively weak relationships between many of the cause-
covariate pairs.  This is an important issue, but it lacks a clear immediate solution.  The strength 
of these relationships is likely due (at least partially) to some of the COD and covariate data 
issues described earlier in this section, including data quality/noise and covariate availability.   
 
Relationships between covariates 
Multicollinearity, which occurs when covariates are strongly correlated, can be a source of 
instability and thus affect predictive accuracy.  We evaluated multicollinearity in our input data 
and found that IMR and U5MR were, unsurprisingly, highly correlated with NMR in both models 
(>0.8 correlation coefficient in the high mortality model; >0.9 in the low mortality model).  
Retaining just one of a set of highly correlated variables in the model is a reasonable solution to 
this problem.   
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Relationships between causes 
In the COD distribution, some causes are more closely linked than others.  This can contribute 
to misclassification of deaths.  For example, sepsis and pneumonia are difficult to distinguish in 
the neonatal period because of similarities in symptoms and challenges with diagnostics.  In 
other cases, it may be difficult to distinguish an underlying cause from the immediate cause.  
For example, a death from the underlying cause of respiratory distress syndrome in a preterm 
baby may be coded as birth asphyxia (i.e. intrapartum) instead of “preterm”, especially if the 
gestational age is miscalculated (e.g. the baby is truly preterm but is misidentified as full term).  
Finally, some causes may be systematically miscoded.  For example, hidden congenital 
abnormalities (e.g. cardiac abnormalities) are likely to be systematically under-reported, 
potentially into the “other” category.   
 
Medium- to long-term solutions to help mitigate some of these problems are discussed in 
chapter 8.   
 
Covariate selection method 
In work such as ours, the covariate selection approach is important to consider when 
investigating model performance because it dictates which covariates are included in the final 
models.  Covariate selection methods can contribute to model stability or instability depending 
on the modelling approach and data involved.  Some general considerations when picking a 
covariate selection method include balancing appropriateness, completeness (e.g. how many 
covariate combinations to test), and computational intensity/time.   
 
There are two issues with our current method which could affect model performance and 
therefore warrant further investigation: 1) our approach does not evaluate all possible covariate 
combinations and 2) we use binomial covariate selection for multinomial models.  Additionally, 
it is useful to look closely at the metric used to calculate GOF since this is also linked to which 
covariates are chosen for a model.  In this subsection, I discuss each of these and whether they 
affect model performance.     
 
Summary of current covariate selection method 
As described in section 4.2.3, our COD modelling method involves a two-step procedure: 1) 
covariate selection to choose a set of covariates for each COD equation and 2) running the 
multinomial regressions using the selected covariates to produce country-specific COD 
distributions.  The covariate selection approach uses a version of forward stepwise selection 
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where we sequentially add covariates depending on their improvement to out-of-sample GOF 
under a jackknife process.  The out-of-sample GOF is calculated using the chi-squared GOF 
metric (Equation 5.1).  This covariate selection process (using all binomial models) has the 
following steps: 
1) Perform univariate regressions on linear, quadratic, and spline forms of each covariate 
and select the form with the best GOF to include in step 2 
2) Run multivariable regressions  
a. rank covariates based on GOF from step 1 
b. use best ranked covariate to begin building the multivariable regression 
c. add to the multivariable regression the covariate with next best GOF which is 
not already in the regression, and run the regression 
i. If overall GOF worse/same, drop covariate and repeat step c 
ii. If overall GOF better, retain covariate and repeat step c 
 
Once the set of covariates with the best out-of-sample GOF for each cause/baseline equation is 
identified, we include them in the multinomial model, and re-estimate all of the model 
coefficients, from which we derive the country-year predictions.  At present, we do not include 
a threshold of GOF improvement for inclusion in the model; any covariate which improves the 
GOF in step c is added to the equation.  A threshold could be added, however, as is done with 
some conventional covariate selection methods.   
 
Searching over all possible covariate combinations 
For each cause equation, there are 2n possible covariate combinations.  Assuming n=13 
covariates (i.e. 8,192 covariate combinations), 7 non-baseline causes, and separate models for 
the early and late neonatal periods, this means evaluating 57,344 regressions for GOF.  Using 
jackknife to perform out-of-sample GOF, assuming 100 study observations (e.g. similar to our 
high-mortality model), therefore means 5,734,400 regressions.  If each regression took one 
second (as it did in our test), this would be about 9.5 weeks of computation on a single core 
computer.  Although the low mortality model has one less cause category and fewer covariates 
included, it has far more observations and deaths in the database, which make fitting each 
regression slower.  Overall, performing covariate selection using out-of-sample GOF on all 
covariate combinations can be a very computationally intensive task.  It is for this reason that 
we have been using the approach described above, which is a partial instead of full search over 
the multidimensional covariate space and therefore substantially less computationally 
intensive.   
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However, the only way to evaluate whether our existing “approximation” is working well is to 
compare its results to those obtained through searching the full space of covariate 
combinations.  We performed this comparison for each of the four models.  We included 13 
covariates in the high mortality model, excluding U5MR and IMR for feasibility (thereby reducing 
the possible covariate combinations from 32,768 to 8,192).  For the low mortality model, we 
included 10 covariates (i.e. 1,024 possible covariate combinations).  For full comparability, we 
re-ran the high mortality covariate selection partial search algorithm excluding U5MR and IMR 
as well.   
 
The partial search algorithm was highly efficient.  The average number of covariate 
combinations tested by the partial search algorithm for the high mortality model ranged from 
26 to 38 across cause and neonatal period, which is less than 0.5% of the 8,192 combinations 
tested with the full search (Table 5.2).  This algorithm was similarly efficient for the low mortality 
model; it searched less than 2.5% of the 1,024 combinations for each equation.  For most causes, 
the partial search performed well.  The median percentage point differences in the % reduction 
from null metric were 2.9 (high mortality model) and 1.3 (low mortality model) between the 
best fit full versus partial search models (Table 5.2).  The partial search algorithm performed 
less well for a few causes, with up to a 39.5 percentage point difference in % reduction from 
null for congenital in the early period high mortality model (Table 5.2).   
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Table 5.2: Comparison of best fit cause equation results using a full versus partial search of 
covariate combinations for the high and low mortality models by neonatal period 
 # of covariate 
combinations 
tested in 
“partial 
search”1 
Rank of best 
“partial 
search” 
model in 
“full search” 
% reduction 
from null of 
best “full 
search” 
model 
% reduction 
from null of 
best “partial 
search” 
model 
Absolute difference 
between % 
reduction from null 
for best “full” and 
“partial” models 
High mortality model; early period  
Preterm 26 30 53.2 44.1 9.1 
Congenital 26 1154 81.4 41.9 39.5 
Sepsis 28 3 81.1 80.7 0.4 
Pneumonia 26 1 13.5 13.5 0.0 
Diarrhoea 35 2 81.1 79.1 2.0 
Tetanus 34 12 87.8 87.0 0.8 
Other 26 38 85.5 80.2 5.3 
High mortality model; late period  
Preterm 36 589 79.1 62.1 17.0 
Congenital 34 60 91.4 87.7 3.7 
Sepsis 33 1 39.5 39.5 0.0 
Pneumonia 26 1 27.3 27.3 0.0 
Diarrhoea 26 1 30.5 30.5 0.0 
Tetanus 27 94 70.3 66.6 3.7 
Other 38 17 64.7 57.8 6.9 
Low mortality model; early period  
Intrapartum 20 1 13.9 13.9 0.0 
Congenital 21 2 52.7 52.2 0.5 
Sepsis 24 16 59.5 57.3 2.2 
Pneumonia 20 27 36.4 23.4 13.0 
Injuries 20 8 17.7 13.9 3.8 
Other 24 23 26.7 18.3 8.4 
Low mortality model; late period  
Intrapartum 20 1 20.1 20.1 0.0 
Congenital 25 2 8.9 8.7 0.2 
Sepsis 25 20 66.5 63.2 3.3 
Pneumonia 19 2 34.2 33.9 0.3 
Injuries 20 2 0.2 0.0 0.2 
Other 25 9 29.7 27.4 2.3 
1 out of 8,192 possible combinations in high mortality model and 1,024 in low mortality model 
 
Figure 5.4 shows examples of results for the % reduction from null calculations for the full and 
partial search algorithms.  A positive % reduction from null indicates that a model has better 
out-of-sample prediction performance than the null model; conversely a negative value 
indicates worse performance than the null.  As can be seen in Figure 5.4, only a small fraction 
of all possible models performed better than the null model.  Some of the partial search results 
were clustered in terms of their GOF across the full space of models (e.g. Figure 5.4a), others 
were more dispersed (e.g. Figure 5.4b), and some were partially clustered and partially 
dispersed (e.g. Figure 5.4c).  For most causes in each model, the partial search algorithm results 
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were located in the top third best fit full search results (i.e. left third of the graph).  Figure 5.4d 
shows an example of a partial search result which performed less well (congenital/early; high 
mortality model).   
 
Figure 5.4: Example graphs of the % reduction from null for the full versus partial search 
algorithm results. a) pneumonia/early, low mortality model; b) pneumonia/late, low mortality 
model; c) sepsis/late, high mortality model; d) congenital/early, high mortality model. 
 
 
Overall, the results suggest that the partial search is highly efficient (i.e. about 1 minute per 
cause) and effective in most cases.  However, there are times when it performs less well (Figure 
5.4d), and it is impossible to know in advance how well the algorithm will perform.  The full 
search algorithm is the only way to guarantee that the selected covariate combination is the 
best fitting of all possible combinations, but it is computationally intensive to run.  For these 
models, the full search with jackknife out-of-sample and multiple computer cores took 1-2 days 
per cause (i.e. about one month for the four models).  This also restricts the number of 
covariates that can be feasibly included (e.g. 13 versus 15 covariates is a difference of nearly 
25,000 covariate combinations to test before out-of-sample considerations).  Based on this 
analysis, it is debatable whether the benefits of the full search (i.e. guarantee to find best fitting 
model) outweigh the benefits of the partial search (i.e. highly efficient, mostly good 
performance, can include more covariates).   
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Binomial covariate selection for multinomial models 
Our current covariate selection process involves choosing covariates that produce the best out-
of-sample predictions for single cause/baseline equations.  The covariates chosen through this 
binomial approach are then used in a multinomial model.  We chose to use binomial equations 
for the covariate selection because a similar multinomial covariate selection approach would 
result in a combinatorial explosion that would be computationally prohibitive.  However, it is 
possible that the equations selected based on binomial covariate selection have a worse GOF 
once placed in the multinomial environment where all of the equations are fitted 
simultaneously.   
 
We conducted an analysis to compare how well-aligned the out-of-sample GOF metrics were 
for each cause between its binomial covariate selection regression and the relevant multinomial 
model.  To evaluate out-of-sample GOF in the multinomial, we did the following for each of the 
four models: 1) included the best fit equations from the binomial covariate selection in the 
multinomial (as usual) and 2) performed jackknife out-of-sample validation using the 
multinomial model on the input dataset.  The second step involved refitting the model 
parameters for each jackknife sample (i.e. n-1 observations) and applying the coefficient values 
to the excluded study or country-year observation.  To compare the results, we calculated the 
average chi-squared (𝜒2̅̅ ̅) metric for each cause in the binomial and multinomial models.  
 
Table 5.3 shows the results of this out-of-sample GOF comparison for the binomial and 
multinomial results.  The binomial and multinomial GOFs appear to be relatively similar for most 
of the causes, with the multinomial on average having slightly worse GOF.  This is unsurprising 
since the strategy is ‘optimized’ for the binomial, and not multinomial, setting.  However, the 
multinomial GOF was substantially worse for a few causes in the high mortality model.  This is 
starkly evident for sepsis in the early period, with a 𝜒2̅̅ ̅ of 286.3 for the multinomial and 7.7 for 
the binomial (Table 5.3), and present but less severe for a few other causes in the high mortality 
model (e.g. other/early; sepsis/late).   
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Table 5.3: Comparison of the average chi-squared out-of-sample goodness-of-fit statistic for 
binomial covariate selection regressions versus multinomial models by cause and period for the 
low and high mortality models 
 Low mortality model High mortality model 
 Early period Late period Early period Late period 
 Binom1 Multi2 Binom Multi Binom Multi Binom Multi 
Intrapartum 13 11 4 5 baseline 23 baseline 11 
Congenital 10 13 3 4 7 9 4 3 
Preterm baseline 15 baseline 8 6 19 4 10 
Sepsis 7 8 5 7 8 286 7 25 
Pneumonia 11 15 7 9 5 8 5 7 
Injuries 4 4 3 3 --- --- --- --- 
Diarrhoea --- --- --- --- 7 4 6 5 
Tetanus --- --- --- --- 17 35 9 10 
Other 20 24 4 6 11 74 9 16 
1 Binom = binomial;  2 Multi = multinomial 
 
We investigated sepsis (early period; high mortality model) further with an aim to better 
understand which covariate(s) may have been responsible for the substantially worse 
performance upon inclusion in the multinomial model.  To do this, we used a manual non-
exhaustive algorithm we developed to help identify potentially problematic covariates when 
COD estimates had unusual behaviour.  The steps were as follows: 1) identify countries with 
unusual or poorly performing estimates (e.g. substantial spikes in cause-specific proportions; 
unrealistic proportions); 2) search their covariate values in the prediction dataset to select 
potentially problematic covariate(s) for further investigation, 3) re-run the covariate selection 
and model without the potentially problematic covariate (removing one covariate at a time if 
more than one), 4) compare the original estimates with those using the “tweaked” equations.  
If no covariate from the relevant cause equation appeared to be causing issues (or if the 
problematic estimates were for the baseline cause), we looked at the other cause equations as 
well.   
 
We found that the period covariate appeared to add volatility when we applied this method to 
the sepsis equation discussed above.  We re-ran the covariate selection without this covariate.  
Figure 5.5 shows validation graphs of the original and the “tweaked” versions for this cause.  
The tweaked version does appear to be performing better, as is also indicated by the change in 
its  𝜒2̅̅ ̅ value from 286 to 49.   
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Figure 5.5: Multinomial validation for sepsis (early period; high mortality model) comparing 
estimated versus observed proportions a) before and b) after “tweaking” the covariate 
equation.  Note: circles are weighted by total neonatal deaths for given study compared to all 
other studies.    
 
 
A consequence of modifying a cause equation in the multinomial model, however, is that other 
causes are likely to change as well because of the push and pull that occurs during the 
simultaneous fitting of the multiple equations.  In this case, for example, the performance of 
congenital worsened from a  𝜒2̅̅ ̅ of 9 to 28.  Although this is worse, the sepsis improvement was 
substantially greater, and thus such a tweak would be justifiable.   
 
Ideally, the covariate selection strategy should align with the modelling process such that the 
best fit equations found through covariate selection are the optimal equations to use in 
whichever model is used for fitting the parameters.  The caveat is that ideal strategies are not 
always computationally feasible.  Based on the results of this preliminary investigation, our 
existing approach seems to be acceptable in most cases.  While it is difficult to predict whether 
the best fit equation selected from the binomial regressions will fit more poorly once in the 
multinomial model, the multinomial fit can be examined empirically as shown above.  Tweaking 
the covariate selection process as we did above is suboptimal as part of a formal modelling 
strategy because the approach is manual, not systematic, and not exhaustive.  However, an 
algorithm could be developed to make this process less subjective.  For example, our manual 
process could be coded and automated such that covariates are investigated if the GOF statistic 
(or the covariate parameter estimates) change a certain amount between the binomial 
covariate selection and multinomial models.  I also discuss some alternative covariate selection 
strategies in section 5.1.4.   
 
Choice of the χ2 metric for goodness of fit 
We use the χ2 metric (Equation 5.1), a standard GOF metric, to estimate the out-of-sample GOF 
in the covariate selection process.  The % reduction from null calculation (Equation 5.2) is also 
  
 
114 
based on the χ2 metric.  Given that covariates are ultimately selected or rejected from the model 
equations based on their out-of-sample GOF, the choice of the χ2 metric plays an important role 
in our covariate selection.   
 
Table 5.4 shows the % reduction from null for the best fit equations of each cause and model 
for our current models.  This provides an indication of how well the selected set of covariates is 
predicting out-of-sample data compared to a null model (i.e. intercept-only model with no 
covariates).    
 
Table 5.4: % reduction from null for the best fitting equations by cause and period in the low 
and high mortality models.   
 Low mortality model High mortality model 
 Early period Late period Early period Late period 
Intrapartum 13.9 20.1 (baseline) (baseline) 
Congenital 52.2 8.7 72.7 86.5 
Preterm (baseline) (baseline) 44.4 63.2 
Sepsis 57.3 63.2 82.0 40.1 
Pneumonia 23.4 33.9 11.8 31.5 
Injuries 13.9 0.0 --- --- 
Diarrhoea --- --- 83.6 38.9 
Tetanus --- --- 88.5 80.2 
Other 18.3 27.4 83.0 56.0 
Note: High mortality results here differ slightly from Table 5.2 because the partial 
search algorithm for that analysis was adjusted to exclude some covariates for 
comparability to the full search algorithm.   
 
There is a relatively wide range in the percent reduction from null, from 0% for injuries (late 
period; low mortality model) because the null model had the best fit to 88.5% for tetanus (early 
period; high mortality model).  Overall, the high mortality model had higher % reductions from 
null than the low mortality model.   
 
In general, the impression obtained from visual inspection of the observed versus estimated 
proportions is consistent with the GOF metric.  For example, the model appears to perform well 
for congenital (late period; high mortality model) which had an 86.5% reduction from null 
(Figure 5.6a).  In contrast, the model both appears to perform poorly and has a low 11.8% 
reduction from null for pneumonia (early period; high mortality model) (Figure 5.6b).   
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Figure 5.6: Estimated versus observed death proportions for a well versus poorly performing 
cause in the high mortality model. a) congenital/late; b) pneumonia/early.  Note: circles are 
weighted by total neonatal deaths for given study compared to all other studies.    
 
 
A few causes, however, appear to have poor GOF but still a relatively high % reduction from null 
based on visual inspection.  This is because the GOF calculation, based on the χ2 metric, 
prioritizes the model fit for observations with larger numbers of deaths.  An example of the 
consequence of this can be seen in Figure 5.7.  Here, both graphs appear to have poor GOF (i.e. 
most points are not along the red diagonal line).  Yet, the % reduction from null for preterm 
(late period, high mortality model; Figure 5.7a) is 63.2%, which is substantially higher than the 
11.8% for pneumonia (included again for comparison; Figure 5.7b).  The key difference appears 
to be that the model is performing well for the largest studies (indicated by circle size) for 
preterm, which influences the χ2 GOF calculation.   
 
Figure 5.7: Model validation for causes with similar performance but divergent % reduction 
from null in the high mortality model. a) preterm/late); b) pneumonia/early.  Note: circles are 
weighted by total neonatal deaths for given study compared to all other studies.    
 
 
This may also help explain why the high mortality model on average has higher % reduction 
from the null than the low mortality model (Table 5.4).  The low mortality model has far more 
input observations than the high mortality model, and there are many datapoints across the 
range of numbers of deaths (see Figure 5.1 for examples).  Thus, even if the model fit attempts 
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to prioritize larger observations, it is difficult to fit all of them well unless there is a strong 
relationship between causes and covariates that truly explains most of the variation.  In 
contrast, the high mortality model has only a few large studies, and thus it is easier for the model 
to prioritize fitting these well.  This suggests that a higher GOF may be achievable if a few data 
points are much larger than the rest.   
 
Such a metric is typically appropriate since large studies tend to be more reliable because they 
suffer less from stochastic noise effects.  In our case, however, there are only a few large studies 
in the input dataset, and we generally believe that the input data quality is variable, including 
for the larger studies.  Thus, prioritizing the fit towards a few studies, including ones that are 
not necessarily high quality, may not be ideal.  Alternative strategies could include adding 
weights to average out the emphasis between study points and number of deaths in a study or 
choosing a different GOF metric.  Ultimately, however, this is a relatively minor issue.  As noted 
above, the majority of causes had decent alignment between the visual GOF and the % 
reduction from null statistic.  Additionally, it is justifiable to use a metric which gives higher 
priority to larger studies (thereby reducing stochastic noise concerns), especially when the 
actual data quality of each study is unknown.  
 
5.1.4 Potential solutions to improve model performance 
Some of the issues highlighted in the previous section are ones which we cannot directly 
influence (e.g. data quality of input studies) or appear to have relatively minor impact on model 
performance (e.g. partial search algorithm for covariate selection).  Others can be solved simply 
(e.g. removing covariates that are collinear).  In this subsection, I focus on two major categories 
of methods that stand out as having potential to more broadly improve the robustness of our 
models.  Ensemble methods aim to reduce instability by accounting for model uncertainty.  
Regularization methods aim to penalize model complexity, which can improve both stability and 
predictive accuracy.   
 
Here, I briefly describe some of these potential solutions in the context of our models.  The goal 
of this work was to identify some plausible solutions to consider for future implementation.  
Where possible, we performed basic analyses to assess feasibility; full implementation and 
validation of each technique was outside the scope of this objective.   
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Ensemble methods 
Ensemble methods are a family of methods used to improve the stability and predictive 
accuracy of statistical models by combining results from multiple models instead of selecting 
only one [163, 164].  This approach focuses on the fact that there is usually uncertainty in 
selecting a model (as demonstrated in section 5.1.2), and therefore selecting a single model may 
be inappropriate.  These methods, increasingly popular in disciplines like machine learning, 
come in many forms but can be divided into two key approaches: parallel versus serial model 
building.  Serial methods, such as boosting, have been shown to perform more poorly with noisy 
data [165].  Given the noisiness of our input data, we focus on parallel ensemble methods in the 
rest of this subsection.    
 
Parallel ensemble methods involve running several different iterations of a model and averaging 
the results together.  The “different iterations” can imply a range of options, including averaging 
across models that use variations of the input data or ones that use different covariate selection 
outputs.  A consequence of this averaging approach is that there is no single model to output 
as a result of the analysis, which can make model interpretability difficult.  After reviewing the 
literature on ensemble methods, we decided to test two approaches that we believed were 
potentially suitable for our models: 1) simple model averaging with random selection from 
among the top cause-specific equations and 2) bagging.  Here we describe each in more detail 
and describe preliminary work we did to test these with our models.   
 
Simple model averaging 
In model averaging, instead of choosing one model through the covariate selection process, 
several models are built and run in parallel, with their results averaged together (different 
weighting schemes have been proposed) to account for uncertainty in model selection [163, 
166].  We applied simple model averaging as follows: 1) identify the top n covariate equations 
for each cause based on the out-of-sample GOF using the full search covariate selection 
algorithm, 2) randomly select an equation from these top n equations for each cause to form 
the multinomial equation set for the model, run the multinomial model, and produce COD 
estimates; 3) perform m iterations of step 2; and 4) produce final prediction estimates by 
averaging together the proportions by cause across all m iterations.  This method aims to 
address instability due to the uncertainty in covariate selection at the individual cause level, but 
also when included in the multinomial model.   
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We performed the above analysis for n = 5 and m = 500.  Figure 5.8 shows variation in the 
proportion of deaths from congenital, preterm, and sepsis for four example countries.  These 
results demonstrate that there is potential for variation in COD estimates at the country-level 
depending on choice of cause equations.  For example, the proportional estimate for congenital 
deaths in Syria had a median value of 0.2, but the IQR was 0.1 to 0.28.  The mean values (not 
shown), which would be used to ensure that the proportions add up to 1, were nearly identical 
to the median values; only one had a difference of more than 0.5 percentage points 
(Syria/congenital: mean was 1.2 percentage points lower than the median).  These results also 
indicate that the “best” GOF model estimates are often within the middle 50% of the model 
averaging results, but can at times be outside that range (Figure 5.8).  This model averaging 
approach could thus provide some stability to our country-level estimates in situations where 
model uncertainty affects the final estimates.   
 
Figure 5.8: Predicted proportion of deaths in 2013 using model averaging over 500 iterations 
for three causes across four example countries.  
 
 
While such an approach decreases some instability, it is unable to deal with a covariate that may 
be heavily skewing the results but shows up in all or most of the top equations.  Potential 
solutions like manual tweaking to test for and remove problematic covariates are inefficient and 
not systematic (though algorithms could be programmed as described in section 5.1.3) 
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Bagging 
Bagging, short for bootstrap aggregation, relies on building different models based on random 
resampling of the input data, and then averaging the predictions from the models [164, 167].  
In doing so, this method can help address model uncertainty arising from the input data [168].  
Bagging involves first generating n bootstrap samples with replacement from the input dataset.  
The modelling process is then run on each of the samples (including the covariate selection 
step), and the average predicted values are used for the final estimates.  Bagging has been 
shown to decrease variance [169] and is considered to be useful for noisy data [170].  The latter 
is particularly important for our models given the noisiness of our input data.  An additional 
benefit for our models is that this method reduces the risk of a “dominant” covariate adding 
instability since it is performed on many bootstrapped samples.    
 
We performed a preliminary bagging analysis with 130 iterations for the early period low 
mortality model.  We left out approximately one-third of the observations for each bootstrap 
sample and then performed predictions on this leftover “out-of-bag” sample with the fitted 
model.  To assess model accuracy, we calculated the normalized root mean squared error 
(NRMSE) metric (Equation 5.4) on the out-of-bag samples.  Figure 5.9 shows an example of the 
bagging results for one country-year (UK, 2005) in the low mortality model.  The decrease and 
then stabilization in the NRSME in this graph are expected.  Here, the NRSME appears to mostly 
stabilize by about 40 iterations, with almost no further decrease by 100 iterations.  This suggests 
that between 40 and 100 iterations would be sufficient in this case to have improved model 
stability through reduced variance.   These results suggest that bagging may help to increase the 
stability of our models.   
 
Figure 5.9: A bagging analysis example: the normalized root mean square error by number of 
iterations for the UK in 2005.  
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Figure 5.10 shows the bagging results alongside the simple model averaging results for Egypt 
(as shown in Figure 5.8) as a demonstration of how the two approaches may compare.  In 
general, the median estimates are similar but not the same, and bagging appears to have wider 
ranges.  This latter result is not surprising because bagging effectively creates different input 
data and re-runs the covariate selection process for each.  If the input data are noisy, as we 
expect ours are, this would mean that the bagging iterations could have a relatively wide spread.   
 
Figure 5.10: Example of bagging versus simple model averaging for three causes (Egypt, 2013).   
 
 
These examples have demonstrated that country-specific differences can arise when using the 
different methods (current, simple model averaging, bagging).  The aggregate results, however, 
appear to have less variation between these methods.  Figure 5.11 shows the aggregated results 
across the low mortality model countries (n=47) for the early neonatal period.  The results are 
remarkably similar across the three compared methods.   
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Figure 5.11: Comparison of the cause-of-death distribution by current, simple model averaging, 
and bagging methods for low mortality model countries (n=47) 
 
These aggregated results are reassuring, and suggest that the current method is working well at 
the global level when compared with methods that better incorporate uncertainty in the input 
data or covariate selection method.  However, our estimates need to be reliable at the country 
level.  Since there are demonstrated differences at the country level (Figures 5.8, 5.10), a model 
averaging method could help improve robustness of the estimates.   While simple model 
averaging and bagging appear to be promising, we need to assess their utility across the range 
of model improvement methods we are considering.  This will also entail evaluating the 
computational feasibility of these model averaging approaches in the context of other modelling 
improvement choices (e.g. the modelling framework, covariate selection method).  Decisions 
around model improvements are discussed in section 5.3.3. 
 
Regularization methods 
The bias-variance trade-off is at the heart of regularization methods.  Increasing the complexity 
of a model (e.g. by adding covariates) tends to reduce bias because the model will be able to 
better fit more of the data points.  But this increases the risk of overfitting, and typically results 
in higher variance.  Simpler models usually have less variance (and thus more stability) since 
they cannot “move” around as much because they have fewer degrees of freedom.  But such 
models have greater risk of underfitting.  Thus, choosing a model involves carefully thinking 
through the interrelated issues of bias versus variance, overfitting versus underfitting, and 
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complexity versus simplicity in terms of model performance.  Regularization methods try to 
balance GOF and complexity through consideration of these trade-offs.   
  
Numerous approaches have been developed in recent decades that aim to balance model fit 
and complexity [171-173].  Regularization methods generally place a penalty on model 
complexity.  Most of these methods focus on two ways in which instability is associated with 
covariates: 1) increasing the number of covariates increases model complexity and therefore 
the risk of model instability and 2) large coefficient values can increase instability.  Implementing 
the penalty, and whether and how it can be tuned, depends on the specific method used.  Some 
analytical methods, like the Akaike information criterion (AIC) and risk inflation criterion (RIC), 
use penalization mechanisms based on calculated scores to choose between models [171].   
Several regression methods, on the other hand, balance fit and complexity through coefficient 
shrinkage [169, 174-176].   
 
A subset of regularization methods exist that may also be able to help address the issue of using 
binomial covariate selection for multinomial models.  These methods are efficient alternatives 
to the full multinomial covariate search that is computationally prohibitive using our current 
approach.  Lasso and ridge regressions are examples of such regularization methods [169].  The 
general approach is as follows: 1) include all covariates in the model itself and 2) maximize the 
log likelihood minus a penalization/regularization term.  This results in coefficient values 
shrinking.  The lasso regression seems well suited to our modelling approach.  Increasing the 
penalization term in this regression will push some covariates to zero, hence performing a form 
of covariate selection within the multinomial model itself.   
 
We attempted to implement the lasso regression within our multinomial modelling framework.  
We did this by adding a penalty term to the likelihood function.  The implementation appeared 
to work in terms of reduction of covariate coefficients towards zero as the lasso penalty 
(lambda) increased in value.  However, we consistently ran into convergence problems, which 
we were unable to solve within Stata.   
 
Some of these issues may be related to Stata’s ability to handle maximum likelihood estimation 
for complex models, especially with user-written code.  Lasso implementation is relatively new 
in Stata, with an official lasso package only released as part of Stata 16 in June 2019 [177].  The 
convergence issues we encountered may be solvable through more extensive re-writing of our 
multinomial modelling code, or by using a different software package (e.g. R).  Alternatively, we 
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could attempt an implementation of a different regularization method.  Since any of these 
changes would entail a more substantial effort, we decided that it would be prudent to do this 
after further decisions around model changes were made.  This was especially the case given 
the possibility of moving to different modelling frameworks (e.g. binomial models, chapter 6; 
Bayesian models, chapter 7) which would change the lasso implementation approach.   
 
In general, regularization methods appear to be a promising approach for adding stability to the 
models while potentially also solving the problem of multinomial covariate selection.  They also 
have the advantage of generally being less computationally intensive than ensemble methods.  
However, the decision on whether to implement regularization methods (and the choice of 
which one) partly depends on which modelling changes are chosen as priorities to improve the 
COD models.  These decisions are discussed in section 5.3.3, as well as chapters six and seven.    
 
5.2 Weighting of empirical data for country-specific estimates 
5.2.1 Introduction 
Our current modelling strategy does not give additional weight to input data from a given 
country for its modelled estimates.  Therefore, country-specific empirical data do not influence 
a country’s modelled COD proportions any more than data from other countries.  The reasoning 
for this was that the majority of studies in our input database were small and not nationally 
representative.  Thus, it was not obvious that the national-level estimates for a country should 
be moved towards the data points from small non-national studies.  However, an increasing 
number of countries now have data from nationally representative VA studies, including for 
neonatal deaths.  How to use these nationally representative VA studies appropriately in our 
modelling process is an important question as we consider model improvements.   
 
These nationally representative studies are not homogenous in their characteristics; they vary 
in size, study design, and various other factors that affect their quality and comparability.  For 
example, many appear to use different hierarchies to assign causes of death, even across VA 
studies done as follow-ups to otherwise standardized DHS.  Such differences in the nationally 
representative studies are not surprising given that they are conducted by a wide range of 
implementers and researchers, just like the smaller non-national studies.  Although a few of 
these are ongoing (e.g. Million Deaths Study in India), most are one-off studies (e.g. a VA study 
follow-up to a DHS survey).  Cross-sectional studies report COD distributions for only one or a 
few years instead of a longer time trend.  For these reasons, and the inherent concerns with VA 
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data (section 2.3.2), we do not believe the COD distributions from these studies should be used 
“as-is” for the country’s estimates in the way that we use high-quality VR data directly.   
 
Currently, we include these nationally representative studies in the high mortality input 
database and treat them the same as all other studies.  There is no mechanism within the model 
for such data to be given more weight.  In the following subsections, I discuss the implications 
of these studies for our models and country-level random effects as a potential modelling 
solution.   
 
5.2.2 How important is this for our models? 
In some ways, the answer to how important this issue is for our models is a matter of 
perspective.   For example, this issue looks less important in our current models than if we are 
forward thinking and consider contemporary data collection trends.  There is also the (perhaps 
more philosophical) question about the role of modelling and how to balance modelling with 
imperfect empirical data.  Here, I discuss each of these perspectives briefly.   
 
On the practical side, inclusion of country-level random effects would not affect the current low 
mortality model estimates because there are no input data from the prediction countries in this 
model.  The lack of such input data is because the prediction countries are those with VR data 
deemed to be of inadequate quality (see section 4.2.2 for more details).  Lower-quality VR data 
from modelled countries could be considered for inclusion in the input dataset, ideally with a 
quality threshold to balance the desire for inclusion of relevant data with concerns about 
quality/reliability (this is discussed further in section 8.4).   
 
For the high mortality model, 37 of 81 countries have studies included in the input database.  
Of these, eight have nationally representative data, accounting for 9% (11/124) of the data 
inputs in the high mortality model.  These nationally representative studies make up 15% of 
deaths in the high mortality input database and 44% of global neonatal deaths occur in these 
countries.  Thus, the nationally representative data points make up a small fraction of our 
dataset, but come from countries that make up a disproportionately large percentage of global 
neonatal deaths.  Nationally representative VA studies are increasing, and thus it is likely that 
the fraction of our input data that will consist of such studies will increase in the future.   
 
On a more philosophical level, it is important to keep in mind the ultimate goal of this work.  
Ideally, there would be no COD modelling because each country would have its own high-quality 
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CRVS system that continuously collects data at the local level.  Cause-of-death modelling is a 
suboptimal alternative, but one of the few viable current options for many countries (see 
section 2.3.4 for more discussion on this topic).  I have explained in section 5.2.1 why we do not 
use data from VA studies as-is.  Yet, if nationally representative COD data are available, giving 
them more weight in the modelling process for that country’s estimate is arguably the correct 
choice given our viewpoint on modelling.  While we retain concerns about the quality of the VA 
data, we also have (different but parallel) concerns about our modelled estimates (as described 
in section 5.1).  Thus, an approach that gives some additional weight to the nationally 
representative data from a country when deriving modelled estimates appears to be a 
reasonable solution.  
 
5.2.3 Country-level random effects as a potential modelling solution 
A mixed effects (ME) model with random country intercepts is a promising solution to address 
the issue of giving more weight to country-specific empirical data.  An ME model has a 
hierarchical modelling structure that allows some parameters to not vary (i.e. the fixed effects 
[FE] component) while others are treated as random variables (i.e. the random effects [RE] 
component) [178].  An example of one equation of a multi-cause multinomial logistic regression 
with no random effect is shown in Equation 5.5.   
ln (
𝑃𝐶|𝑖𝑗
𝑃0|𝑖𝑗
) =  𝛽0 + ∑ 𝛽𝑘𝑋𝑘𝑖𝑗
𝐾
𝑘=1        (Eq. 5.5)  
The left-hand side is the log of the odds of the probability for cause C (PC|ij) over the probability 
of the baseline cause (P0|ij) for the ith prediction observation unit (e.g. year) of the jth group 
(e.g. country).  On the right-hand side, βk is the regression coefficient for the kth covariate (with 
β0 as the intercept and K as the total number of covariates) and Xkij is the kth covariate for the 
ith prediction observation unit of the jth group.   
 
The same regression with a random intercept is shown in Equation 5.6.   
ln (
𝑃𝐶|𝑖𝑗
𝑃0|𝑖𝑗
) =  𝛽0 + ∑ 𝛽𝑘𝑋𝑘𝑖𝑗
𝐾
𝑘=1 + 𝑢𝑗       (Eq. 5.6)  
where uj is the random effect representing the effect of the jth group.   
 
In our case, the random effect would be at the country level, which is based on the assumption 
that there is variation between countries that is not picked up by covariates in the fixed effect 
part of the model.  Introducing country-level random effects into our COD modelling strategy 
will result in a country’s estimates being “pulled” towards that country’s nationally 
representative VA data.   
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We attempted to incorporate random effects into our multinomial models in Stata using various 
methods but were largely unsuccessful.  We investigated GLLAMM [179] and mixlogit [180] 
commands in Stata, but these had a number of issues, ranging from convergence problems to 
being time intensive to incompatibility with our models.  The GSEM function in Stata 13 [181] 
appeared promising, and we implemented it using a simplified version of the low mortality 
model.  We did this with no covariate selection and included only one covariate (NMR) in each 
equation.  Over 24 hours were needed to run just one model with one covariate, making this 
computationally infeasible given our need for covariate selection and multiple (different) 
covariates in each equation of the multinomial.  This method also does not account for 
redistribution of unreported causes, which we need for the high mortality model unless we drop 
studies with any unreported causes.  This latter option is non-ideal, especially given the general 
dearth of input data in the high mortality model.   
 
Mixed effects multinomial logistic models are relatively new for statistical software.  It was only 
in 2017, after we had completed these analyses, that Stata released a mixed effects multinomial 
logit function [182].  The GSEM function in Stata which we described using above was 
introduced in 2013 [183], less than two years before we conducted this analysis.  At the time 
we did this work, few packages existed across different statistical programmes for the type of 
analysis we were trying to conduct, and even fewer seemed to work well for complicated 
models like ours.  For example, concerns were documented in forums and elsewhere about 
convergence and time intensiveness issues for complicated models with GSEM [181, 184, 185].  
Thus, incorporating country-level random effects into our multinomial logistic regressions given 
our existing modelling strategy was not straightforward.   
 
There are two plausible alternatives to consider for further investigating country-level random 
effects as part of our COD modelling strategy.  The first is to replace the multinomial model with 
a set of binomial models and apply the random effects to the latter.  The programming for mixed 
effects in a binomial model is more straightforward since it is a simpler model and is a better-
established method in statistical software, including Stata [186].  We performed this analysis 
and have presented the results in the next chapter.  The second option is to shift the COD 
models to a Bayesian framework, which is well-suited for random effects.  In chapter 7, I present 
our results for a proof-of-concept Bayesian COD model with random effects.   
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5.3 Discussion 
In this chapter, I have detailed three main issues that required further investigation as we 
consider ways to improve the existing neonatal COD models: predictive accuracy, model 
instability, and weighting a country’s modelled estimates towards its empirical data.  In this 
section, I discuss our findings and describe the decision-making process that took place to 
determine which model improvements we would prioritize for implementation.   
 
5.3.1 Model performance issues  
In this section, I described some model performance issues we wanted to further investigate, 
along with factors which may be causing them.  I also introduced a few possible solutions which 
may improve model stability and predictive accuracy.  Two of the key factors appeared to be 
noisy input data (both for cause-of-death distributions and covariates) and the strength of the 
relationships between causes and covariates.  These are likely the greatest challenge for our 
models, and ones which we have little to no control over directly.  If these problems are severe 
enough, then even models which technically can perform well would be unable to accurately 
estimate the outputs.  But there are several results we have presented which are promising, 
and suggest that these issues are not severely impacting our models: 1) the country-specific 
results obtained by the existing models are within reasonable ranges (section 4.3); 2) the results 
from the existing approach are relatively similar to the model averaging methods, which are 
designed to account for uncertainty in modelling processes and input data – including due to 
noise; 3) building stability-enhancing processes (e.g. model averaging, regularization) into the 
code are ways to help mitigate some of these issues even at the country level; and 4) input data 
are generally increasing in quantity and quality, which can help overcome some of these issues 
over time as the input datasets continue to be updated.   
 
I also presented various potential solutions which may help to improve model performance.  In 
particular, ensemble methods like bagging and/or regularization methods like lasso regression 
are major modelling changes that could help to address some key concerns, which include 
uncertainty in our model selection, instability from model complexity, and the use of binomial 
covariate selection for multinomial models.  We have also demonstrated proof-of-concept 
implementation of these to gauge feasibility.  Overall, these preliminary analyses suggest that 
there is scope for such methods to be useful in our work to reduce instability.  Selecting an 
appropriate and feasible method will depend on other model changes (e.g. covariate selection 
method).  Thus, a more thorough investigation of these methods should occur after further 
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decisions are made on model improvement choices.  Full implementation of these would be 
done after decisions around model changes are finalized, as the implementation approaches 
will be different depending on various choices (e.g. modelling framework).   
 
Another potential solution to address the concern of using binomial covariate selection is to use 
a set of binomial models for the modelling as well.  This would mean the covariate selection and 
modelling approaches are consistent.  However, important drawbacks include cause-specific 
deaths not adding up to total deaths without scaling and the inability to adjust for unreported 
causes of death (as can be done in the multinomial model by re-writing the likelihood function).  
We implemented this alternative binomial model strategy and present the results for it in the 
following chapter.   
 
Additional smaller considerations mentioned in section 5.1.3 are also important to catalogue 
and review when discussing model performance improvements.  For covariates, testing for 
multicollinearity and regularly seeking updates on newly available (or updated) covariate time 
series are important.  For COD data, lower-quality VR data from countries modelled in the low 
mortality model could be considered for inclusion in the input data.  This would be particularly 
useful if the mixed effects models are implemented.  For the GOF metric, weights could be 
added such that the weighting is intermediate between giving equal weight to each death and 
equal weight to each study or country-year in the input data (similar to what is done during the 
multinomial regression step).  Alternate GOF metrics can also be identified and tested to see 
how they affect model performance, particularly through predictive accuracy.   
 
In general, there are two broad threads of a modelling process which impact model 
performance: the input data and the statistical modelling processes.  No matter how high-
quality or appropriate one of these is, if the other is not, then the model risks having poor 
“performance”.  In our case, I would argue that there can be improvements made to both.  On 
the modelling side, we can add components to our models which help mitigate some of the 
issues discussed in this section.  These can include practical changes like stability-enhancing 
modelling strategies (e.g. ensemble methods and/or regularization), as well as some which also 
have philosophical underpinnings for our modelling strategy (e.g. random effects).  It is also 
important to integrate internal validation and other relevant checks into the formal modelling 
strategy, instead of conducting them on an ad-hoc basis.  I present recommendations related to 
designing modelling strategies in section 8.6.   
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While the input data are difficult for us to improve directly, there are positive signs that such 
data are generally becoming more plentiful and higher in quality.  For example, an updated 
literature review conducted in Summer 2018 added 51 data points across 14 studies published 
between 2015 and 2018 to the high mortality dataset.  This is a substantial increase over the 
number of studies added through similar literature review updates previously, suggesting that 
more studies are being conducted and published with neonatal COD outcomes.  The size and 
quality of these studies is still heterogenous, but appear to be generally trending in a positive 
direction (potentially due to recent pushes like those for standardizing VA methods).  Similarly, 
there are major efforts in place related to covariate measurement, including improving 
consistency of definitions and introducing more nuanced covariate measures (e.g. quality 
instead of just coverage indicators).  These potential improvements have the real possibility of 
improving some of the issues we highlighted as being factors in our model performance.  
 
In the last two decades, the field of metrics and burden estimation has grown dramatically.  As 
noted in other parts of this thesis, in an ideal world we would not use models to produce 
estimates for neonatal COD distributions; instead, countries would extract such information 
from their own high-quality CRVS systems.  But many countries still lack the infrastructure and 
systems required to produce such internal data.  Until this gap is filled (through increasing 
implementation of CRVS systems or other innovative strategies), there remains value to 
modelling burden, especially when and where empirical data have been lacking.   
 
However, it is critical that such estimates are produced using careful and thoughtful modelling 
approaches, and that the caveats around the input data and modelling are well understood.  
The very reason models are still needed (i.e. inadequate high-quality empirical data) is also part 
of the reason why such modelling faces issues around instability and accuracy.  Thus, 
understanding the sources of potential model performance issues, and building in robustness 
to mitigate these issues should be an essential part of such estimation work.  I attempted to 
highlight some of the issues which may affect our models in this section.  I have also included a 
broader discussion on modelling topics in chapter 8, including recommendations on the uses 
and limits of such models.   
 
5.3.2 Weighting of empirical data for country-specific estimates 
In this section, I summarized the practical and philosophical reasons for weighting the modelled 
estimates towards a country’s own empirical data.  There is a compelling case to be made for 
including country-level random effects in our models, both because of the increasing number 
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of nationally representative studies and because it honours the goal of moving towards using 
empirical instead of modelled data.  The addition of such random effects is not trivial, as 
discussed in section 5.2.3 and as will be discussed in section 6.4 for binomial models.  Thus, if it 
is deemed a priority in the near to medium future, it is likely wiser to implement it alongside 
other improvements, especially since its inclusion will partly dictate which other modelling 
changes are feasible.   
 
An important point to consider about the inclusion of such random effects is what they truly 
represent given the quality issues with the real-world data which are included in our input 
datasets.  How much, for example, are the random effects capturing real COD distribution 
variation between countries versus measurement error/methodology differences between 
input studies.  Understanding the nuances around this point is important for interpreting the 
mixed effect models.  A more detailed discussion of what random effects mean for models such 
as ours is included in section 7.4.   
 
5.3.3 Decision-making process for model improvements 
In general, many of the model improvement strategies discussed above are interlinked or 
dependent on other modelling decisions.  For example, implementation of the lasso regression 
is different in the existing multinomial framework versus the Bayesian framework.  Thus, we 
chose to investigate these modelling issues to the point of allowing us to understand the 
problems and potential solutions, but did not pursue an exhaustive search of each option.  In 
this section, I describe the larger decision-making process around choosing specific model 
improvement priorities.   
 
The work described in this and the following chapter (on binomial COD models) was presented 
as a series of five talks at the 2016 annual Maternal Child Epidemiology Estimation (MCEE) 
meeting (see section 2.3.4 for more information about MCEE).  This meeting was attended by 
experts on issues related to child causes of death, both for neonates and older ages.  The goal 
of the presentations was to obtain feedback on our work, and to choose a set of model 
improvement priorities to implement and finalize for the neonatal and 1-59 month COD models.   
Individuals at the meeting included academic researchers from Johns Hopkins, the London 
School of Hygiene and Tropical Medicine, and the University of Edinburgh.  Representatives 
from the WHO (which officially publishes our neonatal COD estimates) and the Bill and Melinda 
Gates Foundation (which funds MCEE) were also represented.  As such, the decisions around 
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model improvements were not purely academic but were also driven by policy and donor 
priorities.  
 
Based on our presentations and the ensuing discussions, the following decisions were made: 1) 
inclusion of country-level random effects was a key priority, and one that should be 
implemented early as it would have an effect on which other additional strategies were feasible; 
2) a multinomial Bayesian modelling framework should be tested given the suboptimal results 
of the binomial models (discussed in the next chapter) and the difficulty of implementing a 
mixed effects model in the current frequentist framework, and 3) a regularization approach 
using multinomial covariate selection (e.g. lasso) looked like a promising solution to investigate 
in the Bayesian framework.    
 
In the following chapters, I present results for alternative COD modelling strategies: a set of 
binomial models instead of a multinomial model (chapter 6) and multinomial models with mixed 
effects and lasso in the Bayesian framework (chapter 7).    
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6 Alternative modelling approach: set of binomial models  
Although we use multinomial models for our current neonatal cause-of-death (COD) estimation 
approach, the challenges described in chapter 5 led us to investigate using a set of binomial 
models instead.  In particular, we believed that 1) predictive accuracy may improve since our 
current covariate selection approach relies on binomial models and 2) adding country-level 
random effects may be easier in the binomial framework.  In this chapter, I describe our work 
on developing a modelling framework using a set of binomial regressions for the neonatal COD 
estimates, including a comparison with the multinomial results and the addition of country-level 
random effects.  While uncertainty intervals are an essential component of final estimates, I 
have not included them in this chapter since the focus was not to develop publishable estimates, 
but rather to determine whether the binomial framework could help to resolve some of the 
aforementioned challenges.     
 
6.1 Introduction 
Choosing an appropriate statistical model is important for theoretical and practical reasons.  
Factors that contribute to the choice of model range from understanding which probability 
distribution best reflects the underlying data generation mechanism (theoretical) to the 
computational sophistication and intensity required to run different models (practical).   
 
For our work, we originally chose to use the multinomial distribution – where the causes of 
death are fit simultaneously – for a number of reasons.  First, the underlying data generating 
mechanism for a COD distribution is more accurately reflected by the multinomial distribution 
when there are multiple causes of death.  Additionally, modelling the proportional cause 
distribution results in the sum of deaths across the causes to equal 100% of deaths.  In contrast, 
a scaling factor (typically chosen somewhat arbitrarily) is required when using a set of binomial 
models so that the summed deaths across causes can equal the total number of deaths.  
Additionally, analysing a set of binomial models is less efficient and produces larger standard 
errors than a multinomial model [187].  Finally, if a specific cause is not reported in a study, the 
multinomial model can be used to incorporate uncertainty about whether any deaths for that 
cause occurred.  This is not possible when using a set of binomial models.   
 
However, there are important practical reasons for exploring the set of binomial models instead.  
First, our covariate selection step is based on binomial models (section 5.1.3).  This is because 
multinomial covariate selection is computationally prohibitive with our current covariate 
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selection approach.  As discussed in section 5.1.3, even just the full search algorithm using the 
binomial models is computationally intensive.  However, covariates chosen based on out-of-
sample goodness-of-fit (GOF) of binomial models may not result in the best out-of-sample GOF 
in a multinomial model.  Given the challenges of multinomial covariate selection, we considered 
the option of using a set of binomial logistic regressions instead of the multinomial regression 
for the neonatal COD model.  Another important reason for investigating the use of binomial 
models is that programming is simpler for binomial versus multinomial models, which in turn 
means that implementing some techniques like country-level random effects should be simpler 
in the binomial models.  As discussed in section 5.3.3, incorporating country-level random 
effects was deemed a priority for future COD estimation, but we faced challenges doing this in 
the multinomial model (section 5.2.3).  Finally, it is plausible that the covariate-cause 
relationships may be stronger when modelling the odds for a cause against all other causes (as 
we would do in a set of binomial models) instead of against a baseline cause (as is done in the 
multinomial models).   
 
For these reasons, we chose to compare our multinomial logistic regression approach for 
estimating the neonatal COD distribution to one that used a set of binomial logistic models 
instead.  In this chapter, I describe the methods we used to build the binomial estimation 
framework, how the resulting estimates compared to our previous estimation results and the 
incorporation of random effects into this binomial framework.  I also include a discussion on the 
advantages and disadvantages of this new modelling framework.   
 
6.2 Methods 
6.2.1 Input and prediction data 
We used the same input data and covariates for prediction as used for the multinomial models 
described in section 5.1.2.  We assessed the relationship between the covariates and causes of 
death in this input data (similarly to what was done for the multinomial models; section 5.1.3).  
Here, we graphed each covariate against the respective outcome for each cause (e.g. female 
literacy versus log(other/(N-other)) where N is number of all-cause deaths. 
 
6.2.2 Statistical modelling 
All statistical analyses were undertaken using Stata version 12 (www.stata.com).  We used the 
same modelling approach described in section 4.2, with a few changes.  First, in the covariate 
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selection, the baseline cause for the logistic regressions was now all causes except the one being 
estimated.  For example, if the cause being estimated was pneumonia, then the baseline 
“cause” was the sum of deaths across all non-pneumonia deaths.  In contrast, the baseline cause 
in the multinomial model was set to preterm (low mortality model) and intrapartum (high 
mortality model).  We re-ran the covariate selection process using this approach, and selected 
the covariates based on best out-of-sample GOF.  Next, the multinomial model was replaced by 
a set of binomial logistic regression models using the blogit command in Stata.  We used the 
modelled coefficients from the cause-specific regressions to predict the number of deaths for 
each cause.  Unlike the multinomial model, the causes are not all fit simultaneously with this 
method and it is not possible to re-write the COD distribution to account for unreported causes 
(see section 4.2.3 for how the multinomial model is adapted to account for unreported causes).  
Therefore, studies with one or more unreported causes were dropped when fitting the 
regression for that cause.   
 
6.2.3 Assessing predictive accuracy 
To assess predictive accuracy, we used the same method as described in section 5.1.2.  Briefly, 
we applied the coefficients from the binomial model results to the input data to assess the 
differences between the observed and predicted data.  We used the average chi-squared 
statistic (𝜒2̅̅ ̅) as defined in Equation 5.3 (section 5.1.1) to assess the predictive accuracy, allowing 
us compare models with different numbers of observations.  This is useful since studies with 
missing causes were dropped for the relevant binomial models (section 6.2.2) and therefore the 
binomial and multinomial models may have different numbers of observations.   
 
6.2.4 Estimation of cause-specific numbers and proportions of deaths 
We had to adjust the modelled death estimates because a set of binomial models does not 
automatically result in the deaths across causes to sum to the total number of all-cause deaths.  
We chose a proportional scaling factor for this.  To do this, we calculated the ratio of the 
summed cause-specific deaths to the total number of all-cause deaths.  We then divided each 
cause-specific death estimate by this ratio.  We calculated scaled cause-specific proportions by 
dividing the scaled cause-specific deaths by the total number of all-cause deaths.  We calculated 
un-scaled cause-specific proportions by dividing the un-scaled cause-specific deaths by the un-
scaled total number of deaths estimated by the binomial models.  
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6.2.5 Incorporating country-level random effects 
We implemented a mixed effects (ME) modelling structure within the binomial COD models 
using the xtmelogit command in Stata 12.  We then performed both validation and estimation 
analyses.  For the validation exercise, we assumed that the random effect was country-level for 
the low mortality model and study-level for the high mortality model.  The analyses were similar 
to those described in sections 6.2.2-6.2.4, with the following exceptions.  For the covariate 
selection process, we used only the fixed effects components of the ME models.  For estimation 
(including validation), we produced two sets of estimates: 1) using the full ME model (i.e. fixed 
and random effects components) and 2) using only the fixed effects component of the ME 
model.  This allows us to gauge how much the change in results is due to the random effects 
component versus different coefficient values for the covariates (i.e. the fixed effect 
component).  For this exercise, we assumed that the random effects are applicable to all input 
data (i.e. not only to nationally representative studies).   
 
I present the results for the binomial ME analysis as part of a comparison with the previous non-
ME models.  I will use the following terminology to refer to the models: 
o Multinomial – the non-ME multinomial models where all causes are fit simultaneously 
(described in section 4.2.3) 
o Binomial – the set of non-ME binomial models (described in section 6.2.2) 
o Binomial FE – the set of binomial ME regressions, but using only the fixed effects 
component for predictions (described in this section) 
o Binomial RE – the set of binomial ME regressions, using both the fixed and random 
effects components for predictions (described in this section) 
 
6.3 Main results 
In this subsection, I present the key results from the binomial COD analyses, including for 
validation, COD estimation, and inclusion of country-level random effects.  Since the main 
reason for conducting the binomial analyses is to consider using binomial instead of multinomial 
models for the COD estimation, I have included comparisons with the multinomial models 
where relevant.   
 
6.3.1 Relationship between covariates and causes 
Figure 6.1 includes representative examples of the covariate-cause relationships in our data in 
the low mortality model (top row) and high mortality model (bottom row).  There were a few 
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covariate-cause pairs which seemed to visually have a strong association.  For example, both 
pneumonia/GNI (Figure 6.1a) and tetanus/PAB (Figure 6.1d) appeared to have decreasing 
proportional burden as the covariate value increased, which is to be expected.  However, most 
of covariate-cause relationships appeared to lack strong associations (e.g. Figures 6.1b-c and 
6.1e-f).  This included instances for which we would expect to have seen a relationship, such as 
intrapartum/LBW (Figure 6.1b) and preterm/LBW (Figure 6.1e).   
 
Figure 6.1: Examples of covariate-cause relationships in the low (top row) and high (bottom 
row) mortality models for the early neonatal period. a) pneumonia and GNI; b) intrapartum 
and LBW; c) congenital and GFR; d) tetanus and PAB; e) preterm and LBW; and f) other and 
female literacy.   
 
 
These results are similar to the multinomial results presented in section 5.1.3.  Overall, these 
analyses indicate relatively weak relationships between many of the cause-covariate pairs.   
 
6.3.2 Validation results 
The average chi-squared GOF results in Table 6.1 suggest that the binomial and multinomial 
models performed similarly for the low mortality model.  In contrast, the binomial models 
appeared to generally perform better for the high mortality model (i.e. lower 𝜒2̅̅ ̅).  Note that 
the binomial results presented here are based on a baseline in the regression of all deaths other 
than those from the given cause (unlike the multinomial baselines of preterm and intrapartum), 
and these models are run for all causes (i.e. no missing “baseline” cause).   
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Table 6.1: Comparison of the average chi-squared out-of-sample goodness-of-fit statistic for 
the binomial versus multinomial models by cause and period for the low and high mortality 
models. 
 Low mortality model High mortality model 
 Early period Late period Early period Late period 
Binom1 Multi2 Binom Multi Binom Multi3 Binom Multi 
Intrapartum 14 11 5 5 20 22 14 11 
Congenital 14 13 4 4 5 28 3 3 
Preterm 13 15 7 8 10 24 10 10 
Sepsis 7 8 6 7 11 49 11 25 
Pneumonia 11 15 11 9 4 11 7 7 
Injuries 3 4 4 3 --- --- --- --- 
Diarrhoea --- --- --- --- 6 7 4 5 
Tetanus --- --- --- --- 15 44 8 10 
Other 19 24 6 6 11 67 9 16 
1 Binom = binomial;  2 Multi = multinomial; 3 based on the “tweaked” sepsis model described in 
section 5.1.3.   
 
The similarity in predictive accuracy between the binomial and multinomial low mortality 
models can be seen visually as well (Figure 6.2).  The two examples included in this figure 
(intrapartum/early [Figures 6.2a-b] and congenital/late [Figures 6.2c-d]) are strikingly similar 
between the binomial and multinomial models, and this type of similarity is generally true 
across the low mortality model causes.    
 
Figure 6.2: Comparison of binomial (scaled) and multinomial validation results in the low 
mortality model. a) intrapartum/early (binomial); b) intrapartum/early (multinomial); c) 
congenital/late (binomial); d) congenital/late (multinomial).  Note: circles are weighted by 
total neonatal deaths for given country-year compared to all other country-years.    
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The validation graphs for the high mortality model, however, tell a more complicated story.  For 
several causes, the binomial and multinomial models perform similarly (e.g. Figures 6.3a-b), 
while for some causes the binomial models appear to be performing better (e.g. Figure 6.3c-d).  
A few, however, do not appear to have substantial improvements with the binomial model, 
even though their 𝜒2̅̅ ̅ values in Table 6.1 are dissimilar.  For example, sepsis (early period) has 
𝜒2̅̅ ̅ values of 11 and 49 for the binomial and multinomial models, respectively.  However, the 
binomial improvement appears less stark visually and in fact may mostly be limited to the larger 
studies (Figures 6.3e-f).   
 
Figure 6.3: Comparison of binomial (scaled) and multinomial validation results in the high 
mortality model. a) diarrhoea/early (binomial); b) diarrhoea/early (multinomial); c) other/early 
(binomial); d) other/early (multinomial); e) sepsis/early (binomial); f) sepsis/early 
(multinomial).  Note: circles are weighted by total neonatal deaths for given study compared to 
all other studies.    
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When we compared the predicted COD estimates based on the validation exercise (i.e. model 
used to predict on the input data) between the binomial and multinomial models, we found a 
wide range of agreement levels.  The low mortality model generally had moderate (e.g. Figure 
6.4a) to good agreement (e.g. Figure 6.4b).  The high mortality model had lower levels of 
agreement, but also ranged from lower (e.g. Figure 6.4c) to higher (e.g. Figure 6.4d) agreement 
between the binomial and multinomial validation predictions.  These results were consistent 
before and after scaling.   
 
Figure 6.4: Direct comparison of binomial and multinomial validation estimates. a) 
injuries/late, low mortality model; b) sepsis/early, low mortality model; c) preterm/early, high 
mortality model; d) intrapartum/late, high mortality model.  Note: circles are weighted by total 
neonatal deaths for given country-year (or study) compared to all other country-years (or 
studies).    
 
 
In general, the binomial and multinomial estimates appeared to produce similar results for 
many of the causes, especially in the low mortality model.  For some causes, the binomial 
models appeared to be performing better based on the 𝜒2̅̅ ̅  metric.  However, the visual 
evidence was not as compelling for the binomial improvement.  The apparent discrepancy 
between the 𝜒2̅̅ ̅ results and the visual comparison is due to the 𝜒2̅̅ ̅ statistic prioritizing the fit of 
large studies (as discussed in section 5.1.3).  The high mortality model results also highlight that 
we should investigate multinomial covariate selection if we ultimately choose multinomial 
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models for the COD estimation.  Overall, even when the binomial model appeared to have had 
better out-of-sample GOF than the multinomial, this GOF was not necessarily greatly improved.    
 
6.3.3 Estimation results 
Scaling to fit total number of deaths 
The amount of scaling required to fit the binomial death estimates into the envelope of total 
deaths was relatively minor for the low mortality model (Table 6.2).  The mean ratio of summed 
binomial deaths to the envelope was 1.01 across country-years, suggesting on average these 
binomial models overestimated the number of deaths by 1%.  The high mortality model 
predictions, on the other hand, were closer to 10% over the total envelope.  However, the 
amount of scaling needed was more severe for some country-years, as suggested by the scaling 
ratio range (Table 6.2).  
 
Table 6.2: Amount of scaling needed to fit predicted binomial death estimates into envelope of 
total number of deaths using proportional scaling 
 Mean ratio1 (SD) 2 Median ratio (IQR) 3 Ratio range 
High mortality model 
Early period 1.08 (0.09) 1.06 (1.02-1.20) 0.84-1.32 
Late period 1.11 (0.10) 1.09 (1.04-1.14) 0.90-1.44 
Low mortality model 
Early period 1.01 (0.06) 1.01 (0.97-1.05) 0.84-1.22 
Late period 1.01 (0.04) 1.01 (0.99-1.04) 0.78-1.10 
1 ratio refers to scaling ratio as described in section 6.2.3; 1 SD = standard deviation; 1 
IQR = interquartile range 
  
 
Binomial cause-of-death distribution estimates 
The predicted COD distributions obtained using the binomial and multinomial low mortality 
models were relatively similar (Figure 6.5).  The largest differences were seen for intrapartum, 
but these were still relatively minor.  The only cause that appeared to have some systematic 
bias was congenital, which tended to have higher estimates in the multinomial model.  But even 
this was relatively minor, with most of the differences within three percentage points.   
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Figure 6.5: Comparison of binomial and multinomial estimates for all causes of the low 
mortality model (early period).  Note: orange line = mean difference between multinomial and 
binomial models, blue line = no difference (i.e. 0); top and bottom black dashed lines are +/- 
1.96 SDs from the orange line.   
 
 
The high mortality model had larger differences (Figure 6.6).  The sepsis and preterm 
proportions were generally estimated to be higher in the early period binomial models than the 
multinomial model.  In contrast, the remaining causes tended to have higher estimates in the 
early period multinomial model.  The proportions of some causes appeared less variable in the 
binomial compared to multinomial (e.g. pneumonia, tetanus, other), while sepsis had more 
variation in the binomial.  Some systematic patterns also appeared to be present.  The 
multinomial predictions had higher variation for pneumonia, diarrhoea, tetanus, and other as 
the mean between the two models increased.  The opposite was true for sepsis; the binomial 
model predictions had more variation as the mean increased.   
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Figure 6.6: Comparison of binomial and multinomial estimates for all causes of the high 
mortality model (early period). Note: orange line = mean difference between multinomial and 
binomial models, blue line = no difference (i.e. 0); top and bottom black dashed lines are +/- 
1.96 SDs from the orange line.   
 
 
A comparison of the proportional COD estimates for 2015 are shown in Table 6.3.  Similar to the 
analyses above, these suggest that the binomial and multinomial predictions are similar for the 
low mortality model while the high mortality model estimates have more substantial differences 
for some causes (e.g. sepsis).  
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Table 6.3: Comparison of estimated cause-of-death proportions in 2015 for modelled countries 
using the binomial versus multinomial models 
 Low mortality model High mortality model 
 Early period Late period Early period Late period 
 Binom1 Multi2 Binom Multi Binom Multi Binom Multi 
Intrapartum 13.6 14.4 7.7 8.0 24.9 31.0 16.8 21.0 
Congenital 22.6 23.3 29.6 31.2 6.4 9.3 6.2 6.0 
Preterm 43.2 42.2 29.4 27.6 43.2 37.2 23.3 27.9 
Sepsis 5.0 5.0 14.8 14.8 14.2 5.5 37.9 24.1 
Pneumonia 3.9 3.8 7.5 7.4 7.4 10.8 6.7 7.9 
Injuries 0.5 0.7 1.3 1.5 --- --- --- --- 
Diarrhoea --- --- --- --- 0.8 1.2 2.1 1.8 
Tetanus --- --- --- --- 0.2 1.1 2.0 3.0 
Other 11.2 10.4 9.6 9.4 3.0 4.1 5.0 8.3 
1 Binom = binomial;  2 Multi = multinomial 
 
6.3.4 Country-level random effects results 
Covariate selection 
Table 6.4 includes a comparison of the covariates chosen by the covariate selection process in 
the binomial and binomial FE models (since the random effects component was not used for 
covariate selection).  Covariates found to be common between the two are italicized in the 
table.  The selected covariates vary quite a bit between the two model types, with several causes 
having no covariate overlap between the two.  A likely contributing factor to this difference is 
that the non-ME binomial models have no weighting (i.e. each death is weighted equally) 
whereas the ME models, which take into account the non-independence of deaths within 
studies, essentially down-weight deaths in large studies.  
 
The % reduction from null is not clearly better or worse for the binomial versus binomial FE 
model.  For example, the binomial FE model had a higher % reduction from null for 56% (9/16) 
of causes (early and late period) in the high mortality model, while the binomial model without 
random effects had a higher % reduction for 64% (9/14) of causes in the low mortality model 
(Table 6.4).  Some causes had substantial differences in the % reduction from null.  For example, 
sepsis in the early period low mortality model had 68.3% reduction from null in the binomial 
model versus 0.8% in the binomial FE model.  Pneumonia in the early period high mortality 
model had 7.3% reduction from null in the binomial model compared to 49.3% in the binomial 
FE model.  Several causes had less severe, but still large, differences (Table 6.4).  It is possible 
that part of this difference could be resolved using the full search algorithm (see section 5.1.3).  
For example, the sepsis binomial FE model with 0.8% reduction had only DPT in the model while 
the simple binomial model had five covariates, none of which were DPT.  The full instead of 
partial search algorithm may have been able to find a better fitting set of covariates that did not 
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involve DPT.  However, a full search algorithm would be very computationally intensive with the 
ME model, and at least some of the models are likely to encounter convergence difficulties.  
Thus, this may not be a plausible alternative.   
 
Table 6.4: Selected covariates in cause equations and % reduction from null for the binomial 
versus binomial FE models (i.e. binomial ME model using only fixed effects component) 
 Binomial model Binomial FE model 
 Best model1 % red.2 Best model % red. 
High mortality model; early period 
Intrapartum PABs 50.7 
PABs, GFR, LBW, PvLBW, 
period, SBAq, NMRq 
68.5 
Preterm period, ANCs, LBW, PvLBW  81.1 SBAq, period, PAB, IMR, SA, PvLBW 84.3 
Congenital 
U5MR, NMRq, FLRq, 
PvLBW, BCGs, SSA, IMR 
85.7 NMRs, DPTs, PvLBW, SSA 71.8 
Sepsis period, ANCs, BCG, FLR, DPT 81.9 PAB, DPT, period, GFRq, IMRq 76.7 
Pneumonia SBAs, BCG 7.3 BCGq, SBA, GFRs 49.3 
Diarrhoea NMRq, SSA, U5MR, BCG 87.1 DPTq, LBW s, GFR, PAB 54.8 
Tetanus NMR, period, BCG 93.1 PAB 74.1 
Other SSA, ANC 81.7 
PABq, period, LBWq, NMR, 
SBAq, DPT, BCG, U5MR 
91.2 
High mortality model; late period 
Intrapartum GFRs, PABs 52.7 PABs, GFRs, SSA 51.5 
Preterm LBW s, BCG, SA 18.1 DPTs, PAB, SBAq, BCG 29.6 
Congenital U5MRq, SBAs, PvLBW 94.9 NMRq, DPTs, PvLBW 95.1 
Sepsis NMRq, FLRq, period, SSA 37.5 IMR, SA 33.4 
Pneumonia DPTq 5.2 GFR, SA 8.1 
Diarrhoea 
LBWs, U5MRq, period, 
IMR, GFR 
24.0 
ANC, DPT, LBWs, U5MRq, 
NMR, SSA, period 
56.3 
Tetanus U5MR, ANC, BCG, LBWq 91.0 ANC, PAB, PvLBW, IMRq, period    90.8 
Other ANC, period, SSA 25.3 
PABq, DPT, NMR, IMR, LBWq, 
BCGs, SBAq, SA 
47.2 
Low mortality model; early period 
Intrapartum FLRs 38.3 FLRd, U5MR, ANCd 18.6 
Preterm NMRs 4.8 NMRs, U5MR, DPT, IMR 12.9 
Congenital NMR, GINId 65.7 NMR 61.9 
Sepsis GNI, GINI, IMRs, ANCs, NMRd 68.3 DPT 0.8 
Pneumonia GNI, GINI, U5MR 36.4 GNI 26.1 
Injuries GFRs, ANC, GNI 28.2 --- 0.0 
Other GFRs, U5MR, FLR 23.0 DPT, U5MR, GINI, ANC, IMR 29.7 
High mortality model; late period 
Intrapartum DPTd 3.0 FLRd 8.4 
Preterm FLRd, GINI 25.7 DPT, GNI, NMR, U5MR, ANC 18.5 
Congenital IMR, GINI 67.5 IMR, GFRd, FLRs, NMR, DPTs 63.0 
Sepsis GINI, IMRd, FLR, GNI, ANCs   73.8 GINI, GNI, NMR, GFR, ANC 80.0 
Pneumonia ANCs 24.4 IMR, NMR, GFRs 48.7 
Injuries FLR, DPT 3.1 LBW 0.2 
Other GFRs, FLR 28.3 GINId, DPT, FLR, LBW 26.6 
1 covariates common between both models are italicized, see Table 4.2 for covariate acronym 
definitions; 2 % red. = % reduction from null; s spline instead of linear; q quadratic instead of linear 
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Predictive accuracy 
As expected, the random effects component appears to dramatically increase the predictive 
accuracy for the COD models.  An example in the low mortality model (other/late) is included in 
Figure 6.7.  This figure compares the observed versus predicted validation exercise for the 
multinomial (Figure 6.7a), binomial (Figure 6.7b), binomial FE (Figure 6.7c), and binomial RE 
(Figure 6.7d) models.  The first three graphs look very similar (including the binomial FE model), 
with relatively poor GOF between the observed and predicted proportions.  The binomial RE 
model, on the other hand, performs substantially better in this validation exercise.   
 
Figure 6.7: Comparison of the multinomial, binomial, binomial FE, and binomial RE models in 
the low mortality model: example of “other” in the late period   
 
 
A similar pattern is seen for the high mortality model.  An example of intrapartum in the late 
period is shown in Figure 6.8.  Similar to the previous figure, the multinomial (Figure 6.8a), 
binomial (Figure 6.8b), and binomial FE (Figure 6.8c) models are performing relatively poorly, 
while the binomial RE model (Figure 6.8d) appears to have better predictive accuracy in this 
validation exercise.   
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Figure 6.8: Comparison of the multinomial, binomial, binomial FE, and binomial RE models in 
the high mortality model: example of “intrapartum” in the late period   
 
 
Two examples of how country-level COD predictions change when random effects are included 
are shown in Table 6.5.  Afghanistan and Kenya each had one input study.  The binomial RE 
model results show that the estimates are being pulled towards the study data (i.e. binomial RE 
results are between study data and binomial FE results).  This is the expected result of including 
country-level random effects.    
 
Table 6.5: Differences in predicted estimates from the binomial FE and binomial RE models for 
two example countries (Afghanistan and Kenya) 
 Afghanistan Kenya 
 % in 
study 
Average1 
binomial FE2 
prediction 
Average 
binomial RE3 
prediction 
% in 
study 
Average 
binomial FE 
prediction 
Average 
binomial RE 
prediction 
Intrapartum 10.5 35.2 18.7 21.3 42.6 24.6 
Congenital 3.2 6.9 5.6 --- 5.1 3.4 
Preterm 12.5 22.5 15.0 20.0 26.0 21.2 
Sepsis 39.1 15.1 27.2 46.7 13.1 40.6 
Pneumonia --- 11.2 10.8 --- 9.9 6.6 
Diarrhoea 1.2 4.2 1.3 2.7 0.4 1.4 
Tetanus 4.0 1.0 10.2 --- 0.6 0.4 
Other 29.6 3.9 11.1 9.3 2.3 1.8 
1 Average prediction is mean percentage for 2000-2015 prediction;  2 binomial FE = model 
using only fixed effect component of mixed effects binomial model, 3 binomial RE = model 
using fixed and random effects components of mixed effect binomial model 
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6.4 Discussion 
In this chapter, I have presented some results of implementing a neonatal COD modelling 
strategy based on a set of binomial models instead of the existing multinomial approach.  
Compared to the multinomial models, the binomial models have theoretical advantages (e.g. 
alignment between our covariate selection and model regression approaches) and 
disadvantages (e.g. scaling factor required to fit deaths into the total envelope).  Our findings 
suggest that the binomial models (without random effects) are not a clear improvement over 
the existing multinomial models.  For several causes in the low and high mortality models, the 
binomial model performance was similar to that of the multinomial.  When the binomial had 
better goodness of fit, much of this improvement appeared to be due to a better fit for a small 
number of observations with large numbers of deaths.  For causes that had moderate or poor 
fit in the multinomial models, this generally continued to be true for the binomial models.   
 
Prior to this analysis, we believed it was plausible that the covariate-cause relationships may be 
stronger for the binomial models since here we are modelling the odds versus all other causes 
combined (instead of against some baseline cause as is done in the multinomial).  However, we 
found that these underlying cause/covariate relationships appeared to be similar for both the 
binomial multinomial models, often without clear patterns.  These weak underlying 
relationships are potentially a leading cause of the predictive accuracy issues discussed in 
chapter 5.   
 
I also presented results from including country-level random effects in the binomial models.  
This analysis was performed because we were unable to incorporate random effects into our 
multinomial models (section 5.2.3).  We found that adding random effects to the binomial 
models was a non-trivial task.  The approach we used, which relied on using Stata’s xtmelogit 
command, appeared to be generally inefficient and sometimes finicky.  For example, we 
encountered issues with the software crashing at initial value selection, which was potentially a 
software bug at the time we conducted this analysis.  This may be indicative of how nascent 
some of the relevant programming is even within well-established statistical software.  Given 
these issues, we are not confident that this approach would work well if we changed the current 
models (e.g. with updated input data) or included additional modelling components (e.g. model 
averaging).   
 
These results did demonstrate, however, that the random effects performed as expected and 
were able to pull a given country’s estimates towards the empirical data from that country.  This 
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result was consistent across all causes and models.  This is also the key reason that the binomial 
RE model appeared to perform better than the other three models (multinomial, binomial, 
binomial FE) in the validation exercise.  We expect such an improvement since the validation 
uses the input dataset for prediction, and therefore each country (or study) is present in both 
the input and prediction datasets.  The lack of improvement in predictive accuracy for the 
binomial FE model suggests that the only improvement appears to come from inclusion of the 
random effects component.  Thus, the binomial RE model is unlikely to improve predictive 
accuracy for countries that do not have observations in the input dataset.  Currently, that 
consists of all low mortality prediction countries (since their data are not included in the input 
data) and most of the high mortality prediction countries (since only eight countries have 
nationally representative VA studies so far).   
 
As mentioned briefly in section 5.3.2, there are a few important issues to consider when 
implementing and interpreting random effects given the quality of data in our input dataset.  
First, most input studies are single data points and not time series, and most countries with a 
nationally representative study have only one such study (so far).  Additionally, the input 
studies, including the nationally representative ones, have wide ranges in size and quality.  Thus, 
one question is how much a single data point should affect a country’s modelled estimates.  In 
other words, what strength of random effect should be allowed?  And given the methodological 
issues in the input data, how much of the difference between the modelled fixed effect 
estimates and empirical data represents a real difference in the COD distribution compared to 
random or systematic errors in the empirical data.  I discuss each of these issues and other 
related topics in more detail in section 7.4.   
 
If we were to make the switch to binomial instead of multinomial models, there are several 
issues that would still require investigation.  First, we would need to test for model instability 
as was done in chapter 5 for the multinomial models.  This would help inform decisions on 
modelling strategies such as the need for model averaging, and help us understand if the 
differences in predictions between the binomial and multinomial models are arising at least 
partly through instability.  Additionally, we would investigate alternative mixed effects 
programming, including potentially switching to another programming language (e.g. R).  
Finally, we would need to understand which model performance solutions are feasible with this 
mixed effects model.  For example, the full search algorithm presented in section 5.1.3 for 
covariate selection is computationally infeasible with this approach, and several model 
averaging techniques are likely to be difficult to perform.   
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As mentioned in section 5.3.3, the modelling issues from chapter 5 were presented alongside 
the binomial analyses in this chapter during the 2016 annual MCEE meeting.  During this 
meeting of an expert group on child COD issues, it was decided that we would investigate a shift 
to the Bayesian framework for the COD models.  This decision was made for several reasons, 
including the lack of definite predictive accuracy improvements with the binomial models, the 
challenges we encountered while implementing the binomial mixed effects models, and 
because of advantages we saw with the multinomial approach (e.g. not having to drop studies 
with missing input data for certain causes).  A more detailed discussion is included in section 
5.3, and results from our Bayesian proof-of-concept COD models are presented in chapter 7.   
 
 
  
  
 
150 
7 Alternative modelling approach: Bayesian framework with 
random effects 
The frequentist versus Bayesian framework choice is sometimes categorized as a philosophical 
debate about the meaning of probability.  In this work, we sidestep this debate: we chose to 
convert our cause-of-death (COD) models into the Bayesian framework for practical reasons.  
Namely, we had difficulty in incorporating random effects into our existing COD models (section 
5.2.3), and the Bayesian framework is well suited to this problem.  In this section, I describe our 
work on shifting the neonatal COD models from our previous “classical” approach into the 
Bayesian framework, including the incorporation of country-level random effects and 
implementation of covariate selection within this framework.  The work presented here is a 
proof-of-concept demonstration, with ongoing efforts to finalize these Bayesian models in order 
to produce publishable national-level neonatal COD time series estimates.  As such, various 
analyses including out-of-sample validation and calculating credible intervals (i.e. Bayesian 
uncertainty) are important but beyond the scope of this current exercise.   
 
7.1 Introduction 
7.1.1 Overview of Bayesian statistics 
Thomas Bayes first laid out the theorem which is the foundation of Bayesian theory and 
methods in the mid-18th century, at a time when the mathematical field of probability was 
nascent but rapidly expanding [188].  The idea Bayes put forth was simple: one’s belief should 
be updated based on new evidence.  Pierre-Simon Laplace soon furthered and generalized this 
foundation into the Bayesian theory we are familiar with today [188].  But over time, Bayesian 
methods fell out of favour for two key reasons: they were considered more ‘subjective’ than 
other statistical methods and they were less tractable prior to the advent and widespread 
availability of high-speed computers.  Instead, ‘frequentist’ methods, popularized by 
statisticians like R.A. Fisher, J. Neyman, and E. Pearson, dominated statistical thinking for most 
of the 20th century.  But the use of Bayesian methods has become increasingly popular over the 
last few decades in a wide range of disciplines, from computer science and hard sciences like 
physics to social sciences like psychology and economics [189, 190]. 
 
The cornerstone of Bayesian methodology is a specific view of probability.  For Bayesians, 
probabilities are a way to describe uncertainty about our knowledge of the world.  Probability 
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distributions for parameters are a way of expressing this uncertainty; we do not have complete 
information about parameters, so we have some uncertainty (formalized through a probability 
distribution) about what we consider to be reasonable values for these parameters.  This 
probability changes as we are presented with new data and as we update our prior beliefs.  This 
view of probability is embodied by the simple but profound Bayes theorem (Equation 7.1): 
 
P(H|D)= P(D|H)∗P(H)
P(D)
      (Eq. 7.1) 
 
where P(H) is the prior probability of the hypothesis; P(D) is the probability of observing the 
data; P(D|H), or the likelihood, is the probability of observing the data D given our hypothesis 
H; and P(H|D), or the posterior distribution, is the probability of the hypothesis given observing 
the data D.  Thus, the posterior belief is based on a combination of the probabilities associated 
with the hypothesis being true, the data being observed, and the data being observed given the 
hypothesis being true.   
 
The prior P(H) is based on previous beliefs and is thus the part of Bayes theorem that adds some 
level of ‘subjectivity’.  Priors can range from strongly informative to uninformative depending 
on the strength of belief in the hypothesis.  Careful selection of the priors is essential as they 
can have a substantial effect on the posterior distribution, especially when the data (i.e. D 
above) are limited.  The prior is also an important part of the iterative nature of Bayesian 
analyses.  If new evidence is introduced, then the previous posterior would become the new 
prior.   
 
The ultimate objective of Bayesian analysis is to find the posterior distribution.  This provides 
information on the credibility of the parameter values (e.g. based on the posterior probability 
density), as well as the associated uncertainty.  A simplification of Equation 7.1 is to say that the 
posterior distribution is proportional to the likelihood times the prior.  While some posterior 
distributions can be calculated analytically, the majority consist of intractable integrals.  This 
was a major challenge for Bayesian statistics, and was not overcome until the Markov chain 
Monte Carlo (MCMC) class of algorithms became more widely applied to Bayesian computation 
in the last few decades [191, 192].  I discuss the details of Bayesian analysis, including MCMC 
methods, in the next section.   
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7.1.2 Relevant elements of Bayesian modelling 
Just as with frequentist statistics, there are many aspects of Bayesian modelling.  Here, I 
introduce key elements of Bayesian modelling which are relevant for our work.   
 
Model building 
The core elements for performing a Bayesian analysis are to: 1) determine the parameter(s) of 
interest; 2) formulate a probability model that is suitable for the data; 3) choose prior 
distributions based on existing evidence and/or expert opinion; 4) gather the data; 5) construct 
a likelihood function based on the data and probability model; 6) calculate the posterior 
distribution by combining the prior distribution with the likelihood function using Bayes 
theorem; and 7) summarize features of interest from the posterior distribution [193].   
 
The complexity of this last step depends on the nature of the posterior distribution.  When the 
prior and posterior are conjugate distributions (i.e. in the same family of distributions), the 
posterior distribution is simple to solve for analytically.  This requires the right combination of 
distributions for the prior and likelihood (e.g. both Gaussians; beta distribution for prior and 
binomial distribution for likelihood).  However, such conjugate distributions are uncommon in 
real-world Bayesian analyses, and most posterior distributions will instead be intractable 
integrals that must be solved for numerically.  For these, methods have been developed which 
sample from the posterior distribution (next subsection). 
 
Sampling from the posterior distribution 
MCMC (Markov chain Monte Carlo) methods can approximate the posterior distribution 
numerically through many repeat random samples from a distribution, thereby circumventing 
the analytically impossible task of solving intractable integrals.  This methodological 
development, alongside improvements in computational power, revolutionized Bayesian 
statistics by the 1980s [194].  While there are some other methods for determining the posterior 
distribution, MCMC algorithms are the overwhelmingly popular choice.   
 
Monte Carlo refers to a class of algorithms that draws repeat random samples from a 
distribution, thereby allowing estimation of various distribution properties without knowing the 
distribution itself.  Markov chains are stochastic memoryless processes, meaning that a random 
sample depends only on the previous random sample and none of those before this previous 
one.  MCMC methods, which combine these two concepts, are a powerful tool in Bayesian 
analysis because they allow for a sequence of memoryless random samples of the distribution 
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of interest (i.e. the posterior distribution in Bayesian analysis).  In general, MCMC algorithms 
work as follows [195]: 1) initiate the chain with a plausible starting value (or allow the algorithm 
to select a starting value), 2) move to a new random location and calculate the posterior 
probability there; remain at the new location if the posterior probability is higher or go back to 
the previous value if not, and 3) repeat step 2 for as many iterations as are specified for the 
process.  With enough iterations, this will ideally result in a good approximation of the posterior 
distribution.  Multiple chains can be run for the same analysis, with convergence occurring once 
the different chains stably reach the same value.  There are various MCMC algorithms, including 
the popular Gibbs sampling method [196] which we use in this work.  Gibbs sampling draws 
random samples from the conditional probability distribution for a parameter (i.e. the 
distribution when other parameters are held at a fixed value).   
 
Covariate selection 
There are numerous covariate selection approaches when using Bayesian methods [197-199].  
Covariate selection within a Bayesian framework is a quickly growing area of research, with 
more sophisticated methods emerging each year.  The types of methods vary substantially, and 
a thorough investigation of Bayesian covariate methods is beyond the scope of this thesis.  
However, some criteria that can help narrow our search include needing a method that can be 
used for regressions and works with MCMC, as well as ideally improving model stability and 
allowing for multinomial covariate selection.  For these reasons, we chose to investigate the 
implementation of the Bayesian lasso given the potential suitability of the lasso method for our 
models as described in section 5.1.4. 
 
The Bayesian version of the lasso regression [175] works similarly to the classical one.  Namely, 
the lasso involves adding all potential covariates to the model (thus permitting multinomial 
covariate selection) and including a term that penalizes coefficient size.  This is a shrinkage 
method, and thereby aims to improve stability by reducing the covariate coefficient values.  In 
the frequentist version, the penalty term is added to the likelihood function while in the 
Bayesian lasso it is implemented by applying a Laplacian prior (i.e. a double exponential) to the 
parameters.  In the former, the lasso regression will reduce some coefficients to zero and thus 
perform covariate selection.  The coefficient values can never be exactly zero in the Bayesian 
lasso because of the double exponential.  However, with a strong enough penalty many of the 
coefficient values will be very close to zero.  The strength of the Laplacian prior, and thus the 
amount of coefficient shrinkage, is determined by a term (lambda) that can be adjusted to tune 
the penalty.       
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7.1.3 Frequentist versus Bayesian viewpoints 
The key difference between the frequentist and Bayesian frameworks is the lens through which 
each views the concept of probability.  In contrast to the Bayesian view of probability described 
in section 7.1.1, frequentists view probability as a fixed measure that is equal to the frequency 
at which an event occurs.  Uncertainty is only present because we are unable to sample to 
infinity; if we were, we would arrive at the “true” probability for a given event.  Thus, in this 
viewpoint, there is no underlying randomness aside from that in the data generating process; 
parameters and probabilities are fixed entities.  Since there is a “true” probability, the 
frequentist approach views subjectivity as unnecessary or even unscientific.   
 
This difference in what probability means affects how statistical problems are approached.  
Table 7.1 presents a brief comparison of how frequentist and Bayesian methodologies approach 
the various components of hypothesis testing, including data, parameters, and uncertainty.   
 
Table 7.1: Comparison of Bayesian versus frequentist viewpoints 
 Frequentist viewpoint Bayesian viewpoint 
View of probability 
Fixed measure of frequency 
as sampling goes to infinity 
The degree of belief in a statement 
about an unknown variable 
View of data 
Repeatable through random 
sampling 
Fixed 
View of parameters Fixed (but unknown) Probabilistically described 
Prior information 
Considered subjective;  
intentionally not included 
Fundamental to theory 
Output from 
calculations 
P(D|H0) P(H|D) 
Uncertainty 
Variability of data for fixed 
parameter value 
Variability of parameter for fixed 
data 
Computation Fairly simple Can be intensive (hence algorithms) 
 
There are circumstances in which these different probability viewpoints and analytical 
approaches yield strikingly different results for the same problem [200, 201].  However, 
Bayesian and frequentist approaches produce the same or similar results for many problems, 
particularly those with large samples and uninformative priors [201].  Statisticians do not always 
fall cleanly into one of the two camps, and may choose either Bayesian or frequentist 
approaches for pragmatic rather than philosophical reasons.   
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7.1.4 Our work 
In the rest of this chapter, I describe our work in transitioning our neonatal COD models from 
the classical to Bayesian framework.  The three main goals, all within the Bayesian framework, 
were to: 1) reproduce the classical neonatal COD results, 2) include country-level random 
effects, and 3) implement a covariate selection method.  The work presented here is a proof-of-
concept demonstration that such a transition to the Bayesian framework is feasible for our 
models.  For this reason, I have not produced a full set of neonatal COD estimates as I did in 
chapter 4.  Instead, in this chapter I describe our shift to the Bayesian framework, and compare 
the results to the equivalent version of our classical models.   
 
7.2 Methods 
7.2.1 Overview of differences between the classical and Bayesian cause-of-death 
modelling methods 
We tried to keep the Bayesian modelling strategy as similar as possible to the classical approach 
(section 4.2) for this proof-of-concept exercise.  The key changes we made were those which 
were needed to shift the multinomial models into the Bayesian framework.  Many of the other 
features of the modelling approach remained the same between our classical and Bayesian 
models, including dividing countries into three estimation groups and having four separate 
models (early and late neonatal periods each for low and high mortality countries) to estimate 
the COD distributions.  Table 7.2 includes the list of changes for the Bayesian modelling strategy, 
with explanations for why the changes were made.  For comparability with the Bayesian results, 
we re-ran the classical model with the relevant changes described in Table 7.2.  These and the 
Bayesian changes are described in more detail in the following sections.   
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Table 7.2: Differences between the classical and Bayesian modelling strategies 
 Change in Bayesian model Reason for change 
Country groupings 
No change (i.e. high mortality 
model, low mortality model, high-
quality VR countries) 
--- 
Model groupings 
No change (i.e. 4 models: early and 
late period models for high and 
low mortality country groups) 
--- 
Cause 
categories 
Sepsis, pneumonia, diarrhoea, and 
tetanus grouped together as 
“infections” in high mortality 
model 
To reduce the number of input 
studies which need to be dropped 
due to unreported causes  
Input data 
Dropped studies with unreported 
causes for modelled cause 
categories 
To run the multinomial model 
without re-writing the likelihood 
to account for unreported causes  
Covariate selection 
to recreate classical 
results 
Used same covariates selected by 
classical approach (i.e. did not 
perform new covariate selection) 
To ensure direct comparability 
with classical results 
Bayesian covariate 
selection 
Implemented lasso regression 
covariate selection as proof-of-
concept 
To incorporate Bayesian covariate 
selection into multinomial model 
Regression 
approach 
No change for regression type (i.e. 
multinomial logistic regressions); 
did not re-write the likelihood to 
account for unreported causes in 
input studies 
Did not re-write likelihood to 
simplify Bayesian proof-of-
concept model 
Weighting of input 
observations1 
Did not include weighting  
Simpler to remove from classical 
model than to add to Bayesian 
model for proof-of-concept test 
Statistical 
package(s) 
R (v3.2.2) and JAGS within R 
(R2jags, v0.5-7) 
R is well-tested for the types of 
Bayesian analyses we needed 
Random effects Implemented at country level 
Unable to implement in classical 
multinomial model 
Outputs 
No change (i.e. proportional cause 
distribution and number of deaths) 
--- 
1 To give intermediate weighting between equal weight to each death and equal weight to each 
study or country-year in the input data (as described in section 4.2.3). 
 
7.2.2 Bayesian modelling to recreate ‘classical’ results 
The Bayesian statistical analyses were done using R (version 3.2.2) and JAGS within R (package 
R2jags, version 0.5-7).  In this section, I describe the processes we used for building the proof-
of-concept Bayesian multinomial models and comparing them to the classical results.   
 
Data inputs 
We used the same data inputs as those described in section 5.1.2.  Modifications made to the 
input data, as described in Table 7.2, included the following: 
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o Collapsing sepsis, pneumonia, diarrhoea, and tetanus into one broad “infection” 
category for modelling, resulting in a total of five modelled categories (intrapartum, 
preterm, infection, congenital, and other) 
o Dropping input observations with missing data for any of the five above-mentioned 
modelled causes 
 
We made these changes to deal with the “unreported causes” issue for high mortality model 
input studies.  In the classical model, we made assumptions about the cause category into which 
deaths from an unreported cause would have been assigned and re-wrote the likelihood 
function accordingly (section 4.2.3).  For example, if pneumonia, diarrhoea, or tetanus were 
unreported, these were assumed to have been in the “sepsis” category.  To simplify the 
modelling, we chose to not include this step for the proof-of-concept Bayesian exercise.  We 
therefore needed to drop high mortality model input studies which had unreported causes (the 
input vital registration [VR] data for the low mortality model had no unreported causes)1.   
 
The non-sepsis infection categories (pneumonia, diarrhoea, and tetanus) had the largest 
number of unreported causes in studies (e.g. pneumonia was missing for 55% of input 
observations, Table 4.3).  Thus, we grouped these causes alongside sepsis into a broader 
“infection” category for the modelling, which reduced the number of studies we needed to 
drop.  This resulted in a modified high mortality input dataset of 87 observations (17 dropped) 
for the early period model and 76 (15 dropped) for the late period model.  For comparability, 
we also used this modified input dataset when we re-ran the classical model.  
 
Covariate selection for models 
We used the same covariates selected through the classical covariate selection method (section 
4.2.3) for the classical and Bayesian models in order to facilitate a direct comparison between 
the results.  Because we used a collapsed set of causes for the Bayesian high mortality model 
(i.e. combining infectious causes into one category), we re-ran the classical covariate selection 
method for the high mortality model on these same collapsed causes.  We then used the results 
from this covariate selection for both the revised classical and Bayesian models.  Our later work 
on Bayesian covariate selection is described in section 7.2.5. 
 
 
1 Since the completion of the work reported here, Dr. David Prieto-Merino (a member of our team) has 
developed a method to account for unreported causes in this Bayesian framework. 
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Multinomial models 
Like the classical model, we used multi-cause multinomial logistic regression models to fit the 
data for all causes simultaneously.  For these regressions, we estimated the log of the ratio of 
each of the other causes to the baseline cause (the “log-cause ratio”) as a function of the 
selected covariates.  For simplicity, we did not include weights on the input observations (used 
as an intermediate between giving equal weighting to each death versus each study or country-
year) as we did in the classical model (section 4.2.3).  For comparability, we re-ran the classical 
models without this weighting.   
 
Parameter priors 
We used weakly informative Gaussian priors (mean: 0; standard deviation: 100) for the 
parameter priors of the multinomial regression equations.  As a sensitivity test, we also 
evaluated Gaussian priors with standard deviations ranging from 5 to 50.   
 
Sampling from the posterior distribution 
To sample from the posterior distribution, we used the Gibbs sampling method for MCMC.  For 
each of the models, we used 4 MCMC chains and a tenth of the iterations (i.e. thinning) for 
inference.  The other options, including number of iterations (both for burn-in and total) varied 
based on the model.  We chose these based on convergence of the MCMC chains, which we 
determined visually using parameter trace plots and density plots of the posterior distributions.   
 
Predicted proportions and number of neonatal deaths 
To estimate the predicted proportional COD distribution, we applied the posterior distribution 
parameter estimates from each thinned MCMC step to the country-year prediction covariate 
values.  We then averaged these predictions to obtain the final estimated proportional COD 
distribution for each modelled country-year.  We applied these proportions to the envelope of 
neonatal deaths for that country-year to obtain cause-specific numbers of deaths.  Finally, we 
compared the results of these outputs from the Bayesian analysis with the corresponding 
classical results.   
 
7.2.3 Incorporating country-level random effects 
We implemented a mixed effects (ME) modelling structure by adding a country-level random 
intercept to each non-baseline equation of the Bayesian multinomial model.  We assumed a 
Gaussian distribution for the random effects, and “tuned” the strength of these random effects 
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by adjusting the uniform prior on the standard deviation of the Gaussian distribution.  We began 
with a weak prior (which allows potentially large random effects) by allowing the random effect 
to be drawn from a Gaussian distribution with a standard deviation (SD) up to 1.6.  This 
corresponds to the odds ratios (ORs) between countries varying between 1/5 to 5.  Such wide 
variation in the OR is very unlikely to be due to true between-country effects, and thus is an 
overly generous allowance for the variation.  We also applied a very strong prior (i.e. allowing 
small random effects: SD up to 0.01; OR between 1/1.01 and 1.01) to test that the random effect 
implementation was working as expected.  Finally, we tested various SDs to find a medium prior 
(i.e. an estimate partly between the non-ME and observed data).  By applying these different 
SDs to the random effects prior, we were able to “tune” the strength of the country-level 
random effect (i.e. how much the modelled estimates would be pulled towards the country’s 
empirical data).   
 
Similarly to the inclusion of random effects in the binomial models (section 6.2.5), we produced 
two sets of estimates: 1) using the full ME model (i.e. fixed and random effects components) 
and 2) using only the fixed effects component of the ME model.  This allowed us to gauge how 
much the change in results was due to the random effects component versus different 
coefficient values for the covariates (i.e. the fixed effect component).  For this exercise, we 
assumed that the random effects were applicable to all input data (i.e. not only to nationally 
representative studies).  All other aspects of the modelling remained the same as described in 
section 7.2.2.   
 
We also compared the cause-specific goodness-of-fit (GOF) for the non-ME versus ME models 
by calculating their χ2 goodness-of-fit metric (Equation 5.1) based on the observed data versus 
estimated predictions.  We did this for the ME model using only the fixed effect components, 
as well as the full ME model using fixed and random effects.  
 
I present the results for the Bayesian ME analysis as part of a comparison with the classical 
results and the Bayesian non-ME models.  I will use the following terminology to refer to the 
models: 
o Classical – the non-ME classical multinomial models (described in section 4.2.3) 
o MCMC – the non-ME Bayesian models (described in section 7.2.2) 
o MCMC FE – the Bayesian ME regressions, but using only the fixed effects component 
for predictions (described in this section) 
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o MCMC RE – the Bayesian ME regressions, using both the fixed and random effects 
components for predictions (described in this section) 
For some aggregate results (e.g. regional), I include MCMC FE/RE results.  This category means 
MCMC FE results were used for countries with no input data and MCMC RE results were used 
for countries with input data.     
 
7.2.4 Implementing the lasso for Bayesian covariate selection 
We implemented the Bayesian lasso by using Laplacian (i.e. double exponential) priors for the 
parameter estimates.  First, we centered and normalized the covariates in our model to have 
means of 0 and standard deviations of 1.  This was done because the lasso penalty is on the sum 
of the absolute value of the covariate coefficients, and thus depends on the scale of the 
coefficients.  We included all potential covariates in each cause equation of the multinomial and 
gave each one a Laplacian prior with a penalty term (lambda).  For this exercise, we used only 
the linear form of covariates and re-ran the classical model covariate selection accordingly.  We 
tested a wide range of lambdas (1, 10, 50, 100, 500, 1000, 1500, 2500, 3000), evaluated their 
corresponding coefficient values, and generated country-specific proportional COD 
distributions based on each lambda.   
 
7.3 Main results 
7.3.1 Bayesian modelling to recreate classical results 
Here, I describe the results of building the Bayesian model to recreate the classical model 
results, with a focus on convergence of the MCMC chains, parameter estimates obtained, and 
a comparison of results from the two models.  The results presented here are for the early 
neonatal period.   
 
Convergence 
We evaluated convergence visually using trace and density plots.  Once convergence appeared 
to have been reached, we ran several thousand further iterations to verify stability of the chains.  
An example of these at different levels of convergence for the low mortality model with 25,000 
iterations is shown in Figure 7.1.  For the low mortality model, the majority of parameters 
reached convergence by approximately 50,000 iterations, but some needed more than 150,000 
iterations and a few required nearly 250,000.  Running 50,000 iterations took about 11 hours to 
run on a high-performance laptop.  The high mortality model required fewer iterations to reach 
convergence, with most parameters reaching convergence by about 20,000 iterations, nearly 
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all by 50,000, and a final few by around 200,000 iterations.  This model also ran much faster, 
with 50,000 iterations requiring 16 minutes on the same high-performance laptop.   
 
Figure 7.1: Examples of trace (left) and posterior distribution density (right) graphs for varying 
levels of convergence at 25,000 iterations (low mortality model). a) 3rd IMR spline, sepsis – not 
yet converged; b) DPT, intrapartum – nearly converged; constant; c) injuries – converged 
(verified by running further iterations – not shown). 
 
Note: y-axes are “Parameter estimate” for trace plots (left) and “Density” for posterior distribution 
density graphs (right) 
 
We tested whether convergence was reached more quickly for simpler models by removing 
quadratic and spline relationships for the covariates (i.e. keeping only linear relationships for 
each covariate-cause).  The results indicated that reaching convergence with fewer iterations 
was more likely for simpler models.  Figure 7.2 shows an example of this, with the density 
function not showing convergence at 100,000 iterations for a parameter with a spline function 
(7.2a) while showing convergence by 50,000 iterations for a linear parameter function (7.2b) in 
the low mortality model. 
 
Figure 7.2: Comparison of the posterior distribution density for a) “complex” model parameter 
(IMR, 1st spline; sepsis) at 100,000 iterations versus b) “simple” model parameter (IMR, linear; 
sepsis) at 50,000 iterations in the low mortality model.   
 
Note: y-axis is “Density” for both graphs 
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Parameter estimates 
We compared the parameter estimates (i.e. coefficient values) from the classical versus 
Bayesian models.  The parameter estimates from the Bayesian models were nearly the same as 
those of the classical model, even before there was visual evidence of convergence for all of the 
parameters.  Table 7.3 shows an example of this for the low mortality model.  The equation for 
pneumonia/preterm (top) has nearly all of the same coefficient values, and there was visual 
evidence to support the view that convergence had been reached.  The covariate coefficients 
for the injuries/preterm equation were very similar, even though some of those parameters did 
not appear to have reached convergence at 20,000 iterations (e.g. 2nd and 3rd splines of GFR).  
By 200,000 iterations the coefficient values were the same as the classical model.   
 
Table 7.3: Comparison of parameter estimates between the classical and Bayesian models: 
examples from the low mortality model 
 Classical model Bayesian model1 
Parameter estimates for ln(pneumonia/preterm) 
GNI 6.59 x 10-5 6.59 x 10-5 
GINI -0.04 -0.04 
U5MR 0.02 0.02 
constant -0.55 -0.54 
Parameters estimates for ln(injuries/preterm) 
GFR (S1) -41 -40 
GFR (S2) 22 14 
GFR (S3)  109 120 
LBW -0.15 -0.16 
LBW^2 0.01 0.01 
GNI 9.2x10-6 8.6x10-6 
ANC 0.08 0.07 
constant -9.01 -8.19 
1 for 20,000 iterations 
 
We further investigated the difference in parameter estimates over increasing iterations in the 
Bayesian model.  As noted above, we found that the parameter estimates appeared to stabilize 
even before the parameters appeared visually to reach convergence.  For example, some of the 
parameters in Table 7.4 did not appear to have reached convergence until after 50,000 steps.  
However, the parameter estimates did not change substantially between 50,000 and 200,000 
iterations, and were even fairly close to the converged values by 20,000 iterations.  But it is not 
possible to know in advance whether a parameter estimate has stabilized before the MCMC 
chain reaches convergence, and thus such a convergence check is still necessary.   
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Table 7.4: Example of parameter estimates for the classical model versus different numbers of 
iterations of the Bayesian model: ln(preterm/intrapartum) in the high mortality model  
 GFR GFR^2 LBW (S1)1 LBW (S2)2 constant 
Classical -44.5 142.8 11.5x10-3 9.0x10-3 3.0 
Bayes: 2,000 steps -33.8 101.9 18.6x10-3 3.7x10-3 2.3 
Bayes: 20,000 steps -44.0 140.7 11.9x10-3 8.3x10-3 3.0 
Bayes: 50,000 steps -44.8 144.3 11.3x10-3 9.3 x10-3 3.0 
Bayes: 200,000 steps -44.5 142.9 11.5x10-3 9.0 x10-3 3.0 
1 1st spline, 2 2nd spline  
 
We also tested a range of Gaussian priors (section 7.2.2) as a sensitivity analysis and found no 
difference in the results with these different priors.  
 
Comparison of Bayesian versus classical cause-of-death estimates 
As evidenced by the similar coefficient values for the equations, we were able to recreate the 
classical results using the Bayesian model with weakly informative priors for both the low and 
high mortality models.  Examples of the Bayesian versus classical results by country and cause 
for the low and high mortality models are included in Figure 7.3.   
 
Figure 7.3: “Recreating” the classical model results: examples of the % of neonatal deaths with 
the classical versus Bayesian models for the a) low mortality model (intrapartum, Peru) and b) 
high mortality model (sepsis, Central African Republic) 
 
 
 
7.3.2 Incorporating country-level random effects 
In this section, I present results from implementing the Bayesian ME models, including an 
examination of the extent to which parameter estimates changed, a comparison of COD 
predictions, and an assessment of how tuning the random effects prior affects the predictions.  
The first parts of the subsection are results based on allowing a strong random effect.   
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Convergence 
The ME models required more iterations to reach convergence for the fixed components than 
did the non-ME models.  An example of this is shown in Figure 7.4, where the U5MR coefficient 
parameter in the non-ME congenital equation (Figure 7.4a) appears to have reached 
convergence by 15,000 iterations (verified by running 20,000 more iterations – not shown) 
whereas this is not the case in the ME version (Figure 7.4b).  The model run times also increased 
with the Bayesian ME model compared to the non-ME model.  To run 50,000 iterations, the high 
mortality model required 21 minutes instead of 16 while the low mortality model required 15 
hours instead of 11.  Together, this meant that the Bayesian ME models typically required about 
1.5x as long to run as did the non-ME models.   
 
Figure 7.4: Examples of trace and posterior distribution density graphs for the Bayesian a) non-
ME and b) ME models: U5MR in the high mortality congenital equation at 15,000 iterations  
 
Note: y-axes are “Parameter estimate” for trace plots (left) and “Density” for posterior distribution 
density graphs (right) 
 
Parameter estimates 
We found that the parameter estimates between the MCMC and MCMC FE models ranged from 
similar to substantially different when the random effects were allowed to be strong.  Two 
examples from the high mortality model are shown in Table 7.5.  In the top example (preterm), 
the first spline of LBW had similar parameter estimates in the MCMC and MCMC FE models, 
while several of the other parameter estimates were rather different.  The second example 
(congenital) is a demonstration of how sometimes even the sign changed between the two 
models (e.g. U5MR and SSA).   
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Table 7.5: Two examples of parameter estimates between the classical, MCMC, and MCMC FE 
models  
 Classical model MCMC model1 MCMC FE2 model1 
Parameter estimates for ln(preterm/intrapartum)3 
GFR -44.5 -44.6 -12.2 
GFR^2 142.8 142.9 81.4 
LBW (S1) 11.5 x 10-3 11.4 x 10-3 11.0 x 10-3 
LBW (S1) 9.0 x 10-3 9.1 x 10-3 4.7 x 10-3 
Constant 3.0 3.0 0.01 
Parameters estimates for ln(congenital/intrapartum)3 
U5MR -38.9 x 10-3 -38.8 x 10-3 5.2 x 10-3 
U5MR^2 13.7 x 10-5 13.7 x 10-5 -1.9 x 10-5 
SSA -0.02 0.02 -1.49 
GFR -37.6 -37.7 -36.4 
GFR^2 140.6 140.6 168.7 
Constant 2.9 2.9 0.5 
1 for 50,000 iterations; 2 fixed effects are the same for the MCMC FE and MCMC 
RE models; 3 see Table 4.2 for covariate acronym definitions 
 
 
Comparison of the classical, MCMC, and MCMC ME models 
The country-level random effects appeared to work as expected, with the MCMC RE estimates 
pulled towards the observed values for countries with input data.  However, the relationships 
between the MCMC (i.e. non-ME), MCMC FE, and MCMC RE estimates varied.  Some 
representative examples are shown in Figure 7.5 for the high mortality model.  For some 
countries/causes, the MCMC RE and MCMC FE estimate levels were similar to each other but 
different from the non-ME level, with similar time trends for all (e.g. Figure 7.5a).  Some had 
similar time trends but the MCMC RE level was moderately different from the MCMC FE and 
non-ME levels (e.g. Figure 7.5b).  A few countries had multiple input datapoints.  For some, the 
MCMC RE and MCMC FE time trends were different from those for the non-ME model and this 
change was visually consistent with the input data (e.g. Figure 7.5c).  A few others had different 
MCMC RE and MCMC FE time trends compared to the non-ME model, but the trend was not 
visually obvious from the input data (e.g. Figure 7.5d).  In these cases, observations with larger 
sample sizes likely influenced the MCMC RE estimates more heavily.  Finally, some MCMC RE 
estimate levels (but not trends) appeared to be substantially influenced by older input 
datapoints (e.g. Figure 7.5e), while for others the trend was also altered by older data (e.g. 
Figure 7.5f).  This issue of how much older data should influence current estimates is part of a 
larger discussion of how to choose the tuning strength of the RE (see section 7.4 for further 
discussion).   
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Figure 7.5: Examples of the % of neonatal deaths by country and cause with classical, MCMC, 
MCMC FE, and MCMC RE models for high mortality countries with input data. a) 
Congo/preterm; b) Guinea/infection, c) Bangladesh/preterm, d) Nepal/preterm, e) 
Nigeria/intrapartum, f) Bolivia/intrapartum 
 
Notes: Country-level random effects were applied to all studies and not only nationally representative 
ones for the purpose of this proof-of-concept exercise (section 7.2.3); MCMC FE estimates (yellow lines) 
are alongside MCMC estimates (red lines) for Figures 7.5b and 7.5e.   
 
The MCMC FE results varied widely at times from the non-ME and MCMC RE results (when 
assuming a strong random effect).  Figure 7.6 shows representative examples for countries 
which did not have studies in the input dataset.  For some countries/causes with no input data, 
the MCMC FE estimates were consistent with those from the non-ME model (e.g. Figure 7.6a).  
For others, the MCMC FE and non-ME trends were the same but the levels were different (e.g. 
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Figure 7.6b).  There were several countries/causes in which the MCMC FE estimate had a 
different trend from the non-ME model (e.g. Figure 7.6c).   
 
Figure 7.6: Examples of the % of neonatal deaths by country and cause with classical, MCMC, 
and MCMC FE models for high mortality countries without input data. a) Namibia/infection, b) 
Myanmar/infection, c) Bhutan/intrapartum 
 
 
The differences between the MCMC RE and MCMC FE estimates are important to consider.  
Figure 7.7 shows an example of a country (Iran) with one observed datapoint, where the MCMC 
RE and non-ME results were very similar (~20% of neonatal deaths from intrapartum) but the 
MCMC FE result was remarkably different (~40%).  Assuming this choice of random effect 
strength, Iran’s reported estimate would be the MCMC FE result if there had been no input data 
for the country.   
 
Figure 7.7: Example of differences in the % of neonatal deaths estimated by the MCMC FE and 
MCMC RE models (Iran, intrapartum) 
 
 
Such differences are important because the majority of countries in the high mortality model 
have no nationally representative studies in the input dataset, and therefore their estimates 
would come from the fixed component of an ME model.  Later in this section, I discuss our work 
to tune the strength of the random effects to address what are sometimes large differences 
between the MCMC FE and non-ME MCMC models.  Furthermore, the broader implications of 
random effects strength tuning are included in the discussion (section 7.4).   
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When the models were applied to the input dataset for validation, the MCMC RE model with a 
strong random effect performed better (i.e. predicted estimates were closer to the observed 
values) than the non-ME MCMC model for all causes (Table 7.6).  At this random effect strength, 
the non-ME MCMC model performed better than the MCMC FE model for all but the “other” 
cause category (Table 7.6).  However, as the allowed random effect was weakened, the χ2 values 
for the three models moved towards convergence and the MCMC FE outperformed the non-ME 
model for three causes (Table 7.6).   
 
Table 7.6: Comparison of χ2 values for the Bayesian MCMC, MCMC RE, and MCMC FE models 
when allowing strong- versus medium-strength random effects 
 MCMC model 
(non-ME) 
Strong random effect1 Medium random effect1 
 MCMC RE MCMC FE MCMC RE MCMC FE 
Intrapartum 1504 376 2774 649 1483 
Preterm 723 385 1684 562 982 
Congenital 584 325 1146 407 671 
Infection 831 612 1907 685 731 
Other 1159 780 1107 1004 1079 
1 Standard deviation (SD) of random effects prior allowed up to 1.6 for strong prior and 0.7 for 
medium prior (section 7.3.2) 
 
Figure 7.8 shows the proportional COD distribution for the 20 countries with studies in the input 
database.  Overall, the MCMC and MCMC FE models were closer to each other in their 
aggregated results than to the MCMC RE results when assuming a strong random effect.  The 
intrapartum and infection results tended to be higher for the MCMC RE model, while they were 
lower for preterm and congenital.  Note that the country-level random effects were estimated 
using all studies for this proof-of-concept exercise, and not only the nationally representative 
ones.  
 
Figure 7.8: % of neonatal deaths by cause and model type (classical, MCMC, MCMC FE, and 
MCMC RE) for 20 countries with input data in the high mortality dataset  
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This pattern (intrapartum and infection higher; preterm and congenital lower) was replicated in 
the aggregated results for all modelled countries (Figure 7.9), though to a lesser extent.  The 
difference was less pronounced because the last category (brown bar in Figure 7.9) combines 
countries with no input data (i.e. MCMC FE results only) with those with input data (i.e. MCMC 
RE results).   
 
Figure 7.9: % of neonatal deaths by cause and model type (classical, MCMC, MCMC FE, and 
MCMC FE/RE) for 80 high mortality model countries  
 
The regional estimates show some more substantial differences between the model types 
(Figure 7.10).  For example, Sub-Saharan Africa had a higher proportion of preterm deaths in 
the MCMC FE model than the other models and compared to the other regions.  The random 
effects dramatically increased the intrapartum estimate while decreasing preterm in South Asia 
(and to a lesser extent in East Asia and the Pacific).  The Europe and Central Asia region had no 
input studies, and therefore the MCMC FE and MCMC FE/RE results were the same (Figure 
7.10d).   
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Figure 7.10: % of neonatal deaths by cause and model type (classical, MCMC, MCMC FE, and 
MCMC FE/RE) for four regions. a) Sub-Saharan Africa (n=43), b) South Asia (n=5), c) East Asia 
and the Pacific (n=14), d) Europe and Central Asia (n=6) 
 
 
Tuning the strength of the random effects 
We were able to adjust the strength of the country-level random effects by tuning the priors for 
the random effects intercepts.  The choices of the SD of the random effects priors to allow weak 
and strong random effects strengths are explained in section 7.2.3.  Briefly, the strong prior (i.e. 
weak random effects strength) allowed the random effects to be drawn from a Gaussian which 
had an SD of the log of the odds ratio that could vary up to 0.01, while the weak prior (i.e. strong 
random effects strength) allowed an SD up to 1.6.  We tested several SDs in between these two, 
and chose a medium random effect strength by setting the SD to 0.7 (i.e. the odds ratios 
between countries could vary between 1/2 to 2).  Figure 7.11 shows an example of the MCMC, 
MCMC FE, and MCMC RE estimates for 2000-2015 with these strong (Figure 7.11a), medium 
(Figure 7.11b), and weak (Figure 7.11c) random effects.  When the random effect strength is 
allowed to be strong, the MCMC RE estimates are pulled very close to the observed data, while 
in this case the MCMC FE is substantially higher than the MCMC RE, and moderately higher than 
the non-ME MCMC estimate.  With a medium strength random effect, both the MCMC FE and 
MCMC RE estimates came closer to the non-ME estimate.  Finally, when the random effect was 
constrained to be weak, the three estimates were nearly the same.  Thus, adjusting the random 
effect prior can substantially affect both the MCMC RE and MCMC FE estimates.   
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Figure 7.11: Example of the % of neonatal deaths with a) strong, b) medium, and c) weak 
country-level random effects (Afghanistan, preterm) 
 
 
Figure 7.12 shows how the proportional COD distribution changed with the weak, medium, and 
strong random effects for the 20 high mortality countries with input data.  The weak random 
effect effectively gave the same result as the MCMC model (i.e. no random effects), while the 
proportions for intrapartum and preterm had differences of about 10 percentage points with 
the strong compared to no random effect.  The medium strength random effect can be tuned 
to fall anywhere between these two.   
 
Figure 7.12: % of neonatal deaths by cause, model type (classical, MCMC, MCMC FE, and 
MCMC RE), and random effects strength for 20 countries with input data in the high mortality 
dataset  
 
Note: RE = random effect 
 
Overall, the results here indicate that we were able to successfully tune the strength of the 
random effects, with the implications of this discussed in section 7.4. 
 
7.3.3 Implementing the lasso for Bayesian covariate selection 
We tested a range of lambda values (from 1 to 3000) for the lasso penalty while implementing 
the Bayesian lasso covariate selection in the non-ME model.  Overall, the covariate (beta) 
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coefficients moved towards zero as the lambda value increased (e.g. Figure 7.13).  This is the 
expected result of a lasso regression, thus suggesting that our Bayesian lasso implementation 
was successful.   
 
Figure 7.13: Example of covariate (beta) coefficients moving towards zero with an increasing 
Bayesian lasso penalty (other, high mortality model) 
 
 
Across the causes, we found that approximately six to eight covariates were retained in the 
model with a low penalty (e.g. lambda: 10), while a high penalty (e.g. lambda: 3000) resulted in 
0-1 covariates.  A medium penalty (e.g. lambda: 1000) typically resulted in three to five 
covariates in the model, which may represent a reasonable compromise between complex 
models and underfitting.   
 
Table 7.7 shows the covariates chosen by Bayesian lasso using two medium-range penalties 
(lambdas of 1000 and 1500) compared to those selected using our classical approach (section 
4.2.3).  Several of the covariates were the same between the classical model and Bayesian lasso.  
In general, the higher lambda penalty (1500) appears to be closer to the classical model.  Only 
two covariates  showed up in the classical covariate selection but not the Bayesian lasso at a 
lambda of 1000 or higher: GFR in infection and LBW in preterm.  The former was dropped from 
the lasso between a lambda of 100-500, and the latter was dropped between a lambda of 500-
1000.  In general, there is overlap between the classical and Bayesian lasso results, but there 
are also several differences in selected covariates.   
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Table 7.7: Comparison of covariates (and their parameter estimates) selected using the 
classical approach versus two Bayesian lasso models with medium-range penalties  
 
Classical1 
Bayesian lasso2 
 λ=1000 λ=1500 
Preterm    
 Constant: 0.08 Constant: 0.27 Constant: 0.33 
 GFR: -0.50 GFR: -0.08  
 LBW: 0.10   
  SBA: 0.16 SBA: 0.15 
  U5MR: 0.02 U5MR: 0.01 
Congenital    
 Constant: -1.69 Constant: -1.35 Constant: -1.23 
 U5MR: -1.21 U5MR: -0.61 U5MR: -0.44 
  DPT: 0.05 DPT: 0.02 
  NMR: -0.01  
  BCG: 0.01  
Infection    
 Constant: -0.08 Constant: -0.05 Constant: -0.05 
 BCG: 0.47 BCG: 0.27 BCG: 0.21 
 PAB: 0.29 PAB: 0.09 PAB: 0.01 
 LBW: 0.45 LBW: 0.01  
 GFR: 0.54   
  SBA: -0.51 SBA: -0.48 
Other    
 Constant: -2.03 Constant: -1.62 Constant: -1.48 
 PAB: 1.36 PAB: 0.63 PAB: 0.39 
  BCG: 0.01 BCG: 0.01 
  LBW: 0.01  
  U5MR: -0.01  
1 Covariates were scaled to be comparable with the Bayesian lasso approach;  
2 Coefficients below 0.01 were considered to be 0 since coefficients in Bayesian 
lasso cannot go to exactly 0.   
 
 
The COD predictions produced by the Bayesian lasso model varied in their similarity to the 
standard MCMC model presented in section 7.3.1.  For example, some lasso results were 
relatively similar to their standard counterparts (e.g. Figures 7.14a) while others had fairly 
different levels (e.g. 7.14b) for a medium lasso penalty of 1000.  This is unsurprising given that 
the covariates selected by Bayesian lasso were similar but not the same.  The neonatal COD 
distributions were similar for lasso penalties of 1000 versus 1500.    
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Figure 7.14: Examples of the % of neonatal deaths by country and cause between the MCMC 
and MCMC lasso models. a) Pakistan/infection, b) Ethiopia/intrapartum 
 
 
In general, the proportional COD distribution did not have substantial differences between the 
lasso and classical covariate selection approaches at the regional level (Table 7.8), with most 
differences within 5 percentage points.  The most substantial difference was for intrapartum-
related deaths in Sub-Saharan Africa, where the percentage of neonatal deaths predicted using 
the Bayesian lasso versus classical covariate selection approach were 24% versus 37%, 
respectively.  Since intrapartum is the baseline cause, it is difficult to identify a specific reason 
(e.g. covariate) that may be leading to this difference.  The percentage differences across the 
other four causes suggest that the Bayesian lasso had a higher estimate for these causes by two 
to five percentage points each, which likely decreased the intrapartum proportion.   
 
Table 7.8: Neonatal proportional cause-of-death distribution by region using Bayesian lasso 
versus classical covariate selection methods (differences ≥ 5 percentage points italicized) 
 Preterm Intrapartum Infection Congenital Other 
Region1 Lasso Classic Lasso Classic Lasso Classic Lasso Classic Lasso Classic 
CCA 0.41 0.38 0.27 0.26 0.14 0.13 0.11 0.16 0.07 0.07 
LAC 0.38 0.36 0.25 0.29 0.20 0.16 0.10 0.14 0.07 0.05 
NA 0.41 0.37 0.26 0.24 0.15 0.14 0.11 0.19 0.07 0.06 
SEA 0.40 0.43 0.26 0.22 0.17 0.12 0.10 0.18 0.07 0.04 
SA 0.37 0.44 0.24 0.26 0.22 0.19 0.10 0.07 0.07 0.04 
SSA 0.36 0.31 0.24 0.37 0.24 0.20 0.10 0.07 0.07 0.05 
WA 0.38 0.34 0.25 0.33 0.20 0.14 0.10 0.14 0.07 0.04 
1 CCA = Caucasus and Central Asia; LAC = Latin America and Caribbean; NA = North Africa; SEA = 
Southeast Asia; SA = Southern Asia; SSA = Sub-Saharan Africa; WA = Western Asia 
 
The results in this subsection indicate that we were able to successfully implement Bayesian 
lasso in our model.  The final estimates were remarkably similar given that the classical version 
is based on single-cause (instead of multinomial) covariate selection without lasso.  The next 
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section includes details on how the Bayesian lasso implementation can be furthered for 
inclusion in a future model.   
 
7.4 Discussion 
In this chapter, I presented the results of our work on transitioning from the classical neonatal 
cause-of-death models in Stata to a Bayesian framework in R.  We were able to successfully 
reproduce the classical results, and to extend the multinomial model by implementing country-
level random effects.  We also tested the Bayesian lasso for covariate selection.  This proof-of-
concept work suggests that shifting to a Bayesian framework is feasible for these models and 
allows us to add features that we were unable to implement in the existing classical models (e.g. 
random effects).   
 
A key finding was that the Bayesian multinomial model could reproduce the classical 
multinomial results assuming weakly informative parameter priors and the same covariates in 
the cause equations.  Bayesian covariate selection using lasso regression with a medium penalty 
could also produce estimates which were relatively similar to the classical results.  Additionally, 
we could tune the strength of the random effects by changing the prior distribution for the 
between-country variation (by varying the standard deviation of the prior).  We found that the 
goodness-of-fit of the proportional COD distribution improved with inclusion of random effects.  
This is not surprising since the expected outcome of incorporating random effects in our model 
is to pull the modelled estimates closer to the observed data.   
 
This result also largely explains the differences in the goodness-of-fit comparison described by 
IHME for our previous work [202].  There, IHME compared their modelled estimates (using 
mixed effects [203]) against their input data versus our modelled estimates (with no mixed 
effects) against our input data.  This is an unequal comparison, and including hierarchical effects 
in such validation can mask whether the fixed components of the models are performing well.  
This also leads to the broader issue of the interpretation and use of random effects in models 
such as these.   
 
In theory, one includes random effects because of a belief that while some variations in 
outcomes can be explained by factors that influence all groups in the same way, some real 
variation (as opposed to stochastic variation) cannot be explained by measured covariates.  
Thus, applying country-level random effects is justifiable as an acknowledgement that there 
may be real between-country differences which the other covariates in our model are unable 
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to capture.  But this interpretation of what country-level random effects represent does not 
capture the full picture when dealing with real-world data such as those in our input dataset.  
We have demonstrated in this chapter that allowing a strong random effect can pull a country’s 
modelled estimate substantially towards the observed data.  At first glance this seems 
reasonable, especially given our ultimate goal of shifting from modelled estimates to empirical 
data when possible.   
 
But several important data issues complicate this, particularly in the high mortality model.  First, 
the input studies in this model vary widely in quality and generally use VA methods for COD 
attribution.  VA studies are often the only viable option for COD determination in many low-
resource settings but have important biases which can influence their results (section 2.3.2).  
Additionally, most of the high mortality input studies are cross-sectional and report data for a 
short period of time (as opposed to our modelled estimates over 15+ years).  Finally, the 
majority of input studies are local studies with relatively small sample sizes.  These factors can 
affect the quality and generalizability of the observed data.   
 
Given these issues, there is a question about whether the unexplained variation identified 
between countries from the input studies and modelled by the random effects represents real, 
epidemiological between-country differences or is due to data quality issues.  Or in other words, 
are the random effects capturing true between-country variation or methodological 
challenges/differences between studies?  Additionally, how much should one (often small and 
several years old) input study affect the current estimates for a country?  We can try to mitigate 
the generalisability issue by limiting the use of random effects to those derived from nationally 
representative studies and/or newer studies, but these are still limited in number and may 
range widely in quality.  Thus, a subjective decision must be made on how much a country’s 
modelled estimate should be pulled towards what is often at present a single nationally 
representative study datapoint with quality concerns.  Modelled estimates and empirical data 
both have a range of issues, and there is a delicate balance to be struck on how much weight to 
give to each one.  
 
Moreover, this concern carries over to the fixed component of the ME model as well.  We 
demonstrated that when there is a strong random effect, the estimate from the MCMC FE 
model can be substantially different from that of the MCMC RE model (and thus the empirical 
data as well).  But there is a similar question of whether the difference between this MCMC FE 
estimate and the empirical data represents a real difference in the cause distribution or is due 
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to errors (random or systematic) in the empirical data.  This is an especially important issue to 
consider since the majority of countries in our models have no nationally representative input 
data (and therefore the fixed effect component of the ME model would be used for their 
estimate).  
 
An additional element is how deaths are treated within an observation (i.e. study or VR 
datapoint).  Without any weighting scheme, all input deaths are treated independently and 
given the same weighting in the model.  However, this is likely to be incorrect since it is probable 
that there is “clustering” of causes of deaths within observations.  For the classical multinomial 
models, we applied an ad hoc fix such that individual deaths from larger observations carried 
less weight than those from smaller ones.  Random effects act similarly by assuming clustering 
of causes of deaths within observations.  The strength of the random effects influence how 
much “clustering” is allowed, and thus this issue should also be considered when selecting the 
strength of the random effects.   
 
Ultimately, addressing these issues in a mixed effects model comes down to the strength of the 
random effects.  This requires careful consideration and subjective decisions based on the issues 
discussed above, as well as the overall goal of the project.  In our case, we sought to include 
country-level random effects in acknowledgement that modelled estimates are non-ideal and 
are unlikely to capture all variation between countries, and also because we believe in the 
principle of shifting towards empirical data when possible.  However, the data quality concerns 
of the input studies (whether as individual studies or when combined into one dataset for 
analysis [section 5.1]) are real and need to be considered as well.  Given these issues with both 
the modelled and empirical data, I would recommend a medium random effects strength, which 
serves as a compromise between the modelled estimate and empirical data for countries with 
input studies.  This strength could also be adjusted over time (e.g. if input data increase in 
standardization/quality). 
 
The work presented in this chapter shows that it is possible to implement a Bayesian 
multinomial neonatal COD model.  Taking the model beyond this stage involves additional 
model building and analysis steps.  First, a way to deal with unreported causes in the input data 
needs to be developed and implemented so that all studies, including those that do not report 
on all causes in our model, can be included in the analysis2.  Importantly, any model used to 
 
2 As mentioned earlier, Dr. David Prieto-Merino has now developed a method to account for missing 
causes for our models in the Bayesian framework. 
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produce estimates must also include credible intervals.  Though we did not do this at this stage, 
it is a necessity for actual estimates since uncertainty is one of the most important concerns for 
such modelling exercises.  This can be done by taking a sample of n iterations (e.g. n = 1000) 
after convergence of the MCMC chains and estimating the COD distribution for each of these 
iterations.  The iterations should be taken with sufficient spacing to avoid autocorrelation.  The 
95% credible interval can then be computed from these n samples for each country/year/cause.  
The models should also be tested for predictive accuracy and stability, particularly once all of 
the model features are implemented (see sections 5.1 and 8.6 for more details).   
 
Further work on Bayesian covariate selection would also be useful.  We tested only the Bayesian 
lasso as a more complete review of covariate selection was beyond the scope of this thesis.  We 
chose the Bayesian lasso because our initial review of the literature suggested that the lasso 
was a good fit both for multinomial covariate selection and for the potential stability issues in 
our models (section 5.1).  However, other methods, including Bayesian ridge regression and 
various information criterion, may also be useful to investigate.  Additionally, we implemented 
Bayesian lasso by testing a range of lambda values (i.e. the penalty term), which is a common 
method for tuning the penalty.  However, selecting the lambda parameter using out-of-sample 
cross-validation is more robust (though it will also substantially increase the time required to 
run the model).  The final Bayesian covariate selection method will also need to be implemented 
in the mixed effects model.     
 
The work I have presented here on shifting our classical models to a Bayesian framework fits an 
increasing trend on these topics.  Over the last decade, Bayesian methods have become more 
popular in global health, including for mortality and COD estimation.  For example, UN-IGME 
now uses Bayesian methods for neonatal, under-5, and maternal all-cause mortality estimates 
[204-206].  IHME shifted to using Bayesian methods for their 2010 Global Burden of Disease 
estimates for 235 causes of death in 187 countries, including for the neonatal age group [203, 
207].  Some key differences between the IHME and MCEE approaches for COD estimation, 
especially regarding the modelling approaches and input data, are described in sections 2.3.4 
and 8.2.    
 
Based on the overall results of this exercise, I believe that shifting the neonatal COD models to 
the Bayesian framework is feasible and appropriate.  The inclusion of country-level random 
effects is an important modelling feature which we were unable to include in the classical 
models.  In addition, we believe that the estimates are unlikely to have substantial unintentional 
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(or inexplicable) differences from the classical approach given that we were able to recreate the 
classical results, and that we demonstrated the ability to tune the random effects strength and 
the Bayesian lasso penalty.  Thus, the Bayesian neonatal COD framework in this proof-of-
concept exercise offers additional flexibility without many drawbacks.  The key disadvantage of 
this approach is that it can require substantially greater computing resources and time, 
especially with the addition of any out-of-sample cross-validation.  The remaining tasks to 
finalize a model that can be used to produce publishable national-level COD estimates will 
require some time but are doable.  I therefore recommend that the neonatal COD models be 
shifted to the Bayesian framework.      
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8 Discussion 
The overall goal of this thesis was to help improve our understanding of the temporal and causal 
distributions of deaths within the neonatal period, including both conducting analyses to fill 
knowledge gaps and making improvements to existing statistical models.  Here, I provide a 
summary of our findings, a comparison with other work, a discussion of overall strengths and 
limitations, and an overview of future work.  I also provide recommendations on various topics 
related to neonatal estimation modelling, including on input data improvements, core 
modelling principles, and uses/limits of such models.   
 
8.1 Summary of main findings 
The main findings are divided into three parts: 1) estimating risk of death by day within the 
neonatal period (chapter 3), 2) estimating cause-of-death distributions for the early and late 
neonatal periods (chapter 4), and 3) identifying limitations of the current cause-of-death  
modelling approach and investigating model improvements (chapters 5-7).   
 
8.1.1  Estimating risk of death by day within the neonatal period 
The days immediately after birth are the riskiest for human survival, yet neonatal mortality risks 
are generally not reported by day.  Early neonatal deaths are sometimes under-reported or 
might be misclassified by day of death or as stillbirths.  We modelled daily neonatal mortality 
risk and estimated the proportion of deaths on the day of birth and in week 1 for 186 countries 
in 2013.  For 57 countries with high-quality vital registration data, we used the data as reported.  
For the remaining 129 countries, we applied an exponential model to data from 206 
Demographic and Health Surveys (DHS) in 79 countries to estimate the proportions of neonatal 
deaths per day and used bootstrap sampling to develop uncertainty estimates.   
 
We found that 36% (uncertainty range: 34-38%) of all neonatal deaths occurred on the day of 
birth (day 0) and that 73% (72-74%) occurred in the first week.  Thus, in 2013, an estimated 1.00 
million (0.94 million-1.05 million) neonatal deaths occurred on day 0 and 2.02 million (1.99 
million-2.05 million) occurred in week 1.  Strikingly, these proportions had little variation by 
neonatal mortality rate, income, or region.  Of all neonatal deaths, Sub-Saharan Africa had the 
highest risk of neonatal death and, therefore, had the highest risk of death on day 0 (11.2 [10.6-
11.8] per 1,000 livebirths); the highest number of deaths on day 0 was seen in southern Asia 
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(n=392,300 [369,100-412,500]).  We also developed simple analytical methods to identify DHS 
where substantial misclassification of deaths between days 0 and 1 or underreporting of very 
early neonatal deaths was likely to have occurred.   
 
These results represent a starting point for understanding the burden of day 0 and week 1 
deaths in each country.  On average, our results likely represent the day 0 and week 1 
proportions for many of the modelled countries, but our approach will mask any variation that 
does exist between countries.  We hope that our estimates will be improved upon as better 
data become available, including with external validation if high-quality day-of-death data are 
made available.   
 
Our results highlight the fact that the risk of early neonatal death is very high across a range of 
countries and contexts.  Timely, cost-effective, and feasible interventions to improve neonatal 
and maternity care could save many lives if implemented during these riskiest hours and days 
after birth. 
 
8.1.2  Estimating cause-of-death distributions for the early and late neonatal periods 
Understanding the cause-of-death (COD) distribution is important for selecting appropriate 
interventions to reduce mortality and morbidity.  Both available data and our understanding of 
biology and pathology suggest that the COD distribution differs substantially between the early 
(days 0-6) and late (days 7-27) neonatal periods.  Our work furthered the previous neonatal COD 
modelling by producing separate COD distribution estimates by neonatal period.  We estimated 
these early and late neonatal period COD distributions for 194 countries between 2000 and 
2013.  For 65 countries with high-quality vital registration (VR) data, we used each country’s 
observed proportional cause distributions as reported.  For the remaining 129 countries, we 
used multinomial logistic models to estimate these distributions.  
 
We found that the neonatal COD distribution differed between the early and late periods and 
varied with neonatal mortality rate level.  Although preterm, intrapartum, and infection were 
the leading cause categories of neonatal death in both the early and late neonatal periods, their 
distributions were substantially different between the two periods.  Preterm birth (41%) and 
intrapartum complications (27%) accounted for most early neonatal deaths while infections 
caused nearly half of late neonatal deaths.  Generally, low mortality countries had higher 
proportions of deaths from congenital disorders and lower proportions from intrapartum and 
infections, while the opposite was true in high mortality settings.  Between 2000 and 2013, 
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neonatal deaths decreased for most causes.  Of the approximately 2.8 million neonatal deaths 
in 2013, 0.99 (0.70–1.31) million deaths were estimated to be caused by preterm birth 
complications, 0.64 (0.46-0.84) million by intrapartum complications and 0.43 (0.22-0.66) 
million by sepsis and other severe infections.  Preterm birth complications were the leading 
cause of death in all regions of the world.   
 
As with all such modelling exercises, our estimates should be viewed as an interim measure to 
help policymakers, particularly in settings with little or no data currently.  Such results are not a 
panacea for actual data collection, and we applaud the many efforts underway currently to 
improve CRVS systems and other COD data collection throughout the world.  However, given 
the current lack of ubiquity in adequate CRVS systems, statistical modelling remains necessary 
to estimate COD distributions for the majority of countries.   
 
The results from this work reinforce the idea that COD distributions are different across the 
early and late neonatal periods.  Thus, both timing and causes of neonatal deaths should be 
considered carefully when implementing interventions.   
 
8.1.3 Improving the current neonatal cause-of-death models 
The work on improving the existing neonatal COD models had two key steps: 1) identifying 
potential issues and limitations with our models and 2) investigating and implementing 
potential strategies to address these concerns.  I focused on model stability and predictive 
accuracy, as well as whether and how to weight empirical data for country-specific COD 
estimates.   
 
First, I identified several factors which could contribute to model performance issues.  Some of 
these, such as the amount and quality of the input data, are outside of our direct control.  
Others, such as the covariate selection method and statistical framework, are modelling choices 
we made and can refine to improve model performance.  I demonstrated that certain strategies, 
such as ensemble methods, may be able to improve stability.  The lasso regression appeared to 
be a promising technique for multinomial covariate selection and stability improvement, but we 
were unable to fully implement it in our classical framework.  Second, I discussed practical and 
philosophical reasons for adding country-level random effects to our models.  However, we 
were unable to incorporate these into our existing classical multinomial models.   
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We tested two key alternative modelling strategies to help address some of the issues described 
above.  First, we implemented the COD models in a binomial modelling framework, including 
with random effects.  However, we found that this framework did not have a substantial impact 
on improving model performance.  We also encountered some challenges while implementing 
the random effects which suggested we may be faced with further difficulties if increasing the 
complexity of the modelling strategy (e.g. with lasso regression or ensemble methods).   
 
Next, we successfully implemented a proof-of-concept Bayesian model with country-level 
random effects, and demonstrated the feasibility of applying Bayesian lasso as a multinomial 
covariate selection strategy within this framework.  We were able to recreate the classical 
neonatal COD results in the Bayesian framework with weakly informative priors, indicating that 
shifting to this model would not have unintended or unexplainable differences from the original 
models.  I recommended applying a medium random effects strength at the country level based 
both on our analyses of testing weak, medium, and strong random effect priors, as well as the 
nuances around what random effects mean for models such as ours (section 7.4).  Finally, we 
demonstrated a successful implementation of the Bayesian lasso.  Ultimately, I believe that 
shifting the neonatal COD models to the Bayesian framework is feasible and advisable since it 
allows us to incorporate modelling features which we were unable to implement in the classical 
framework.  In section 8.4, I discuss some future work to finalize these proof-of-concept models.   
 
There were many lessons learned about statistical modelling and neonatal estimates while 
conducting the work presented in this thesis.  I have included a discussion of implications and 
recommendations later in this chapter.   
 
8.2 Comparison with other work 
We chose to conduct the risk by day of death and COD by neonatal period analyses as these 
were gaps that we believed needed to be addressed at the time.  For the risk by day of death 
analysis, individual studies had been conducted in various countries, but no systematic, 
nationally comparable estimates had yet been published when we conducted our analysis.  We 
are still unaware of comparable work.  A brief history of neonatal COD estimation is included in 
section 2.3.4.  Our group (under the Maternal Child Epidemiology Estimation [MCEE] umbrella) 
and the Institute for Health Metrics and Evaluation (IHME) both produce nationally comparable 
neonatal COD.  MCEE (previously CHERG) first published neonatal COD estimates in 2005 [13], 
but these were not separated into the early and late neonatal periods prior to the work 
presented in this thesis [141].  IHME first published COD estimates by neonatal period in 2012 
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[93], with consistent publication of period-specific neonatal COD estimates beginning in their 
GBD study published in 2017 [103].  Here, I briefly describe how our approach compares to that 
of IHME.   
 
Previous work has compared the under-5 COD mortality estimates between MCEE (including 
our neonatal estimates) and IHME [208].  These results showed that IHME and MCEE neonatal 
COD estimates were similar for several causes, including intrapartum, sepsis, pneumonia, and 
congenital.  The two key causes with differences were complications of preterm birth and other.  
The 2013 global COD estimates for preterm were 0.965 (0.615-1.537) million by MCEE and 0.693 
(0.554-0.854) million by IHME, and the “other” estimates were 0.232 (0.145-0.373) million by 
MCEE and 0.452 (uncertainty not available) million by IHME [208].  When estimates are different 
between the two groups, it is difficult to tease apart the reasons because there are several major 
methodological and input data differences between the IHME and MCEE models.   
 
IHME models causes of death for the neonatal age group as part of their larger global burden of 
disease modelling strategy.  This involves modelling 250+ causes of death using an ensemble 
approach within a Bayesian mixed effects single-cause framework [203].  While the different 
statistical approaches will certainly have an impact on the results, the input data decisions are 
likely to play a larger role in explaining the MCEE versus IHME differences.  One major difference 
is that IHME combines all of the input data into one model, whereas we separate our models 
into two categories (low and high mortality models).  We do this for two key reasons: the COD 
distributions are different for low versus high mortality countries, and the amount of data from 
low mortality countries (through VR data) is so much greater that it would vastly overpower the 
high mortality input study data.   
 
A consequence of this modelling difference is that IHME models over 250 causes while we model 
eight major cause categories.  Their use of low mortality VR inputs for high mortality countries 
allows for ICD-level cause categories.  Producing estimates by finer cause categories would be 
desirable if the input data supported it.  However, almost no high mortality countries have 
reliable VR data, and verbal autopsy (VA) studies report far fewer cause categories (often even 
less than eight).  Thus, estimating hundreds of causes for countries with no relevant supporting 
data means drawing the inputs mostly from low mortality countries which tend to have 
substantially different COD distributions.  This conveys an unwarranted level of certainty about 
COD modelling.  The reason the imperfect solution of verbal autopsies even exists is because 
many countries lack reliable CRVS systems.  While the data issues with VA are well known, they 
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are at present one of our only ways to obtain empirical COD data without CRVS systems.  These 
studies only reporting a handful of death categories is also an implicit acknowledgement of how 
much uncertainty there is around COD assignment without conventional autopsies or well-
conducted medical certification.  To go from such empirical data to modelling hundreds of 
causes seems beyond what the data can support.  Even hierarchical models that give weight to 
neighbouring and/or regional data in the absence of input data from a given country cannot 
solve the problem that many countries lacking adequate VR data are clustered (e.g. Sub-Saharan 
African countries).   
 
Ultimately, the differences in the results between MCEE and IHME are indicative of the central 
issue with modelling, and the reason it is done: we lack reliable empirical data.  Modelling 
decisions around input data inclusion/exclusion and processing, and statistical method choices, 
will influence over the results.  As data inputs improve in quantity and quality, modelled 
estimates between different groups will ideally converge.  I discuss several of these issues in 
later subsections, including improving input data (section 8.5), core principles for modelling 
(section 8.6), and uses and limitations of models (section 8.7).   
 
8.3 Strengths and limitations 
The work presented in this thesis has several strengths and limitations, most of which are 
described in detail in the previous chapters.  In this section, I summarize some of the key overall 
strengths and limitations of our modelling approaches, with a particular focus on the cause-of-
death estimation work since it constitutes the majority of this thesis.   
 
8.3.1 Strengths 
A key strength of our modelling work is that it is part of a larger effort that has been underway 
for over fifteen years to improve our understanding of the neonatal mortality burden and 
associated issues such as stillbirths, preterm birth, and morbidity.  As such, the work presented 
in this thesis has benefited from the knowledge, data, and modelling processes that have been 
built up over time through this wider effort.  This includes a strong expertise and institutional 
memory of various data-related issues, including around specific input studies, nuances around 
timing and causes of death (including mapping of ICD codes to broader cause categories and 
understanding implausible model outputs), and reasons for historical modelling decisions.  The 
neonatal COD database began in 2003, and has been added to with updated literature reviews 
(such as those conducted for the work presented here).  Additionally, this long-standing effort 
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allowed us to use networks to obtain additional input data for inclusion in our models, such as 
finer-grained COD data than were included in publications.   
 
Our neonatal COD estimation work falls under the CHERG/MCEE umbrella.  This means that we 
have collaborations with several research partners (e.g. Johns Hopkins Bloomberg School of 
Public Health, University of Edinburgh) and multilateral organizations (e.g. WHO, UNICEF).  This 
provides us with the opportunity of formally presenting our work one to two times per year to 
individuals with widespread areas of expertise (e.g. technical, policy) and viewpoints (e.g. 
researchers, policymakers, donors).  Thus, the work presented in this thesis was not done within 
a research silo, but rather as part of an interactive process with feedback from a variety of 
perspectives.  This will ideally make the results of our work more useful and credible to 
policymakers and others who need such estimates for decision making.  Through this 
collaborative process, for example, it became clear that there was a desire from countries to 
have country-specific data play a larger role in their COD predictions.   
 
The neonatal estimates we produce are part of the UN system’s official cause-of-death 
estimates, and are published by the WHO and UNICEF.  This increases the likelihood of impact, 
and has allowed us to engage outside of the research community.  An important benefit is that 
our estimates go through the WHO’s formal country consultation process.  This process involves 
providing the preliminary estimates to health ministries of all WHO member countries for 
feedback.  Through this, we have received feedback from several countries.  Typically, these 
have been countries with medium-to-high quality VR data.  However, the mechanism for 
countries to feedback to us before we finalize our estimates is an important one, and one which 
could become even more valuable as countries enhance their data collection systems.  More 
generally, the longstanding nature of this work and the UN collaborations have meant that this 
work is not a one-off, but is part of an ongoing process of trying to enhance and improve child 
cause-of-death modelling.   
 
Additionally, this connection with the WHO has allowed us to directly feedback to their teams 
working on covariate time series updates.  This resulted in a useful back-and-forth through 
which they corrected (or smoothed) various time series issues which we identified (e.g. 
unrealistic spikes in otherwise stable covariates).   
 
We have aimed to make our data and code transparent and available.  To do this, I revised our 
code to make it user-friendly; our full models can be run to reproduce the published results by 
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“one-click” once the statistical software (Stata) and code are downloaded.  To improve 
accessibility, our data inputs and modelling files are hosted on the WHO’s Global Health 
Observatory (https://www.who.int/gho/).  We will follow the same transparency processes for 
the revised modelling strategy proposed in this thesis, which has the added advantage of being 
written in the free software programme R.  We also believe strongly in the Guidelines for 
Accurate Transparent Health Estimates Reporting (GATHER) [209] and have strived to adhere to 
them for our work.   
 
8.3.2 Limitations 
A key limitation for our modelling work is the quality and quantity of input data.  I have discussed 
this in detail throughout the thesis (particularly in chapters 2 and 5).  This is a limitation but also 
the very reason for the work we have done; the availability and/or quality of the data needed 
for relevant decision-making is still lacking in many countries.  Thus, in many cases modelling 
remains the only viable option for such estimates (see section 2.3 for limitations of other options 
such as hospital death records).  We tried to mitigate data quality issues where possible.  In the 
risk by day of death analysis, we sought to correct for day-of-death misclassification with our 
model, and also developed simple analytical methods to identify some types of misclassification.  
In the neonatal COD death analysis, a key goal was to identify data issues and build robustness 
into our models.  While the lack of sufficient empirical data also meant external validation of 
our models was not feasible, we conducted internal validation to assess model performance.   
 
Our models are somewhat limited in scope because they mostly produce estimates at the 
national level or higher.  This fails to capture variation within countries.  However, developing 
subnational estimates is still challenging because the data quantity and quality are typically even 
more limited than at the national level.  India is the only country for which we have produced 
state-level estimates [210].  Expanding the set of countries with reliable subnational modelled 
estimates may become feasible if more high-quality subnationally representative data are 
available.  However, maintaining consistent and updated subnational input data (covariates and 
outcomes) for several countries will be challenging and time consuming.  This is because, unlike 
national covariate time series, such data are not yet standardized, collated, and available for 
immediate use.   
 
A couple additional points about the type of COD modelling we have presented are worth 
highlighting.  First, one issue is the attribution of death to a single cause.  This does not allow 
for co-morbidities, which are a frequent occurrence in neonatal deaths, and may thus 
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underestimate the impact of a given cause.  At present, the majority of input studies and VR 
countries only provide data with deaths attributed to one cause, and thus we have little choice 
over this for our modelling.  Second, there is the risk that modelled time series estimates can 
be interpreted as “tracking” changes in causes of death.  As noted earlier in the thesis, our 
estimates are predictions of what might be occurring in countries.  To track changes in burden 
due to specific causes of death requires each country to collect representative and consistent 
data on cause of death on a continuing basis.  Our estimates are not a panacea for actual data 
collection.   
 
The work in this thesis focuses almost entirely on neonatal mortality.  Yet, neonates are part of 
a broader continuum, from pregnancy to birth to childhood and beyond.  In particular, maternal 
health and complications (especially around the time of birth) and causes of intrapartum 
stillbirths are closely related to neonatal mortality.  This is a well understood continuum [211, 
212], and integrated service delivery and health packages have been designed with this in mind 
[213, 214].  The WHO perinatal death certificate and the recent introduction of the Application 
of ICD-10 to Deaths during the Perinatal Period (ICD-PM) classification system constitute efforts 
to better capture deaths within the continuum of antepartum stillbirths, intrapartum stillbirths, 
and the neonatal period (with inclusion of information about contributing maternal conditions) 
[215]. However, incorporating this idea into the COD modelling strategy is challenging for a 
number of reasons, including inadequate input data with relevant joint information (e.g. 
maternal and neonatal outcomes/co-morbidities).   
 
Finally, we have tried to incorporate or account for uncertainty in various ways throughout the 
modelling process.  Aside from publishing estimates with uncertainty intervals, we investigated 
ways to further account for uncertainty in our models.  For example, we tested how to account 
for uncertainty in the covariate selection process (e.g. through simple model averaging) and the 
input dataset (e.g. through bagging).  However, there are sources of uncertainty which we have 
not yet addressed, including in the covariate time series data.  The covariate time series data 
are provided to us with no uncertainty intervals, and we use these point estimates as-is in our 
input and prediction datasets.  However, modelling strategies can be used such as perturbing 
the covariate data which can help to better account for such uncertainty.  Carefully thinking 
through all sources of input and modelling uncertainty is important, and statistical approaches 
can be used when the data provided lack uncertainty intervals.  I discuss this more in sections 
8.4 and 8.6.    
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Overall, the limitations described here are common to this type of modelling.  One positive 
development is that the quantity and quality of relevant data are increasing, which can help 
improve the models (and ideally, eventually replace them).  Later in this chapter, I describe 
some efforts underway by others to improve the types of data we use in our models (section 
8.5) and discuss uses and limits of these types of models (section 8.7).   
 
8.4 Future work on neonatal cause-of-death estimation  
Here, I discuss some possible future work, including steps to finalize the Bayesian neonatal COD 
models described in chapter 7, addressing a few remaining methodological issues, and 
suggestions for analyses to help improve our understanding of variations in neonatal COD 
distributions. 
 
Taking the Bayesian neonatal COD models beyond the proof-of-concept stage requires some 
additional work.  As noted in chapter 7, a way to deal with unreported causes in the input data 
within the Bayesian framework has already been developed by a team member.  I also discussed 
a method for deriving credible intervals (section 7.4), which are essential for publishable 
estimates.  While I demonstrated the feasibility of the Bayesian lasso, the covariate selection 
method needs more work.  Key steps include implementing cross-validation to select the 
lambda penalty value with the best out-of-sample goodness-of-fit and implementing the 
Bayesian lasso within the mixed effects framework.  Additionally, a broader review of Bayesian 
covariate selection could yield other alternative strategies for further testing.  Once the core 
modelling strategy is finalized, model performance should be evaluated using internal cross-
validation (such as described in section 5.1).  Alternative covariate selection methods could also 
be evaluated against the lasso results for predictive accuracy.  Finally, methods to improve 
model performance (e.g. ensemble methods) could be considered for implementation based on 
the results of the model performance exercise.  
 
A few methodological issues could also be addressed by future work.  First, there are no data 
from modelled countries in the low mortality input dataset at present.  Lower-quality VR data 
from modelled countries should be considered for inclusion in the input dataset for the Bayesian 
mixed effects model.  This would allow a country’s estimates in the low mortality model to also 
be influenced by the country’s own data (via a random effect), as is proposed for nationally 
representative VA data in the high mortality model.  These VR data could be included by 
lowering the quality threshold currently used to select high-quality VR countries (appendix 
B.1.1).  For example, we currently include a criterion of ≥80% CRVS coverage for high-quality VR 
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data which could be reduced (e.g. ≥50% CRVS coverage).  Retaining a quality threshold provides 
a balance between the desire for inclusion of relevant data with concerns about their lower 
quality and reliability.  Second, some of the countries for which we produce modelled estimates 
are improving their CRVS systems, while others are newly introducing such systems.  One 
question is how the time series should be compiled for the years before the data are available.  
Plausible options are to perform regression-based imputations or somehow incorporate the 
modelled estimates for those years.  Third, ways to better build accurate amounts of uncertainty 
into the modelling process could be investigated.  As mentioned in section 8.3, we have not 
accounted for all relevant sources of uncertainty (e.g. uncertainty in covariate values).  Methods 
like perturbing the data or drawing covariate values from an assumed distribution may be useful 
to investigate.  How such methods would work within the full modelling framework would be 
important to consider so that the number of total iterations and time needed to run the model 
do not become infeasible.  Finally, better ways to communicate uncertainty in the final results 
are needed.  Publishing numbers with uncertainty intervals has been insufficient because it is 
too easy to focus only on the point estimate.  Innovative data visualization solutions are 
emerging [216], including maps which make it impossible to ignore uncertainty by using colour 
grids which integrate uncertainty with final estimates [217].  While not essential, addressing 
these types of methodological issues can enhance the neonatal COD models.   
 
On a broader level, there is substantial variation in the neonatal COD distribution across 
countries, even amongst countries with high-quality VR.  This is true for all of the major causes, 
including direct complications of preterm birth (one of the leading causes of neonatal death).  
For instance, amongst high-quality VR countries with 100 or more deaths in 2015, the 
proportion of deaths from preterm complications ranged from 20% (Japan) to 71% (Macedonia) 
[218].  Such variation appears to be greater than could be plausibly attributed to 
epidemiological variation, and thus likely reflects at least some variations in coding practices.   
 
Death certificate data in which multiple causes of death are recorded provide an opportunity to 
better understand these differences across countries.  This is important for two main reasons.  
First, given the high burden of neonatal deaths in many countries, a clearer picture is needed 
for why countries have reported such wide differences in proportions.  Are there genuine 
differences in causes of death, or are at least some of the differences an artefact of coding 
practices?  Such an analysis could also investigate whether countries are adhering to the 
relevant ICD-10 coding rules.  For those that are not, the results can help guide them on where 
their coding practices are not in line with the rules.  This is useful because correctly determining 
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the sequence of causes related to a death, from immediate to underlying, can help target 
interventions more appropriately.  Second, VA studies have also reported wide ranges for the 
proportion of deaths from the main neonatal causes of death.  VA data quality varies between 
studies, but is generally worse than high-quality VR data.  By carefully evaluating VR data, crude 
but useful metrics could be developed for gauging the plausibility of VA data.  For example, a 
reasonable lower bound could be calculated for absolute risk of neonatal death from direct 
complications of preterm birth based on VR data from low mortality countries.  This could serve 
as a way to gauge the plausibility of this aspect of VA data, and may help study investigators 
choose appropriate causal hierarchies when analysing their VA data.   
 
8.5 How can “input” data be improved? 
Input data are arguably the most important component of a model and can have a substantial 
impact on the reliability of model outputs.  In our case, input data have meant data on national 
covariate time series and neonatal outcomes (i.e. COD distributions and timing of deaths).  
There are two types of input-related improvements relevant for our work: 1) those relating 
directly to the quantity and quality of individual datasets (e.g. data from a CRVS system or study) 
and 2) those related to the aggregating of multiple such datasets for use in models like ours.  
What I call “input” data throughout this thesis are of course just data; they were not primarily 
collected for use in our models.  This means both that we have little to no direct influence over 
them and that they are designed to be used for purposes different than ours.  With this in mind, 
I briefly discuss some key topics related to input data improvements.   
 
First, major efforts are currently underway throughout the health and development sectors to 
improve each of the main data sources we use for our models.  For example, momentum to 
introduce or improve CRVS systems in countries has been increasing.  Between 2013 and 2018, 
nine countries moved from being modelled in our estimates to having high-quality VR that could 
be used as reported.  Various programmes exist to scale up CRVS systems in the coming decade 
across many countries [27], including a joint WHO/World Bank global CRVS investment plan [28] 
and the Bloomberg Data for Health Initiative [27].  Similarly, more countries and organizations 
are investing in large nationally representative VA studies in countries without adequate CRVS 
system.  A number of improvements to VA methods have been proposed and tested, including 
standardization of VA tools [67, 73, 219] and probabilistic algorithms for assigning deaths [73, 
75].  Additionally, many discussions and proposals have been made around selecting and 
improving child and maternal health-related covariates as the SDG era has begun [220-222].  
None of these efforts are simple or short-term challenges; at minimum they require substantial 
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amounts of careful planning, funding, and commitments.  But they are based on years of lessons 
learned and are promising attempts to work on these long-standing data issues.  Such 
investments in on-the-ground data collection are essential for improving modelled estimates 
and to ultimately replace estimates with empirical data.   
 
A number of innovative ideas have also been proposed that relate to these topics.  For example, 
minimally invasive autopsy (MIA; sometimes called minimally invasive tissue sampling) is a 
promising alternative to conventional autopsies [84] (section 2.3.3).  While unlikely to replace 
VA studies in the short term, the method could be coupled with at least some of them to help 
improve the accuracy of empirical COD data in countries lacking adequate CRVS systems.  
Various ideas to link different data collection methods have also been proposed, including 
integrating VA studies with CRVS systems [30] and linking different data systems within 
countries [29, 223].  Other methods, such as maternal and perinatal audits [81] and sample 
registration systems like the one used in India [38] also have the potential to improve data if 
implemented more widely.   
 
Some improvements are particularly useful when aggregating various datasets.  First, 
standardization is key.  Certain standards already exist for various data collection methods (e.g. 
ICD coding for VR data [224]) and reporting of studies/results (e.g. STROBE guidelines for 
observational studies [225]).  For neonatal causes of deaths, agreeing and adhering to specific 
case definitions and causal hierarchies is particularly important.  For example, there still appears 
to be some confusion or disagreement amongst researchers about which causal hierarchies to 
use when assigning neonatal causes of death.  Some VA studies publish results comparing 
multiple hierarchies [226, 227], but the majority select one (which is not always consistent 
between different studies).  Resolving these issues will help make empirical neonatal COD data 
more comparable.  Publishing VA data in a format that allows subsequent application of causal 
hierarchies is a solution that can help resolve this discrepancy while also adding transparency 
to the COD attribution process.  At minimum, more complete reporting of the methods used, 
including the specific case definitions and hierarchies selected, is needed.  Finally, improving the 
timeliness of published COD data would be useful.  The lag between data collection and 
publication is sometimes five or more years.  A potential solution is a central repository where 
data can be added once data collection is complete, though the well-established concerns of 
researchers about such a repository must be addressed for it to be successful.   
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The hope of input data improvement in relation to modelling is two-fold: that 1) the COD models 
will become more reliable as input data increases in quantity and quality, and 2) data will 
improve to the point that models are no longer needed.   
 
8.6 What core principles should be followed when producing modelled 
estimates? 
Data are expanding, demands for modelled estimates are growing, and building complex models 
is becoming easier with advances in statistical methods and software.  Thus, this is an apt time 
to map out some core principles around the production of modelled estimates.  While there are 
no perfect models, accuracy and reliability should be the main goals.  This requires a carefully 
planned modelling strategy and a deep understanding of the input data.  Equally important are 
the ways in which the modelled results are reported and shared.  With this in mind, I include 
some recommendations here on core principles to follow when conducting such analyses.  I 
have based these on lessons learned through the course of this thesis.  
 
Note: throughout the model planning phase, it is important to revisit whether the research 
question being asked is a reasonable one to answer through modelling.  This would include 
consideration of existing knowledge on the topic, availability of appropriate input data, 
limitations of feasible modelling approaches, and implications of the findings given any 
modelling limitations.  Further discussion of risks of inappropriate modelling are included in 
section 8.7.   
 
Carefully developing a thorough and comprehensive modelling strategy should be the first step 
of the modelling process.  This includes thinking through the core components of the full 
modelling approach, including the input data, outputs, statistical methods and software, model 
performance, uncertainty, and reporting and sharing of results.  In Table 8.1, I include some 
recommendations for each of these topics.   
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Table 8.1: Core components of a systematic strategy for producing modelled estimates 
Component Recommendations 
Overall Consider the intended audience for results; engage some of them if possible 
for feedback on the modelling strategy and planned outputs 
Put together an advisory panel with knowledge on the range of topics 
relevant to the modelling exercise (e.g. types of input data, statistical 
methods, understanding the outputs, dissemination) 
Develop a full initial modelling strategy before conducting analyses 
Input data Use as many data gathering methods as feasible, including literature reviews 
(with multiple languages if possible), grey literature searches, and contacting 
individuals and organizations 
Seek a deep understanding of the data sources, including possible sources of 
measurement error (systematic and random) to understand data biases and 
uncertainty  
Try to be as consistent as possible with the data (e.g. extract information 
using the same rules, apply the same data cleaning procedures) 
Save raw versions of the input data (i.e. create new files after data 
aggregation or cleaning; do not overwrite raw files) 
Document all decisions around changes to the input data and cleaning 
Desired 
outputs 
Consider whether the desired outputs/results are feasible and appropriate 
to produce given the input data  
Select appropriate output measure(s) depending on the data and the 
intended use of the results (e.g. risks versus proportions) 
Once the model is run, check outputs in detail to ensure results are sensible 
Uncertainty Consider all sources of uncertainty (e.g. in input data, statistical methods) 
Incorporate methods to account for as much uncertainty as possible 
Include uncertainty intervals in all published estimates  
Statistical 
methods 
Investigate, test, and choose an appropriate statistical model based on the 
type of data (e.g. data generating process), intended outputs (e.g. 
proportional distribution), and desired modelling features (e.g. hierarchical 
structure) 
Review the literature to fully understand advantages, disadvantages, and any 
recent advances for the selected methods 
Revise methods based on model performance checks and feedback 
Model 
performance 
Incorporate strategies for testing aspects of model performance (e.g. 
predictive accuracy, model instability) into the core modelling approach  
Test for model performance with whatever data are available.  Use internal 
validation (e.g. out-of-sample cross-validation) at a minimum, but external 
validation if data rich 
Consider additional checks based on uncertainty in model inputs or 
processes (e.g. perturb input data, test results with model variations) 
Software Select software with the flexibility and/or packages needed to complete the 
analysis based on the desired statistical methods 
Automate as much as possible to reduce error, improve consistency, and 
ensure reproducibility (e.g. use scripts for even minor analyses; avoid Excel) 
Seek answers (including user-written packages) for encountered challenges 
through online statistical software user forums or other websites  
Reporting 
results 
Adhere to all aspects of the GATHER guidelines [209] 
Consider creative ways to report uncertainty of inputs and results (e.g. maps 
overlaying results with uncertainty using a colour grid [217]) 
Make data and code fully accessible, publicly available, and easy to use (e.g. 
“one-click” automation to run code) 
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There are a few additional recommendations that I want to highlight based on our experiences 
with the modelling exercises in this thesis.  First, I do not believe that modelled time series 
estimates such as ours should be updated every one to two years.  Historically, such estimates 
were produced at wide intervals, with several years between estimates.  In the last five years, 
however, updates every one to two years have become the norm.  This was partially driven by 
IHME’s decision to update their GBD results annually [228].  The CHERG/MCEE updates are 
generally now done every two years (though literature reviews may occur every 2-3 years 
instead).  However, we are modelling outcomes which do not change that quickly, and our 
models are unlikely to be able to capture rapid changes if they did occur.  Frequently updating 
the estimates can give the illusion of both “tracking” outcomes and of there being more 
certainty in the results than is true.  Such assumptions are not justified and can be risky, 
including if they give the impression that on-the-ground data collection is no longer essential.  
Thus, I recommend releasing updated estimates every three to five years instead.  This provides 
enough time for there to be real changes (e.g. in a country’s COD distribution), and also serves 
as a reminder that these are modelled estimates and not regularly collected empirical data.   
 
Second, it is the responsibility of modellers to provide clear explanations to non-modellers on 
how to use and interpret both the modelled results and the models themselves.  These are 
complex models with many different components (e.g. range of input data of differing quality, 
various statistical methods), but the outputs are typically simple (e.g. COD proportions by 
country and year).  Thus, it is easy to forget that these relatively straightforward results are 
outputs of a complex statistical machinery using a diverse set of input data.  Uncertainty 
intervals are required with modelled estimates, but are not by themselves enough to make clear 
the uncertainty and complexity of the whole process.  Therefore, modellers should publish a 
guidance document alongside their data and code which explains the input data and the limits 
of the model (see Appendix D for an example based on our neonatal COD modelling exercise).  
Such a document is especially important given the push to have models be made publicly 
available.  This is a positive development and is providing much-needed transparency.  But it 
also means that others can adapt the models for their data, even if the models are not suitable 
for such an analysis.  For example, some have tried to use our models to produce subnational 
COD estimates with prediction covariate data that were well outside the range of our input data.  
This required extensive discussions to explain why their proposed analysis was beyond the 
scope of our models, at least without performing rigorous checks and validation exercises.   
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In general, careful consideration is needed when trying to extend models beyond their original 
purpose.  The first question is whether the model can support the desired extension (as 
described in the example above).  Additionally, models can sometimes be extended by doing 
sub-models within the model.  MCEE did this for the child COD models (including ours) by adding 
subnational estimates for India.  This required a separate process to identify, collate, and clean 
state-level prediction data.  Thus, incorporating this into a regularly updated modelling system 
(currently every one to two years) requires an active effort to update not only the main 
prediction database each time, but this additional one as well.  If more countries are added for 
subnational estimates, the effort required will burgeon.  Just the database updating process 
then transforms into one with many moving parts, which increases the risk of diminishing the 
reliability of the outputs.  Thus, the consequences of adding components to the model should 
be thought through as carefully as the original modelling strategy itself.     
 
The GATHER guidelines state that authors should “provide the results of an evaluation of model 
performance, if done…” [209].  I would go further to suggest that testing model performance 
should be an essential component of such modelling exercises.  Even though having the data 
for external validation is still uncommon in this field, internal validation using approaches like 
cross-validation is almost always feasible.  In this thesis, I have demonstrated why testing model 
performance is useful, including for helping to identify where robustness is needed and can be 
built into the model.   
 
Finally, I believe that such modelled estimates should not be published in academic journals 
unless there is a genuinely new research contribution.  These estimates have been published 
for years in academic journals, sometimes with little change between the previous versions.  
“Salami slicing” is also an issue, where one large study is published in many small parts rather 
than as one paper.  Groups that produce these estimates simultaneously host them on online 
platforms (e.g. WHO’s Global Health Observatory, IHME’s Global Health Data Exchange site); 
the results are thus already publicly available outside of the academic journal system.  These 
online versions are typically more complete as well (e.g. code, input data, full country-year 
estimates).  UN-IGME serves as an example of how nationally comparable estimates can be 
published.  They produce an annual report (i.e. Levels and Trends in Child Mortality) about the 
given year’s mortality estimates, and provide detailed country-specific estimates.  Their 
academic journal articles are largely restricted to detailing methodological updates or 
innovations [105, 229], comparisons with other estimates [54], and larger summary papers at 
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key times (e.g. end of the MDGs) [206].  I believe that it should be the exception, not the rule, 
that regular updated estimates are published in academic journals.   
 
8.7 What are reasonable uses and limits of such modelling?   
The question of uses and limits of modelled estimates is a complex discussion whose full breadth 
is beyond the scope of this thesis (numerous insightful articles have been written regarding this 
topic [55, 230-235]).  Here, I touch on two interrelated questions that are of particular relevance 
to the work presented in this thesis: what is the role of modelled estimates and how far 
can/should models be pushed to fill knowledge gaps.   
 
There is increasing pressure to do more with existing data.  For mortality estimation, this has 
meant modelling estimates with finer-grained categories of causes, ages, sex, and location (e.g. 
subnational, local area) and over longer periods of time.  The main limitation for achieving such 
finer gradation is not a technical one.  It is possible to design a model that will extrapolate from 
any number of data points to as fine-grained a distribution as desired.  However, just because 
models can be used to produce such estimates does not mean that they should be.  Key 
limitations are the availability and quality of relevant input data that are the foundation of 
modelled estimates.   
 
Thus, a balance is needed between what is desired versus what is appropriate to model given 
various limitations (e.g. input data availability and quality).  Ignoring this greatly increases the 
risk of false precision.  Such overconfidence is particularly dangerous in a field where having 
enough data for external validation is rare.  These issues have arisen in our work, as seen by the 
lack of external validation for our modelled estimates.  We tried to mitigate this as best as 
possible through internal validation, but there are limits to how much this can prevent concerns 
such as overfitting.  These limits become more severe as we go towards finer-grained estimates 
for which there are even fewer available empirical data.   
 
There are serious potential risks to “over-modelling”.  First, to the extent that modelled 
estimates are seen by some as a substitute for data collection, excessive confidence can lead to 
undervaluing primary data collection.  Detrimental consequences of this include reallocation of 
funds meant for on-the-ground data collection and reduction of in-country capacity for health 
statistics, both of which are thought to already be occurring [231, 232].  Second, to the extent 
that modelled estimates are intended to inform policy decisions, false precision can be 
dangerous.  Reliability is likely to be low for models with very limited relevant input data, 
  
 
199 
thereby increasing the chances of inaccurate results.  It is better to tell a policymaker that the 
desired numbers are unavailable or highly uncertain than to provide estimates which may be 
far from reality or describe trends that do not exist.   
 
These issues have not gone unnoticed by health ministries and other users of modelled 
estimates.  Some key concerns and criticisms of modelled estimates include how to interpret 
discrepancies between different estimates (e.g. MCEE versus IHME) or between estimates and 
empirical data (e.g. DHS study), difficulty in understanding the perceived “black box” nature of 
modelling methods (including when estimates change due to methodology or data updates), 
and the disconnect between national-level estimates and local-level decision-making needs 
[230, 231, 233].  These concerns highlight the fact that more work is needed to improve the 
usefulness and credibility of modelled estimates.  Stretching models beyond their reasonable 
limits is likely to exacerbate these challenges.   
 
Questions on the uses and limits of modelled estimates are not going away soon.  In the last 
two decades, the field of metrics and burden estimation has grown dramatically.  This is due at 
least in part to the Millennium Development Goals (MDGs) [55], which had 60 country-specific 
indicators for 21 targets across eight goals [236].  This necessitated a monitoring framework 
that could track progress over time for a range of metrics, including in data-poor countries.  This 
type of monitoring framework, which lends itself naturally to nationally comparable time trend 
estimates, is being reinforced by the even more metrics-heavy Sustainable Development Goals 
(SDGs), which have 232 indicators across 169 targets for 17 goals [237].   
 
The push for more measurement, evaluation, and progress tracking is generally a positive one, 
but questions remain on how best to achieve these.  Modelled estimates appear well-suited to 
fill the gaps left by the lack of adequate empirical data, especially when needing regularly 
updated country-specific comparable numbers such as for the SDGs.  Such estimates may seem 
especially attractive because, compared to ground-level data collection, they are cheaper, 
faster, and can yield more comprehensive sets of numbers.  These advantages can make it easy 
to forget or overlook the fact that modelled estimates are an imperfect solution, and can even 
be an inappropriate one at times.  For example, unlike continuously collected empirical data, 
current covariate-based models are not capable of “tracking”.  They predict estimates based on 
regressions and are unable to capture rapid changes on the ground or changes not captured by 
available covariates.  However, words like “monitoring” and “surveillance” [228], alongside 
frequent (e.g. every 1-2 year) updates, can give the misleading impression that models are in 
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fact tracking progress in countries.  Modelled estimates are at their best, I believe, when they 
are appropriate, robust, and communicated to be temporary solutions until good empirical data 
can replace them.  In almost all cases, modelled estimates cannot and should not replace 
empirical data.  However, if communicated properly, they can in fact play an important role in 
highlighting the gaps in and need for strong empirical data.   
 
In these discussions, it is important to be clear about how the demands for and uses of modelled 
estimates vary at different levels and amongst different consumers of health information.  At 
the global level, modelled estimates have frequently been used for awareness and advocacy 
(including to seek funding for specific conditions), as nationally comparable indicators (e.g. for 
the MDGs/SDGs), and as tools to help donors and organizations “track” progress for their own 
purposes [230].  These uses also partly drive the pressure for annual estimates and finer-grained 
details.  Such updates can be used to maintain attention on topics of interest and to satisfy the 
MDG/SDG monitoring framework mentioned earlier.  The fact that many international donors 
share these priorities helps reinforce the pressures and perceived value of producing and 
expanding frequently updated modelled estimates [55, 230].  In contrast, such modelled 
estimates have been less in demand at the national, subnational, and programme levels [238].    
At these levels, where the focus is on making specific funding and policy decisions, 
decisionmakers have generally preferred empirical data which are easier to understand and 
justify (see concerns/criticisms of modelled estimates earlier in this section).  The demand for 
and uses of modelled estimates are thus often substantially different at the global level 
compared to the national level or below.  In the end, there is value when discussing modelled 
estimates in asking who desires them and for what purpose, and in being humble about their 
utility in different situations.  The article by AbouZahr and colleagues titled “Global estimates of 
country health indicators: useful, unnecessary, inevitable?” [230] is a particularly eloquent 
summary of these issues.   
 
Whether, when, and how modelled estimates should be used are important questions that 
continue to be debated in the field.  Empirical data is often still so limited that models may 
currently serve an important purpose, including for a broad perspective on the levels of burden 
and risk.  But this same sparsity of empirical data also limits what can be reasonably modelled.  
Given these limitations, sometimes modelling is not the right choice, even if it is the easier or 
only choice.  Making these determinations should be the joint responsibility of those who 
produce, fund, and use models.   
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8.8 Overall conclusions 
The work presented in this thesis constitutes a modest attempt to fill some gaps in our 
understanding of neonatal deaths and to improve neonatal cause-of-death modelling.  The 
findings on daily risk of death (chapter 3) and causes of deaths in the early/late neonatal periods 
(chapter 4) highlight how quickly temporal and causal distributions change within the first four 
weeks of life.  An understanding of such changes is useful for decision making, including to help 
prioritize implementation of the right interventions at the right time.  With our deeper dive into 
the neonatal cause-of-death models (chapters 5-7), we were able to identify potential ways to 
improve the models, including to make them more robust, incorporate multinomial covariate 
selection, and add country-level random effects.     
 
Beyond wanting the results themselves to be useful, I hope that the discussions included here 
can contribute to conversations about the role of modelling and estimation in global health.  As 
the field of health metrics continues to grow, modelled estimates are likely to become even 
more common.  Such estimates can play an important role in global health, especially in filling 
knowledge gaps where adequate empirical data are lacking.  However, the desire to eliminate 
remaining gaps must be balanced by an understanding of what can be feasibly and appropriately 
addressed through modelling exercises, including an assessment of whether the available input 
data can support the intended models.  Otherwise, modelled estimates can potentially do more 
harm than good, especially if they lead to the reduction of national-level capacity or ground-
level data collection efforts.   
 
Over the last two decades, the decline of neonatal mortality and the rise of health metrics have 
each been impressive.  These are both positive developments, but with caveats.  In 2018, an 
astounding 2.5 million babies were still estimated to have died in their first month of life [3].  
More rapid progress is needed if we are to reach the Sustainable Development Goals target of 
12 or fewer neonatal deaths per 1,000 livebirths for all countries by 2030 [138].  At the same 
time, modelled estimates – and more generally, the field of health metrics – are still finding 
their place between researchers, donors, policymakers, and implementers.  While neither the 
challenges nor the solutions to any of this are simple, there is both great momentum and hope 
for simultaneously improving neonatal health, data collection systems, and health metrics.   
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Appendix A: Further details on timing of neonatal deaths 
A.1  Description of included and excluded input data 
A.1.1  Vital registration data 
In the analysis, vital registration (VR) data from 57 countries were used as reported.  Key 
exclusion criteria for VR data included: 1) <50 neonatal deaths, 2) <20% of neonatal deaths on 
day 0, and 3) <80% adult VR coverage.  Table A.1 shows the details of the VR data used for this 
work, and Table A.2 includes information about VR data that we excluded.   
 
Table A.1: Vital registration data included in the timing of neonatal deaths analysis  
Country Year MDG 
region1 
Neonatal 
deaths (#) 
Country 
 
Year MDG 
region 
Neonatal 
deaths (#) 
Argentina 2010 LAC 5891 Kuwait 2009 WA 363 
Australia 2006 DR 774 Kyrgyzstan 2010 CCA 2396 
Austria 2010 DR 214 Lithuania 2010 DR 83 
Bahrain 2009 WA 56 Luxembourg 2006-10 DR 52 
Belgium 2006 DR 315 Macedonia 2010 DR 134 
Belize 2007 LAC 68 Maldives 2008 SA 59 
Brazil 2010 LAC 27687 Malta 2008-10 DR 60 
Bulgaria 2010 DR 394 Mauritius 2010 SSA 121 
Canada 2009 DR 1404 Mexico 2010 LAC 18002 
Chile 2009 LAC 1359 Moldova 2010 DR 299 
Colombia 2009 LAC 5945 Netherlands 2010 DR 509 
Costa Rica 2009 LAC 462 New Zealand 2008 DR 188 
Croatia 2010 DR 145 Norway 2010 DR 104 
Cyprus 2008-10 DR 59 Panama 2009 LAC 459 
Czech 
Republic 
2010 DR 196 Paraguay 2009 LAC 1158 
Denmark 2006 DR 174 Poland 2010 DR 1454 
Dominica 2006-10 LAC 56 Serbia 2010 DR 316 
Ecuador 2010 LAC 1809 Slovakia 2010 DR 217 
Estonia 2009-10 DR 80 Slovenia 2009-10 DR 74 
Finland 2010 DR 91 South Africa 2009 SSA 13360 
France 2009 DR 1852 Spain 2010 DR 1025 
Georgia 2010 CCA 506 Sweden 2010 DR 183 
Germany 2010 DR 1541 Switzerland 2010 DR 510 
Greece 2010 DR 568 Trinidad / Tobago 2008 LAC 219 
Hungary 2010 DR 313 United Kingdom 2010 DR 2414 
Iceland 2005-9 DR 57 United States 2008 DR 18091 
Ireland 2010 DR 188 Uruguay 2009 LAC 209 
Italy 2009 DR 1470 Venezuela 2007 LAC 5857 
Japan 2010 DR 1167     
1 LAC = Latin America and Caribbean; CCA = Caucasus and Central Asia; DR = Developed regions; SA = 
Southern Asia; SSA = Sub-Saharan Africa; WA = Western Asia 
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Table A.2: Vital registration data excluded from the timing of neonatal deaths analysis based 
on exclusion criteria 
Country  Year MDG 
region1 
Reason for exclusion 
Albania 2004 DR <80% adult VR coverage 
Antigua and Barbuda 2009 LAC <20% deaths on day 0 
Armenia 2010 CCA <80% adult VR coverage 
Azerbaijan 2007 CCA <80% adult VR coverage 
Bahamas 2008 LAC <20% deaths on day 0 
Barbados 2008 LAC <20% deaths on day 0 
Belarus 2009 DR no day of death breakdown 
Bosnia and 
Herzegovina 
1991 DR no day of death breakdown 
Brunei Darussalam 2009 SEA no day of death breakdown 
Cuba 2010 LAC <20% deaths on day 0 
Dominican Republic 2005 LAC <80% adult VR coverage 
Egypt 2010 NA no day of death breakdown 
El Salvador 2009 LAC <80% adult VR coverage 
Fiji 2009 Oceania <20% deaths on day 0 
Grenada 2010 LAC <20% deaths on day 0 
Guatemala 2008 LAC <20% deaths on day 0 
Guyana 2008 LAC <80% adult VR coverage 
Haiti 2003 LAC <80% adult VR coverage 
Honduras 1990 LAC <80% adult VR coverage 
Iraq 2008 WA <80% adult VR coverage 
Israel 2009 DR no day of death breakdown 
Jamaica 2006 LAC <80% adult VR coverage 
Jordan 2009 WA <80% adult VR coverage 
Kazakhstan 2010 CCA no day of death breakdown 
Kiribati 2001 Oceania no day of death breakdown 
Latvia 2010 DR no deaths on days 1-6 
Malaysia 2008 SEA <80% adult VR coverage 
Mongolia 1994 EA <80% adult VR coverage 
Montenegro 2009 DR <20% deaths on day 0 
Morocco 2008 NA <80% adult VR coverage 
Nicaragua 2010 LAC <80% adult VR coverage 
Oman 2009 WA <80% adult VR coverage 
Peru 2007 LAC <80% adult VR coverage 
Philippines 2008 SEA no day of death breakdown 
Portugal 2010 DR no day of death breakdown 
Qatar 2009 WA no day of death breakdown 
Republic of Korea 2010 EA no day of death breakdown 
Romania 2010 DR <20% deaths on day 0 
Russian Federation 2010 DR no day of death breakdown 
Saint Lucia 2008 LAC <20% deaths on day 0 
St Vincent/Grenadines 2010 LAC <20% deaths on day 0 
Saudi Arabia 2009 WA <80% adult VR coverage 
Seychelles 2008 SSA no day of death breakdown 
  
 
222 
Country  Year MDG 
region1 
Reason for exclusion 
Singapore 2010 SEA <80% adult VR coverage 
Sri Lanka 2006 SA <20% deaths on day 0 
Suriname 2009 LAC <20% deaths on day 0 
Tajikistan 2005 CCA <80% VR coverage 
Thailand 2006 SEA <80% adult VR coverage 
Turkmenistan 1998 CCA <80% adult VR coverage 
Ukraine 2010 DR no day of death breakdown 
Uzbekistan 2005 CCA no day of death breakdown 
Zimbabwe 1990 SSA <80% adult VR coverage 
1 LAC = Latin America and Caribbean; DR = CCA = Caucasus and Central Asia; 
Developed regions; EA = Eastern Asia; NA = Northern Africa; SA = Southern Asia; 
SEA = South-eastern Asia; SSA = Sub-Saharan Africa; WA = Western Asia 
 
A.1.2  Demographic and Health Surveys 
We used data from 206 Demographic and Health Surveys (DHS) as inputs into our model in this 
analysis.  Table A.3 includes information about these included surveys.  No DHS available at the 
time of this analysis were excluded.   
 
Table A.3: Demographic and Health Surveys included in timing of neonatal deaths analysis  
Country Year MDG 
region1 
Neonatal 
deaths  (#) 
Country 
 
Year MDG 
region 
Neonatal 
deaths (#) 
Azerbaijan 2006 CCA 68 Kyrgyzstan 1997 CCA 61 
Albania 2008 DR 16 Lesotho 2009 SSA 173 
Armenia 2010 CCA 11 Lesotho 2004 SSA 158 
Armenia 2005 CCA 25 Liberia 2007 SSA 174 
Armenia 2000 CCA 33 Liberia 1986 SSA 338 
Bangladesh 2007 SA 220 Madagascar 2008 SSA 304 
Bangladesh 2004 SA 286 Madagascar 2003 SSA 190 
Bangladesh 1999 SA 283 Madagascar 1997 SSA 256 
Bangladesh 1996 SA 281 Madagascar 1992 SSA 215 
Bangladesh 1993 SA 358 Malawi 2010 SSA 616 
Benin 2006 SSA 490 Malawi 2004 SSA 282 
Benin 2001 SSA 201 Malawi 2000 SSA 492 
Benin 1996 SSA 184 Malawi 1992 SSA 187 
Bolivia 2008 LAC 235 Maldives 2009 SA 39 
Bolivia 2003 LAC 276 Mali 2006 SSA 633 
Bolivia 1998 LAC 229 Mali 2001 SSA 737 
Bolivia 1994 LAC 221 Mali 1995 SSA 609 
Bolivia 1989 LAC 208 Mali 1987 SSA 178 
Botswana 1998 SSA 72 Mauritania 2000 SSA 220 
Brazil 1996 LAC 82 Moldova 2005 DR 8 
Brazil 1986 LAC 116 Morocco 2003 NA 160 
Burkina Faso 2010 SSA 421 Morocco 1992 NA 162 
Burkina Faso 2003 SSA 312 Morocco 1987 NA 242 
Burkina Faso 1998 SSA 239 Mozambique 2003 SSA 385 
Burkina Faso 1993 SSA 262 Mozambique 1997 SSA 393 
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Country Year MDG 
region1 
Neonatal 
deaths  (#) 
Country 
 
Year MDG 
region 
Neonatal 
deaths (#) 
Burundi 2010 SSA 241 Namibia 2006 SSA 116 
Burundi 1987 SSA 134 Namibia 2000 SSA 79 
Cambodia 2010 SEA 217 Namibia 1992 SSA 118 
Cambodia 2005 SEA 208 Nepal 2011 SA 178 
Cambodia 2000 SEA 298 Nepal 2006 SA 180 
Cameroon 2011 SSA 352 Nepal 2001 SA 263 
Cameroon 2004 SSA 227 Nepal 1996 SA 352 
Cameroon 1998 SSA 151 Nicaragua 2001 LAC 107 
Cameroon 1991 SSA 112 Nicaragua 1998 LAC 136 
CAR2 1994 SSA 196 Niger 2006 SSA 327 
Chad 2004 SSA 228 Niger 1998 SSA 359 
Chad 1996 SSA 330 Niger 1992 SSA 284 
Colombia 2010 LAC 183 Nigeria 2008 SSA 1102 
Colombia 2005 LAC 169 Nigeria 2003 SSA 290 
Colombia 2000 LAC 68 Nigeria 1999 SSA 215 
Colombia 1995 LAC 93 Nigeria 1990 SSA 343 
Colombia 1990 LAC 40 Pakistan 2006 SA 481 
Colombia 1986 LAC 52 Pakistan 1990 SA 307 
Comoros 1996 SSA 74 Paraguay 1990 LAC 74 
Congo 2005 SSA 160 Peru 2007 LAC 85 
Cote d'Ivoire 1998 SSA 135 Peru 2004 LAC 81 
Cote d'Ivoire 1994 SSA 282 Peru 2000 LAC 225 
DRC3 2007 SSA 368 Peru 1996 LAC 372 
Dominican R4 2007 LAC 234 Peru 1991 LAC 211 
Dominican R 2002 LAC 233 Peru 1986 LAC 111 
Dominican R 1999 LAC 8 Philippines 2008 SEA 99 
Dominican R 1996 LAC 117 Philippines 2003 SEA 119 
Dominican R 1991 LAC 87 Philippines 1998 SEA 127 
Dominican R 1986 LAC 171 Philippines 1993 SEA 152 
Ecuador 1987 LAC 106 Rwanda 2010 SSA 245 
Egypt 2008 NA 170 Rwanda 2007 SSA 157 
Egypt 2005 NA 270 Rwanda 2005 SSA 313 
Egypt 2000 NA 269 Rwanda 2000 SSA 345 
Egypt 1995 NA 342 Rwanda 1992 SSA 214 
Egypt 1992 NA 281 Sao Tome/ Principe 2008 SSA 34 
Egypt 1988 NA 329 Senegal 2010 SSA 323 
Eritrea 2002 SSA 148 Senegal 2005 SSA 353 
Eritrea 1995 SSA 100 Senegal 1997 SSA 264 
Ethiopia 2011 SSA 435 Senegal 1992 SSA 188 
Ethiopia 2005 SSA 436 Senegal 1986 SSA 196 
Ethiopia 2000 SSA 588 Sierra Leone 2008 SSA 210 
Gabon 2000 SSA 121 South Africa 1998 SSA 96 
Ghana 2008 SSA 89 Sri Lanka 1987 SA 62 
Ghana 2003 SSA 155 Sudan 1989 SSA 285 
Ghana 1998 SSA 93 Swaziland 2006 SSA 61 
Ghana 1993 SSA 152 Tanzania 2010 SSA 212 
Ghana 1988 SSA 180 Tanzania 2004 SSA 275 
Guatemala 1998 LAC 110 Tanzania 1999 SSA 129 
Guatemala 1995 LAC 232 Tanzania 1996 SSA 215 
Guatemala 1987 LAC 147 Tanzania 1991 SSA 293 
Guinea 2005 SSA 251 Thailand 1987 SEA 75 
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Country Year MDG 
region1 
Neonatal 
deaths  (#) 
Country 
 
Year MDG 
region 
Neonatal 
deaths (#) 
Guinea 1999 SSA 284 Timor-Leste 2009 SEA 206 
Guyana 2009 LAC 44 Togo 1998 SSA 272 
Haiti 2005 LAC 138 Togo 1988 SSA 121 
Haiti 2000 LAC 205 Trinidad/Tobago 1987 LAC 45 
Haiti 1994 LAC 111 Tunisia 1988 NA 117 
Honduras 2005 LAC 145 Turkey 1998 WA 87 
India 2005 SA 2164 Turkey 1993 WA 108 
India 1998 SA 2379 Turkmenistan 2000 CCA 125 
India 1992 SA 2918 Uganda 2006 SSA 220 
Indonesia 2007 SEA 310 Uganda 2000 SSA 246 
Indonesia 2002 SEA 287 Uganda 1995 SSA 197 
Indonesia 1997 SEA 348 Uganda 1988 SSA 215 
Indonesia 1994 SEA 506 Ukraine 2007 DR 11 
Indonesia 1991 SEA 450 Uzbekistan 1996 CCA 57 
Indonesia 1987 SEA 221 Viet Nam 2002 SEA 29 
Jordan 2009 WA 142 Viet Nam 1997 SEA 60 
Jordan 2007 WA 134 Yemen 1997 WA 418 
Jordan 2002 WA 91 Yemen 1991 WA 248 
Jordan 1997 WA 120 Zambia 2007 SSA 220 
Jordan 1990 WA 180 Zambia 2001 SSA 243 
Kazakhstan 1999 CCA 47 Zambia 1996 SSA 247 
Kazakhstan 1995 CCA 26 Zambia 1992 SSA 262 
Kenya 2008 SSA 182 Zimbabwe 2010 SSA 170 
Kenya 2003 SSA 201 Zimbabwe 2005 SSA 121 
Kenya 1998 SSA 146 Zimbabwe 1999 SSA 98 
Kenya 1993 SSA 155 Zimbabwe 1994 SSA 92 
Kenya 1989 SSA 188 Zimbabwe 1988 SSA 88 
1 LAC = DR = CCA = Caucasus and Central Asia; Developed regions; EA = Eastern Asia; Latin America and 
Caribbean; NA = Northern Africa; SA = Southern Asia; SEA = South-eastern Asia; SSA = Sub-Saharan Africa; 
WA = Western Asia; 2 CAR = Central African Republic; 3 DRC = Democratic Republic of the Congo; 4 
Dominican R = Dominican Republic 
 
 
 
 
 
 
 
  
  
 
225 
A.2  Country groupings by MDG region and income 
We used MDG regions and World Bank income level categories to classify the 186 countries we 
included in this work into region and income groups, respectively.  The countries in each 
category are below. 
 
A.2.1  Country groupings by region 
Developed regions (DR) – 46 countries 
Albania, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, 
Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, 
Ireland, Israel, Italy, Japan, Latvia, Lithuania, Luxembourg, Macedonia (TFYR of), Malta, 
Montenegro, Netherlands, New Zealand, Norway, Poland, Portugal, Republic of Moldova, 
Romania, Russian Federation, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Ukraine, 
United Kingdom, United States 
 
North Africa (NA) – 5 countries 
Algeria, Egypt, Libya, Morocco, Tunisia 
 
Sub-Saharan Africa (SSA) – 49 countries  
Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African 
Republic, Chad, Comoros, Congo, Cote d'Ivoire, Democratic Republic of the Congo, Djibouti, 
Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, 
Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Namibia, 
Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Somalia, 
South Africa, South Sudan, Sudan, Swaziland, Togo, Uganda, United Republic of Tanzania, 
Zambia, Zimbabwe 
 
South-Eastern Asia (SEA) – 11 countries 
Brunei Darussalam, Cambodia, Indonesia, Lao People's Democratic Republic, Malaysia, 
Myanmar, Philippines, Singapore, Thailand, Timor-Leste, Viet Nam 
 
Eastern Asia – 4 countries 
China, Democratic People's Republic of Korea, Mongolia, Republic of Korea 
   
Southern Asia (SA) – 8 countries 
Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, Sri Lanka 
  
Western Asia (WA) – 14 countries 
Bahrain, Iran, Iraq, Jordan, Kuwait, Lebanon, Occupied Palestinian Territory, Oman, Qatar, Saudi 
Arabia, Syrian Arab Republic, Turkey, United Arab Emirates, Yemen 
 
Caucasus & Central Asia – 8 countries  
Armenia, Azerbaijan, Georgia, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Uzbekistan 
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Oceania – 9 countries 
Fiji, Kiribati, Marshall Islands, Micronesia (Federated States of), Papua New Guinea, Samoa, 
Solomon Islands, Tonga, Vanuatu 
  
Latin America & the Caribbean – 32 countries  
Antigua and Barbuda, Argentina, Bahamas, Barbados, Belize, Bolivia, Brazil, Chile, Colombia, 
Costa Rica, Cuba, Dominica, Dominican Republic, Ecuador, El Salvador, Grenada, Guatemala, 
Guyana, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Saint Lucia, 
Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago, Uruguay, Venezuela  
 
Source: Millennium Development Goals Report 2012 
http://www.un.org/millenniumgoals/pdf/MDG%20Report%202012.pdf 
 
 
A.2.2 Country groupings by income 
We used the 2010 World Bank income categories, which were defined as a GNI per capita as 
follows: 1) low-income: $1,005 or less; 2) lower-middle-income: $1,006 to $3,975; 3) upper-
middle-income: $3,976 to $12,275, and 4) high-income: $12,276 or more.  The World Bank did 
not include the Occupied Palestinian Territory in their groupings.  The full list of countries by 
income level is as follows:  
 
Low-income – 35 countries  
Afghanistan, Bangladesh, Benin, Burkina Faso, Burundi, Cambodia, Central African Republic, 
Chad, Comoros, Democratic Republic of the Congo, Democratic People's Republic of Korea, 
Eritrea, Ethiopia, Gambia, Guinea, Guinea-Bissau, Haiti, Kenya, Kyrgyzstan, Liberia, Madagascar, 
Malawi, Mali, Mozambique, Myanmar, Nepal, Niger, Rwanda, Sierra Leone, Somalia, Tajikistan, 
Togo, Uganda, United Republic of Tanzania, Zimbabwe 
 
Lower-middle-income ($1,006 to $3,975) – 54 countries  
Angola, Armenia, Belize, Bhutan, Bolivia, Cameroon, Cape Verde, Congo, Cote d’Ivoire, Djibouti, 
Egypt, El Salvador, Fiji, Georgia, Ghana, Guatemala, Guyana, Honduras, India, Indonesia, Iraq, 
Kiribati, Lao People's Democratic Republic, Lesotho, Marshall Islands, Mauritania, Micronesia 
(Federated States of), Mongolia, Morocco, Nicaragua, Nigeria, Pakistan, Papua New Guinea, 
Paraguay, Philippines, Republic of Moldova, Samoa, Sao Tome and Principe, Senegal, Solomon 
Islands, South Sudan, Sri Lanka, Sudan, Swaziland, Syrian Arab Republic, Timor-Leste, Tonga, 
Turkmenistan, Ukraine, Uzbekistan, Vanuatu, Viet Nam, Yemen, Zambia 
 
Upper-middle-income ($3,976 to $12,275) – 50 countries  
Albania, Algeria, Antigua and Barbuda, Argentina, Azerbaijan, Belarus, Bosnia and Herzegovina, 
Botswana, Brazil, Bulgaria, Chile, China, Colombia, Costa Rica, Cuba, Dominica, Dominican 
Republic, Ecuador, Gabon, Grenada, Iran, Jamaica, Jordan, Kazakhstan, Latvia, Lebanon, Libya, 
Lithuania, Macedonia (TFYR of), Malaysia, Maldives, Mauritius, Mexico, Montenegro, Namibia, 
Panama, Peru, Romania, Russian Federation, Saint Lucia, Saint Vincent and the Grenadines, 
Serbia, Seychelles, South Africa, Suriname, Thailand, Tunisia, Turkey, Uruguay, Venezuela 
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High-income ($12,276) – 46 countries  
Australia, Austria, Bahamas, Bahrain, Barbados, Belgium, Brunei Darussalam, Canada, Croatia, 
Cyprus, Czech Republic, Denmark, Equatorial Guinea, Estonia, Finland, France, Germany, 
Greece, Hungary, Iceland, Ireland, Israel, Italy, Japan, Kuwait, Luxembourg, Malta, Netherlands, 
New Zealand, Norway, Oman, Poland, Portugal, Qatar, Republic of Korea, Saudi Arabia, 
Singapore, Slovakia, Slovenia, Spain, Sweden, Switzerland, Trinidad and Tobago, United Arab 
Emirates, United Kingdom, United States 
 
Source: World Bank, http://data.worldbank.org/indicator;  
http://www.un.org/en/development/desa/policy/wesp/wesp_current/2012country_class.pdf 
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Appendix B: Further details on cause-of-death estimation by neonatal 
period 
B.1 Country groupings by estimation method and MDG region 
B.1.1  Country groupings by estimation method 
Grouping by estimation method 
The 194 countries in this analysis were separated into 3 groups based on the quality if their vital 
registration (VR) data and under-5 mortality rates (U5MR).  U5MR was used instead of the 
neonatal mortality rate (NMR) in order to be consistent with Child Health Epidemiology 
Reference Group (CHERG) researchers working in parallel to develop estimates for children 1-
59 months old.  We kept the same country groupings as previous work [15], with the exception 
of a few countries (see “Changes to country groupings” in section 4.2.6). 
 
As defined in the previous work [15], countries were considered to have high-quality VR data if 
they 1) had 80% or higher coverage, 2) did not have excessive use of non-specific/ill-defined VR 
codes, and 3) provided sufficient details in the coding such that the deaths could be grouped in 
the programmatically-relevant categories used in this work.  Countries that lacked high-quality 
VR data were included in the low mortality model if their U5MR from 2000-2010 was ≤35 (per 
1,000 live births) and in the high mortality model if their U5MR was >35.   
  
High-quality VR – 65 countries 
Antigua and Barbuda, Argentina, Australia, Austria, Bahamas, Bahrain, Barbados, Belgium, 
Belize, Brazil, Bulgaria, Chile, Colombia, Costa Rica, Croatia, Cuba, Czech Republic, Denmark, 
Dominica, Estonia, Finland, France, Germany, Greece, Grenada, Guyana, Hungary, Iceland, 
Ireland, Israel, Italy, Japan, Kuwait, Latvia, Lithuania, Luxembourg, Macedonia (TFYR of), Malta, 
Mauritius, Mexico, Montenegro, Netherlands, New Zealand, Norway, Panama, Poland, Republic 
of Korea, Republic of Moldova, Romania, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the 
Grenadines, Serbia, Singapore, Slovakia, Slovenia, South Africa, Spain, Suriname, Sweden, 
Trinidad and Tobago, United Kingdom, United States, Uruguay, Venezuela 
 
Low mortality model – 49 countries 
Albania, Andorra, Armenia, Belarus, Bosnia and Herzegovina, Brunei Darussalam, Canada, Cabo 
Verde, China, Cook Islands, Cyprus, Ecuador, Egypt, El Salvador, Fiji, Georgia, Honduras, Jamaica, 
Jordan, Lebanon, Libya, Malaysia, Maldives, Monaco, Nicaragua, Niue, Oman, Palau, Paraguay, 
Peru, Portugal, Qatar, Russian Federation, Samoa, San Marino, Saudi Arabia, Seychelles, Sri 
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Lanka, Switzerland, Syrian Arab Republic, Thailand, Tonga, Tunisia, Turkey, Tuvalu, Ukraine, 
United Arab Emirates, Vanuatu, Vietnam 
 
High mortality model – 80 countries 
Afghanistan, Algeria, Angola, Azerbaijan, Bangladesh, Benin, Bhutan, Bolivia, Botswana, Burkina 
Faso, Burundi, Cambodia, Cameroon, Central African Republic, Chad, Comoros, Congo, Cote 
d’Ivoire, Democratic People’s Republic of Korea, Democratic Republic of the Congo, Djibouti, 
Dominican Republic, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guatemala, 
Guinea, Guinea-Bissau, Haiti, India, Indonesia, Iran, Iraq, Kazakhstan, Kenya, Kiribati, Kyrgyzstan, 
Lao People’s Democratic Republic, Lesotho, Liberia, Madagascar, Malawi, Mali, Marshall Islands, 
Mauritania, Micronesia, Mongolia, Morocco, Mozambique, Myanmar, Namibia, Nauru, Nepal, 
Niger, Nigeria, Pakistan, Papua New Guinea, Philippines, Rwanda, Sao Tome and Principe, 
Senegal, Sierra Leone, Solomon Islands, Somalia, South Sudan, Sudan, Swaziland, Tajikistan, 
Timor-Leste, Togo, Turkmenistan, Uganda, United Republic of Tanzania, Uzbekistan, Yemen, 
Zambia, Zimbabwe 
 
B.1.2 Country groupings by region 
We used MDG regions as described in Appendix A.2.1, with the following changes: 
o Developed regions – 49 countries instead of 46 (added Andorra, Monaco, San Marino) 
o Southern Asia – 9 countries instead of 8 (added Iran from Western Asia)  
o Western Asia – 12 countries instead of 14 (removed Iran and Occupied Palestinian 
Territory) 
o Oceania – 14 countries instead of 9 (added Cook Islands, Nauru, Niue, Palau, and Tuvalu) 
o Latin America & the Caribbean – 33 countries instead of 32 (Saint Kitts and Nevis) 
 
B.2 Details of vital registration and study input data  
B.2.1 ICD to CHERG cause-of-death code conversions 
Here, I have included the mapping from the 9th and 10th International Classification of Diseases 
(ICD-9 and ICD-10) to the 7 programmatically relevant cause categories we used in our work for 
the VR data (Table B.1).  This table has been updated for subsequent work.  The most recent 
version is available on the “Disease burden and mortality estimates” section of the WHO 
website:  http://www.who.int/healthinfo/global_burden_disease/estimates/en/index3.html 
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Table B.1: Mapping between ICD codes and CHERG cause categories used in neonatal cause-of-
death modelling work 
 ICD-10 codes ICD-9 codes 
Complications of 
preterm birth 
P01.0-P01.1, P07, P22, P25-
P28, P52, P61.2, P77 
434.9, 518.1-518.9, 761.0-761.1, 
765, 769-770.0, 770.2-770.9, 772.1, 
774.2, 776.6, 777.5-777.6, 786.3 
Intrapartum-related 
complications 
P01.7-P02.1, P02.4-P02.6, 
P03, P07, P10-P15, P20-P21, 
P24, P50, P90-P91 
348.1-348.9, 437.1-437.9, 723.4, 
761.7-762.1, 762.4-762.6, 763, 767-
768, 770.1, 772.2, 779.0-779.2 
Congenital disorders D55-D68.9, E01-E07, E70-
E84, G10-G99, H, I, K, L, M, 
N, P35, P76, Q 
056, 240-243, 245-259, 272-277, 
279.3-286, 288.2, 303, 330-348.0, 
349-426, 429-434.0, 435-437.0, 438-
451, 520-723.0, 724-728, 731-759, 
775.2, 777.0, 795.2 
Sepsis and other 
severe infections 
A00-A35, A38-A99, B, G00-
G09, P36-P39 
000-031, 034-055, 057-134, 136-
139, 320-326, 491, 730, 771, 780.6, 
785.4 
Pneumonia A36-A37, J, P23 032-033, 460-490, 492-518.0 
Injuries S, V, W, X, Y 800-999 
Other C, D00-D54.9, D69-D99, 
E00, E08-E69, E85-E99, P00, 
P01.2-P01.6, P02.2-P02.3, 
P02.7-P02.9, P04-P06, P08, 
P29, P51, P53-P61.1, P61.3-
P74, P78, P80-P83, P93-P94 
135, 140-239, 244, 260-271, 278-
279.2, 287-288.1, 288.3-289, 427, 
452-459, 760, 761.2-761.6, 762.2-
762.3, 762.7-762.9, 764, 766, 772.0, 
772.3-774.1, 774.3-775.1, 775.3-
776.5, 776.7-776.9, 778.0, 779.5-
779.6 
 
We excluded the following ICD codes as non-specific/ill-defined: 
1) ICD-10 – F, O, P92, P95-96, R 
2) ICD-9 – 295.4, 305.6, 205.9, 308.9, 311.0, 317.0, 319.0, 779.3, 779.8-799 (except for 780.6, 
785.4, 786.3, and 795.2 as mentioned above) 
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B.2.2 Missing vital registration data years 
Table B.2 describes the missing data years for the high-quality VR countries used in the low 
mortality model.  
 
Table B.2: List of years with missing data for high-quality vital registration countries 
Country Years with  
missing data 
Country Years with  
missing data 
Antigua / 
Barbuda 
2010-2012 Latvia 2011-2012 
Argentina 2011-2012 Lithuania 2011-2012 
Australia 2005, 2012 Luxembourg 2012 
Austria 2012 Macedonia  2001-2004, 2011-
2012 
Bahamas 2009-2012 Malta 2012 
Bahrain 2010-2012 Mauritius 2012 
Barbados 2009-2012 Mexico 2011-2012 
Belgium 2000-2002; 2010-
2012 
Montenegro 2000-2004, 2010-
2012 
Belize 2008-2012 Netherlands 2012 
Brazil 2011-2012 New Zealand 2010-2012 
Bulgaria 2012 Norway 2012 
Chile 2010-2012 Panama 2010-2012 
Colombia 2010-2012 Poland 2012 
Costa Rica 2010-2012 Republic of Korea 2012 
Croatia 2012 Republic of Moldova none 
Cuba 2011-2012 Romania 2012 
Czech Republic 2012 Saint Kitts / Nevis 2009-2012 
Denmark 2000, 2010-2012 Saint Lucia 2000-2001, 2007, 
2009-2012 
Dominica 2011-2012 Saint Vincent / Grenadines 2011-2012 
Estonia 2009, 2012 Serbia 2012 
Finland 2012 Singapore 2012 
France 2010-2012 Slovakia 2011-2012 
Germany 2012 Slovenia 2011-2012 
Greece 2012 South Africa 2000-2005, 2008, 
2010-2012 
Grenada 2000, 2011-2012 Spain 2012 
Guyana 2000, 2009-2012 Suriname 2010-2012 
Hungary 2012 Sweden 2011-2012 
Iceland 2010-2012 Trinidad and Tobago 2003, 2009-2012 
Ireland 2000-2006, 2011-
2012 
United Kingdom 2011-2012 
Israel 2011-2012 United States 2011-2012 
Italy 2004-2005, 2011-
2012 
Uruguay 2002-2003, 2005-
2006, 2010-2012 
Japan 2012 Venezuela 2008-2012 
Kuwait 2000, 2012   
 
  
 
232 
B.2.3 Search terms used for the high mortality setting cause-of-death literature 
review 
Below is a list of the full search terms for the literature review we performed to find neonatal 
COD studies in high mortality settings.   
 
Our search covered the following areas (including variations, alternatives, and MESH for these 
terms): 
Cause-specific (one or more of these): haemorrhage, jaundice, abnormality, malformation, 
neural tube defect, sudden infant death syndrome, congenital malformations, congenital 
abnormalities, necrotic, respiratory distress, prematurity, preterm birth, asphyxia, tetanus, 
sepsis, birth injury, intrapartum, birth, cause, foetal alcohol syndrome, rubella, diarrhoea, 
dysentery, cholera, gastroenteritis, digestive tract infection, pneumonia, respiratory infections, 
bronchitis, croup, meningitis, encephalitis, meningococcal 
AND 
Age group (one or more of these): infant/newborn, neonatal, perinatal  
AND  
Mortality terms (one or more of these): death, mortality, fatality 
AND 
High mortality countries/regions: Argentina, Bolivia, Brazil, Brazil, Chile, Colombia, Ecuador, 
French Guiana, Guyana, Paraguay, Peru, Suriname, Uruguay, Venezuela, Mexico, Belize, Costa 
Rica, El Salvador, Guatemala, Honduras, Nicaragua, Puerto Rico, Panama, West Indies, Antigua, 
Bahamas, Barbados, Cuba, Dominica, Dominican Republic, Grenada, Guadeloupe, Haiti, 
Jamaica, Martinique, Antilles, Anguilla, Saint Kitts, St Kitts, Saint Lucia, St Lucia, Saint Vincent, St 
Vincent, Trinidad, Tobago, Virgin Islands, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, 
Uzbekistan, Borneo, Brunei, Cambodia, East Timor, Indonesia, Laos, Malaysia, Mekong Valley, 
Myanmar, Burma, Philippines, Singapore, Thailand, Vietnam, Bangladesh, Bhutan, India, Nepal, 
Pakistan, Sri Lanka, China, Korea, Macao, Mongolia, Taiwan, Afghanistan, Bahrain, Iran, Iraq, 
Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Syria, Turkey, United Arab Emirates, 
Yemen, Fiji, New Caledonia, Papua New Guinea, Vanuatu, Micronesia, Melanesia, Guam, Palau, 
Polynesia, Samoa, Tonga, Armenia, Azerbaijan, Georgia, Albania, Estonia, Latvia, Lithuania, 
Bosnia, Herzegovina, Serbia, Bulgaria, Belarus, Croatia, Czech Republic, Hungary, Macedonia, 
Moldova, Montenegro, Poland, Romania, Russia, Bashkiria, Dagestan, Slovakia, Slovenia, 
Ukraine, Cameroon, Central African Republic, Chad, Congo, "Democratic Republic of the Congo", 
Equatorial Guinea, Gabon, Burundi, Djibouti, Eritrea, Ethiopia, Kenya, Rwanda, Somalia, Sudan, 
Tanzania, Uganda, Angola, Botswana, Lesotho, Malawi, Mozambique, Namibia, South Africa, 
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Swaziland, Zambia, Zimbabwe, Benin, Burkina Faso, Cote d'Ivoire, Gambia, Ghana, Guinea, 
Guinea-Bissau, Liberia,  Mali, Mauritania, Niger, Nigeria, Senegal, Sierra Leone, Togo, Algeria, 
Egypt, Libya, Morocco, Tunisia, Comoros, Madagascar, Mauritius, Reunion, Seychelles, 
developing country, third world country, less developed, sub-Saharan, Caribbean, Pacific 
Islands, Mexico, Latin America, South America,  Indian Ocean Islands, Central America, Asia, 
Africa, Far East 
AND  
NOT “case reports”, editorial, comment, practice guideline 
 
B.2.4 Details of study data used as inputs into the high mortality model 
Below is a table describing the studies and surveys included in the high mortality model input 
dataset (Table B.3).  New studies have an asterisk (*) in front of the author name.  While most 
studies were included in the dataset as a single observation, those stratified by neonatal period 
or in other ways (e.g. setting location) were included as multiple observations.  The full dataset 
can be found at the WHO Global Health Observatory (www.who.int/gho).   
 
Table B.3: Details of the high mortality model input dataset 
First author Year 
published 
Country Additional 
strata 
Median 
data 
year 
# of 
causes 
reported 
# of deaths 
used in 
analysis 
Adazu [239] 2005 Kenya  2002 5 75 
Aguilar [240] 1998 Bolivia  1995 8 79 
*Akgun [241] 2012 Turkey  2003 4 34 
Aleman [242] 1998 Nicaragua  1993 6 72 
Anand [243] 2000 India  1993 8 50 
Asling-Monemi [244] 2003 Nicaragua  1995 6 56 
Awasthi [245] 1998 India  1994 7 286 
Baiden [246] 2006 Ghana  1999 4 1001 
Balci [247] 2008 Turkey early/late 2006 5 68 
Bang [248] 1999 India  1994 6 36 
*Bapat [249] 2012 India early/late 2006 5 102 
Baqui [132] 2006 India early/late not given 7 477 
Barros [250] 1987 Brazil  1982 7 113 
Barros [251] 2008 Brazil  2004 8 54 
Bassani [252] 2010 India  2002 7 10892 
Bezzaoucha [253] 2010 Algeria early/late 2003 5 2167 
Bhatia [254] 1989 Bangladesh  1982 7 513 
Bhutta [255] - Pakistan  2001 7 152 
Campbell [256] 2004 Egypt  2000 7 103 
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First author Year 
published 
Country Additional 
strata 
Median 
data 
year 
# of 
causes 
reported 
# of deaths 
used in 
analysis 
Chowdhury [257] 1996 Bangladesh  1983 5 474 
Chowdhury [258] 2005 Bangladesh early/late 1992 5 43 
Chowdhury [146] 2010 Bangladesh   2004  8 332 
Darmstadt [259] 2010 Bangladesh time period 2002 7 56 
Darmstadt [259] 2010 Bangladesh time period 2005 7 125 
Datta [260] 1988 India  not given 8 163 
Deribew [261] 2007 Ethiopia  2005 8 45 
*DHS [262] 2005 Bangladesh  2002 8 302 
*DHS [263] 2006 Honduras  2004 7 142 
*DHS [264] 2007 Nepal  2004 8 220 
*DHS [265] 2008 Pakistan  2006 8 1484 
*DHS [266] 2009 Mozambique  2007 5 718 
Djaja [267] 2003 Indonesia  2001 8 178 
Dommisse [268] 1991 South Africa early/late 1988 7 276 
Edmond [269] 2008 Ghana early/late 2004 5 582 
Ekanem [270] 1994 Nigeria  1991 7 24 
El-Zibdeh [271] 1988 Saudi Arabia  1983 7 78 
Fantahun [272] 1998 Ethiopia  1992 7 47 
Fauveau [273] 1990 Bangladesh  1982 8 201 
Fikree [274] 2002 Pakistan  1992 8 497 
Fonseka [275] 1994 Sri Lanka  1987 7 253 
Garenne [276] 2007 Morocco time period 1987 8 109 
Garenne [276] 2007 Morocco time period 1987 8 329 
*Gill [277] 2011 Zambia  2007 7 58 
Gomes [278] 1997 Brazil early/late 1991 6 138 
Greenwood [279] 1987 Gambia  1982 8 32 
Halder [280] 2009 Bangladesh  2007 8 49 
Hinderaker [281] 2003 Tanzania early/late 1995 5 71 
Jehan [282] 2009 Pakistan early/late 2004 5 49 
Karabulut [283] 2009 Turkey early/late 2006 6 178 
Khalique [284] 1993 India early/late 1990 8 21 
Khan [285] 1993 Pakistan  1986 7 80 
*Khanal [264] 2011 Nepal early/late 2006 5 183 
Khanjanasthiti [286] 1984 Thailand  not given 8 22 
Kishan [287] 1988 Libya  1984 6 245 
*Krishnan [288] 2012 India time period 1983 5 154 
*Krishnan [288] 2012 India time period 2003 5 106 
Leach [133] 1999 Gambia  1992 8 130 
Liu [289] 1985 China  1980 7 956 
Lucas [290] 1996 Sri Lanka  1993 6 120 
Manandhar [291] 2010 Nepal  2007 5 640 
*Matendo [292] 2011 Congo  2005 6 56 
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First author Year 
published 
Country Additional 
strata 
Median 
data 
year 
# of 
causes 
reported 
# of deaths 
used in 
analysis 
Matijasevich [293] 2008 Brazil time period 1982 4 115 
Matijasevich [293] 2008 Brazil time period 1993 4 88 
Matijasevich [293] 2008 Brazil time period 2004 4 47 
Mendieta [294] 2001 Paraguay  1996 6 3638 
Nandan [295] 2005 India  2001 8 299 
*Nga [296] 2012 Viet Nam  2009 7 225 
Pattison [297] 2013 South Africa  2006 7 45848 
Perry [298] 2003 Bangladesh  1997 8 102 
Perry [298] 2003 Haiti  1997 8 28 
Phukan [299] 1998 India  1994 7 101 
Pison [300] 1993 Senegal  1987 6 26 
Pratinidhi [301] 1986 India  1982 7 135 
Rahman [302] 1989 Bangladesh early/late 1985 7 69 
Rajindrajith [303] 2009 Sri Lanka  1999 6 17946 
*RHS [263] 1997 Honduras  1994 7 121 
*RHS [263] 2002 Honduras  1999 7 143 
Samms-Vaughan [304] 1990 Jamaica  1986 7 885 
Schumacher [305] 2002 Guinea  1998 8 94 
Settel [306] 2004 Tanzania location 2000 8 75 
Settel [306] 2004 Tanzania location 2000 8 119 
Settel [306] 2004 Tanzania location 2000 8 124 
Shah [307] 2010 India  2006 8 22 
Sharifzadeh [308] 2008 Iran  2005 7 87 
Shrivastava [309] 2001 India early/late 1995 8 895 
Singhal [310] 1990 India early/late 1984 7 50 
Sivagnanasundram [311]  1985 Sri Lanka early/late 1982 8 46 
Tikmani [312] 2010 Pakistan  2005 7 41 
*Turnbull [313] 2011 Zambia  2008 6 35 
Vaid [314] 2007 India early/late 2000 8 102 
Waiswa [315] 2010 Uganda  2007 7 58 
Walraven [316] 2003 Gambia  2000 6 70 
Woods [317] 2001 South Africa  2001 7 253 
Yassin [318] 2000 Egypt  1994 8 39 
 
B.3 Key methodological differences between current and previous 
estimates  
Three previous rounds of estimation, from 2005 to 2012, were done to estimate neonatal causes 
of death.  A summary of key methodology differences between these different estimation 
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rounds is presented in section 4.2.  A detailed list of the differences is included below in Table 
B.4. 
 
Table B.4: Methodological differences between the current and previous CHERG estimates 
Publication 
year 
2005 2010 2012 Current 
Estimation 
year(s) 
2000 2008 2000-2010 2000-2013 
Goal of 
estimation 
Neonatal cause-
of-death 
distribution for 
193 countries in 
2000 
Neonatal cause-
of-death 
distribution for 
193 countries in 
2008 
 
Neonatal cause-
of-death 
distribution for 
193 countries 
from 2000-2010 
 
Neonatal cause-
of-death 
distribution for 
194 countries 
from 2000-2013 
by early and 
late periods 
Countries in 
each model 
VR: 45 
Low mortality: 37 
High mortality: 
111 
VR: 73 
Low mortality: 37 
Low/high 
averaged: 22 
High mortality: 61 
VR: 61 
Low mortality: 51 
High mortality: 
81 
VR: 65 
Low mortality: 
49 
High mortality: 
80 
Thresholds 
for 
classifying 
countries 
into high-
quality VR, 
low 
mortality 
model, or 
high 
mortality 
model 
- High quality VR 
= >90% coverage 
- Low mort 
model = 
countries 
without high-
quality VR data 
and NMR<10 (or 
NMR<15 in WHO 
EURO/AMRO 
regions) 
- High mort 
model = 
remaining 
countries 
 
- High quality VR = 
>80% coverage 
- Low mort model 
= countries 
without high-
quality VR and 
NMR<15 
- averaged model 
= 
countries without 
high-quality VR 
and NMR between 
15-20: low/high 
mortality models 
averaged  
- High mort model 
= countries 
without high-
quality VR data 
and NMR>20 
- High quality VR 
= >80% coverage 
+ quality criteria 
(e.g. limited non-
specific/implausi
ble codes) 
- Low mort model 
= countries 
without 
adequate VR and 
with U5MR≤35 
from 2000-2010. 
- High mort 
model = 
countries without 
adequate VR and 
with U5MR>35 
from 2000-2010. 
- High quality 
VR = >80% 
coverage + 
quality criteria 
(e.g. limited 
non-
specific/implaus
ible codes) 
- Low mort 
model = 
countries 
without 
adequate VR 
and with 
U5MR≤35 from 
2000-2013. 
- High mort 
model = 
countries 
without 
adequate VR 
and with 
U5MR>35 from 
2000-2013. 
Input data High mortality 
model: 13685 
deaths 
Low mortality 
model: 96,797 
deaths 
High mortality 
model: 23,220 
deaths 
Low mortality 
model: 1,005,478 
deaths  
High mortality 
model: 56,890 
deaths 
Low mortality 
model: 1,013,599 
deaths 
High mortality 
model: 98,222 
deaths 
Low mortality 
model:1,267,40
4 deaths  
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Publication 
year 
2005 2010 2012 Current 
 
 
Covariate 
selection 
-High mortality 
model: expert 
opinion on which 
covariates may 
be associated 
with outcomes 
-Low mortality 
model: forward 
stepwise with 5% 
sig. level 
Same covariates 
used as previous 
round 
-High and low 
mortality models: 
jackknife 
procedure to 
minimize out-of-
sample 
prediction error.   
- Allowed 
relationship 
between 
covariate and 
outcome to be 
linear or 
quadratic 
-High and low 
mortality 
models: 
jackknife 
procedure to 
minimize out-
of-sample 
prediction 
error.   
- Allowed 
relationship 
between 
covariate and 
outcome to be 
linear, 
quadratic, or 
spline 
Multinomial 
model 
All causes in 
multinomial 
Infections in 
multinomial with 
sepsis/pneumonia 
split done after; 
tetanus as single-
cause 
Infections in 
multinomial with 
sepsis/pneumoni
a split done after; 
tetanus as single-
cause 
All causes 
included in 
multinomial 
Causes Preterm, 
Intrapartum, 
Congenital, 
Infection, 
Diarrhoea, 
Tetanus, Other 
Preterm, 
Intrapartum, 
Congenital, Sepsis, 
Pneumonia, 
Diarrhoea, 
Tetanus, Other 
Preterm, 
Intrapartum, 
Congenital, 
Sepsis, 
Pneumonia, 
Diarrhoea, 
Tetanus, Other 
Preterm, 
Intrapartum, 
Congenital, 
Sepsis, 
Pneumonia, 
Diarrhoea, 
Tetanus, Other 
(+ injuries for 
VR and low 
mortality model 
countries) 
Uncertainty Jackknife Jackknife Bootstrap Bootstrap 
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B.4 Additional results 
This section includes additional results for the work presented in chapter 4.  These results 
correspond to sections 4.3 (main results) and 4.4 (sensitivity analyses) of the main thesis.   
B.4.1 Comparison of input data and prediction covariate values 
Table B.5 is similar to Table 4.5 in section 4.3, but the prediction data are now for Indian states.  
In the analysis, we predicted the proportional cause-of-death distribution at the state-level for 
India and aggregated the estimates to develop national estimates.   
 
Table B.5: Comparison of high mortality model input data and covariates for Indian states  
 High mortality model input data Indian state-level prediction data1 
 Mean 
(SD)2 
Median  
(IQR)3 
Range  
(min-max) 
Mean 
(SD) 
Median 
(IQR) 
Range  
(min-max) 
NMR4 33.0 
(15.9) 
30.2 
(18.8-47.2) 
10.5-70.1 26.8 
(11.6) 
26.8 
(18.1-33.9) 
6.3-59.9 
IMR 62.1 
(30.0) 
58.7 
(35.7-81.6) 
14.7-142.0 40.2 
(17.3) 
38.8 
(27.1-52.2) 
9.2-95.5 
U5MR 88.6 
(45.8) 
89.1 
(52.9-125.4) 
17.1-227.0 54.9 
(25.2) 
51.0 
(36.1-72.5) 
11.8-122.0 
LBW 18.9 
(11.3) 
15.9 
(10.6-27.6) 
2.5-50.0 20.4 
(8.4) 
21.0  
(15.0-26.0) 
0.0-43.0 
GFR 0.127 
(0.043) 
0.118 
(0.092-0.158) 
0.057-0.235 0.089 
(0.007) 
0.088 
(0.083-0.096) 
0.080-0.103 
ANC 67.5 
(26.5) 
73.9 
(50.0-92.0) 
5.0-98.3 77.8 
(13.2) 
75.2  
(70.1-88.8) 
33.1-99.5 
DPT 67.9 
(24.6) 
73.5 
(60.5-83.5) 
0.0-99.0 68.9 
(14.4) 
70.6 
(61.2-78.1) 
30.2-96.9 
BCG 78.8 
(23.9) 
87.0 
(73.0-93.0) 
0.0-100.0 87.2 
(10.9) 
89.7 
(85.0-96.1) 
45.4-99.5 
PAB 63.3 
(25.0) 
68.0 
(51.4-83.5) 
0.0-98.5 72.6 
(15.5) 
76.9 
(60.6-85.4) 
31.3-97.1 
FLR 51.9 
(24.7) 
48.7 
(34.6-77.3) 
4.0-94.0 62.9 
(14.7) 
63.8 
(52.7-70.3) 
35.4-94.0 
SBA 48.7 
(33.1) 
45.3 
(18.9-83.7) 
0.0-100.0 59.8 
(16.8) 
59.4 
(48.1-70.0) 
25.5-99.6 
1 bolded values are those outside the input data range; 2 SD = standard deviation; 3 IQR = interquartile 
range; 4 see Table 4.2 for covariate acronym definitions, the region covariate was “Southern Asia” for 
all Indian states 
 
B.4.2 Regression coefficients for the low and high mortality models 
The following table includes the regression coefficients from the multinomial regressions for 
the two models used in this work.   
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Table B.6: Regression coefficients for the low and high mortality models 
 Early neonatal period Late neonatal period 
Covariates with regression 
coefficients1 
Covariate with regression 
coefficients 
Low mortality model1 
Intrapartum: 
Preterm 
FLRL (-0.018); const (0.572) FLRS1 (-0.030); FLRS2 (-0.025); FLRS2 
(0.134); DPTS1 (0.002); DPTS2 (0.006); 
DPTS2 (0.064); const (1.173) 
Congenital: 
Preterm 
GINIL (-0.008); DPTL (0.015); FLRL (0.004); 
IMRS1 (-1.669); IMRS2 (11.454); IMRS2 (-
13.670); U5MRS1 (1.417); U5MRS2  
(-9.443); U5MRS2 (13.523); LBWS1 (0.185); 
LBWS2 (-1.133); LBWS2 (2.726); const  
(-0.807) 
NMRL (-0.039); DPTL (0.007);  
const (-0.307) 
Sepsis: 
Preterm 
GNIL (-2.6x10-5); GINIL (0.025); ANCL 
(0.029); IMRS1 (-0.274); IMRS2 (2.647); 
IMRS2 (-4.009); DPTS1 (-0.013); DPTS2 
(0.034); DPTS2 (-0.555); const (-3.267) 
FLRL (-0.009); GINIL (0.031); DPTS1 (-
0.026); DPTS2 (0.062); DPTS2 (-1.125); IMR 
(0.049); IMRQ (-0.001); const (0.643) 
Pneumonia: 
Preterm 
GNIL (-6.7x10-5); const (-2.078) GNIL (-4.8x10-5); ANCS1 (0.072); ANCS2 (-
0.205); ANCS2 (2.250); const (-6.979) 
Injuries: 
Preterm 
GFRL (-104.414); GFRQ (763.714);  
const (-0.903) 
const (-2.942) 
Other: 
Preterm 
GFRL (103.863); GFRQ (-908.192); const (-
4.231) 
LBWL (0.029); NMRS1 (-0.212); NMRS2 
(1.117); NMRS2 (-1.514); DPTL (-0.090); 
DPTQ (0.001); const (2.433) 
High mortality model1 
Preterm: 
Intrapartum 
BCGL (0.007); PABL (-0.007); SBAL (0.010); 
DPTL (-0.004); LBWS1 (0.028); LBWS2 (-
0.006); GFRS1 (-11.980); GFRS2 (14.787); 
const (0.602) 
LBWS1 (0.038); LBWS2 (-0.054); PABS1 (-
0.011); PABS2 (0.000); GFRS1 (-21.739); 
GFRS2 (19.502); SSA (0.305); const (2.764) 
Congenital: 
Intrapartum 
LBWL (0.009); NMRL (-0.073); NMRQ 
(0.001); U5MRL (-0.022); U5MRQ (0.000); 
BCGS1 (0.004); BCGS2 (0.003); early 
(0.223); const (0.364) 
SBAL (-0.021); SBAQ (0.000); U5MRL (-
0.021); U5MRQ (0.000); late (0.739); SSA 
(-0.186); const (-0.070) 
Sepsis: 
Intrapartum 
LBWL (0.013); BCGL (0.022); BCGQ (0.000); 
early (-0.765); SA (0.253); const (-2.303) 
PABL (0.019); PABQ (0.000); LBWS1 (0.023); 
LBWS2 (-0.018); late (1.510); const  
(-1.708) 
Pneumonia: 
Intrapartum 
U5MRL (0.006); LBWL (0.009); early  
(-0.674); const (-1.713) 
PABL (-0.029); PABQ (0.000);  
const (-0.092) 
Diarrhoea: 
Intrapartum 
DPTL (-0.005); GFRL (12.725); NMRL 
(0.282); NMRQ (-0.003); early (-1.725); SA 
(-0.226); SSA (-1.491); const (-8.746) 
DPTL (-0.003); BCGL (-0.011); GFRL (-
3.800); FLRL (-0.022); LBWS1 (0.139); 
LBWS2 (-0.192); const (-1.332) 
Tetanus: 
Intrapartum 
PABL (-0.011); ANCL (-0.018); NMRL 
(0.043); early (-0.985); const (-1.642) 
NMRL (0.038); IMRL (-0.010); U5MRL 
(0.011); PABL (-0.020); late (0.839); const 
(-2.186) 
Other: 
Intrapartum 
GFRS1 (-22.942); GFRS2 (33.572); SSA (-
0.746); const (0.824) 
GFRS1 (-25.195); GFRS2 (25.625); late 
(0.474); SSA (0.317); const (1.317) 
1 see Table 4.2 for covariate acronym definitions; const = constant; most regression coefficients are 
rounded to 3rd decimal place but GNI rounded to 6th decimal place because GNI values are on order of 
thousands instead of the much smaller values of the other coefficients 
L linear; Q quadratic; S1 first restricted cubic spline; S2 second restricted cubic spline; S3 third restricted 
cubic spline 
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B.4.3 Comparison of estimated cause-of-death proportions between current and 
previous estimates 
Differences in global estimates between previous CHERG estimates and this round are 
shown in Table B.7.  Since time trends are a recent addition, we have compared the data 
reported in the earlier studies with the relevant year from our current work.  For example, the 
paper published in 2005 had estimates for 2000, so we have compared the 2000 predictions 
from that paper and our work.   
 
Table B.7: Comparison of estimated proportions between current and previous estimation 
rounds 
 Percentages from previous work (%) Percentages from current work (%) 
2000 estimates [13] 
Preterm  27.9 (0.19-0.35) 33.1 (23.1-44.0) 
Intrapartum1 22.8 (0.15-0.27) 24.8 (16.4-32.8) 
Infections2 26.0 (0.17-0.31) 21.5 (10.5-35.9) 
Congenital 7.4 (0.06-0.12) 8.3 (5.0-14.2) 
Tetanus 6.5 (0.05-0.20) 3.8 (1.0-9.7) 
Diarrhoea 2.8 (0.02-0.10) 0.9 (0.1-4.7) 
Other 6.6 (0.05-0.16) 7.6 (3.8-13.2) 
2008 estimates [14] 
Preterm  28.9 (20.1-34.0) 34.6 (24.4-46.2) 
Intrapartum1 22.8 (15.7-27.9) 23.8 (16.8-31.5) 
Sepsis 14.6 (10.0-20.6) 16.0 (8.2-24.7) 
Pneumonia 10.8 (7.4-15.2) 5.5 (2.8-10.4) 
Congenital 7.6 (5.7-10.7) 9.6 (6.2-15.0) 
Tetanus 1.7 (0.9-2.3) 2.1 (0.6-5.5) 
Diarrhoea 2.2 (1.6-5.9) 0.7 (0.1-3.6) 
Other 11.4 (8.9-24.7) 7.7 (3.7-13.2) 
2010 estimates [15] 
Preterm  30.2 (25.6-37.1) 35.0 (24.6-46.9) 
Intrapartum 20.1 (17.1-24.5) 23.6 (16.8-31.0) 
Sepsis 11.0 (7.0-15.4) 16.0 (8.2-24.7) 
Pneumonia 9.1 (5.8-13.1) 5.2 (2.7-10.0) 
Congenital 7.6 (5.8-10.2) 10.1 (6.4-15.6) 
Tetanus 1.6 (0.6-7.7) 1.8 (0.5-4.8)  
Diarrhoea 1.4 (0.5-4.2) 0.6 (0.2-3.3) 
Other 5.1 (3.2-7.9) 7.6 (3.7-13.2)   
1 Intrapartum-related conditions were previously referred to as “birth asphyxia”; 2 infections include 
sepsis and other severe infections as well as pneumonia, which in recent years have been estimated 
separately.  To compare with previous estimates, however, these are included in the aggregate 
infection category for estimates.   
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Note that these estimates are not necessarily directly comparable.  One reason for this is that 
UN-IGME updates their NMR, U5MR, and IMR time series each year, and so the values estimated 
for 2008 in one year may be different from those from another year.  Since our model includes 
these as covariates, the covariate values for the same year may be different for these values, 
which could affect the proportions.  But as is seen in Table B.7, the previous and current 
estimates generally fall within each other’s uncertainty bounds.   
 
B.4.4 Comparison of different proportional cause-of-death distributions for China 
Comparison of proportional COD distributions for China from the WHO, our low mortality 
model, and our high mortality model are included in Table B.8. 
 
Table B.8: Proportional cause-of-death distribution estimated for China by the WHO, low 
mortality model, and high mortality model 
 Intra-
partum 
Preterm Con-
genital 
Sepsis Pneumonia Injuries Diarrhoea Tetanus Other 
Estimates from the WHO 
2000 0.35 0.25 0.08 0.07 0.09 0.04 0.02 0.01 0.09 
2001 0.34 0.24 0.09 0.06 0.09 0.04 0.02 0 0.11 
2002 0.33 0.24 0.09 0.06 0.09 0.04 0.02 0 0.13 
2003 0.32 0.24 0.09 0.06 0.09 0.04 0.02 0.01 0.14 
2004 0.31 0.23 0.1 0.05 0.08 0.04 0.02 0 0.15 
2005 0.3 0.23 0.1 0.05 0.08 0.04 0.02 0 0.17 
2006 0.29 0.23 0.11 0.05 0.08 0.04 0.02 0 0.18 
2007 0.28 0.23 0.12 0.05 0.07 0.04 0.02 0 0.18 
2008 0.28 0.23 0.12 0.04 0.07 0.04 0.02 0 0.19 
2009 0.27 0.23 0.13 0.04 0.07 0.04 0.02 0 0.2 
2010 0.26 0.23 0.14 0.04 0.07 0.04 0.02 0 0.2 
2011 0.25 0.23 0.14 0.04 0.07 0.04 0.02 0 0.21 
2012 0.25 0.23 0.15 0.04 0.07 0.04 0.02 0 0.21 
2013 0.25 0.23 0.15 0.04 0.07 0.04 0.02 0 0.21 
Estimates using the low mortality model1 
2000 0.15 0.42 0.15 0.08 0.07 0.01 --- --- 0.12 
2001 0.15 0.41 0.15 0.09 0.08 0.01 --- --- 0.11 
2002 0.15 0.42 0.15 0.09 0.07 0.01 --- --- 0.11 
2003 0.15 0.42 0.16 0.09 0.07 0.01 --- --- 0.11 
2004 0.14 0.41 0.17 0.09 0.07 0.01 --- --- 0.10 
2005 0.14 0.41 0.18 0.09 0.07 0.01 --- --- 0.10 
2006 0.14 0.40 0.20 0.10 0.06 0.01 --- --- 0.10 
2007 0.14 0.40 0.20 0.10 0.06 0.01 --- --- 0.10 
2008 0.13 0.38 0.21 0.11 0.06 0.01 --- --- 0.10 
2009 0.13 0.38 0.23 0.10 0.06 0.01 --- --- 0.10 
2010 0.13 0.38 0.23 0.10 0.06 0.01 --- --- 0.10 
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 Intra-
partum 
Preterm Con-
genital 
Sepsis Pneumonia Injuries Diarrhoea Tetanus Other 
2011 0.13 0.38 0.23 0.09 0.05 0.01 --- --- 0.10 
2012 0.13 0.38 0.24 0.09 0.05 0.01 --- --- 0.10 
2013 0.13 0.39 0.24 0.09 0.05 0.01 --- --- 0.10 
Estimates using the high mortality model2 
2000 0.18 0.42 0.13 0.09 0.03 --- 0 0.01 0.13 
2001 0.18 0.41 0.14 0.1 0.03 --- 0 0.01 0.13 
2002 0.19 0.4 0.15 0.1 0.03 --- 0 0.01 0.14 
2003 0.19 0.39 0.16 0.1 0.03 --- 0 0.01 0.14 
2004 0.19 0.37 0.18 0.1 0.03 --- 0 0 0.14 
2005 0.19 0.36 0.19 0.1 0.03 --- 0 0 0.13 
2006 0.18 0.35 0.21 0.1 0.03 --- 0 0 0.13 
2007 0.18 0.35 0.22 0.1 0.03 --- 0 0 0.13 
2008 0.17 0.34 0.24 0.1 0.02 --- 0 0 0.13 
2009 0.17 0.33 0.25 0.1 0.02 --- 0 0 0.12 
2010 0.17 0.33 0.25 0.1 0.02 --- 0 0 0.12 
2011 0.17 0.33 0.25 0.1 0.02 --- 0 0 0.13 
2012 0.17 0.33 0.25 0.1 0.02 --- 0 0 0.13 
2013 0.17 0.32 0.25 0.1 0.02 --- 0 0 0.13 
1 Diarrhoea and tetanus are not included in the low mortality model; 2 Injuries are not included in 
the high mortality model 
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Appendix C: Further details on issues with the current multinomial 
models  
 
C.1 Details of additional study input data  
Table C.1 describes the studies and surveys which were added in 2015 to the high mortality 
model input dataset described in Table B.3.  Thus, the updated high mortality input dataset 
includes the studies listed in Table B.3 as well as those listed here in Table C.1.  As noted earlier, 
most studies were included in the dataset as a single observation, but those stratified by 
neonatal period or in other ways (e.g. setting location) were included as multiple observations.   
 
Table C.1: Details of additional studies/surveys added to the high mortality model input 
dataset in 2015  
First author Year 
published 
Country Additional 
strata 
Median 
data 
year 
# of 
causes 
reported 
# of deaths 
used in 
analysis 
Debelew [319] 2014 Ethiopia  2013 6 110 
DHS [320] 2011 Afghanistan  2007 7 506 
DHS [321] 2013 Bangladesh  2008 8 286 
Dogra [322] 2015 India location 2012 5 46 
Dogra [322] 2015 India location 2012 5 80 
Dogra [322] 2015 India location 2012 5 51 
Fottrell [323] 2013 Bangladesh time period 2008 4 324 
Fottrell [323] 2013 Bangladesh time period 2010 4 249 
Jain [324] 2013 India early/late 2005 6 60 
Ma [325] 2014 China early/late 2011 8 244 
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Appendix D: Example of guidance document when publishing 
modelled estimates  
Below is an example of a guidance document to aid interpretation of modelled results.  This 
document could be part of or in addition to other necessary documentation (e.g. detailed 
methods).     
 
  
Introduction 
The purpose of this document is to help guide the interpretation and future use of the 
neonatal cause-of-death estimates and models from the Maternal Child Epidemiology 
Estimation Group (MCEE).  Potential input data and modelling limitations are included here to 
give context to the produced estimates.  Caution is also advised if trying to adapt the models 
for further analyses.   
 
Publicly available files 
This document should be read in conjunction with the documentation at: 
https://www.who.int/healthinfo/global_burden_disease/estimates/en/index2.html.  This site 
includes detailed descriptions of the modelling methods, result files, and full statistical code 
for the MCEE neonatal cause-of-death models.   
 
Comments about the input data and interpretation of results 
The validity of our estimates relies on the quality of the input/prediction data, and our modelling 
techniques.  The majority of cause-of-death input data came from verbal autopsy (VA) studies 
for the high mortality model and vital registration (VR) data for the low mortality model.  VA 
data are known to be of variable quality, and the reported cause distributions depend heavily 
on factors like the causal hierarchies and case definitions used to attribute deaths.  Lack of both 
standardized VA methods and full reporting of methods can make comparisons between studies 
challenging.  Accurate cause attribution using VA is especially problematic for causes that are 
difficult to distinguish between, such as neonatal sepsis and pneumonia, or difficult to identify, 
such as congenital disorders without external signs.  VA for neonatal deaths has the added 
complication that the sick baby is unable to communicate symptoms to a caretaker.     
 
High-quality VR data also have limitations.  ICD-10 codes are not ideal for neonatal causes, 
particularly because several programmatically relevant causes are relegated to the often-
unused fourth digit in the codes.  ICD coding practices can also vary between (and within) 
countries and over time.  Such variations reduce our model’s ability to predict true variation in 
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causes of death.  Other issues in VR coding include changes during the transition between ICD 
revisions, differences in relegating certain causes to non-specific/ill-defined cause categories, 
and the assumption inherent in our exclusion of such codes that the deaths attributed to them 
are a random sample of all deaths.  Finally, the availability and quality of VR data in a country 
may change over time, especially in countries with newly emerging surveillance systems.  
Developing consistent time trend estimates given such changes can be challenging.   
 
There is also heterogeneity in data quality for the covariates in our models, both between and 
within covariate time series.  This is because of a combination of what is being measured, how 
it is measured, and how the time series data are put together.  The covariate data in our models 
are a mixture of data reported by countries, determined from household surveys, modelled, 
and/or imputed.  A particular covariate time series may have a combination of these sources 
across countries or over time for the same country.  Such variation may not always be known 
or fully understood, and is usually impossible to specifically identify within national covariate 
time series data.  Specific sources for covariate time series data can be found through the link 
included in the “Publicly available files” section above.   
 
Regression-based models such as ours inherently depend on the relationship between outcome 
variables and covariates, which should ideally come from the same population and time period.  
While we sought to include as much local covariate information as possible for the input studies, 
52% of the total covariate information came from national data instead of from local/regional 
data.  Additionally, when re-categorizing reported VA causes of death, we had to make choices, 
for example placing deaths reported as being due to “very low birth weight” into the preterm 
complication category.  This may introduce a degree of misclassification as some “very low birth 
weight” deaths may be attributable to congenital abnormalities.  We made those choices that 
we believed would introduce the least misclassification, but until VA methods improve, this will 
continue to be a challenge.  Similar issues exist in ICD coding, but are more common in VA 
studies because of the limited and lower quality information collected.   
 
Comments about interpretation of the results 
When interpreting the estimates from the neonatal cause-of-death models, it is important to 
remember that the results (e.g. cause-of-death proportions by country and year) are outputs of 
a complex statistical machinery with several different components (e.g. range of input data of 
differing quality, various statistical methods).     
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As with all such modelling exercises, our estimates should be viewed as an interim measure to 
help policymakers, particularly in settings with little or no data currently.  It is important to 
distinguish estimates from data.  For most countries, our cause-specific estimates are not based 
on empirical data from that country, but from a model bringing together data from many 
countries.  The model then predicts the cause-of-death distribution, and changes in the cause-
of-death distribution, in individual countries based on covariate values for the individual 
country.  Some countries contribute little or no input data to the modelling process.  Our 
estimates should not therefore be interpreted as “tracking” changes in causes of death for the 
majority of countries, but rather as predictions of what might be occurring in countries.  To track 
changes in burden due to specific causes of death requires each country to collect 
representative and consistent data on cause of death on a continuing basis.  Our estimates are 
not a panacea for actual data collection.   
 
Comments about adaption of these models for other analyses 
Careful consideration should be taken if trying to extend these models beyond their original 
purpose.  An assessment must first be made about whether the existing models can support the 
desired extension.  For example, it may be tempting to apply the estimated covariate 
coefficients to subnational prediction data.  However, if the range of the proposed prediction 
data is outside the range of the model input data, such an analysis is beyond the scope of these 
models.  This is one example; careful consideration is needed before any desired adaptation of 
the models.  If the model is applied to or adapted for alternative analyses, rigorous checks and 
validation exercises should be performed to assess suitability and model performance.   
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